Company ID,Company,Company Legal Name,Competitors,Description,Primary Industry Sector,Primary Industry Group,Primary Industry Code,All Industries,Verticals,Keywords,Company Financing Status,Total Raised,Business Status,Ownership Status,Universe,Employees,Exchange,Ticker,Year Founded,Last Updated Date,Parent Company,HQ Country,HQ Location,Last Known Valuation,Last Known Valuation Date,Last Known Valuation Deal Type,Last Financing Date,Last Financing Size,Last Financing Size Status,Last Financing Valuation,Last Financing Valuation Status,Last Financing Deal Type,Last Financing Deal Type 2,Last Financing Deal Class,Last Financing Debt Date,Last Financing Status,Last Financing Debt Size,Last Financing Debt,First Financing Date,First Financing Size,First Financing Size Status,First Financing Deal Type,First Financing Valuation,First Financing Valuation Status,First Financing Deal Type 2,First Financing Deal Class,First Financing Status,First Financing Debt,Revenue,Revenue Growth %,Net Income,Net Debt,Market Cap,Gross Profit,Enterprise Value,EBITDA,EBIT,Total Patent Document,Total Patent Families,Active Patent Document,Pending Patent Document,Patent Expiering the Next Year,Inactive Family Documents,Top CPC Codes,Total Clinical Trials,Acquirers,#Active Investors,Active Investors,Financing Status Notes,Former Investors,Other Investors
234048-88,89bio (NAS: ETNB),"89bio, Inc.","Akero Therapeutics, CymaBay Therapeutics, Astria Therapeutics, Altimmune, Galectin Therapeutics, Adicet Bio, aTyr Pharma, Clementia Pharmaceuticals, Athenex, Sagimet Biosciences, NGM Biopharmaceuticals, Intercept Pharmaceuticals, ARMO BioSciences, Metacrine, Ultragenyx Pharmaceutical, Sutro Biopharma, Amgen, Blade Therapeutics, Strongbridge Biopharma, Gilead Sciences, Petra Pharma, Lixte Biotechnology Holdings, OncoMed Pharmaceuticals, Cidara Therapeutics, Biogen, Madrigal Pharmaceuticals, Viamet Pharmaceuticals Holdings, Rheos Medicines, Celgene, Predictive Biosciences, Auspex Pharmaceuticals, vTv Therapeutics, Genfit, Genentech, Biosplice Therapeutics, Scynexis, Cirius Therapeutics, Boehringer Ingelheim, Allogene Therapeutics, Hyperion Therapeutics, InterMune, Iconic Therapeutics, Amplyx Pharmaceuticals, Pfizer Pakistan","89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*","Life Sciences, LOHAS & Wellness","biologics, healthcare innovation, healthcare research, liver treatment programs, medical innovation, medical research, peptides, pharmaceutical, protein",Formerly VC-backed,981.44,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",93,NAS,ETNB,2018,2025-04-26,,United States,"San Francisco, CA",207.89,2019-11-11,IPO,2025-01-29,287.0,Actual,,,Public Investment 2nd Offering,,Public Investment,2025-01-29,Completed,,,2018-10-25,60.0,Actual,Early Stage VC,,,Series A,Venture Capital,Completed,,0.0,0.0,-367.08,-402.41,1013.13,,533.29,-384.62,-384.66,83,11,55,23,5,5,"Heterocyclic compounds, Peptides, Preparations for medical, dental or toiletry purposes, Specific therapeutic activity of chemical compounds or medicinal preparations, Sugars",7,,,,"The company raised $189.63 million in its second public offering on the Nasdaq stock exchange under the ticker symbol of ETNB on January 29, 2025. A total of 21,671,428 shares (including the over-allotment option) were sold at $8.75 per share. The underwriters were granted an option to purchase up to an additional 4,285,714 shares from the company to cover over-allotments, if any. Previously, the company raised $125 million in its second public offering on the Nasdaq Stock Exchange under the ticker symbol of ETNB on November 13, 2024. A total of 11,455,882 shares were sold at $8.5 per share. The underwriters were granted an option to purchase up to an additional 2,205,882 shares from the company to cover over-allotments, if any.","Longitude Capital, OrbiMed, Pontifax Venture Capital, RA Capital Management, Teva Pharmaceutical Industries, Venrock",
228212-83,A2Z Cust2Mate Solutions (NAS: AZ),A2Z Cust2Mate Solutions Corp.,,"A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.",Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Government, Other Retail",,"automotive industry, defense products, electronics technology, military product, retail, shopping app, software developer, unmanned robotic systems",Corporation,75.22,Generating Revenue,Publicly Held,"M&A, Publicly Listed",89,NAS,AZ,2018,2025-04-26,,Israel,"Tel Aviv, Israel",,,,2024-12-12,12.46,Estimated,,,PIPE,,Corporate,2024-12-12,Announced/In Progress,,,2019-12-12,0.15,Actual,Reverse Merger,,,,Corporate,Completed,,7.17,-0.37,-17.0,-12.34,256.34,1.99,186.87,-18.35,-19.22,,,,,,,,,,2,"Clal Insurance Enterprises Holdings, ECC Ventures 1","The company (NAS: AZ) is in talks to receive approximately $12.46 million of development capital from undisclosed investors through a private placement as of December 12, 2024. The net proceeds will be used for continued development and expansion of existing business, including fulfillment of contracted smart cart backlog orders and acceleration of the onboarding process for new clients, and for working capital purposes. Previously, the company (NAS: AZ) received $2.40 million of development capital from undisclosed investors on August 12, 2024, through a private placement. The company is being actively tracked by PitchBook.",,
12867-40,Actelis Networks (NAS: ASNS),"Actelis Networks, Inc.","Extreme Networks, Adtran, FiberLight, COMLINK, Belden, Etherwan Systems, Call One, Telarus, Interop Technologies, Lumen Technologies, Nitel, Moxa, Overture Networks, Inteliquent","Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The company operates as one operating segment: developing and marketing access broadband equipment for copper and fiber networks.",Information Technology,Communications and Networking,Connectivity Products,"Connectivity Products*, Other Communications and Networking, Wireless Communications Equipment","Cybersecurity, Internet of Things, Manufacturing, TMT","endpoint security, enterprise networking, fiber networking, fiber networking software, iot network and devices platform, iot network infrastructure, iot security, iot/ot security, networking equipment, networking service, ot security",Formerly VC-backed,189.61,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Publicly Listed, Venture Capital",49,NAS,ASNS,1998,2025-04-26,,United States,"Fremont, CA",67.53,2022-05-13,IPO,2023-12-20,1.5,Estimated,,,PIPE,,Corporate,2023-12-20,Completed,,,1999-07-06,6.8,Actual,Early Stage VC,15.3,Actual,Series A1,Venture Capital,Completed,,7.76,0.3842,-4.37,-0.62,6.21,4.27,7.73,-3.73,-3.76,111,29,56,3,52,52,"Coding, Telephonic communication, Transmission, Transmission of digital information",,,1,Tokarz Group,"The company (NAS: ASNS) received an estimated $1.5 million of development capital from undisclosed investors on December 20, 2023 through a private placement. The company intends to use the net proceeds from the offering for working capital and general corporate purposes.","Adams Street Partners, Amos Ben-Meir, Anschutz Investment, Argo Group International Holdings, ATA Ventures, Draper Fisher Jurvetson Management, DuPont Capital Management, Global Catalyst Partners Japan, Individuals' Venture Fund, Innovacom (Paris), MVC Capital BDC, New Enterprise Associates, Saints Capital, Salomon Encore, Seabury Venture Partners, Smac Partners, The Carlyle Group, U.S. Venture Partners, Vertex Ventures Israel, Walden International, Western Technology Investment",
399444-13,Airtouch (TAE: ARTS),Airtouch Solar Ltd,,"Airtouch Solar Ltd provides water-free robotic cleaning solutions for solar PV panels. Its products include Airtouch 3.0, Airtouch 3.0 Portable, Airtouch Tracker, Airtouch IoT System, and others.",Information Technology,Computer Hardware,Other Hardware,Other Hardware*,"CleanTech, Robotics and Drones","automated cleaning, autonomous robotic systems, autonomous robots, cleaning roof, robots cleaners, solar",Corporation,18.0,Generating Revenue,Publicly Held,Publicly Listed,,TAE,ARTS,2016,2024-10-31,,Israel,"Beit Shemesh, Israel",124.0,2021-03-08,IPO,2021-03-08,18.0,Estimated,124.0,Estimated,IPO,,Public Investment,2021-03-08,Completed,,,2021-03-08,18.0,Estimated,IPO,124.0,Estimated,,Public Investment,Completed,,0.2,,,,9.86,,,,,13,5,6,3,4,4,"Cleaning in general, Generation of electric power by conversion of infrared radiation, visible light or ultraviolet light",,,,,"The company raised $18 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of ARTS on March 8, 2021. After the offering, the company was valued at $124 million.",,
152413-21,Alarum Technologies (TAE: ALAR),Alarum Technologies Ltd.,"Distil Networks, SonicWall, F-Secure, RiskIQ, OneSpan, Clavister Holding, Bitglass, Darktrace, Sealpath, Skyhigh Networks, Netskope, Tigera, WatchGuard Technologies, Anonos, Cloudflare, Barracuda Networks, Nagios, Ethyca, vArmour, Imperva, SecureAuth, Cisco Systems, PureSec, Ground Labs, Excite Technology Services, GFI USA, Forcepoint, Tenable, TIBCO Software, Gemalto, Fasoo, Axonius, Pulse Secure, NSFOCUS, Check Point Software Technologies, SECUDE, Deny-All, Zscaler, FilmTrack, Aruba Networks, Attivo Networks, Rubrik, SolarWinds, Portnox","Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.",Information Technology,Software,Network Management Software,"Business/Productivity Software, Network Management Software*","FinTech, TMT","company data security, cyber protection, data exfiltration, data security, data security tool, fraud prevention, identity & access management, identity and access management, manufacturing",Formerly Angel backed,61.46,Profitable,Publicly Held,"Pre-venture, Publicly Listed",65,TAE,ALAR,,2025-04-26,,Israel,"Tel Aviv, Israel",,,,2023-09-14,4.25,Actual,,,PIPE,,Corporate,2023-09-14,Completed,,,2007-01-01,5.0,Actual,Angel (individual),,,Angel (individual),Individual,Completed,,31.82,0.2,5.78,-13.49,51.88,23.91,56.11,7.51,6.6,1,1,,,1,1,,,,,,"The company (TAE:ALAR) received $4.25 million of development capital from undisclosed investors on September 14, 2023 through a private placement. The company intends to use the net proceeds from the private placement predominantly to support and strengthen its balance sheet, as well as for other corporate purposes.",Kibbutz Sasa Holdings,
55795-69,Albaad Massuot Yitzhak (TAE: ALBA),Albaad Massuot Yitzhak Ltd.,,"Albaad Massuot Yitzhak Ltd is engaged in the manufacturing of hygiene products such as wipes and sanitary products. Its products include cleansing wipes and pads, self-tan flick, makeup removal, natural radiance wipes, sunscreen wipes, moist toilet tissue, intimate wipes and personal care products, among others.",Consumer Products and Services (B2C),Consumer Non-Durables,Personal Products,Personal Products*,Manufacturing,"baby wipes, car wipes, dairy wipes, manufacturing, skin wipes, wet wipes",Corporation,,Profitable,Publicly Held,Publicly Listed,1996,TAE,ALBA,1985,2025-04-08,,Israel,"Massuot Yitzhak, Israel",,,,1994-01-01,,,,,IPO,,Public Investment,1994-01-01,Completed,,,1994-01-01,,,IPO,,,,Public Investment,Completed,,461.18,0.0054,12.04,188.28,95.23,93.3,294.48,51.58,28.27,,,,,,,,,,,,,,
56012-14,Alcobra,Alcobra Ltd,"Inspirion Delivery Sciences, BioDelivery Sciences International, Marinus Pharmaceuticals, H. Lundbeck, Promentis Pharmaceuticals, Tris Pharma, Spinifex Pharmaceuticals, Enzon Pharmaceuticals, Confluence Pharmaceuticals, Nektar Therapeutics, Purdue Pharma, Alphora Research, Johnson&Johnson Innovative Medicine, TauRx Pharmaceuticals, Intellipharmaceutics International, Opiant Pharmaceuticals, Acura Pharmaceuticals, Bristol-Myers Squibb, Vertex Pharmaceuticals, Otsuka Holdings, Collegium Pharmaceutical, AgeneBio, Sunovion Pharmaceuticals, Alkermes, Allergan, Avalo Therapeutics, Cognition Therapeutics",Developer of a proprietary drug for disabled care patients intended to become a leading global player in the pharmaceutical industry through disruptive efficiency and innovation. The company's pharmaceutical operations are focused on the development of new medications to help patients with cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome.,Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,"Drug Discovery, Pharmaceuticals*",,"cognitive dysfunction, hyperactivity disorder, medication, pharmaceutical",Corporate Backed or Acquired,58.0,Clinical Trials - Phase 2,Acquired/Merged,"M&A, Publicly Listed, Venture Capital",27,,,2008,2025-03-19,,Israel,"Tel Aviv, Israel",46.7,2017-11-16,Merger/Acquisition,2017-11-16,46.7,Actual,46.7,,Merger/Acquisition,,Corporate,2017-11-16,Completed,,,2013-05-22,25.0,Actual,IPO,89.02,Estimated,,Public Investment,Completed,,,,,,,,,,,,,,,,,,8,Arcturus Therapeutics,,,"The company was acquired by Arcturus Therapeutics for $46.7 million through a reverse merger, resulting in the combined entity trading on the NASDAQ Stock Exchange under the ticker symbol ARCT on November 16, 2017. The company is no longer actively tracked by PitchBook.","Brosh Capital Partners, Hadasit Bio-Holdings, Knoll Capital Management",
140120-92,Algomizer (TAE: GIX),Algomizer Ltd.,"WEB, Automattic","Gix Internet Ltd is a MarTech (Marketing Technology) solutions provider, mainly for online performance-based-marketing, that maximizes exposure, increases impact and drives profits from target audiences. Gix's products provide clear growth opportunities and success, through various technologies, in this challenging and dynamic market.",Information Technology,IT Services,IT Consulting and Outsourcing,IT Consulting and Outsourcing*,"AdTech, Marketing Tech, Mobile, TMT","algorithmic tools, marketing technology software, marketing technology solutions, online marketing firm, online marketing service, optimization software",Corporate Backed or Acquired,5.0,Generating Revenue,Publicly Held,"M&A, Publicly Listed",23,TAE,GIX,1978,2025-01-17,Discount Investment,Israel,"Petah Tikva, Israel",27.93,2019-06-20,PIPE,2020-10-14,,,,,PIPE,,Corporate,2020-10-14,Completed,,,2002-08-12,,,IPO,,,,Public Investment,Completed,,,,,,1.37,,,,,,,,,,,,,Discount Investment,1,Xylo Technologies,"Medigus acquired a 15% stake in the company (TAE: GIX) on October 14, 2020 through a private placement.",,
58953-34,AllMeD Solutions (TAE: ALMD),AllMeD Solutions Ltd.,,"Allmed Solutions Ltd develops, manufactures and markets minimally invasive products internationally in various medical disciplines.",Healthcare,Healthcare Devices and Supplies,Therapeutic Devices,"Diagnostic Equipment, Surgical Devices, Therapeutic Devices*",Manufacturing,"health care devices, healthcare device, medical device, medical equipment, medical product, stent, therapeutic device",Corporation,3.46,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",19,TAE,ALMD,2001,2025-02-03,,Israel,"Caesarea, Israel",,,,2023-01-04,3.46,Estimated,,,PIPE,,Corporate,2023-01-04,Completed,,,,,,Accelerator/Incubator,,,,Other,Completed,,0.0,0.0,-2.35,-11.65,9.69,,-2.33,-2.75,-2.9,31,7,16,,15,15,"Filters implantable into blood vessels, Shaping or joining of plastics",,,2,"Gefen Biomed Investments, HekaBio","The company (TAE: ALMD) received ILS 12 million of development capital from Dr. David Milch and other undisclosed investors on January 4, 2023, through a private placement. The company's chairman, Dr. David Milch, invested over NIS 3.5 million. The proceeds from the placement, together with the present cash balance and expected future considerations from prior strategic transactions substantially enhance the company's financial stability and will enable the company to support its subsidiaries and achieve its goals. Previously, the company (TAE: ALMD) received an undisclosed amount of development capital from HekaBio and other undisclosed investors on December 1, 2022, through a private placement.",Biomedix Incubator,
41626-36,Allot Communications (NAS: ALLT),Allot Ltd.,"Infinera, Elitecore Technologies, AppLogic Networks, NEC (Japan), Sandvine (Internet Service Providers), Bear-Line, Vanrise, Aptilo Networks, Adtran, Juniper Networks, Celtro Communication, Blackberry, Cellwize","Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.",Information Technology,Computer Hardware,"Computers, Parts and Peripherals","Computers, Parts and Peripherals*, Internet Service Providers",TMT,"broadband service, broadband service optimization, internet protocol service",Formerly VC-backed,194.38,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",495,NAS,ALLT,1996,2025-04-26,,Israel,"Hod HaSharon, Israel",426.41,2011-11-09,Public Investment 2nd Offering,2016-06-16,,,,,Merger/Acquisition,,Corporate,2016-06-16,Failed/Cancelled,,,,30.0,Actual,Later Stage VC,,,,Venture Capital,Completed,,92.2,-0.0103,-5.87,-11.52,238.55,63.69,226.54,-0.45,-6.67,134,40,103,2,29,29,"Pictorial communication, Telephonic communication, Transmission of digital information, Wireless communication networks",,,,,"The company (NAS: ALLT) was in talks to be acquired by BlackBerry on June 16, 2016. Subsequently, the deal was cancelled. Previously, The company raised $90.13 million in a secondary public offering on the NASDAQ stock exchange under the ticker symbol of ALLT in November 2011.","BancBoston Ventures, DFJ Tamir Fishman, Gemini Israel Ventures, Genesis Partners, Jafco Investment (Asia Pacific), Jerusalem Venture Partners, Partech, Tamar Ventures, Walden Israel Venture Capital",Blackberry
183377-35,Alpha Tau Medical (NAS: DRTS),"Alpha Tau Medical, Ltd.","MaveriX Oncology, RadioMedix, Oncosec Medical, Sermonix Pharmaceuticals, Perspective Therapeutics, CSL Behring, Genentech, Amgen, RefleXion (Biotechnology), P-Cure, Biogen, Celgene","Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Drug Discovery","HealthTech, Life Sciences, Oncology, TMT","alpha radiation cancer therapy, cancer care, cancer therapy, cancer therapy product, cancer treatment, cancer treatment product, therapy technology",Formerly VC-backed,149.71,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",125,NAS,DRTS,2016,2025-04-26,,Israel,"Jerusalem, Israel",665.0,2022-03-08,Reverse Merger,2023-08-10,,,,,Secondary Transaction - Private,,Venture Capital,2023-08-10,Completed,,,2016-01-01,,,University Spin-Out,,,,Corporate,Completed,,0.0,0.0,-31.75,-47.06,185.8,,164.66,-34.62,-35.72,180,37,89,79,12,12,"Conversion of chemical elements, Electrotherapy, Preparations for medical, dental or toiletry purposes",29,,,,"Althera Medical sold a stake in the company to Deep Insight on August 10, 2023.","Alan Patricof, Althera Medical, Arc Ventures (United States), Das & Co., Deep Insight (Herzliya), Dynamic Loop Capital, Grand Decade, Happiness Capital, Healthcare Capital (Special Purpose Acquisition Company), HekaBio, Medison Ventures, MUUS Climate Partners, Orot Luces, OurCrowd, Regah Ventures, Ronald Cohen, Shavit Capital, Yozma Group Korea",
41966-29,Amdocs (NAS: DOX),Amdocs Ltd.,"Optiva, Salesforce, ServiceNow, Anaplan, Automatic Data Processing, Pegasystems, StudyStream (Business/Productivity Software), SAP, TIBCO Software, ATDI, Extreme Networks, Nutanix, CMTSU Liquidation, Cisco Systems, Sage Group, Infosys, Infor Global Solutions, Workday, Equinox Information Systems, InfoVista, Lexmark International, VMware, Telestream, MetTel, MicroStrategy (Business/Productivity Software), Synchronoss Technologies, Blackberry, 8X8, TASS Technology Solutions, Netcracker Technology, Logi Analytics, Amelia, Coupa, Astellia, Zoho Corporation, BroadSoft, Autodesk, HubSpot, Teradata, Ciena, TEOCO, SugarCRM, Genpact, Sigma Systems Canada, PayPal Holdings, Oracle, Openet, Virtusa, Tuxera, SADA Systems, Slack, The Ceridian (UK and Ireland unit), Saguna, Coforge, Calix, Epicor Software, Imperva, BMC Software, Okta, Oracle NetSuite, NTT Data Group, Samsung SDS Company, Tableau Software, Alteryx, Tomia, EPAM Systems, Amazon Web Services, Sutherland Global Services, Avaya, Evolving Networks Ltd, Red Hat, SAS Institute, Fair Isaac, Firebase, Adobe, NTT, Schneider Electric (Electrical Equipment), Vivo Collaboration","Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.",Information Technology,Software,Business/Productivity Software,Business/Productivity Software*,"Mobile, TMT","catalog management, communication service, customer management, media services company, networking technology, revenue management",Formerly PE-Backed,502.27,Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed, Venture Capital",29058,NAS,DOX,1982,2025-04-26,,United States,"Saint Louis, MO",4460.58,1999-06-08,IPO,2020-06-17,650.0,,,,General Corporate Purpose,,Debt,2020-06-17,Completed,650.0,"Bonds - 650.00M¬†$ (Senior, Unsecured; Fixed)",1997-12-05,,,Buyout/LBO,,,,Private Equity,Completed,Revolving Credit - 45.00M¬†$ (All Assets; Syndicated; Floating); Term Loan A - 115.00M¬†$ (All Assets; Syndicated; Floating); Term Loan B - 90.00M¬†$ (All Assets; Syndicated; Floating),4869.85,-0.0156,496.37,444.78,9647.14,1750.73,9923.05,816.63,623.01,894,548,633,22,239,239,"Electric digital data processing, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Telephonic communication, Transmission of digital information, Wireless communication networks",,,,,"The company received $650 million of debt on June 17, 2020.","HarbourVest Partners, SAIC Venture Capital, Welsh, Carson, Anderson & Stowe",
158893-66,Apollo Power (TAE: APLP),Apollo Power Ltd,,Apollo Power Ltd through SolarPaint develops solar energy technologies.,Energy,Energy Equipment,Alternative Energy Equipment,Alternative Energy Equipment*,"CleanTech, TMT","functional coatings technology, solar, solar energy harvester, solar energy harvesting, solar painting system",Formerly Angel backed,,Generating Revenue/Not Profitable,Publicly Held,"Pre-venture, Publicly Listed",109,TAE,APLP,2014,2025-01-04,,Israel,"Nachsholim, Israel",,,,2017-10-08,,,,,Reverse Merger,,Corporate,2017-10-08,Completed,,,,,,Seed Round,,,Seed Round,Individual,Completed,,3.46,0.237,-23.24,10.75,46.36,0.61,84.85,-17.79,-22.33,46,27,11,29,6,6,"Boards, substations or switching arrangements for the supply or distribution of electric power, Capacitors, Generation of electric power by conversion of infrared radiation, visible light or ultraviolet light, Inorganic semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation, Shaping or joining of plastics",,,2,"Florida-Israel Business Accelerator, OR City Holdings","The company acquired OR City Holdings (TAE: OR) through a reverse merger, resulting in the combined entity trading on the TAE Stock Exchange under the ticker symbol APLP on October 8, 2017.",Israel Innovation Authority,
149303-17,Aquarius Engines (TAE: AQUA),Aquarius Engines Ltd.,,"Aquarius Engines is engaged in the development, production and sale of engines and generators based on internal combustion.",Business Products and Services (B2B),Commercial Products,Electrical Equipment,Electrical Equipment*,"CleanTech, Climate Tech, Industrials, LOHAS & Wellness","automotive battery, combustion engine, electric engine, electric power supply, engine generator, grid infrastructure, non-battery storage, power generator",Formerly VC-backed,102.52,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",60,TAE,AQUA,2014,2025-02-27,,Israel,"Rosh Haayin, Israel",297.39,2020-12-02,IPO,2020-12-02,66.32,Actual,297.39,Estimated,IPO,,Public Investment,2020-12-02,Completed,,,2015-05-30,2.5,Actual,Seed Round,10.0,Actual,Seed Round,Venture Capital,Completed,,0.0,0.0,-14.21,-1.7,16.63,,6.35,-12.34,-13.63,69,7,58,9,2,2,"Cyclically operating valves for machines or engines, Internal-combustion piston engines, Machines or engines, in general or of positive-displacement type, Shafts, Springs",,,,,"The company raised NIS 223 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of AQUA on December 2, 2020. A total of 6,214,000 shares were sold at a price of NIS 35.9 per share. After the offering, there was a total of 27,855,153 outstanding shares priced at a price of NIS 35.9 per share, valuing the company at NIS 1 billion.The total proceeds, before expenses, to the company was NIS 192 million and to the selling shareholders was NIS 31 million. In the offering, the company sold 5,349,241 shares and the selling shareholders sold 864,759 shares.","GlenRock Israel, Marius Nacht, Musashi Seimitsu Industry Company, Shlomo Elia, TPR Company",
64907-38,Arad (TAE: ARD),Arad Ltd,Arad Technologies,"Arad Ltd designs, manufactures, sells and supports water meters such as advanced water automatic meter reading (AMR) and advanced metering infrastructure (AMI) solutions. The company provides water meters to residential, bulk, irrigation and water management companies.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,"Electronic Equipment and Instruments*, Environmental Services (B2B)","Manufacturing, TMT","bulk water meter, water boxes, water machine, water measurement, water measurement solutions, water measuring system, water meter",Corporation,,Profitable,Publicly Held,Publicly Listed,1180,TAE,ARD,1941,2023-10-06,,Israel,"Dalia, Israel",,,,2004-12-07,,,,,IPO,,Public Investment,2004-12-07,Completed,,,2004-12-07,,,IPO,,,,Public Investment,Completed,,394.04,0.0909,24.29,74.72,357.89,116.67,426.04,50.37,34.33,54,18,28,1,25,25,"Measuring not specially adapted for a specific variable, Measuring volume, volume flow, mass flow or liquid level",,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of ARD on December 7, 2004.",,
170988-31,Arbe Robotics (NAS: ARBE),Arbe Robotics Ltd.,"Ouster, Mobileye, Velodyne Lidar, Echodyne, Texas Instruments, Metawave, Uhnder, NXP Semiconductors (Television Systems and Set-Top Box Business Lines)","Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.",Information Technology,Software,Business/Productivity Software,"Application Specific Semiconductors, Business/Productivity Software*, Electronic Equipment and Instruments","Artificial Intelligence & Machine Learning, Mobility Tech","automotive radar, autonomous driving, autonomous machine, imaging radar, imaging sensors, radar chips, radar device",Formerly VC-backed,215.08,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, M&A, Private Equity, Publicly Listed, Venture Capital",180,NAS,ARBE,2015,2025-04-26,,Israel,"Tel Aviv, Israel",631.0,2021-10-07,Reverse Merger,2025-01-07,28.75,Actual,,,PIPE,,Corporate,2025-01-07,Announced/In Progress,,,2016-04-01,0.65,Actual,Seed Round,1.65,Actual,Seed Round,Venture Capital,Completed,,0.77,-0.477599999999999,-49.32,8.34,143.02,-0.78,172.48,-49.07,-49.65,45,13,26,17,2,2,"Antennas, Printed circuits, Radio direction-finding, Semiconductor devices not covered by class h10, Systems for controlling or regulating non-electric variables",,,,,"The company (NAS: ARBE) is in talks to receive $28.75 million of development capital from undisclosed investors through a private placement as of January 7, 2025. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. Previously, the company raised $7.81 million in its second public offering on the Nasdaq Stock Exchange under the ticker symbol of ARBE on November 4, 2024. The company is being actively tracked by PitchBook.","100Partner Capital, 360 Capital, AI Alliance Fund, Arc Ventures (United States), Beijing Automotive Group Industrial Investment, Canaan Partners Israel, Catalyst Investments, China Everbright, Climate First, Geneva Insurance Group, High House Investment, Hyundai CRADLE, iAngels, Icebreaker (Mumbai), Industrial Tech Acquisitions, Kreos Capital, LoftyInc Capital Management, M&G, Maniv Mobility, MissionBlue Capital Partners, MobilityXlab, MoreTech Ventures, Next Gear Ventures, Noah Pickholtz, O.G. Venture Partners, OurCrowd, RIO Ventures Holdings, Silverhorn Investment Advisors, Special Situations Funds, Taya Ventures, Ten Venture Partners, Texas Ventures, Valhalla Investment Group, Varana Capital",
62232-85,AshotAshot Ashkelon Industries (TAE: ASHO),Ashot Ashkelon Industries Ltd.,,"Ashot- Ashkelon Industries Ltd produces metal products, aviation parts, armored combat vehicle systems, and heavy metal products. It supplies technological systems and components for the international aerospace, defense, automotive, and other industries. The company's products include gears, transmissions, gearboxes long and short shafts for jet engines, landing gear components, and tungsten-based products, among others. The company's domicile, and partly in the United States, the subsidiary's domicile. Marketing and sales activities are mainly in Israel, in the USA and Europe.",Business Products and Services (B2B),Commercial Products,Aerospace and Defense,Aerospace and Defense*,"Industrials, Manufacturing","aerospace and defense, aerospace molds, gear cutting, landing gear, landing gear components, optical inspection",Private Equity-Backed,,Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed",511,TAE,ASHO,1967,2025-03-23,,Israel,"Ashkelon, Israel",98.85,2022-06-30,Buyout/LBO,2022-06-30,84.0,Actual,98.85,Estimated,Buyout/LBO,,Private Equity,2022-06-30,Completed,,,1992-06-02,,,IPO,,,,Public Investment,Completed,,105.55,0.2048,7.46,19.83,333.13,22.69,452.68,19.38,15.04,8,5,1,,7,7,Couplings for transmitting rotation,,,1,FIMI Opportunity Funds,"The company was acquired by FIMI Opportunity Funds through a $84 million LBO on June 30, 2022. The transaction values the company at an estimated $98.85 million.",Israel Military Industries,
41995-18,AudioCodes (TAE: AUDC),AudioCodes Limited,"ZTE, Radisys, Casa Systems, Grandstream Networks, beroNet, Ericsson, Peerless Network, Nokia, Sinch, Sangoma Technologies, Harmonic (Other Communications and Networking), Bandwidth (US), CommScope Holding Company, Philips Broadband Networks, Ooma, Vecima Networks, DASAN Zhone Solutions, Adtran, Aptilo Networks, Interop Technologies, MariTEL, Syniverse Technologies, Patton, Fujitsu, 8X8, Cisco Systems, Acme Packet","AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.",Information Technology,Communications and Networking,Telecommunications Service Providers,"Telecommunications Service Providers*, Wireless Communications Equipment",TMT,"data communication, data network, internet calling, voice over packet",Formerly VC-backed,47.0,Profitable,Publicly Held,"Publicly Listed, Venture Capital",946,TAE,AUDC,1993,2025-04-26,,Israel,"Lod, Israel",,,,1999-05-28,47.0,Estimated,,,IPO,,Public Investment,1999-05-28,Completed,,,,,,Early Stage VC,,,,Venture Capital,Completed,,242.18,-0.009,15.31,-25.92,278.77,158.16,274.35,16.37,12.49,100,35,50,5,45,45,"Electric digital data processing, Pictorial communication, Speech analysis techniques or speech synthesis, Telephonic communication, Transmission of digital information",,,,,"The company raised $47 million in its initial public offering on the Nasdaq Stock Exchange under the ticker symbol of AUDC on May 28, 1999.","Genesis Partners, Pitango Venture Capital",
435442-78,Aura Air (TAE: AUSA-M),Aura Smart Air Ltd.,"Jets Air Pro, Dyson, Blue Air Heating, Molecule (Biotechnology)",Aura Smart Air Ltd is engaged in the development and marketing of air purification platforms inside buildings and air monitoring. The company's products include Aura Air; Aura Air Mini; and Ray Filters.,Consumer Products and Services (B2C),Consumer Non-Durables,Household Products,Household Products*,CleanTech,"air disinfectants, air purification product, air purifier, air quality, air quality device, air quality sensor, pollutant removal",Formerly VC-backed,17.75,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",24,TAE,AUSA-M,2018,2024-12-23,,Israel,"Tel Aviv, Israel",10.0,2023-02-26,Merger/Acquisition,2023-02-26,10.0,Estimated,10.0,Estimated,Merger/Acquisition,,Corporate,2023-02-26,Failed/Cancelled,,,,1.5,Actual,Grant,,,,Other,Completed,,3.8,,,,1.01,,,,,5,2,3,,2,2,Air-conditioning,,,,,"The company was in talks to be acquired by Molekule for an estimated $10 million on an undisclosed date. Subsequently, the deal was cancelled. Previously, the company raised ILS 35 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of AUSA on June 14, 2021. After the offering, the company was valued at ILS 167 million.","Florida-Israel Business Accelerator, Google for Startups, Highroad (Israel), Israel Innovation Authority, Merchavia Holdings And Investments, The Israeli Insurtech Accelerator",Molekule
53997-94,Avgol Industries (TAE: AVGL),Avgol Industries 1953 Limited,,"Avgol Industries 1953 Ltd is engaged in development, manufacturing and marketing of nonwoven fabrics for diapers, adult incontinence products, disposable feminine hygiene products, disposable medical products, wipes, fabrics used to produce masks, gowns and additional medical products.",Consumer Products and Services (B2C),Consumer Non-Durables,Personal Products,"Other Consumer Non-Durables, Personal Products*",Manufacturing,"adult incontinence product, baby diapers, feminine hygiene, feminine hygiene product, hygiene product, nonwoven fabric, nonwoven fabric product, polypropylene",Formerly PE-Backed,1.27,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, M&A, Private Equity, Publicly Listed",915,TAE,AVGL,1953,2025-03-16,Indorama Ventures,Israel,"Tel Aviv, Israel",108.81,2023-09-19,Secondary Transaction - Private,2023-09-19,37.03,Estimated,108.81,Estimated,Secondary Transaction - Private,,Corporate,2023-09-19,Failed/Cancelled,,,2007-01-28,,,IPO,,,,Public Investment,Completed,,350.03,0.1005,-0.62,135.47,126.09,48.37,255.64,43.57,17.43,42,23,4,3,35,35,"Filters implantable into blood vessels, Making textile fabrics",,Indorama Ventures,,,"An undisclosed investor had been in talks to sell a 34.03% stake in the company to Indorama Ventures Public for ILS 142.46 million. Subsequently, the deal was canceled on October 26, 2023. Previously, the company (TAE: AVGL) was acquired by Indorama Ventures Public (BKK: IVL) for $440 million on July 26, 2018. The acquisition offers extensive value creation and synergy within Indorama Ventures, including growth opportunities in adjacent segments through the strong innovation pipeline. The addition of Avgol reinforces IVL's existing leading position in this segment. IVL is now able to offer a full suite of personal hygiene-oriented nonwoven products that best serve customer needs.","Ethemba Capital, Goldrock Partners, Israel Petrochemical Enterprises, Leumi Partners, Mustang Mezzanine Fund, Rinkelberg Capital",
165529-36,Avrot Industries (TAE: AVRT),Avrot Industries Ltd,,"Avrot Industries Ltd provides covering & inner coating of steel pipes for transportation uses. It manufactures and markets plastic pipes for transporting liquids. The company also provides cleaning, coating & painting of metal products & through its holdings manufactures & distributes plastic pipes & tubes. Its plastic pipes used for conveying water, gas, sewage, fuel.",Business Products and Services (B2B),Commercial Products,Other Commercial Products,Other Commercial Products*,Manufacturing,"pipe manufacturer, pipes fittings, plastic pipe product, plastic pipeline, steel pipe maker, steel pipe product",Corporation,,Generating Revenue,Publicly Held,"M&A, Publicly Listed",,TAE,AVRT,1984,2024-12-12,Shapir Engineering and Industry,Israel,"Beerot Yitzhak, Israel",23.0,2021-11-01,Merger/Acquisition,2021-11-01,23.0,Actual,23.0,,Merger/Acquisition,,Corporate,2021-11-01,Completed,,,1992-01-01,,,IPO,,,,Public Investment,Completed,,,,,,15.07,,,,,,,,,,,,,Shapir Engineering and Industry,,,The company was acquired by Shapir Engineering and Industry (TAE: SPEN) for $23 million in November 2021.,,
234068-14,Axilion (TAE: AILN),Axilion Ltd.,,"Axilion Smart Mobility Ltd is an artificial intelligence-based software company. The company is focused on developing, applying, and implementing software systems (SaaS) based on artificial intelligence, which enables cities to manage their entire mobility system optimally. Its solutions optimize traffic light systems' timing using a comprehensive analysis of the traffic light network, road users, and network demand. These solutions help in reducing air pollution, prioritize public transit, and improve road-user safety.",Information Technology,Software,Communication Software,"Communication Software*, Other Transportation","Artificial Intelligence & Machine Learning, Internet of Things, Mobility Tech, SaaS","communication software system, enterprise asset management, enterprise resource planning, erp, intelligent transportation system software, smart city application, smart traffic light, smart traffic light timing software, traffic signals network coordination, transit signal priority",Formerly VC-backed,24.86,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",55,TAE,AILN,2009,2025-01-10,,Israel,"Tel Aviv, Israel",386.6,2020-12-02,Reverse Merger,2021-01-06,18.86,Actual,,,PIPE,,Individual,2021-01-06,Completed,,,2009-01-01,,,University Spin-Out,,,,Corporate,Completed,,0.59,0.1578,-6.19,-3.46,2.51,-0.32,-1.77,-6.13,-6.39,6,2,,,6,6,,,,2,"Apio Africa, Ramot at Tel Aviv University","The company (TAE:AILN) received ILS 61 million of development capital from undisclosed investors on January 6, 2021 through a private placement. Previously, the company acquired Apio Africa (TAE: AILN) through a reverse merger, resulting in the combined entity trading on the TAE under the ticker symbol AILN on December 2, 2020. Also, the company joined EIT KIC Urban Mobility and UnternehmerTUM on December 2, 2020 and received EUR 3,000 in funding.","Arik Steinberg, EIT KIC Urban Mobility, John Casesa, John Procari, Leading Cities, Mark Josephson, Shy Datika, UnternehmerTUM",
41515-75,B.O.S. Better Online Solutions (NAS: BOSC),B.O.S. Better Online Solutions Ltd.,,"BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.",Information Technology,Computer Hardware,Other Hardware,"Application Software, Other Hardware*, Other IT Services","Internet of Things, Manufacturing, TMT","aidc hardware, automation systems, electronic components consolidation, rfid software, robotics r&d, supply chain product",Corporation,12.28,Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",80,NAS,BOSC,1990,2025-04-26,,Israel,"Rishon LeZion, Israel",113.11,2000-05-04,PIPE,2020-12-30,2.0,Actual,,,PIPE,,Corporate,2020-12-30,Completed,,,1996-04-02,,,IPO,,,,Public Investment,Completed,,39.95,-0.0957,2.3,-1.2,21.98,9.29,19.22,2.06,1.5,1,1,,,1,1,,,,,,"The company (NAS:BOSC) received $2 million of development capital from undisclosed investors on December 30, 2020, through a private placement.","Apex Mutavim, Catalyst Investments, EN Shoham Business",
53309-98,BATM Advanced Communications (LON: BVC),"BATM Advanced Communications, Ltd.",,"BATM Advanced Communications Ltd is an Israel-based technology company. The company organizes its business operations into three divisions: Networking, Cyber Division, and Diagnostics Division. Networking includes marketing, research, and development of data communication products, which includes high-performance connectivity solutions for the network edge, Cyber Division mostly includes the provision of integrated hardware and software solutions for network encryption, including hardware security modules (HSMs). Diagnostics division is mainly engaged in the sale and distribution of in vitro diagnostics (IVD) reagents and instruments, including the development and production of proprietary products. Its geographical segments are the United States of America, Israel, and Europe.",Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Network Management Software, Other Healthcare Technology Systems","Cybersecurity, Life Sciences, Manufacturing, TMT","biomedical, biowaste treatment, cyber security, data and telecommunication, data networking technology, medical laboratory systems",Formerly PE-Backed,21.87,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed",1021,LON,BVC,1992,2025-04-26,,Israel,"Hod HaSharon, Israel",18.71,1996-07-11,IPO,2019-07-01,18.0,Actual,,,PIPE,,Corporate,2019-07-01,Completed,,,,,,PE Growth/Expansion,,,,Private Equity,Completed,,117.34,0.0052,-22.3,-22.92,81.73,36.8,78.24,0.55,-4.42,,,,,,,,,,,,The company (LON:BVC) received $18 million of development capital from undisclosed investors in July 2019 through a private placement.,Goldrock Partners,
55497-88,Beamr Imaging (NAS: BMR),Beamr Imaging Ltd.,"Pixel Power, AnyClip (Media and Information Services), Ittiam, JW Player, Imagine Communications, Gbox, Bitmovin, Reach Engine, Cincopa, Ooyala, GetAccept, TwentyThree, Twilio, Vidyard, Vizrt, KloudFuse, Kollective, SSIMWAVE, EdgeCast Networks, MediaKind, Wistia, Telestream, Vidizmo, Brainshark, Anvato, Showpad, VBrick, Brightcove, vzaar, Virool, SalesLoft, InPlayer, Ateme, KZO Innovations, Zight, Sprout Video, Promo","Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.",Information Technology,Software,Multimedia and Design Software,"Media and Information Services (B2B), Multimedia and Design Software*","SaaS, TMT","media optimization, technology platform, video optimization, video software technology, video stream, video streaming tools",Formerly VC-backed,41.09,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",21,NAS,BMR,2009,2025-04-26,,Israel,"Herzliya, Israel",51.53,2023-03-01,IPO,2024-02-15,11.99,Actual,,,Public Investment 2nd Offering,,Public Investment,2024-02-15,Completed,,,,,,Angel (individual),,,Angel (individual),Individual,Completed,,3.06,0.0533,-3.35,-16.23,38.8,2.82,59.06,-3.62,-3.79,97,27,73,3,21,21,"Coding, Image data processing or generation, in general, Image or video recognition or understanding, Pictorial communication",,,4,"Disruptive Technologies Venture Capital, Innovation Endeavors, Ion Pacific, Marker","The company raised $11.99 million in its second public offering on the Nasdaq stock exchange under the ticker symbol of BMR on February 15, 2024. A total of 1,714,200 shares were sold at $7 per share. Previously, The company raised $7.8 million in its initial public offering on the Nasdaq stock exchange under the ticker symbol of BMR on February 28, 2023. A total of 1,950,000 shares were sold at $4 per share. The underwriters were granted an option to purchase up to an additional 292,500 shares from the company and selling shareholders to cover over-allotments, if any. The company is being actively tracked by PitchBook.","Mybulb, Verizon Ventures",
459451-09,Bee-io Honey (TAE: BHNY),Bee-io Honey Ltd.,,Beeio Honey Ltd is developing an industrial process for the production of cultured honey. It produces honey without bees in a process that combines natural nectar flowers with unique biological processes that turn the nectar into honey.,Consumer Products and Services (B2C),Consumer Non-Durables,Food Products,Food Products*,"Climate Tech, FoodTech, Life Sciences","alt-proteins, fermented protein, food tech, honey bee pollination, honey processing, honey producer, honey product, honey production, honey syrup",Formerly VC-backed,2.47,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",15,TAE,BHNY,2018,2024-12-03,,Israel,"Rehovot, Israel",11.63,2021-05-26,Reverse Merger,2021-05-26,,,11.63,Actual,Reverse Merger,,Corporate,2021-05-26,Completed,,,,,,Early Stage VC,,,,Venture Capital,Completed,,0.0,0.0,-1.6,-1.33,1.18,,2.78,-1.11,-1.42,,,,,,,,,Whitestone (Business/Productivity Software),,,"The company acquired Whitestone through a reverse merger, resulting in the combined entity trading on the Tel Aviv Stock Exchange under the ticker symbol BHNY on May 26, 2021.",Paz Capital,
264853-00,Beyon3D (TAE: BYON),Beyon 3D Ltd,,"Beyon 3D Ltd is developing a robotic system to create concrete products for the construction industry. It has completed its pioneering technology, reinventing the process of design and manufacturing of innovative constructive and decorative building products, redefining quality and aesthetics in the field.",Information Technology,Computer Hardware,Other Hardware,Other Hardware*,"3D Printing, Manufacturing","additives manufacturing, production speed, robotics manufacturing system",Corporation,12.55,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",,TAE,BYON,2011,2025-03-19,,Israel,"Herzliya, Israel",77.15,2021-05-30,IPO,2021-06-20,,,,,PIPE,,,2021-06-20,Completed,,,2021-05-30,12.55,Actual,IPO,77.15,Estimated,,Public Investment,Completed,,,,,,4.67,,,,,4,1,4,,,,"Manipulators, Shaping or joining of plastics",,,1,Raw Ventures,"The company raised ILS 41 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of BYON on May 30, 2021. After the offering, the company was valued at ILS 252 million.",,
105769-00,Beyond Air (NAS: XAIR),Beyond Air Inc.,"Savara, VERO Biotech, Bedfont, Respira Therapeutics, Bellerophon Therapeutics, Pulmatrix, Aerogen, Enterprise Therapeutics, Mallinckrodt Pharmaceuticals, Airgas, Praxair","Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.",Healthcare,Healthcare Devices and Supplies,Therapeutic Devices,"Other Devices and Supplies, Therapeutic Devices*",Life Sciences,"biopharmaceutical company, biopharmaceutical firm, biopharmaceutical system, drugs formulation, nitric oxide, pharmaceutical, respiratory disease",Formerly VC-backed,69.65,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, M&A, Publicly Listed, Venture Capital",107,NAS,XAIR,2011,2025-04-26,,United States,"Garden City, NY",38.5,2024-03-22,Public Investment 2nd Offering,,11.5,Actual,,,Debt Refinancing,,Debt,,Completed,,Term Loan - (Recurring revenue based lending loans),2012-11-22,1.25,Actual,Early Stage VC,,,,Venture Capital,Completed,Term Loan - (Senior),3.02,3.3875,-52.3,-8.94,19.22,-2.14,11.87,-48.24,-51.61,110,24,30,26,54,54,"Devices for introducing media into, or onto, the body, Preparations for medical, dental or toiletry purposes",10,,,,The company completed a $11.5 million of debt refinancing on an undisclosed date.,"KokiCare, Western Technology Investment",
497492-47,Beyond Oil (CNQ: BOIL),Beyond Oil Ltd.,,Beyond Oil Ltd is a food-tech company that has developed a solution to reduce free fatty acid from oil while preserving the oil's quality and nutritional value. The company develops products that extend the usable life of frying oil improve food quality and reduce frying oil costs. It offers FryDay which is an active filter powder that eliminates harmful Free Fatty Acids (FFA) generated in the oil. Geographically the company generates the majority of its revenue from Israel followed by the United Kingdom and the United States.,Consumer Products and Services (B2C),Consumer Non-Durables,Food Products,"Food Products*, Machinery (B2B)",,"food processing company, food service company, food tech, food tech company, food-tech, food-tech business",Corporation,14.06,Generating Revenue,Publicly Held,"M&A, Publicly Listed",14,CNQ,BOIL,2012,2025-04-24,,Israel,"Migdal HaEmek, Israel",,,,2025-03-12,7.58,Estimated,,,PIPE,,Corporate,2025-03-12,Announced/In Progress,,,2022-05-25,,,IPO,,,,Public Investment,Completed,,0.33,0.2852,-5.52,-2.82,170.75,0.1,72.7,-2.6,-2.91,12,5,8,2,2,2,"Edible oils or fats, Producing",,,2,"Fandango Collection & Recycling, West Coast Reduction","The company (CNQ: BOIL) is in talks to receive CAD 10.85 million of development capital from Clal Insurance Enterprises Holdings (TAE: CLIS) through a private placement as of March 12, 2025. The net proceeds of the Offering will be used to expand and support the distribution of the Company's products as disclosed in the Company's recent press releases. Previously, the company (CNQ: BOIL) received CAD 2.02 million of development capital from undisclosed investors on September 16, 2024, through a private placement. The company is being actively tracked by PitchBook.",,Clal Insurance Enterprises Holdings
58683-43,BioHarvest Sciences (NAS: BHST),BioHarvest Sciences Inc.,,"BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Drug Discovery","Cannabis, LOHAS & Wellness","agricultural technology, anthocyanins, molecular, nutraceuticals, nutritional ingredients, polyphenol, therapeutic solutions",Formerly VC-backed,17.51,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",87,NAS,BHST,2007,2025-04-26,,Canada,"Vancouver, Canada",,,,2024-06-21,5.0,Estimated,,,PIPE,,Corporate,2024-06-21,Announced/In Progress,,,2014-08-01,,,Early Stage VC,,,,Venture Capital,Completed,,25.19,0.9877,-12.91,11.43,113.5,13.94,114.18,-6.92,-8.17,13,4,7,1,5,5,"Microorganisms or enzymes, Preparations for medical, dental or toiletry purposes",3,,2,"Canna-V-Cell Sciences, GreenSoil Investments (Israel)","The company (CNQ: BHSC) is in talks to receive $5 million of development capital from an undisclosed investor on June 21, 2024, over two tranches through a private placement. The company closed tranche 1 raising $4.33 million on June 28, 2024. Each unit includes one common share, one-quarter of a $7.68 warrant and one-quarter of an $11.52 warrant. Funds raised through this private placement will be allocated to advancing the company's contract development and manufacturing organization business unit, expanding the company's manufacturing capabilities within the newly acquired 80,000-square-foot campus and for general corporate purposes. Previously, The company (CNQ: BHSC) received CAD 3.5 million of development capital from undisclosed investors on October 4, 2021, through a private placement. The company is being actively tracked by PitchBook.",,
51185-89,BioLineRx (TAE: BLRX),BioLinerx Ltd.,"X4 Pharmaceuticals, Dendreon, TScan Therapeutics, Arbutus Biopharma, Rein Therapeutics, Viela Bio, Black Diamond Therapeutics, Kite Pharma, Regulus Therapeutics, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, AnTolRx, Cyclenium Pharma, Immunitas Therapeutics, Sagimet Biosciences, Jounce Therapeutics, Circle Pharma, Oncorus, Agenus, Apexigen, Intellia Therapeutics, Immune Design, Forma Therapeutics, Astex Pharmaceuticals, Alios BioPharma, Gilead Sciences, Voyager Therapeutics, Amal Therapeutics, GlycoMimetics, Mission Therapeutics, Xenetic Bioscience, Tmunity, Genentech, Eidos Therapeutics, Moderna, Arrowhead Pharmaceuticals, Ra Pharmaceuticals, Intas Pharmaceuticals, Oncolytics Biotech, Spexis, Spring Bank Pharmaceuticals, Genomic Health, Amunix Pharmaceuticals, OncBioMune, Axolabs","BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*","Life Sciences, Oncology","biopharmaceutical company, biopharmaceutical company development, biopharmaceutical company operator, biopharmaceutical industry, clinical stage, myocardial infarction",Formerly VC-backed,275.94,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, M&A, Private Equity, Publicly Listed, Venture Capital",28,TAE,BLRX,2003,2025-04-26,,Israel,"Modiin, Israel",74.85,2019-02-05,Public Investment 2nd Offering,2024-11-20,10.0,Actual,,,PIPE,,Private Equity,2024-11-20,Announced/In Progress,,,2004-05-05,15.0,Actual,Early Stage VC,,,,Venture Capital,Completed,,28.94,5.0292,-9.22,-4.52,11.7,19.68,22.55,2.1,-1.97,164,20,78,35,51,51,"Heterocyclic compounds, Investigating or analysing materials by determining their chemical or physical properties, Peptides, Preparations for medical, dental or toiletry purposes, Specific therapeutic activity of chemical compounds or medicinal preparations",25,,2,"Guangzhou Gloria Biosciences, Kreos Capital","The company raised $6.86 million in its second public offering on the Tel Aviv Stock Exchange under the ticker symbol of BLRX on January 7, 2025. A total of 34,332,122 ADS shares were sold at $0.2 per share. The total proceeds, before expenses, to the company was $6.86 million. Previously, the company (TAE: BLRX) is in talks to receive $9 million of development capital from Highbridge Capital Management through a private placement as of November 20, 2024. The offering consists of 16,471,449 American depositary shares and warrants, each ADS representing fifteen ordinary shares, par value NIS 0.10, of the company, at a combined purchase price of $0.5464 per ADS and accompanying ordinary warrant. The company intends to use the net proceeds from the offering for general corporate purposes and to advance its pancreatic program as well as pipeline expansion. Subsequently, the company filed for a second public offering on the Nasdaq stock exchange under the ticker symbol of BLRX on December 29, 2023. They intend to sell 4,121,493 ADS at a price of $0.5464 per ADS. The expected offering amount is $2.2519 million. Previously, the company (TAE: BLRX) received $6 million of development capital from undisclosed investors on April 1, 2024, through a private placement. The company is being actively tracked by PitchBook.","BVF Partners, Giza Venture Capital, Hadasit Bio-Holdings, Jerusalem Capital Partners, Lincoln Park Capital, Novartis, OrbiMed, Pitango Venture Capital, Ridgeback Capital, Star Ventures, Teva Pharmaceutical Industries",Highbridge Capital Management
180968-50,BiomX (ASE: PHGE),BiomX Inc.,"NovaBiotics, Quench Bio, Xeno Biosciences, PEP-Therapy, SynDevRx, Eligo Bioscience, Symbiotix Biotherapies, Enterome, ContraFect, Spero Therapeutics, Evelo Biosciences, Seres Therapeutics, MicroBiome Therapeutics, Vaiomer, 4D pharma, EnBiotix, Synergy Pharmaceuticals, Vir, Rebiotix, Axial Therapeutics, Armata Pharmaceuticals, OrphoMed, Snipr Biome, Rheos Medicines, Vedanta Biosciences, Locus Biosciences, Kaleido BioSciences, Adenium Biotech, AvidBiotics, Synlogic, Suono Bio, Destiny Pharma, Iterum Therapeutics, Angle (United Kingdom), MaaT Pharma, Da Volterra, AmpliPhi Biosciences, Finch Therapeutics, APS Biocontrol, Advanced Cell Diagnostics, Locanabio, ViThera Pharmaceuticals, Summit Therapeutics, Evoke Pharma, Genomic Expression, Corbus Pharmaceuticals, Second Genome, Metabiomics, Arena Pharmaceuticals, ApoCell, Menarini Silicon Biosystems, Optibiotix Health","BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Drug Discovery","Life Sciences, Oncology","antibiotic resistance, antibiotics, bacteriophage, chronic disease, cystic fibrosis, diabetes, diabetic foot, microbiome, microbiome modulation, microbiome therapeutics, phage therapy",Formerly VC-backed,109.39,Clinical Trials - Phase 2,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",71,ASE,PHGE,2015,2025-04-26,,United States,"Gaithersburg, MD",71.22,2019-10-23,Reverse Merger,2025-02-27,12.0,Actual,,,PIPE,,Corporate,2025-02-27,Completed,,,,,,Accelerator/Incubator,,,,Other,Completed,,0.0,0.0,-17.73,-7.27,15.25,,18.13,-16.09,-17.89,30,7,2,21,7,7,"Microorganisms or enzymes, Preparations for medical, dental or toiletry purposes",3,,8,"AMR Action Fund, Cystic Fibrosis Foundation, Deerfield Management, Johnson & Johnson Innovation - JJDC, Mirae Asset Capital, Nantahala Capital Management, OrbiMed, Takeda Ventures","The company (ASE:PHGE) received $12 million of development capital from Deerfield Management, Cystic Fibrosis Foundation and Nantahala Capital Management on February 27, 2025 through a private placement","8VC, Chardan Healthcare Acquisition, Chong Kun Dang Pharmaceutical, Consensus Business Group, FutuRx, Handok, Israel Innovation Authority, KB Investment, Mirae Asset Global Investments, Mirae Asset Venture Investment, RM Global Partners, RMGLOBAL Healthcare Fund Management, SBI Holdings, SBI JI Innovation Fund, Seventure Partners",
58687-66,BioView (TAE: BIOV),"BioView, Ltd.",,"Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.",Healthcare,Healthcare Devices and Supplies,Diagnostic Equipment,"Diagnostic Equipment*, Other Healthcare Technology Systems","Life Sciences, Manufacturing, Oncology","cancer scanning equipment, duet scanning, laboratory equipment, legato, microbial detection, scanning systems",Formerly VC-backed,,Generating Revenue/Not Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed, Venture Capital",34,TAE,BIOV,2000,2025-04-06,,Israel,"Rehovot, Israel",,,,2022-06-15,,,,,Merger/Acquisition,,Corporate,2022-06-15,Failed/Cancelled,,,2006-03-07,,,IPO,,,,Public Investment,Completed,,6.88,-0.2621,-0.84,-2.45,11.23,4.17,6.59,-0.36,-0.81,21,7,2,,19,19,"Investigating or analysing materials by determining their chemical or physical properties, Optical elements, systems or apparatus",,,,,"The company was in talks to be acquired on an undisclosed date. Subsequently, the deal was cancelled. Previously, Marathon Investments sold shares of the company's (XTAE: BIOV) common stock in 2008.",Ybox Real Estate,
157589-65,BladeRanger (TAE: BLRN),BladeRanger Ltd,,Blade Ranger Ltd provides automated robots and drones for cleaning and inspecting solar panels and solar power plants.,Information Technology,Computer Hardware,Other Hardware,"Other Commercial Products, Other Hardware*","Artificial Intelligence & Machine Learning, Industrials, Robotics and Drones, SaaS","analytics platform, autonomous machine, business intelligence platform, cleaning solar panels, cleaning system, cleaning tools, drones technology, inspection system, intelligent robotics, robotics r&d, solar",Formerly VC-backed,6.78,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",7,TAE,BLRN,2015,2025-04-24,,Israel,"Ramat Gan, Israel",28.08,2020-12-10,IPO,2020-12-10,6.78,Actual,28.08,Estimated,IPO,,Public Investment,2020-12-10,Completed,,,2016-01-01,,,Seed Round,,,Seed Round,Venture Capital,Completed,,,,,,1.22,,,,,1,1,,1,,,Motor vehicles,,,2,"Cogniteam, Shikun & Binui","The company raised NIS 22.6 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of BLRN on December 10, 2020. After the offering, there was a total of 7,300,656 outstanding shares at NIS 12.81 per share, valuing the company at NIS 93.52 million.",Capital Nature,
98656-03,Blender (TAE: BLND),Blender P2P Israel Ltd.,"LendUp, Opyn (Specialized Finance), Lendable (London), Giromatch, Fundera, Fundbox, LendingCrowd, Floryn, Credibly, Prosper (Consumer Finance), Marketlend, Raisin, Lending Works, LendingTree, Circleback Lending, Wise (Financial Software), Chime, Nav, Spotcap NL, Zopa, auxmoney, Revolut, Kriya (Financial Services), Gedesco Services Spain, Lendvo, Rhino, Assetz Capital, Spotcap, Modo (Financial Software), Bondora, Novicap, Upstart Holdings, Orchard App, Oradian, Avant (Chicago), Pagaya",Blender Financial Technologies Ltd is engaged in the development and operation of credit and savings systems in Israel.,Information Technology,Software,Financial Software,"Financial Software*, Specialized Finance",FinTech,"credit system, financial trading platform, fintech lending, lending service platform, lending technology, p2p lending platform",Formerly VC-backed,69.46,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",70,TAE,BLND,2014,2025-03-21,,Israel,"Ramat Gan, Israel",,,,2021-02-16,24.56,Actual,,,IPO,,Public Investment,2021-02-16,Completed,,,,,,Accelerator/Incubator,,,,Other,Completed,,,,,,10.22,,,,,,,,,,,,,,10,"Asia Plus Securities, Aviv Group, Doron Aviv, Eti Langermann, Fattal, Giora Ofer, Lahav Fund, Orange Blossom Ventures, Psagot Investment House, V Ventures","The company raised ILS 80.5 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of BLND on February 16, 2021. After the offering, the valuation of the company at ILS 292.5 million.","Blumberg Capital, Elevator Fund",
234202-15,Blue Wave Water Capital (TAE: BLWV-M),Blue Wave Water Capital Ltd,,"Blue Wave Water Capital Ltd Formerly Pharmocann Global Ltd is an Israel-based company engaged in producing medical-related cannabis products which include oil, ointments, tablets, inhalers, rectal and vaginal suppositories, and pre-rolled cigarettes of various types of THC/CBD strains.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,"Cultivation, Pharmaceuticals*",Cannabis,"cannabis growers, cannabis plant cultivator, cannabis research, marijuana strain, medical cannabis",Corporation,0.69,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,20,TAE,BLWV-M,1997,2025-02-20,,Israel,"Ramat Yishai, Israel",66.55,2019-06-17,Reverse Merger,2019-06-17,0.69,Actual,,,PIPE,,,2019-06-17,Completed,,,2019-06-17,,,Reverse Merger,66.55,Estimated,,Corporate,Completed,,0.0,0.0,-0.83,-0.11,2.32,,1.07,-0.62,-0.67,,,,,,,,,,1,Medical Compression System,"The company (TAE: PMCN) received NIS 2.5 million of development capital from undisclosed investors on June 17, 2019, through a private placement.",,
165198-52,Bonus BioGroup (TAE: BONS),Bonus BioGroup Ltd.,,"Bonus BioGroup Ltd is an clinical-stage biotechnology company developing next-generation therapies for a variety of indications in the regenerative medicine field. Its products products, BonoFill and MesenCure.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,Biotechnology*,Life Sciences,"biotech, biotechnology services, bone graft, tissue",Corporation,1.37,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",58,TAE,BONS,1981,2025-02-12,,Israel,"Haifa, Israel",,,,2018-09-01,4.91,Actual,,,PIPE,,Corporate,2018-09-01,Completed,,,2002-08-15,,,IPO,,,,Public Investment,Completed,,0.0,0.0,-7.46,0.91,57.33,-0.67,38.54,-6.65,-7.4,3,1,2,,1,1,Methods or apparatus for sterilising materials or objects in general,5,,1,Southern Israel Bridging Fund,"The company (TAE:BONS) received ILS 18 million of development capital from Southern Israel Bridging Fund on September 1, 2018 through a private placement.",,
41493-97,Brainstorm Cell Therapeutics (NAS: BCLI),BrainStorm Cell Limited,"CuraSen, NeuroNascent, Vertex Pharmaceuticals, ProMIS Neurosciences, Lycera, Neurogene, Alterity Therapeutics, Coya Therapeutics, Quince Therapeutics, Neurona Therapeutics, Cognition Therapeutics, AB Science, Alzheon, Sangamo Therapeutics France, Abeona Therapeutics, Minerva Neurosciences, Anavex Life Sciences, Concert Pharmaceuticals, Calimmune, CalciMedica, CervoMed, Lysosomal Therapeutics, Denali Therapeutics, Cadent Therapeutics, Metabolic Solutions Development Company, Voyager Therapeutics, MedDay Pharmaceuticals, SAGE Therapeutics, Amarantus BioScience Holdings, AZTherapies, ViaCyte, TiGenix, Tiburio Therapeutics, Alector, Seneca Biopharma, Semma Therapeutics, Adverum Biotechnologies, Oncimmune, Flex Pharma, Regenxbio, Lysogene, Yumanity Therapeutics, Ablynx, Orgenesis, Verge Genomics, Galapagos (Biotechnology)","Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Drug Discovery, Other Healthcare Technology Systems","HealthTech, Life Sciences","biotech company, biotech platform, biotechnology, biotechnology company, medical needs, stem cell therapy developer",Corporation,37.1,Generating Revenue,Publicly Held,Publicly Listed,27,NAS,BCLI,2000,2025-04-26,,United States,"New York, NY",,,,2024-06-28,4.0,Actual,,,PIPE,,Corporate,2024-06-28,Completed,,,2000-09-22,,,University Spin-Out,,,,Corporate,Completed,,0.0,0.0,-11.62,0.53,6.36,,13.62,-11.31,-11.55,52,7,33,11,8,8,"Investigating or analysing materials by determining their chemical or physical properties, Microorganisms or enzymes, Preparations for medical, dental or toiletry purposes",6,,3,"Abbhi Investments, Indy MD Angels, Ramot at Tel Aviv University","The company (NAS: BCLI) received $4 million of development capital from undisclosed investors on June 28, 2024, through a private placement.",,
52103-71,Brainsway (TAE: BWAY),Brainsway Ltd.,"MagVenture, NeuroStar, Magstim, Pemco Inc -Manufacturer of Medical & Industrial Products., Flow Neuroscience","BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.",Healthcare,Healthcare Devices and Supplies,Other Devices and Supplies,Other Devices and Supplies*,"Life Sciences, Manufacturing","clinical trials, magnetic resonance, magnetic stimulation, medical device, medical technology, neurostimulation device, neurostimulation therapy",Corporation,50.26,Profitable,Publicly Held,"Private Equity, Publicly Listed",120,TAE,BWAY,2003,2025-04-26,,Israel,"Jerusalem, Israel",,,,2024-09-30,20.01,Estimated,,,PIPE,,Private Equity,2024-09-30,Completed,,,2007-01-04,7.86,Actual,IPO,,,,Public Investment,Completed,,41.02,0.2904,2.92,-63.72,171.63,30.58,131.72,2.88,1.11,124,22,108,10,6,6,"Electrotherapy, Healthcare informatics, Magnets",38,,5,"IBI Investment House, Phoenix Financial (Multi-line Insurance), Shavit Capital, Valor Equity Partners, Yelin Lapidot Investment House","The company (TAE: BWAY), received an estimated $20.01 million of development capital from Valor Equity Partners on September 30, 2024, through a private placement. The company will issue 2,103,745 American Depositary Shares (representing 4,207,490 ordinary shares), at a purchase price of $9.51 per ADS. The company intends to use the proceeds from the placement for strategic initiatives including expanding market awareness, enhancing data analysis capabilities, developing its R&D roadmap, evaluating other potential opportunities in the TMS industry, and expanding access to Deep TMS.",,
471575-71,Buff Technologies (TAE: BUFT),Buff Technologies Ltd,,"Buff Technologies Ltd is engaged in the business of gaming. The games offered by the company include Fortnite, WarZone, PUBG, and CSGO among others.",Information Technology,Software,Entertainment Software,Entertainment Software*,Gaming,"gaming, gaming software, rewards software, saas",Corporation,9.18,Generating Revenue,Publicly Held,Publicly Listed,,TAE,BUFT,2021,2025-03-03,,Israel,"Kfar Shmaryahu, Israel",,,,2021-08-11,9.18,Estimated,,,IPO,,Public Investment,2021-08-11,Completed,,,2021-08-11,9.18,Estimated,IPO,,,,Public Investment,Completed,,,,,,15.46,,,,,,,,,,,,,,,,"The company raised NIS 30 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of BUFT on August 11, 2021.",,
41466-43,Camtek (NAS: CAMT),Camtek Ltd.,"Jenoptik, Teledyne FLIR, Teledyne Technologies, Trimble, Topcon, OrboGraph","Camtek Ltd is engaged in the manufacturing of metrology and inspection equipment and software solutions for the semiconductor industry. Its systems inspect wafers for various semiconductor market segments, including Advanced Packaging, Heterogenous Integration (HI), Compound Semiconductors, Memory, and foundries among others. Geographically, it derives maximum revenue from China followed by Asia Pacific, Korea, United States, and Europe. The company's products and services include Surface Inspection, Bump Inspection and Metrology, and others.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,"Electronic Equipment and Instruments*, Other Commercial Products, Other Semiconductors","Advanced Manufacturing, Industrials, Manufacturing","3d printing, optical inspection, print circuit, printed circuit boards, printed circuit boards printing, touch panels",Corporation,118.44,Profitable,Publicly Held,"Private Equity, Publicly Listed",656,NAS,CAMT,1987,2025-04-26,,Israel,"Migdal Haemek, Israel",362.44,2019-06-19,Corporate,2019-06-19,74.3,Actual,362.44,Estimated,Corporate,Corporate,Corporate,2019-06-19,Completed,,,2000-07-28,39.2,Actual,IPO,153.03,Estimated,,Public Investment,Completed,,429.23,0.361,118.52,-180.96,3034.31,209.95,3464.13,118.16,107.49,257,126,130,20,107,107,"Image data processing or generation, in general, Investigating or analysing materials by determining their chemical or physical properties, Measuring length, thickness or similar linear dimensions, Printed circuits, Semiconductor devices not covered by class h10",,,4,"Chroma ATE, Migdal Insurance and Financial Holdings, Priortech Group, VI Group","A 20.5% stake in the company was acquired by Chroma Ate for $74.3 million on June 19, 2019. Chroma will acquire a total of 6,117,440 Camtek shares from Priortech Ltd., the controlling shareholder of Camtek, for $58.1 million, and a further 1,700,000 new shares to be issued by Camtek, for $16.2 million. The total cash consideration to be received by Camtek and Priortech amounts to $74.3 million, and is calculated based on a share-price of $9.50 per Camtek share, which reflects a 29% premium on Camtek's closing price as of February 8, 2019. After the closing of the transaction, Chroma will hold approximately 20.5%, while Priortech will hold approximately 24% of the total issued and outstanding shares of Camtek.",FIMI Opportunity Funds,
54535-60,Can-Fite BioPharma (TAE: CANF),Can-Fite BioPharma Ltd.,"Nurix Therapeutics, Tvardi Therapeutics, Mustang Bio, TScan Therapeutics, Gilead Sciences, Edgewise Therapeutics, Celgene, Gotham Therapeutics, Kite Pharma, Rexahn Pharmaceuticals, SAGE Therapeutics, Protalix Biotherapeutics, JW Therapeutics, BioInvent International, NexImmune, Polaris Group (California), Active Biotech, Relmada Therapeutics, VelosBio, Foghorn Therapeutics, Sorrento Therapeutics, Reata Pharmaceuticals, Attune Pharmaceuticals, IDEAYA Biosciences, Roivant Sciences, Abliva, Amgen, Proteostasis Therapeutics, ImmunityBio, C4 Therapeutics, Accuronix Therapeutics, Aura Biosciences, Cullgen, CrossBeta Biosciences, Pyxis Oncology, Forma Therapeutics, Arvinas, Altor BioScience, Corvus Pharmaceuticals, Kronos Bio, Bonti, Voyager Therapeutics, Centrexion Therapeutics, Enlivex Therapeutics, Monte Rosa Therapeutics, Juno Therapeutics, IFM Therapeutics, Plexium, Bristol-Myers Squibb, Allena Pharmaceuticals, Cantex Pharmaceuticals, Centrose, Istesso, Exo Therapeutics, Apexigen, Cedilla Therapeutics, 7 Hills Pharma, Dianomi Therapeutics, Jounce Therapeutics, Scorpion Therapeutics, Sova Pharmaceuticals, Acorda Therapeutics, Pfizer Pakistan, Immusoft, SiteOne Therapeutics, Progenra, InterAx, Relay Therapeutics, Urovant Sciences, Kymera Therapeutics, Neuropn Therapeutics, Bluebird Bio, OncBioMune, Phenex (Biotechnology), Beactica Therapeutics, Jacobio Pharmaceuticals, Vividion Therapeutics","Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Drug Discovery, Pharmaceuticals","Life Sciences, Oncology","biopharmaceutical, drug discovery, drug discovery unit, metabolic disease cure, pharmaceutical discovery, platform technology, therapeutic target",Formerly VC-backed,129.59,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",5,TAE,CANF,1994,2025-04-26,,Israel,"Petah Tikva, Israel",,,,2025-04-14,3.0,Estimated,,,PIPE,,Corporate,2025-04-14,Announced/In Progress,,,2000-10-01,2.0,Actual,Early Stage VC,,,,Venture Capital,Completed,,0.67,-0.0929,-7.88,-7.78,17.01,,4.84,-8.16,-8.17,239,49,103,21,115,115,"Investigating or analysing materials by determining their chemical or physical properties, Preparations for medical, dental or toiletry purposes, Specific therapeutic activity of chemical compounds or medicinal preparations, Sugars",21,,,,"The company (TAE: CANF) is in talks to receive $3 million of development capital from undisclosed investors through a private placement as of April 14, 2025. Previously, the company (TAE: CANF) received $7.5 million of development capital from undisclosed investors on January 11, 2023 through a private placement. The company intends to use the net proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes. The company is being actively tracked by PitchBook.","Armistice Capital, Ascend Technology Ventures, Ascend Venture Group, Azritech Ventures, Bassini Playfair Wright Israel Ventures, Biocom Venture Capital Fund, BioMedical Innovations Management, Giza Venture Capital, Mediseed, SCP Vitalife Partners, XT Venture Capital, Yozma",
416505-52,CannaboTech (TAE: CNTC),Cannabotech UK Ltd.,,"Cannabotech Ltd is engaged in the research and development of cannabis-based drugs. It is a biomedical company focused on the benefits of cannabinoids and medicinal mushrooms, applying the pure power of nature and science to health issues.",Healthcare,Pharmaceuticals and Biotechnology,Other Pharmaceuticals and Biotechnology,Other Pharmaceuticals and Biotechnology*,"Cannabis, Life Sciences, Oncology","cannabinoids-based medicine, cannabis medical, cannabis medicine, cannabis pharmaceuticals, cannabis research, cannabis therapy",Formerly Angel backed,23.93,Generating Revenue,Publicly Held,"Pre-venture, Publicly Listed",22,TAE,CNTC,2019,2025-01-19,,United Kingdom,"London, United Kingdom",33.47,2021-07-27,IPO,2021-07-27,7.0,Actual,33.47,Estimated,IPO,,Public Investment,2021-07-27,Completed,,,2019-01-01,0.2,Actual,Capitalization,,,,Individual,Completed,,,,,,0.45,,,,,4,2,,2,2,2,"Preparations for medical, dental or toiletry purposes",,,1,UK Innovation Agency,"The company raised ILS 23 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of CNTC on July 27, 2021. After the offering, the valuation of the company at ILS 110 million.",,
277682-77,Cannibble FoodTech (CNQ: PLCN),Cannibble FoodTech Ltd.,,"Cannibble Food Tech Ltd develops and manufactures powder food mix products that are enhanced variously with hemp seeds, hemp protein, CBD, and THC. The company has developed proprietary formulas for powder-based edibles that are subsequently enhanced with active cannabinoids, which it markets under the brand name ""The Pelicann"".",Consumer Products and Services (B2C),Consumer Non-Durables,Food Products,"Beverages, Food Products*, Specialty Retail","Cannabis, E-Commerce, FoodTech, LOHAS & Wellness, Manufacturing","bio-engineered food, cannabinoid product, cannabis product, cbd hemp oils, cbd infused edible, cbd product, functional food, recreational cannabis",Formerly Angel backed,1.14,Generating Revenue/Not Profitable,Publicly Held,"Pre-venture, Publicly Listed",,CNQ,PLCN,2018,2024-06-24,,Israel,"Rosh Haain, Israel",,,,2022-03-03,,,,,IPO,,Public Investment,2022-03-03,Completed,,,2018-12-01,0.66,Actual,Equity Crowdfunding,,,,Individual,Completed,,0.02,-0.832,0.18,0.01,0.38,-0.04,0.49,0.19,0.18,,,,,,,,,,,,"The company raised an undisclosed amount of funding in its initial public offering on the Canadian Securities Exchange under the ticker symbol of PLCN on March 2, 2022.",,
56345-05,Cell Source (PINX: CLCS),Cell Source Inc,"CytomX Therapeutics, Kite Pharma, Cellectis, Gilead Sciences, Demegen, Epigenomics, SQZ Biotech, Celgene, Genomic Health, Novartis, Allogene Overland Biopharm, Bluebird, Precision (Ohio)",Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.,Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,Biotechnology*,,"cell therapy, transplantation, treatment services",Corporation,,Generating Revenue,Publicly Held,"Private Equity, Publicly Listed",,PINX,CLCS,2012,2025-04-26,,United States,"New York, NY",,,,,,,,,PIPE,,Private Equity,,Completed,,,2014-07-01,,,Reverse Merger,,,,Corporate,Completed,,0.0,0.0,-5.23,9.76,11.95,,22.16,-4.23,-4.23,,,,,,,,,,2,"Aeon Group (Miami), Cell Source (Israel)",The company (OTCQB: CLCS) received an undisclosed amount of development capital from Aeon Funds through a private placement.,,
230087-53,Cellebrite DI (NAS: CLBT),Cellebrite DI Ltd.,"Nuix, Google Domains, OpenText, West Technology Group, Oxygen Forensics, PenLink (Nebraska), Logikcull, Magnet Forensics (Acquired), Firebase, Axon Enterprise, Axiom","Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze, and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.",Information Technology,IT Services,IT Consulting and Outsourcing,"IT Consulting and Outsourcing*, Other Commercial Services",,"digital analytics, digital analytics platform, digital analytics tool, digital forensic, digital forensic tools, digital intelligence, enterprise resource planning, erp, mobile data extraction, mobile forensic",Formerly PE-Backed,410.0,Generating Revenue/Not Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed",1167,NAS,CLBT,1999,2025-04-26,,United States,"Vienna, VA",2307.69,2021-08-30,PIPE,2024-09-18,,,,,PIPE,,Corporate,2024-09-18,Completed,,,2007-01-01,17.5,Actual,Merger/Acquisition,17.5,Estimated,,Corporate,Completed,,401.2,0.2341,-283.01,-436.25,4703.19,338.61,4374.5,-283.6,-294.2,9,3,4,3,2,2,"Measuring electric variables, Transmission of digital information",,Sun Electronics (Wireless Communications Equipment),4,"Axon Enterprise, Light Street Capital Management, Makena Capital Management, TWC Tech Holdings II","The company (NAS:CLBT) received an undisclosed amount of development capital on September 18, 2024 through a private placement.",Israel Growth Partners,
41951-44,Check Point Software Technologies (NAS: CHKP),Check Point Software Technologies Ltd.,"Zscaler, SentinelOne, Tenable, Aruba Networks, ManTech Cyber Solutions International, Webroot, CrowdStrike Holdings, Quick Heal Technologies, VMware, Arista Networks, IBM Deutschland, Mimecast, IKARUS Security Software, Avast Software, CommVault Systems, NetScout Systems, Cisco Systems, International Business Machines, Unisys, Palo Alto Networks, Optiv Security, Google Cloud Platform, Biprogy, Cadre Information Security, Nexgate, WithSecure, Citrix Systems, Samsung SDS Company, Qualys, Cloudflare, Hewlett Packard Enterprise, F-Secure, Pulse Secure, AirWatch, F5 (IT Consulting and Outsourcing), WatchGuard Technologies, SecureWorks, Akamai Technologies, Hitachi Vantara, Imperva, Sophos, Extreme Networks, CipherCloud, Barracuda Networks, Amazon Web Services, BullGuard, Kudelski Security, Forcepoint, Cryptzone Group, SonicWall, Trellix, Trend Micro, Aurora Systems Consulting","Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.",Information Technology,Software,Network Management Software,"IT Consulting and Outsourcing, Network Management Software*","Cybersecurity, TMT","cloud application workload protection, cyber security, data security, it services company, network security, secure networking, software technology, technology security, technology security service",Formerly VC-backed,,Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",6669,NAS,CHKP,1993,2025-04-26,,Israel,"Tel Aviv, Israel",3748.5,2016-01-01,Secondary Transaction - Private,2018-09-01,546.03,Actual,,,Share Repurchase,,Other,2018-09-01,Completed,,,1995-01-01,,,Early Stage VC,,,,Venture Capital,Completed,,2604.0,0.064,852.7,-1462.2,22383.52,2271.5,23327.45,969.1,881.9,270,116,199,10,61,61,"Computing arrangements based on specific computational models, Electric digital data processing, Transmission of digital information, Wireless communication networks",,,4,"Buckingham Capital Management, Compass Capital, Cypress Wealth Advisors, Knight Capital Group","The company (NASDAQ: CHKP) repurchased 325,000,000 shares worth ILS 2 billion in September 2018.","Blumberg Capital, BRM Group, Draper Fisher Jurvetson Management, Forgepoint Capital, U.S. Venture Partners, Venrock",
53768-53,Check-Cap (NAS: CHEK),Check-Cap Ltd.,"QuidelOrtho, Beckman Coulter, IntroMedic, Atmo Biosciences, Insightec, Abingdon Health, CapsoVision","Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.",Healthcare,Healthcare Devices and Supplies,Diagnostic Equipment,Diagnostic Equipment*,"Life Sciences, Oncology","cancer testing, cancer testing services, colorectal cancer prevention, colorectal cancer screening, multi disciplinary imaging, proprietary imaging software, screening test",Formerly VC-backed,90.88,Generating Revenue,Publicly Held,"Debt Financed, M&A, Private Equity, Publicly Listed, Venture Capital",85,NAS,CHEK,2005,2025-04-26,,Israel,"Isfiya, Israel",60.83,2015-02-19,IPO,2024-03-25,,,,,Merger/Acquisition,,Corporate,2024-03-25,Announced/In Progress,,,2011-03-24,9.77,Actual,Later Stage VC,47.47,Estimated,,Venture Capital,Completed,,0.0,0.0,-12.56,-17.82,4.62,,-13.0,-13.82,-13.87,121,28,89,6,26,26,"Compounds containing metals not covered by subclasses c01d or c01f, Devices for introducing media into, or onto, the body, Diagnosis, Image data processing or generation, in general, Measurement of nuclear or x-radiation",9,,1,Israel Innovation Authority,"The company reached a definitive agreement to be acquired by Nobul through a reverse merger, resulting in the combined entity trading on the NASDAQ and TSX Stock Exchange on March 25, 2024. The merger aims for Nobul to create a public company with a focus on AI-driven fintech and strategic acquisitions. Previously The company (NAS: CHEK) received $35 million of development capital from undisclosed investors on July 2, 2021, through a private placement. The company intends to use the net proceeds from this offering to advance the ongoing clinical development of C-Scan, including the company's U.S. pivotal study and for general corporate purposes. The company is being actively tracked by PitchBook.","Biomedix Incubator, BXR Group, Counter Point Ventures, Docor International Management, Emigrant Capital, EVX Ventures, Fosun Pharma, General Electric Ventures, Intempo Ventures, Jacobs Investments, MNS, MSQ Ventures, Pontifax Venture Capital, Symetryx Corporation, Yoav Kimchy","Keystone Dental, Nobul"
165996-01,Chemomab Therapeutics (NAS: CMMB),Chemomab Therapeutics Ltd.,,"Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*",Life Sciences,"antibody, biologics, biotech company, drug discovery, fibrosis treatment, immune system treatment, liver fibrosis, lung fibrosis",Formerly VC-backed,90.5,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",20,NAS,CMMB,2011,2025-04-26,,Israel,"Tel Aviv, Israel",49.71,2019-12-01,Later Stage VC,2024-07-30,10.0,Actual,,,PIPE,,Corporate,2024-07-30,Completed,,,2016-09-01,5.0,Actual,Early Stage VC,10.9,Actual,Series A,Venture Capital,Completed,,0.0,0.0,-13.94,-13.94,24.7,,15.09,-14.69,-14.74,26,4,19,7,,,"Peptides, Preparations for medical, dental or toiletry purposes",6,,5,"Anchiano Therapeutics, HBM Healthcare Investments, OrbiMed, Rivendell Investments, Sphera Biotech Master Fund LP","The company (NAS: CMMB) received $10 million of development capital from HBM Healthcare Investments, Sphera Master Fund LP and a few other existing investors on July 30, 2024, through a private placement. The company uses the net proceeds from the PIPE, together with the Company's existing cash and cash equivalents, to fund its development programs for CM-101 and for general corporate purposes and working capital. Previously, the company filed its second public offering on the Nasdaq stock exchange under the ticker symbol of CMMB on January 13, 2023. They intended to sell 10,909,091 ADS at the price of $1.65 per ADS. The expected offering was $18 million. Subsequently, the offering was withdrawn on June 2, 2023.","Altium Capital Management, Apeiron Investment Group, Cormorant Asset Management, Milestone Venture Capital, Peter Thiel, Presight Capital, RedStone Capital (Moscow), SBI Holdings, SBI JI Innovation Fund, Shavit Capital",
165198-88,CI Systems (Israel) (TAE: CISY),CI Systems (Israel) Ltd,,"CI Systems (Israel) Ltd develops, manufactures, sells and services sophisticated electro optical testing, measurement and simulation solutions. Its products include Blackbodies & Accessories, Laser Testers, and Boresight Systems, among others. It sales its products in Simi Valley, California and Migdal HaEmek, Israel. It also provides test benches for Electro-Optical systems.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,"Aerospace and Defense, Electronic Equipment and Instruments*, Other Semiconductors","Manufacturing, TMT","electronic cards, electro-optical precision test, infrared, laser tester, metrology solutions, optical test equipment, semiconductor process industry, temperature monitoring, test systems divisions",Corporation,,Profitable,Publicly Held,Publicly Listed,,TAE,CISY,1977,2025-04-13,,Israel,"Migdal Haemek, Israel",,,,1993-06-07,,,,,IPO,,Public Investment,1993-06-07,Completed,,,1993-06-07,,,IPO,,,,Public Investment,Completed,,33.6,-0.0868999999999999,0.34,-8.0,77.04,12.02,39.28,1.66,0.42,63,26,43,3,17,17,"Coating metallic material, Investigating or analysing materials by determining their chemical or physical properties, Measurement of intensity, velocity, spectral content, polarisation, phase or pulse characteristics of infrared, visible or ultraviolet light, Optical elements, systems or apparatus, Pictorial communication",,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of CISY on June 7, 1993.",,
60549-67,Cipia (TAE: CPIA),Cipia Vision Ltd.,"PointGrab, Bosch (Automotive), Mobileye, Seeing Machines, Smart Eye","Cipia Vision Ltd is a provider of in-cabin sensing solutions for the automotive industry. It offers driver monitoring systems (DMS), and occupancy monitoring systems (OMS) for cars and fleets. Its proprietary technology uses edge-based computer vision and artificial intelligence (AI) to create safer in-car experiences.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,"Automation/Workflow Software, Electronic Equipment and Instruments*, Electronics (B2C)","Artificial Intelligence & Machine Learning, Augmented Reality, Mobility Tech","computer vision company, drivers monitoring system, fleet connectivity, fleet management, gesture recognition, passenger experience, passenger safety, passenger safety & experience, passenger safety and experience, pupil dilation measurement, user awareness",Formerly VC-backed,77.39,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",77,TAE,CPIA,2006,2024-10-30,,Israel,"Herzliya, Israel",101.58,2021-11-24,IPO,2022-09-29,9.49,Actual,,,PIPE,,Corporate,2022-09-29,Completed,,,,,,Accelerator/Incubator,,,,Other,Completed,,,,,,13.58,,,,,3,3,,2,1,1,"Conjoint control of vehicle sub-units of different type or different function, Image or video recognition or understanding",,,1,Cartridge Holdings,"The company (TAE: CIPIA) received ILS 32.6 million of development capital from Mr. Alexandre Weinstein, Cartridge Holdings and Mr. Eli Talmor on September 29, 2022 through a private placement. The newly raised funds will be used to continue investment in research and development of Cipia's vehicle in-cabin sensing solutions, and to strengthen its marketing and sales activities with emphasis on the US, European, and Chinese markets. Previously, The company raised $22 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of CPIA on November 24, 2021. After the offering, the company was valued at $101.58 million.","Agate Medical Investments, Arie Capital, Ceva, Eli Talmor, GlenRock Israel, Intercapital Partners, Jebsen Capital, Jeremy Coller, Kuang-Chi, Mac Gp, Mitsui Global Investment, Mizrahi Tefahot Bank, Plug and Play Tech Center, Startup Autobahn, SUNP",
229198-87,Clearmind Medicine (NAS: CMND),Clearmind Medicines Inc.,MindMed (Pharmaceuticals and Biotechnology),"Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,"Biotechnology, Pharmaceuticals*",Life Sciences,"biotech, biotech drugs, biotech firm, biotechnology, depression, mental health issues, pharmaceutical biotechnology, pharmaceuticals innovation, psychedelic drugs",Corporation,15.98,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,6,NAS,CMND,2017,2025-04-26,,Canada,"Vancouver, Canada",,,,2024-01-16,2.4,Actual,,,PIPE,,Corporate,2024-01-16,Completed,,,2018-05-15,,,IPO,,,,Public Investment,Completed,,0.0,0.0,-4.96,-5.87,5.24,,-0.33,-4.89,-4.94,28,7,9,18,1,1,"Foods, foodstuffs or non-alcoholic beverages, not otherwise provided for, Preparations for medical, dental or toiletry purposes",1,,1,Xylo Technologies,"The company (NAS: CMND) received $2.4 million of development capital from undisclosed investors on January 16, 2024, through a private placement. The company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working capital.",,
41608-54,CNBX Pharmaceuticals (PINX: CNBX),CNBX Pharmaceuticals Inc.,"Cannabis Science, PharmaCyte Biotech, Avenir Wellness Solutions, Roche, Zynerba Pharmaceuticals, Skye Bioscience, Zogenix, Corbus Pharmaceuticals, MDxHealth, Genus Pharmaceuticals, Tetra Bio-Pharma, Exact Sciences, Eli Lilly and Company, Mundipharma Reasearch Gmbh & Co Kg, Vicore Pharma Holding, Cepheid, InMed Pharmaceuticals, Siemens Healthineers, Sequenom, GE HealthCare Technologies, Philips, Gen-Probe","CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Pharmaceuticals","Cannabis, Life Sciences, Oil & Gas, Oncology","biotech, biotechnology, biotechnology work, cancer treatment system, drug screening platform, drug screening platform technology",Corporation,10.5,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,2,PINX,CNBX,2004,2024-12-03,,United States,"Bethesda, MD",,,,2018-09-26,7.5,Actual,,,PIPE,,Corporate,2018-09-26,Completed,,,2014-04-25,,,Reverse Merger,,,,Corporate,Completed,,0.0,,-0.3,1.35,0.14,,1.55,-0.31,-0.31,,,,,,,,1,,2,"American Mining, D-Beta One EQ","The company (OTC: CNBX) received $7.5 million of development capital from undisclosed investors on September 26, 2018, through a private placement.",,
459405-64,Cognyte Software (NAS: CGNT),Cognyte Software Ltd.,"Exabeam, Rayzone Group, ThetaRay, Cellebrite DI",Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.,Information Technology,Software,Network Management Software,Network Management Software*,,"cyber intelligence, security analytics, security analytics platform, security analytics software, security investigation",Corporation,,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,2600,NAS,CGNT,2020,2025-04-26,,Israel,"Herzliya, Israel",,,,2021-02-01,,,,,IPO,Spin-Off,Public Investment,2021-02-01,Completed,,,2021-02-01,,,IPO,,,Spin-Off,Public Investment,Completed,,350.63,0.1188,-12.05,-77.19,697.98,246.92,620.26,6.91,-6.74,,,,,,,,,,,,"The company was spun out of Verint Systems through an initial public offering on the Nasdaq stock exchange under the ticker symbol of CGNT on February 1, 2021.",Verint Systems,
41484-70,Compugen (TAE: CGEN),"Compugen, Ltd.","Agenus, Merrimack Pharmaceuticals, Bolt Biotherapeutics, Jounce Therapeutics, Aduro Biotech, Dynavax Technologies, ImmunityBio, Metabomed, Adaptimmune Therapeutics, Inovio Pharmaceuticals, Ayala Pharmaceuticals, Pyxis Oncology, Immunocore Holdings, Vical, CureVac, AsherBio, Enlivex Therapeutics, NexImmune, ImmunoGen, Immune Design, GeoVax Labs, BioNTech, CytImmune Sciences, Arvinas, JW Therapeutics, Gamida Cell, OyaGen, Recursion Pharmaceuticals, MaveriX Oncology, Owkin, Scorpius Holdings, Aura Biosciences, VBI Vaccines (Drug Delivery), Novartis, Zynerba Pharmaceuticals, Immunovative Therapies","Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,Drug Discovery*,"Life Sciences, Oncology","cancer drug delivery, diagnostic discovery, diagnostic tools, drug discovery, drug discovery firm, drug discovery tech, drug discovery unit, pharmaceutical need",Formerly VC-backed,141.22,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",74,TAE,CGEN,1993,2025-04-26,,Israel,"Holon, Israel",497.78,2014-03-02,Public Investment 2nd Offering,2023-01-31,50.0,Actual,,,Public Investment 2nd Offering,,Public Investment,2023-01-31,Completed,,,,,,Later Stage VC,,,,Venture Capital,Completed,,27.86,-0.1672,-14.23,-100.34,133.01,19.93,27.73,-12.71,-13.2,495,136,145,68,282,282,"Enzymes, Investigating or analysing materials by determining their chemical or physical properties, Measuring or testing processes involving enzymes, nucleic acids or microorganisms, Peptides, Preparations for medical, dental or toiletry purposes",5,,2,"Bristol-Myers Squibb, U.S. Venture Partners","The company raised $50 million in its second public offering on the Nasdaq stock exchange under the ticker symbol of CGEN on January 31, 2023.","Ampal, Evergreen Venture Partners, Genesis Partners, Giza Venture Capital, Israel Seed Partners, XT Venture Capital",
58812-76,CompuLab (TAE: CLAB),CompuLab Ltd.,"Axiomtek Company, Aaeon Technology, American Portwell Technology, Trenton Systems, ADLINK Technology, SMART Wireless Computing, Diamond Point International (Europe), General Micro Systems, Stealth, Eurotech, Congatec, Portwell (Computers, Parts and Peripherals), Kontron, Aqeri Holding, Rtd Embedded Technologies, DYNICS, Lanner Electronics, Ezurio, Flytech Technology Company, Toradex, Contec Company, Avnet, TechNexion","C-LAB Ltd is a developer and manufacturer of embedded computer systems, fan-less Mini PCs and a line of fan-less computing systems, including workstations, entry-level servers, and PCs for industrial and homeland security. The company's products are divided into three categories, Computer on modules, cover a broad range of products such as medical devices, telecommunication systems, transportation systems, robotics, automotive devices, ATMs, military systems, aerospace and many others. Miniature fan-less PCs are stand-alone fan-less computers that are used in many industrial, personal and commercial applications. The company has developed an advanced Airtop line of computers which consists of professional workstations, entry level servers, and industrial and HLS PCs.",Information Technology,Computer Hardware,"Computers, Parts and Peripherals","Computers, Parts and Peripherals*","Manufacturing, TMT","aerospace technology, commercial application, embedded computer, medical devices, telecommunication system, transportation system",Formerly PE-Backed,12.5,Generating Revenue,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",78,TAE,CLAB,1992,2025-04-04,,Israel,"Yokneam Illit, Israel",85.5,2013-01-02,PE Growth/Expansion,2021-02-28,,,,,IPO,,Public Investment,2021-02-28,Completed,,,2013-01-02,12.5,Actual,PE Growth/Expansion,85.5,Actual,,Private Equity,Completed,,30.0,,,,29.8,,,,,6,3,2,,4,4,Electric digital data processing,,,,,"The company raised an undisclosed amount of funding in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of CLAB on February 28, 2021.",TechnoPlus Ventures,
98391-61,Continual,Continual Ltd,,"Continual Ltd is engaged in the development of AI platform for mobile connectivity. The solutions offered by the company include journey Analytics, Mobility Experience Optimization, Crowd & Commute Analytics, and Mobility Experience Platform.",Information Technology,Communications and Networking,Connectivity Products,"Automotive, Connectivity Products*","Artificial Intelligence & Machine Learning, Big Data, Industrials, Mobility Tech","connectivity solutions, crowd analytics, mobile network optimization, mobile operator, service assurance, smart mobility",Formerly VC-backed,8.51,Generating Revenue,Acquired/Merged,"Publicly Listed, Venture Capital",29,,,2013,2024-12-12,,Israel,"Caesarea, Israel",2.5,2023-04-30,Merger/Acquisition,2023-04-30,2.5,Actual,2.5,Estimated,Merger/Acquisition,,Corporate,2023-04-30,Completed,,,,,,Accelerator/Incubator,,,,Other,Completed,,,,,,1.71,,,,,3,3,,,3,3,,,Radcom,,,"The company was acquired by Radcom (NAS: RDCM) for $2.5 million on April 30, 2023. This acquisition will enrich RADCOM's analytics in location and mobility, thereby helping operators optimize the subscribers' journey while traveling and further enhancing its 5G analytics to ensure users enjoy the best customer experiences. The company is no longer actively tracked by PitchBook.","CEIIF, Ibex Investors, Khasm Labs, Microsoft for Startups, Momenta Ventures",
53524-81,CyberArk Software (NAS: CYBR),CyberArk Software Ltd,"Tenable, Rapid7, Check Point Software Technologies, Telos (Network Management Software), Cybera (Tennessee), CrowdStrike Holdings, Splunk, F5 (IT Consulting and Outsourcing), VMware, QSight IT, OneLogin, Ioactive, Onion ID, Qualys, Oracle, Cisco Systems, ANXeBusiness, Osirium, Citrix Systems, Excite Technology Services, BT Global Services, SSH Communications Security, CommVault Systems, Nutanix, CipherCloud, Network Box USA, Juniper Networks, Pulse Secure, Arcon, ForeScout Technologies, Keyfactor, Zscaler, Dell EMC, Gen Digital, Coalfire Systems, Trustwave, Secure Thingz, SailPoint Technologies, Security PS, Okta, Opswat, SecureWorks, Tuebora, Samsung SDS Company, NetApp (Systems and Information Management), Cyber Security, Box (IT Services), Secret Double Octopus, AirWatch, Forcepoint, Cryptzone Group, Xceedium, BalaBit, Delinea, SecurEnvoy, Leviathan Security Group, BeyondTrust Software (Acquired 2018), OverWatchID, Wallix Group, Conjur, HashiCorp, Thycotic, Lieberman Software","CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.",Information Technology,Software,Network Management Software,"IT Consulting and Outsourcing, Network Management Software*","Cybersecurity, TMT","access management, cybersecurity firm, cybersecurity system, data protection, identity & access management, identity and access management, information security, insider threat, sensitive information",Formerly VC-backed,235.16,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, M&A, Publicly Listed, Venture Capital",3793,NAS,CYBR,1999,2025-04-26,,United States,"Newton, MA",1930.88,2015-06-11,Public Investment 2nd Offering,,,,,,Secondary Transaction - Open Market,,,,Completed,,,2000-07-01,6.0,Actual,Early Stage VC,32.94,Actual,Series A,Venture Capital,Completed,,1000.74,0.331,-93.46,-808.67,17275.43,792.37,15481.57,-29.74,-71.72,427,182,335,32,60,60,"Electric digital data processing, Graphical data reading, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Transmission of digital information, Wireless communication networks",,,,,Ponte Partners sold a stake in the company (NAS:CYBR) for an undisclosed amount. The company will not receive any proceeds from the offering.,"Bloom8, Bregal Sagemount, Cabaret-ArbaOne, CrossContinentalVentures, Infinity Group, Islamic Development Bank, Israel Venture Partners, J.P. Morgan, Jerusalem Venture Partners, Koa Labs, Nomura Private Equity Capital, SCP Management (New York), SoftBank Capital, The Goldman Sachs Group, Vertex Ventures Israel",Check Point Software Technologies
153335-17,DiagnosTear,DiagnosTear Ltd.,,"DiagnosTear Technologies Inc is an ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. Its TeaRx technology is a diagnostic platform intended for rapid, Point-of-Care Testing (POCT) of ophthalmic pathologies through multi-parameter analysis of non-invasively collected tear fluid. The first CE-IVD and Israeli MoH-approved test based on the TeaRx platform is intended for diagnosis of Dry Eye Syndrome. This product is not FDA-cleared yet. Beyond DES, It is developing innovative tests based on the TeaRx platform for additional ophthalmic indications. Its pipeline includes TeaRx Red Eye; The first test of its kind for differential assessment of adenoviral conjunctivitis, Herpetic Keratitis and Allergic conjunctivitis.",Healthcare,Healthcare Devices and Supplies,Diagnostic Equipment,Diagnostic Equipment*,,"diagnostic kits, dry eye diagnostics, eye treatment, onsite diagnostics, single-use collecting device, standalone diagnostic tools",Formerly VC-backed,3.53,Generating Revenue,Privately Held (backing),"Publicly Listed, Venture Capital",7,,,2013,2025-04-07,,Israel,"Tel Aviv, Israel",,,,2023-06-12,3.53,Actual,,,PIPE,,Corporate,2023-06-12,Completed,,,2020-10-01,,,Later Stage VC,,,,Venture Capital,Completed,,0.0,0.0,-11.67,-1.66,10.6,,18.43,-11.51,-11.59,22,6,12,1,9,9,Investigating or analysing materials by determining their chemical or physical properties,,DiagnosTear Technologies,,,The company (CNQ:DTR) received $3.53 million of development capital from DiagnosTear Technologies on an undisclosed date through a private placement.,BioLight Life Sciences,
100184-14,Ecoppia (TAE: EEAM-M),Ecoppia Ltd.,,"EEAMI Ltd, Formerly Ecoppia Scientific Ltd offers cloud-based, connected platform and a suite of robotic solutions for smart management of solar plants. The company's robots clean solar panels globally every night, with no water, no electricity, and no human intervention. The robotic systems are cloud-based, utilizing information processing for an optimal and continuous solar electricity generation.",Information Technology,Computer Hardware,Other Hardware,Other Hardware*,"CleanTech, Climate Tech, TMT","clean technology, intermittent renewable energy, operation support management, operations and maintenance cloud, panel cleaners, panel cleaning, photovoltaic panels, solar panels, solar photovoltaic",Formerly PE-Backed,135.5,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",126,TAE,EEAM-M,2013,2025-01-24,,Israel,"Herzliya, Israel",300.0,2020-12-01,IPO,2020-12-01,82.5,Estimated,300.0,Estimated,IPO,,Public Investment,2020-12-01,Completed,,,,,,Early Stage VC,,,,Venture Capital,Completed,,1.04,-0.655799999999999,-16.68,-0.25,2.31,0.4,-43.08,-16.68,-16.92,,,,,,,,,,,,"The company raised $82.5 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of ECPA on December 1, 2020. After the offering, the company was valued at $300 million.","CIM Group, Gandyr Investments, GlenRock Israel, Harel Insurance Investments & Financial Services, Swarth Group",
40438-63,Elbit Systems (TAE: ESLT),Elbit Systems Ltd.,"Northrop Grumman, L3 Harris Technologies, Saab, Thales Group, BAE Systems, Airbus Group, Kratos Defense & Security Solutions, RTX, Safran Group, Triumph Group, Lockheed Martin, Cobham, Astronautics Corporation of America, Gulfstream Aerospace, Mercury Systems, Collins Aerospace, General Dynamics, Rafael Advanced Defense Systems, Rolls-Royce Holdings, General Dynamics United Kingdom, OHB, Airbus (France), Embraer, Meggitt, Panavia Aircraft Gesellschaft Mit Beschr‚àö¬ßnkter Haftung, Esterline Technologies, Ontic Engineering & Manufacturing, Tactical Air Support, Fokker Technologies, Raytheon, Leonardo (Italy), MDA, GE Aerospace, Duotech Services, Exelis, Blue Origin, Boeing, SpaceX, United Aircraft Corporation, Teledyne FLIR, Defence Equipment & Support (DE&S), Teledyne Technologies, Woodward, DynCorp International, Textron, MBDA Holdings, Diehl Stiftung, Pratt & Whitney, FreeFlight Systems, KBR","Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.",Business Products and Services (B2B),Commercial Products,Aerospace and Defense,Aerospace and Defense*,"Industrials, Manufacturing","communication system, homeland security, homeland security service, homeland security solutions, homeland security technology, military communications, technology company",Corporation,210.12,Profitable,Publicly Held,"M&A, Publicly Listed",19712,TAE,ESLT,1966,2025-04-26,,Israel,"Haifa, Israel",,,,2019-04-10,185.0,Actual,,,PIPE,,Corporate,2019-04-10,Completed,,,1996-11-28,,,IPO,,,,Corporate,Completed,,6827.87,0.1427999999999999,321.14,1103.63,16846.48,1641.82,13099.64,629.95,471.56,905,213,655,81,169,169,"Diagnosis, Electric digital data processing, Image data processing or generation, in general, Optical elements, systems or apparatus, Radio direction-finding",2,,,,"The company (TAE:ESLT) received $185 million of development capital from Israeli institutional investors on April 11, 2019 through a private placement.",,
60453-10,Eloxx Pharmaceuticals (PINX: ELOX),"Eloxx Pharmaceuticals, Inc.","Homology Medicines, CRISPR Therapeutics, Editas Medicine, Galectin Therapeutics, Dimension Therapeutics, Celtaxsys, Regenacy Pharmaceuticals, True North Therapeutics, Imara, EdiGene, MnPharm, Pliant Therapeutics, Arcus Biosciences, Renova Therapeutics, Morphic Therapeutic, Beam Therapeutics, Harmony Biosciences, Metabomed, Alector, Corvus Pharmaceuticals, Dicerna Pharmaceuticals, Aruvant, Intellia Therapeutics, Fulcrum Therapeutics, Biohaven, viDA Therapeutics, BiOrion, Kadmon Holdings, Voyager Therapeutics, GlycoMimetics, Lysogene, Immunocore Holdings, Sygnature Discovery, Egenesis, Alnylam Pharmaceuticals, Galecto, OrphAI Therapeutics, Akarna Therapeutics, Angion Biomedica, Synpromics, Denali Therapeutics, Lysosomal Therapeutics, Caribou Biosciences, Artizan Biosciences, Icosavax, MicroCures, Verge Genomics, Clovis Oncology, Gene Signal, Regenerx, Akebia Therapeutics, Aria Pharmaceuticals, Recursion Pharmaceuticals, Spark Therapeutics, X-37, Agilis Biotherapeutics, Xenetic Bioscience, Ultragenyx Pharmaceutical, Aura Biosciences, Priothera, Recombinetics, Sangamo Therapeutics, Tricida, Talaris Therapeutics, Protalix Biotherapeutics, Galapagos (Biotechnology), Mitochon Pharmaceuticals, Yumanity Therapeutics, Bluebird Bio, Horizon Discovery, ToolGen, CeGaT, Cellectis, Idorsia Pharmaceuticals, Passage Bio, Allogene Therapeutics, Calimmune, Batavia Biosciences, 4D Molecular Therapeutics, Phyton Biotech, uniQure, Owkin, Vanda Pharmaceuticals, BenevolentAI, Brammer Bio, Alvotech, Regenxbio, Supernus Pharmaceuticals, TRACON Pharmaceuticals, OMass Therapeutics, Lanthio Pharma, Perthera, Tesaro","Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Drug Discovery",Life Sciences,"biopharmaceutical therapy, biotechnology company, chemistry, cystic fibrosis, genetic disease, genetic therapy, pharmaceutical, small molecule",Formerly VC-backed,90.61,Generating Revenue,Publicly Held,"Debt Financed, Private Equity, Publicly Listed, Venture Capital",18,PINX,ELOX,2013,2025-04-26,,United States,"Watertown, MA",,,,2023-09-20,1.61,Actual,,,Public Investment 2nd Offering,,Public Investment,2023-09-20,Completed,,,2013-11-21,8.5,Actual,Early Stage VC,,,Series A,Venture Capital,Completed,,0.0,0.0,-20.48,0.98,0.01,,16.49,-18.6,-19.34,212,46,60,15,137,137,"Microorganisms or enzymes, Peptides, Preparations for medical, dental or toiletry purposes, Specific therapeutic activity of chemical compounds or medicinal preparations, Sugars",8,,,,"The company raised $1.60 million in its second public offering on the Nasdaq Stock Exchange under the ticker symbol of ELOX on September 20, 2023. A total of 305,590 shares were sold at $5.255 per share. Previously Sevion Therapeutics sold its stake in the company (NAS:ELOX) on an undisclosed date. The company will not receive any proceeds from the offering.","Catalyst Investments, China Everbright, DSC Investment, EQT Life Sciences, GF Securities, Korea Investment Partners, Medison Ventures, OPKO Health, Phillip Frost, Pontifax Venture Capital, Quark Venture, Roche Venture Fund, SBI JI Innovation Fund, Sevion Therapeutics",
268363-99,Else Nutrition Holdings (TSE: BABY),Else Nutrition Holdings Inc.,,"Else Nutrition Holdings Inc is an Israel-based food and nutrition company focused on developing clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. The company has developed a revolutionary, plant-based, non-soy alternative to dairy-based formula. The product line of the company includes Baby Snacks, Baby Feeding Accessories, Infant Formula, Toddler Nutrition Products, Children's Nutrition Products, Adult Nutrition Products, and other Complementary Food Products.",Consumer Products and Services (B2C),Consumer Non-Durables,Food Products,Food Products*,FoodTech,"alt-proteins, baby nutrition, infant nutrition, infant nutrition business, nutrition product, nutrition product retailer, plant-based nutrition product, plant-based protein",Corporation,56.54,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",32,TSE,BABY,2012,2025-04-26,,Israel,"Tel Aviv, Israel",,,,2025-02-06,0.35,Actual,,,PIPE,,Corporate,2025-02-06,Completed,,,2019-06-26,7.5,Actual,Reverse Merger,,,,Corporate,Completed,,6.55,-0.0513,-11.61,0.94,2.18,0.14,5.23,-11.43,-11.61,26,3,14,8,4,4,"Foods, foodstuffs or non-alcoholic beverages, not otherwise provided for",2,,3,"A-Labs, Canaccord Genuity, NewH2 Ventures","The company (TSE: BABY) received $350,752.74 of development capital from undisclosed investors on February 6, 2025, through a private placement. The company expects to use the proceeds from the offering to pay amounts owing to certain creditors of the company.",,
182082-43,Elsight (ASX: ELS),Elsight Ltd.,,"Elsight Ltd is engaged in the development and commercialization of Halo in the UAV market. Elsight's Halo provides BVLOS (Beyond the Visual Line of Sight) connectivity for drones, UAVs, and other unmanned/uncrewed systems on-air and on land. The company generates revenue from sale of physical goods, Data Usage, Service level agreements and other services, and Halo as a service.",Information Technology,Communications and Networking,Connectivity Products,"Business/Productivity Software, Connectivity Products*, Other Commercial Products, Security Services (B2B)","Industrials, Manufacturing","data recording, data transmission, mobile connectivity services, security solutions, surveillance, video capture",Formerly VC-backed,21.96,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",,ASX,ELS,2009,2025-03-02,,Israel,"Or Yehuda, Israel",47.07,2018-03-05,PIPE,2020-12-29,8.3,Actual,,,PIPE,,Corporate,2020-12-29,Completed,,,,,,Seed Round,,,Seed Round,Venture Capital,Completed,,,,,,49.97,,40.25,,,19,10,15,,4,4,"Equipment for fitting in or to aircraft, Propulsion of electrically-propelled vehicles, Systems for controlling or regulating non-electric variables, Transmission, Wireless communication networks",,,1,The Fineline Group,"The company (ASX: ELS) received $8.3 million of development capital from undisclosed investors on December 29, 2020, through a private placement. The net proceeds will be used to fund its growth through accelerating sales and marketing activities as well as offering further investment for ongoing product development.","Awz Ventures, Jade Ventures",
58791-52,Elspec Engineering (TAE: ELSPC),Elspec Ltd.,"Schneider Electric (Electrical Equipment), Fluke ( Electronic Equipment and Instruments), Eaton","Elspec Engineering Ltd is a provider of power quality solutions & services. It provides electrical power quality analyzers, real-time power factor correction systems, and energy saving solutions to the industrial, commercial, and utility industries. It has three research and development departments such as software and signal processing engineers, hardware analog, digital and power electricians.",Business Products and Services (B2B),Commercial Products,Electrical Equipment,"Electrical Equipment*, Industrial Supplies and Parts","Industrials, Manufacturing","electrical equipment, electrical equipment provider, electrical equipment supply, energy saving, industrial supplies, power quality, power quality analysis, power quality analyzers, power quality meter, power quality solution, power quality system, scada software",Corporation,,Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",147,TAE,ELSPC,1988,2024-01-19,,Israel,"Caesarea, Israel",,,,2013-12-01,4.27,Actual,,,Secondary Transaction - Private,,Corporate,2013-12-01,Completed,,,2004-05-01,,,IPO,,,,Public Investment,Completed,,27.03,0.1278,3.41,-2.42,33.42,14.01,36.6,4.56,3.38,15,4,8,1,6,6,Measuring electric variables,,,,,SKY Fund sold a stake in the company (TAE: ELSPC) to an undisclosed buyer for ILS 15.1 million in December 2013.,"SKY Fund, XT Venture Capital, Yozma",
51258-79,Eltek,Eltek Ltd.,"Somacis, QCG, Yokogawa Electric, ABB (Distributors/Wholesale), Computime Group","Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,Electronic Equipment and Instruments*,"Manufacturing, TMT","circuit board, circuit board design, circuit board layout, circuit board maker, circuitry, equipment items",Corporate Backed or Acquired,10.0,Profitable,Acquired/Merged (Operating Subsidiary),"M&A, Publicly Listed",329,,,1970,2025-04-26,Nistec,Israel,"Petah Tikva, Israel",,,,2024-02-12,10.0,Actual,,,Public Investment 2nd Offering,,Public Investment,2024-02-12,Completed,,,1997-01-22,7.5,Actual,IPO,,,,Public Investment,Completed,,46.53,-0.0036,4.22,-11.22,55.26,10.34,62.2,5.91,4.37,,,,,,,,,,,,"The company raised $10 million in its second public offering on the Nasdaq stock exchange under the ticker symbol of ELTK on February 12, 2024. A total of 625,000 shares were sold at $16 per share.",Nistec,
65712-70,EndyMed Medical,EndyMed Medical Ltd,"Solta Medical, Ulthera","Endymed Ltd is a medical technology company that designs, develops, and commercializes energy based aesthetic treatment systems for the professional markets. It offers energy based medical aesthetic treatment systems for professional and consumer markets. It provides solution for nonablative and fractional tightening and contouring treatments for the face, neck and body, acne scar and stretchmark treatment, cellulite reduction and RF Microneedling treatments.",Healthcare,Healthcare Devices and Supplies,Surgical Devices,"Other Consumer Durables, Other Devices and Supplies, Surgical Devices*",,"aesthetic treatment technology, medical equipment, radiofrequency technology",Corporation,7.0,Profitable,Publicly Held,"Private Equity, Publicly Listed",46,,,2007,2025-03-05,,United States,"New York, NY",,,,,,,,,PIPE,,Private Equity,,Completed,,,2012-01-01,,,Reverse Merger,,,,Corporate,Completed,,18.94,-0.17,-1.82,-5.83,,8.76,,-1.62,-2.08,23,8,17,,6,6,"Diagnosis, Electrotherapy",1,,3,"Applisonix, OHMK Medical Technology, Poalim Equity",The company (TAE:ENDY) received an undisclosed sum of development capital from Poalim Capital Markets through a private placement.,,
63248-77,Enlivex Therapeutics (NAS: ENLV),Enlivex Therapeutics Ltd.,"Sorrento Therapeutics, Pyxis Oncology, Inovio Pharmaceuticals, Dynavax Technologies, JW Therapeutics, Ayala Pharmaceuticals, Apexigen, Jounce Therapeutics, NexImmune, Kite Pharma, Immunocore Holdings, GeoVax Labs, Gamida Cell, Arvinas, Agenus, BioNTech, Immune Design, Aurora Biopharma, Adaptimmune Therapeutics, Amgen, Immunovative Therapies, Altor BioScience, Verge Genomics, IFM Therapeutics, Rakuten Medical, Corvus Pharmaceuticals, Vical, Aura Biosciences, Recursion Pharmaceuticals, Sygnature Discovery, OrphAI Therapeutics, Cedilla Therapeutics, Mustang Bio, Bluebird Bio, CytImmune Sciences, MediGene, Merrimack Pharmaceuticals, Zynerba Pharmaceuticals, Celgene, Gotham Therapeutics, Scorpius Holdings, NOVADIP, BenevolentAI, Immatics, Juno Therapeutics, Chemocentryx, OncBioMune","Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*","Life Sciences, Oncology","allogeneic drugs, autologous drugs, cancer oncology, cancer research, cytokines release syndrome, immune care, immunotherapy",Formerly PE-Backed,48.4,Generating Revenue,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",49,NAS,ENLV,2005,2025-04-26,,Israel,"Jerusalem, Israel",110.0,2018-04-23,Later Stage VC,2024-05-29,15.0,Actual,,,PIPE,,Corporate,2024-05-29,Completed,,,,,,Buyout/LBO,,,,Private Equity,Completed,,0.0,0.0,-15.01,-22.96,23.28,,1.99,-15.54,-16.08,47,14,29,7,11,11,"Microorganisms or enzymes, Peptides, Preparations for medical, dental or toiletry purposes, Specific therapeutic activity of chemical compounds or medicinal preparations",7,,1,Hadasit Bio-Holdings,"The company (NAS: ENLV) received $15 million of development capital from undisclosed investors on May 29, 2024 through a private placement. The Company intends to use the net proceeds for working capital and general corporate purposes.","BioBlast Pharma, Korea Investment Partners, Pontifax Venture Capital",
58706-20,Entera Bio (NAS: ENTX),EnteraBio Ltd.,,"Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.",Healthcare,Pharmaceuticals and Biotechnology,Drug Delivery,"Biotechnology, Drug Delivery*, Drug Discovery","HealthTech, Life Sciences, TMT","biomedical, delivery technology, drugs delivery, macromolecules therapeutics technology, oral drug delivery, pharmaceutical",Formerly VC-backed,70.4,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",20,NAS,ENTX,2009,2025-04-26,DNA Biomedical,Israel,"Jerusalem, Israel",91.43,2018-06-28,IPO,2023-12-22,6.6,Estimated,,,PIPE,,Corporate,2023-12-22,Completed,,,2010-06-02,,,Joint Venture,,,,Other,Completed,,0.18,,-9.54,-8.39,109.01,0.01,71.48,-9.54,-9.59,75,9,38,36,1,1,"Preparations for medical, dental or toiletry purposes",6,,2,"Capital Point, DNA Biomedical","The company (NAS: ENTX) received approximately $6.6 million of development capital from undisclosed investors on December 22, 2023 through a private placement. The company intends to use the net proceeds from the private placement for general working capital purposes.","Arie Belldegrun, Corundum Open Innovation, David Bonderman, Joshua Kazam, Oramed Pharmaceuticals, Pontifax Venture Capital, SDL Ventures, Ybox Real Estate",
58711-78,Epitomee Medical (TAE: EPIT),Epitomee Medical Ltd.,"Gelesis Holdings, Rani Therapeutics, Emisphere Technologies",Epitomee Medical Ltd is engaged in developing and commercializing ingestible therapeutic devices.,Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*, Therapeutic Devices","Life Sciences, LOHAS & Wellness","biologics delivery system, diabetes medication, ingestible capsules, obese care, obesity treatment, overweight treatment, weight loss capsules",Formerly VC-backed,230.61,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",41,TAE,EPIT,2005,2025-04-24,,Israel,"Caesarea, Israel",800.0,2021-12-15,IPO,2021-12-15,162.0,Actual,800.0,Actual,IPO,,Public Investment,2021-12-15,Completed,,,,1.0,Actual,Seed Round,,,Seed Round,Venture Capital,Completed,,0.0,,-1.46,-17.73,67.68,,49.69,-2.02,-2.47,56,8,42,14,,,"Devices for introducing media into, or onto, the body, Filters implantable into blood vessels, Preparations for medical, dental or toiletry purposes",5,,,,"The company raised $51 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of EPIT on December 15, 2021. After the offering, the company was valued at $251 million.","7 Health Ventures, Agate Medical Investments, Barak Capital, Consensus Business Group, Gcb Services, Leumi Partners, Mauro Wjuniski, XT Venture Capital",
101731-42,Erika Carmel (TAE: BCUR),Erika Carmel Ltd,,"Erika B-Cure Laser Ltd is engaged in the development and production of laser devices for the treatment of pain and wounds. Its devices provide treatment for Knee Pain, Lower Back Pain, Neck Pain, Shoulder Pain, Finger Joint pain, and Burns.",Healthcare,Healthcare Devices and Supplies,Other Devices and Supplies,Other Devices and Supplies*,,,Corporation,,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,40,TAE,BCUR,2009,2023-07-04,,Israel,"Haifa, Israel",,,,2021-08-01,,,,,IPO,,Public Investment,2021-08-01,Completed,,,2021-08-01,,,IPO,,,,Public Investment,Completed,,8.73,-0.1324,-2.62,-1.07,5.4,6.63,6.98,-1.96,-2.51,,,,,,,,6,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of ERKA on August 1, 2021.",,
56627-29,Ethernity Networks (LON: ENET),Ethernity Networks Ltd.,,"Ethernity Networks Ltd technology solutions provider that develops and delivers data processing technology and solutions used in high-end Carrier Ethernet applications across the telecom, mobile, security, and data center markets. The company's only operating segment is the development and delivery of high-end network processing technology. Geographically, it derives a majority of its revenue from the United States and also has a presence in Asia, Europe, Israel, and the United States. Its product categories include ENET Network Appliances, PON Devices ACE-NIC SmartNICs, ENET Flow Processors, and FPGA Boards.",Information Technology,Software,Business/Productivity Software,"Application Specific Semiconductors, Business/Productivity Software*, Other Hardware","Mobile, TMT","data process technology, data processing, integrated circuit design, network virtualization, networking equipment, telecommunication software",Formerly VC-backed,32.58,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",,LON,ENET,2003,2025-04-26,,Israel,"Airport City, Israel",58.23,2017-06-29,IPO,2024-05-17,1.0,Actual,,,PIPE,,Corporate,2024-05-17,Completed,,,2013-12-01,,,Early Stage VC,,,,Venture Capital,Completed,,3.78,0.2861,-6.36,-0.79,0.12,2.34,4.3,-4.67,-6.08,11,7,10,1,,,"Electric digital data processing, Transmission of digital information, Wireless communication networks",,,3,"Bergen Asset Management, New Technology Capital Group, Pix Vine Capital","The company (LON: ENET) received GBP 800,000 of development capital from New Technology Capital Group on May 17, 2024, through a private placement.","Alice Ventures, Cipio Partners",
58754-26,Evogene (Drug Discovery) (TAE: EVGN),Evogene Ltd,"Novonesis, Cibus, Caribou Biosciences, Chr. Hansen, Precision BioSciences, Novartis, AgBiome, Genuity Science, Bayer, BioConsortia","Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.",Healthcare,Pharmaceuticals and Biotechnology,Discovery Tools (Healthcare),Discovery Tools (Healthcare)*,"AgTech, Life Sciences, TMT","ag biotech, agriculture technology, alt-proteins, biology, biology company, computational biology, computational biology services, life science products, plant biotech, plant biotechnology, plant genomics, plant-based protein",Formerly VC-backed,129.94,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",143,TAE,EVGN,1999,2025-04-26,,Israel,"Rehovot, Israel",355.03,2013-11-25,Public Investment 2nd Offering,2024-08-26,0.86,Actual,,,Public Investment 2nd Offering,,Public Investment,2024-08-26,Completed,,,2002-01-01,0.9,Actual,Early Stage VC,,,,Venture Capital,Completed,,8.51,0.509,-16.48,-2.44,7.35,5.83,20.6,-16.43,-18.94,728,65,411,44,273,273,"Image data processing or generation, in general, Investigating or analysing materials by determining their chemical or physical properties, Microorganisms or enzymes, Peptides",,,,,"01/21/25 Shreya Pednekar: Industry Group Changed by the Industry Group Team. Please do not Change/Remove these codes until 8 months after this date.Added/Verified Discovery Tools (Healthcare) as PIG /// The company raised $861,250 in its second public offering on the Tel Aviv Stock Exchange under the ticker symbol of EVGN on August 26, 2024. A total of 265,000 shares were sold at $3.25 per share.","AAF Group, Alpha Capital Anstalt, Altium Capital Management, ARK Investment Management, Compugen, CVI Investments, GlenRock Israel, Hunza Ventures, Monsanto, SilverArc Capital Management",
11905-75,Evoke (LON: EVOK),Evoke plc,PartyPoker,"Evoke PLC is an online betting and gaming company. The Group owns and operates internationally brands including William Hill, William Hill Vegas, 888casino, 888sport, 888poker, and Mr Green.",Information Technology,Software,Entertainment Software,Entertainment Software*,Gaming,"entertainment service, mobile gaming, online casino, online gaming, online gaming content, online gaming space",Corporation,1462.24,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed",10622,LON,EVOK,1997,2025-04-26,,Gibraltar,"Gibraltar, Gibraltar",1119.64,2022-04-07,PIPE,2024-05-02,562.87,,,,Debt Refinancing,Bank Debt,Debt,2024-05-02,Completed,562.87,"Bonds - 500.33M¬†$ (Senior, Secured; Equity Clawback; Fixed); Revolving Credit - 62.54M¬†$ (Syndicated; Floating)",2005-09-29,267.22,Actual,IPO,1067.3,Estimated,,Public Investment,Completed,,2241.77,0.0255,-245.32,1966.62,285.43,1470.15,2280.74,290.43,-4.47,,,,,,,,,,,,"The company completed a debt refinancing round on April 30, 2024.",,
165022-66,Fibrolan,Fibrolan Ltd,,Provider of fiber-optic broadband systems. The company provides fiber optic internet broadband services to its customers in Israel and internationally.,Information Technology,Communications and Networking,Connectivity Products,"Connectivity Products*, Fiberoptic Equipment",TMT,"fiber optic broadband, fiber optic internet",Corporation,,,Privately Held (no backing),Publicly Listed,,,,1996,2022-09-13,,Israel,"Yokneam, Israel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
277145-29,Fire & Gas Detection Technologies (TAE: FGAS),"Fire & Gas Detection Technologies, Inc.",,Fire & Gas Detection Technologies Ltd is engaged in the business of providing flame detection systems to the Oil & Gas industry.,Information Technology,Computer Hardware,Electronic Equipment and Instruments,Electronic Equipment and Instruments*,Manufacturing,"flame and gas detector, flame detection product, flame detection system, gas detector product",Corporation,,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,57,TAE,FGAS,2017,2024-11-06,,United States,"Brea, CA",,,,2020-09-08,,,,,IPO,,Public Investment,2020-09-08,Completed,,,2020-09-08,,,IPO,,,,Public Investment,Completed,,10.32,0.1512,-4.51,4.99,64.32,3.93,71.54,-3.53,-4.09,,,,,,,,,,,,"The company raised its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of FGAS on September 8, 2020. A total of 26,970,400 shares were sold.",,
53301-52,Fiverr International (NYS: FVRR),Fiverr International Ltd.,"Crowdspring, ShoCase, DesignCrowd, oDesk, Done (Social/Platform Software), Freelancer, Get (Business/Productivity Software), Yext, Cloudwords, Workana, Contently, Field Agent, Canva, Gigwalk, 99designs, Upwork Global, Guru (Philadelphia), GoodBox, Reedsy","Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Wiring and Translation, and Video and Animation among others.",Information Technology,Software,Social/Platform Software,"Media and Information Services (B2B), Social/Platform Software*",HR Tech,"customer base, freelancers search, online marketplace service, payment collection, web portal",Formerly VC-backed,340.53,Profitable,Publicly Held,"Publicly Listed, Venture Capital",762,NYS,FVRR,2010,2025-04-26,,Israel,"Tel Aviv, Israel",650.9,2019-06-13,IPO,2020-05-29,120.0,Actual,,,Public Investment 2nd Offering,,Public Investment,2020-05-29,Completed,,,2011-01-01,5.0,Actual,Early Stage VC,,,Series A,Venture Capital,Completed,,391.48,0.0833,18.25,-104.05,966.68,320.92,1083.02,-6.34,-16.82,149,33,67,,82,82,"Electric digital data processing, Electrophonic musical instruments, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Pictorial communication, Transmission of digital information",,,,,"The company raised $120 million in its second public offering on the New York stock exchange under the ticker symbol of FVRR on May 29, 2020. A total of 2,000,000 shares were sold at $60 per share. The underwriters were granted an option to purchase up to an additional 300,000 shares from the company to cover over-allotments, if any.","Accel, Bessemer Venture Partners, Cerca Partners, Columbus Nova Technology Partners, GHC Capital, Guy Gamzu, ION Asset Management, Kadima Group, Lightbank (Service Provider), Qumra Capital, Square Peg Capital, TriplePoint Capital, Union Tech Ventures",
162195-31,Flying Spark (TAE: FLYS),Flying Spark Ltd,,"Flying Spark Ltd is engaged in producing protein powder that is extremely rich in iron, calcium, magnesium, and dietary fibers, and is an excellent source of amino acids. Its white color and mild taste and aroma enable easy incorporation of the protein into a variety of food and feed products.",Consumer Products and Services (B2C),Consumer Non-Durables,Food Products,"Biotechnology, Food Products*","AgTech, Climate Tech, LOHAS & Wellness, Supply Chain Tech","animal ag, animal agriculture, healthy protein, insect-based food, insects farming, protein food, protein-rich meals, raw food",Formerly VC-backed,9.71,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",7,TAE,FLYS,2015,2023-11-07,,Israel,"Ashdod, Israel",27.67,2021-06-23,IPO,2021-06-23,7.69,Estimated,27.67,Estimated,IPO,,Public Investment,2021-06-23,Completed,,,,0.5,Actual,Early Stage VC,,,,Venture Capital,Completed,,,,,,,,,,,32,6,15,1,16,16,"Electric digital data processing, Fodder, Preservation of foods, foodstuffs or non-alcoholic beverages, Transmission of digital information",,,7,"Crimson Seed Capital, Horizon 2020, Ikea Bootcamp, Intempo Ventures, MassChallenge, Thai Union Group, The Kitchen FoodTech Hub","The company raised ILS 25 million in its initial public offering on the Tel Aviv stock exchange under the ticker symbol of FLYS on June 23, 2021. After the offering, the company was valued at ILS 90 million.",,
61959-97,Freightos (NAS: CRGO),Freightos Limited,"Cogoport, Cargo.one, Freightview, GoComet, Saloodo!, GlobalTranz Enterprises, Transfix, Shippabo, Cargomatic, Beacon (London), Flexe, Loadsmart, BigCommerce, Flock Freight, Riege Software, Air Freight Bazaar, project44, Magaya, Dakosy, Traffic Tech, Uber Freight, WiseTech Global, Zencargo, TraceLink, Portrix Logistics Software, Expeditors International of Washington, Kerry Logistics Network, Shipa, Con-linq, Kuehne + Nagel, SeaRates, K‚àö¬∫hne + Nagel ∆í√•R, FourKites, InstaFreight (Logistics), CargoSprint, Pilot - A Maersk Company, SEKO Logistics, AIT Worldwide Logistics, Flexport, Controlpay, MercuryGate International, Sennder, Convoy (Road), Aeronet Worldwide, Cargonexx, e-CARGOWARE, BNSF Logistics, GT Nexus","Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters. forwarders, and dozens of airlines and ocean carriers. WebCargo by Freightos is a freight platform connecting carriers and forwarders in particular an air cargo eBooking platform. Freightos.com is a digital international freight marketplace for importers and exporters for instant pricing, booking, and shipment management. The company operates in two segments-Platform segment and Solutions segment. Geographically, the company operates in Europe, Hong Kong, United States which is majority revenue generator and others.",Business Products and Services (B2B),Commercial Services,Logistics,"Business/Productivity Software, Logistics*, Media and Information Services (B2B)","Mobility Tech, Supply Chain Tech","freight marketplace, logistics unit, online shipment management, quotation system, shipping company, supply chain management, supply chain tech",Formerly VC-backed,104.95,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",378,NAS,CRGO,2012,2025-04-26,,Israel,"Jerusalem, Israel",500.0,2023-01-26,Reverse Merger,2023-01-26,435.0,Actual,500.0,Actual,Reverse Merger,,Corporate,2023-01-26,Completed,,,2012-11-13,0.55,Actual,Early Stage VC,,,Series A,Venture Capital,Completed,,23.79,0.1728,-22.49,-36.32,120.35,15.5,110.45,-20.83,-23.91,2,2,1,,1,1,,,,4,"Composite Analysis Group, Gesher I Acquisition, MandG Investment Managers, Qatar Airways Group","The company acquired Gesher I Acquisition through a reverse merger, resulting in the combined entity trading on the NASDAQ under the ticker symbol CRGO on January 26, 2023.","Aleph (Israel), Annox Capital, Chaim Meir Tessler, Climate First, Cukierman & Co. Investment House, General Electric Ventures, Gold Lion Holdings, Google for Startups, High House Investment, Master (HK) Toys, MoreVC, MSR Capital, Noah Pickholtz, OurCrowd, Sadara Ventures, Saints Capital, Singapore Exchange, Wolfpack Ventures",
51014-17,Fuel Doctor Holdings (PINX: CHEV),,,"Charging Robotics Inc is engaged in the development, production and installation of wireless charging systems for various applications. Its products includes Handicap EV charging, Solutions for automatic car parks and Energy Storing Robots.",Business Products and Services (B2B),Commercial Services,Consulting Services (B2B),"Consulting Services (B2B)*, Environmental Services (B2B)","CleanTech, Industrials, TMT","recycling, recycling service provider",Corporation,,Generating Revenue,Publicly Held,Publicly Listed,2,PINX,CHEV,,2025-04-24,,United States,"Calabasas, CA",,,,2011-08-24,,,,,Reverse Merger,,Corporate,2011-08-24,Completed,,,2011-08-24,,,Reverse Merger,,,,Corporate,Completed,,0.0,0.0,-0.84,0.24,287.84,,2.42,-0.81,-0.81,,,,,,,,,,1,Silverhill Management Services,"The company acquired Silverhill Management Services through a reverse merger, resulting in the combined entity trading on the PINX Stock Exchange under the ticker symbol FDOC on August 24, 2011.",,
180961-84,G Medical Innovations Holdings (PINX: GMVDF),G Medical Innovations Holdings Ltd.,"Preventice Solutions, Merge Healthcare, BioTelemetry, iRhythm Technologies, Omnicomm Systems, ArisGlobal, CardioSecur, Current Health","G Medical Innovations Holdings Ltd is a mobile health (mHealth), telemedicine solutions, and monitoring service platforms. It develops and markets clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for e-health projects. The company offers a suite of both consumer and clinical grade products and platforms which are positioned to reduce inefficiencies in healthcare delivery, improve access, reduce costs, increase the quality of care, and make healthcare more personalized and precise. Its operating segment includes Products, Patient Services, and Covid-19 testing. The company generates maximum revenue from the Patient Services segment.",Healthcare,Healthcare Devices and Supplies,Monitoring Equipment,"Decision/Risk Analysis, Monitoring Equipment*","HealthTech, TMT","electronic health technology, health technology, healthcare mobile monitoring, mobile health app, mobile health data, mobile health product",Corporation,35.85,Generating Revenue,Publicly Held,"M&A, Publicly Listed",74,PINX,GMVDF,2014,2025-04-26,,Israel,"Rehovot, Israel",51.5,2021-06-28,IPO,2024-07-22,9.0,Estimated,,,Public Investment 2nd Offering,,Public Investment,2024-07-22,Failed/Cancelled,,,2021-06-28,11.48,Actual,IPO,51.5,Estimated,,Public Investment,Completed,,4.42,-0.1091,-24.63,1.8,0.01,0.78,6.9,-14.64,-15.86,24,8,10,1,13,13,"Diagnosis, Electrotherapy",3,,,,"The company filed for a second public offering on the Nasdaq stock exchange under the ticker symbol of GMVD on July 27, 2023. They intend to sell 26,471,000 shares. The expected offering amount was $9 million. Subsequently, the offering was withdrawn on July 22, 2024.",,
61888-06,Galmed Pharmaceuticals (NAS: GLMD),Galmed Pharmaceuticals Ltd,"Pfizer Pakistan, Celgene, GlaxoSmithKline Consumer Nigeria, Pfizer Manufacturing Austria, Vicore Pharma Holding, Gilead Sciences, G1 Therapeutics, Avalyn Pharma, Eli Lilly and Company, Loxo Oncology, Ability Pharma, Genentech, Ona Therapeutics","Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,Pharmaceuticals*,,"pharmaceutical, proprietary, proprietary drug, proprietary drug delivery, proprietary drug delivery system, proprietary drug design",Corporation,38.78,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,8,NAS,GLMD,2000,2025-04-26,,Israel,"Tel Aviv, Israel",144.11,2014-03-13,IPO,2023-07-18,0.48,Actual,,,Public Investment 2nd Offering,,Public Investment,2023-07-18,Completed,,,2014-03-13,38.3,Actual,IPO,144.11,Estimated,,Public Investment,Completed,,0.0,0.0,-7.52,-15.33,3.55,,-11.85,-7.94,-8.02,,,,,,,,12,,,,"The company raised $475,000 in its secondary public offering on the Nasdaq stock exchange under the ticker symbol of GLMD on July 18, 2023. A total of 380,000 shares were sold at $1.25 per share.",,
108274-78,Gan Shmuel Foods (TAE: GSFI),Gan Shmuel Foods Ltd,,"Gan Shmuel Foods Ltd is an Israel based company, engages in the manufacture and sale of citrus fruits for the beverage and food industry. Its products include natural juices, concentrated citrus juices, crystal clear concentrated juices, cloudy citrus concentrates, comminuted citrus juices, citrus bases, pineapple and tropical fruit blends, and tomato products. The company is also involved in providing fruit and vegetable solutions.",Consumer Products and Services (B2C),Consumer Non-Durables,Beverages,Beverages*,Manufacturing,"beverages production, beverages products, food product, fruit products, juice processing, tomato product",Corporate Backed or Acquired,,Profitable,Publicly Held,"M&A, Publicly Listed",273,TAE,GSFI,1941,2025-04-06,,Israel,"Hefer, Israel",255.16,2015-02-16,Merger/Acquisition,2015-02-16,127.58,Actual,255.16,Estimated,Merger/Acquisition,,Corporate,2015-02-16,Failed/Cancelled,,,1993-01-01,,,IPO,,,,Public Investment,Completed,,308.29,0.192,42.47,7.87,119.53,97.06,181.8,59.31,51.18,13,3,7,2,4,4,"Foods, foodstuffs or non-alcoholic beverages, not otherwise provided for, Preparations for medical, dental or toiletry purposes",2,,,,"The company (TAE: GSFI) was in talks to be acquired by Frutarom Industries (TASE: FRUT) for NIS 500 million on February 16, 2015. Subsequently the deal was cancelled. Previously, the company completed an initial public offering on the TASE under the ticker symbol of GSFI in 1993.",,NovaTaste Austria
58660-48,Gauzy (NAS: GAUZ),Gauzy Ltd,,"Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.",Business Products and Services (B2B),Commercial Products,Electrical Equipment,"Electrical Equipment*, Security Services (B2B)","Manufacturing, Nanotechnology","adas manufacturer, adas system, automotive application, glass technology, liquid crystal technology, materials science, smart glasses, switchable glass",Formerly PE-Backed,218.5,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed, Venture Capital",636,NAS,GAUZ,2009,2025-04-26,,Israel,"Tel Aviv, Israel",323.92,2024-06-07,IPO,2024-06-07,75.0,Actual,323.92,Estimated,IPO,,Public Investment,2024-06-07,Completed,,,2012-01-01,1.0,Actual,Seed Round,4.13,Actual,Seed Round,Venture Capital,Completed,,103.53,0.3276,-53.18,42.76,192.07,29.74,223.16,-34.92,-41.6,83,25,69,7,7,7,"Coating compositions, Devices for introducing media into, or onto, the body, Layered products, Materials for miscellaneous applications, not provided for elsewhere, Optical devices or arrangements for the control of light by modification of the optical properties of the media of the elements involved therein",,,3,"Avery Dennison, Hamilton Global Opportunities, OTV","The company raised $75 million in its initial public offering on the Nasdaq stock exchange under the ticker symbol of GAUZ on June 7, 2024. A total of 4,411,765 shares were sold at $17 per share. After the offering, there was a total of 19,054,409 outstanding shares at $17 per share, valuing the company at $323.93 million. The underwriters were granted an option to purchase up to an additional 661,765 shares from the company to cover over-allotments, if any.","3A, BlueRed Partners, Cerity Partners Ventures, D2 Digital Ventures, Davidson Technology Growth Debt, Eli Dahan, Eran Litvak, FirstTracks Ventures, Hyundai CRADLE, Ibex Investors, Klirmark Capital, Orion Infrastructure Capital, Plug and Play Tech Center, Schechter Wealth, Sollange, Startup Autobahn, TB Innovations, Waarde Capital, Walleye Capital, Zer01ne",
233266-51,Gefen Technologies,Gefen Technologies Ltd.,,"Gefen International A.I Ltd is a digital distribution platform for the agent-based business sector that transforms agent-based networks into digital sales fleets, based on Software-as-a-Service or transaction models. The company is engaged in two business segments which include the Agent solution segment, and Licensing fee segment. The majority of revenue is generated from the Agent solution segment which derives revenue from insurance commissions. The license fees segment generates its revenues from license use by customers.",Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Financial Software, Other Financial Services, Other Insurance","FinTech, InsurTech, SaaS","automated prospecting, crm, customer relationship management, digital sales, digital sales site, digital tools, digital transformation, digital transformations, insurtech firm, marketing analytics, saas portal",Formerly VC-backed,39.21,Generating Revenue/Not Profitable,Privately Held (backing),"Debt Financed, Publicly Listed, Venture Capital",15,,,2014,2024-06-26,,Israel,"Tel Aviv, Israel",95.76,2021-07-21,IPO,2021-07-21,18.71,Actual,95.76,Estimated,IPO,,Public Investment,2021-07-21,Completed,,,2018-05-01,,,Accelerator/Incubator,,,,Other,Completed,,,,,,0.34,,2.14,,,2,1,2,,,,Domestic- or space-heating systems,,,,,"The company raised AUD 25 million in its initial public offering on the Australian Securities Exchange Limited under the ticker symbol of GFN on July 21, 2021. A total of 25,000,000 shares were sold at AUD 1 per share.","Ellerston Capital, Jade Ventures, Perennial Partners (Funds and Trusts), Plug and Play Tech Center, Regal Partners, Tax & Legal Tech Springboard",
178989-49,GenCell (Israel) (TAE: GNCL),GenCell Ltd.,"Green NH3, Starfire Energy","Gencell Ltd is engaged in the business of distributing power supply and power backup solutions based on fuel cells. The products are used in the telecom sector, the private sector, healthcare sector, and the industrial sector.",Energy,Energy Equipment,Alternative Energy Equipment,Alternative Energy Equipment*,"CleanTech, Climate Tech, LOHAS & Wellness, Manufacturing","alternative energy asset, analytics and grid management, climate tech company, electrochemical generator, fuel cell technology, grid infrastructure, hydrogen power, power backup platform",Formerly VC-backed,117.64,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",140,TAE,GNCL,2011,2025-01-02,,Israel,"Petah Tikva, Israel",360.12,2022-01-18,PIPE,2022-01-18,36.01,Estimated,360.12,Estimated,PIPE,,Corporate,2022-01-18,Completed,,,2017-06-01,,,Later Stage VC,,,,Venture Capital,Completed,,9.55,0.9632,-19.43,-9.27,8.26,-0.95,17.6,-19.77,-21.35,50,20,23,13,14,14,"Chemical or physical processes, Electrolytic or electrophoretic processes for the production of compounds or non-metals, Non-metallic elements, Peptides, Processes or means",,,2,"Harel Insurance Investments & Financial Services, Migdal Insurance and Financial Holdings",The company raised $11 million in its second public offering on the Tel Aviv Stock Exchange under the ticker symbol of GNCL in April 2021.,"BIRD Foundation, Gandyr Investments, Israel-China Accelerator Program, Landa Ventures, Meitav Investment House, Paz Oil Company, TDK Ventures",
10717-75,Gilat Satellite Networks (NAS: GILT),Gilat Satellite Networks Ltd,"EION Wireless, Hughes Network Systems, Verizon Wireless, Sierra Wireless, Maritime Telecommunications Network (Acquired in 2006), Kymeta, Lumen Technologies, Globalstar, Reorganized, Thaicom, TeleQuality Communications, Marlink, Silvus Technologies, Avanti Communications Group, Spectrum, ViaSat, Telemar (Italy), TDS Telecommunications, M5 Technologies, Ultisat, Clear-Com, Wataniya Palestine Mobile Telecommunications, Thuraya Telecommunications, Hispasat, Hawaiian Telcom Holdco, Frontier Communications, Pasternack Enterprises, Ooredoo Tunisie, Ooredoo Myanmar, Inmarsat, Iridium Communications, VT iDirect, Ooredoo Kuwait, Cox Communications, MegaPath Holding, Dish Network, Lightpath (Bethpage), MEASAT Satellite Systems, Eutelsat Communications, ITC Global, Arqiva, NSSLGlobal, Ooredoo, Hughes Communications India","Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.",Information Technology,Communications and Networking,Telecommunications Service Providers,"Connectivity Products, Telecommunications Service Providers*, Wireless Communications Equipment","SaaS, TMT","deployment logistic, digital satellite communication, network management, networking product, satellite based broadband, satellite communication",Corporation,69.44,Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed, Venture Capital",1118,NAS,GILT,1987,2025-04-26,,Israel,"Petah Tikva, Israel",532.5,2020-10-05,Merger/Acquisition,,,,,,Secondary Transaction - Private,,Private Equity,,Completed,,,1993-03-26,,,IPO,,,,Public Investment,Completed,,305.45,0.1479,24.85,-110.81,362.64,113.33,250.38,38.91,25.35,411,114,230,10,171,171,"Antennas, Pictorial communication, Transmission, Transmission of digital information, Wireless communication networks",,,,,Barinboim Group sold a stake in the company to an undisclosed buyer.,"Bank Hapoalim, Barinboim Group, FIMI Opportunity Funds, Veritas Venture Partners, York Capital Management","Comtech Telecommunications, The Gores Group"
158668-39,Global-e (NAS: GLBE),Global-e Online Ltd.,"BigCommerce, 1ofa100, Brandshop, Siderblue, Handshake (Media and Information Services), Mockup ( Media and Information Services), Anatwine, Sevenxcloud, Back Bay Research Group, Rithum (Media and Information Services), Magento Commerce, Flow Commerce, Virid Interatividade Digital, Miva, Squarespace, Spotby, The Hardwicke Group",Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from and anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce. The company derives maximum revenue from the United States.,Business Products and Services (B2B),Commercial Services,Media and Information Services (B2B),"Media and Information Services (B2B)*, Other Commercial Services","E-Commerce, Marketing Tech","cross-border ecommerce, cross-border retail, ecommerce marketing, ecommerce platform, ecommerce retail, localization tools",Formerly PE-Backed,483.4,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",1084,NAS,GLBE,2013,2025-04-26,,Israel,"Petah Tikva, Israel",3555.92,2021-05-12,IPO,2021-09-13,883.2,Actual,,,Secondary Transaction - Open Market,,Other,2021-09-13,Completed,,,2013-06-01,,,Angel (individual),,,Angel (individual),Individual,Completed,,752.76,0.3208,-75.55,-449.58,6136.95,339.43,8773.18,101.61,-67.93,,,,,,,,,,,,"Existing shareholders sold a 9.48% stake in the company (NAS: GLBE) for $883.2 million on September 13, 2021. A total of 13,800,000 shares were sold at a price of $64 per share. The underwriters were granted an option to purchase up to an additional 1,800,000 shares from the selling stockholders to cover over-allotments if any. The company will not receive any proceeds from the offering. The over-allotment options were exercised in full by the underwriters.","Apax Partners, DHL Express Singapore, Evelyn Cohen, Gigi Levy-Weiss, Red Dot Capital Partners, Shopify Ventures, Temasek Holdings, Vitruvian Partners",
165074-23,Golan Renewable Industries (TAE: GRIN),Golan Renewable Industries Ltd,,"Golan Renewable Industries Ltd is a manufacturer of a broad line of PE-X pipe systems and solutions, and works in the field of e-beam radiation, solar boilers and pre-manufactured walls for sanitary installations.",Business Products and Services (B2B),Commercial Products,Building Products,"Building Products*, Other Materials","Industrials, Manufacturing","drainage pipes, material product, pipe manufacturer, pipelines tubes, plastic product, polyethylene chain, polyethylene pipes",Corporation,,Profitable,Publicly Held,Publicly Listed,256,TAE,GRIN,1976,2024-12-05,,Israel,"Shaar HaGolan, Israel",,,,2005-01-17,,,,,IPO,,Public Investment,2005-01-17,Completed,,,2005-01-17,,,IPO,,,,Public Investment,Completed,,108.94,-0.0557,6.81,27.64,97.61,29.95,163.38,17.68,10.57,16,6,2,5,9,9,"Horticulture, Pipes, Producing",,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of GLPL on January 17, 2005.",,
234057-43,HeraMED (ASX: HMD),HeraMED Ltd.,"Owlet Baby Care, Nemo Healthcare","HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.",Healthcare,Healthcare Devices and Supplies,Monitoring Equipment,Monitoring Equipment*,"FemTech, HealthTech, Mobile","femtech vertical, pregnancy care center, pregnancy monitoring, pregnancy monitoring platform, wellness, wellness device, wellness product, wellness technology",Formerly VC-backed,23.31,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",17,ASX,HMD,2011,2025-03-09,,Israel,"Netanya, Israel",23.0,2023-07-25,Secondary Transaction - Private,2024-11-11,0.68,Actual,,,PIPE,,Corporate,2024-11-11,Announced/In Progress,,,2014-01-01,3.0,Estimated,Corporate,,,Corporate,Corporate,Completed,,0.24,-0.3998,-3.62,-1.44,8.97,0.14,9.45,-3.38,-3.6,11,4,5,1,5,5,Diagnosis,,,1,Jianmin Pharmaceutical Group Company,"The company (ASX: HMD) is in talks to receive AUD 1.02 million of development capital from undisclosed investors through a private placement as of November 11, 2024. Previously, the company (ASX: HMD) received AUD 3.1 million of development capital from undisclosed investors on December 19, 2024 over 2 tranches through a private placement. The company closed Tranche 1 raising AUD 2.63 million on October 29, 2024 and Tranche 2 raising AUD 476,688 on December 19, 2024. The proceeds of the Placement will fund working capital to support commercial deployments, pilots and integration of HeraCARE into large health systems, private clinics and several platforms across Australia, the US and Europe. The company is being actively tracked by PitchBook.","Hofon Pharma, Hua Li Pharmaceutical Group, Israel Innovation Authority, Mayo Clinic Ventures",
58706-11,Highcon (TAE: HICN),Highcon Systems Ltd.,"Nano Dimension, Palamides Gesellschaft Mit Beschr‚àö¬ßnkter Haftung, Rotatek Printing and Packaging Technologies, MicroFab Technologies, Inca Digital Printers, The ExOne Company, MBO Postpress Solutions, Nikon SLM Solutions, Scodix, EnvisionTEC, Vader Systems, Shapeways Holdings",Highcon Systems Ltd is engaged in the research and development of machines for digital cutting and creasing solutions for post-print processes in the Folding Carton and Corrugated carton industry.,Business Products and Services (B2B),Commercial Products,Machinery (B2B),Machinery (B2B)*,"Industrials, Manufacturing","converting process, creasing machine, cutting and creasing, cutting and creasing machine, digital cutting, digital finishing, digital finishing systems",Formerly VC-backed,108.17,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed, Venture Capital",87,TAE,HICN,2009,2025-04-15,,Israel,"Yavne, Israel",165.0,2020-12-01,IPO,,,,,,Merger/Acquisition,,Corporate,,Upcoming,,,,,,Early Stage VC,,,,Venture Capital,Completed,,18.18,1.1704,-13.79,19.73,0.27,1.87,18.67,-9.75,-11.89,109,23,70,12,27,27,"Compositions of macromolecular compounds, Cutting, Making containers of paper, cardboard or material worked in a manner analogous to paper, Mechanical working or deformation of paper, cardboard or material worked in a manner analogous to paper, Soldering or unsoldering",,,,,"The company is in talks to be acquired by an undisclosed investor on April 10, 2025. The company entered into administration on March 27, 2025. Previously, the company (TAE:HICN) received $18.5 million of development capital from undisclosed investors on March 3, 2022 through a private placement. This placement investment further strengthens the company's already healthy balance sheet. The company is being actively tracked by PitchBook.","American Greetings, Chaim Meir Tessler, GEOC Hengtong Investment, GoCapital, Jerusalem Venture Partners, Landa Ventures, LeadingResponse, Marc Daubach, Marker, OurCrowd, Ybox Real Estate, Yunzhong Public Relations Consulting",
267729-13,HUB Security (NAS: HUBC),HUB Security Ltd.,"Utimaco, International Business Machines, Fortanix, Thales","Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.",Information Technology,Software,Network Management Software,"Computers, Parts and Peripherals, Financial Software, Network Management Software*","Cybersecurity, FinTech, SaaS","confidential computing, confidential computing company, cyber security, data protection & encryption, data protection and encryption, data protection solution, data security, edge security, encrypted backup solution, hardware server, iot security",Formerly VC-backed,60.09,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",223,NAS,HUBC,2017,2025-04-26,,Israel,"Tel Aviv, Israel",1280.0,2023-01-01,Reverse Merger,2023-01-01,50.0,Actual,,,PIPE,,Corporate,2023-01-01,Completed,,,2020-05-07,5.0,Actual,Early Stage VC,,,Series A,Venture Capital,Completed,,33.36,-0.1127,-49.06,29.73,18.23,4.22,37.49,-30.63,-33.28,12,4,1,1,10,10,Containers for storage or transport of articles or materials,,,1,Mount Rainier Acquisition,"The company (TAE:HUB) received $50 million of development capital from Mount Rainier Acquisition on January 1, 2023 through a private placement.","A-Labs, AVP, Clover Wolf Capital, OurCrowd",
453332-35,Human Xtensions (TAE: HUMX),Human Xtensions LTD,,"Human Xtensions Ltd is engaged in the business of developing handheld digital solutions for minimally invasive surgery. It develops unmediated surgical systems that combine the capacity of robotics with the benefits of handheld tools and ergonomic bed mounts. The company's product, HandX, is designed as a light-weight, hand-held device that translates the surgeon's natural hand motions into complex movements inside the patient.",Healthcare,Healthcare Devices and Supplies,Surgical Devices,Surgical Devices*,Digital Health,"anatomy technology, artefficient surgery, digital handheld device, endoscopic solutions, modular surgical tools, surgical robotics",Formerly VC-backed,69.2,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",50,TAE,HUMX,2012,2024-06-07,,Israel,"Netanya, Israel",83.45,2020-01-24,Later Stage VC,2020-12-01,46.93,Actual,,,IPO,,Public Investment,2020-12-01,Completed,,,2015-06-25,3.93,Actual,Early Stage VC,10.69,Actual,Series A,Venture Capital,Completed,,0.18,-0.865699999999999,-6.16,-1.1,2.24,-0.72,-0.92,-5.91,-6.25,120,14,77,26,17,17,Diagnosis,,,1,DNV Capital,"The company raised NIS 158 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of HUMX on December 1, 2020.","IBI Investment House, Infinity Group, Psagot Investment House",
54486-19,IceCure Medical (NAS: ICCM),IceCure Medical Ltd.,"Angiodynamics, Orbital Therapy, Hygea Medical, Cianna Medical, Endocare, Novian Health, CryoTherapeutics, CPSI Biotech, Boston Scientific, Deam, Sanarus, Blaze Bioscience, UE LifeSciences, Galil Medical, Endomag","Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.",Healthcare,Healthcare Devices and Supplies,Other Devices and Supplies,"Other Devices and Supplies*, Surgical Devices","Life Sciences, Oncology","benign tumor, breast cancer therapy, breast cancer treatment, breast tumor, cryotherapy therapy, uterine fibroid",Corporate Backed or Acquired,51.55,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",66,NAS,ICCM,2006,2025-04-26,Epoch Partners (Acquired/Merged),Israel,"Caesarea, Israel",9.47,2015-02-17,Merger/Acquisition,2024-10-15,18.0,Estimated,,,Public Investment 2nd Offering,,Public Investment,2024-10-15,Announced/In Progress,,,,0.7,Actual,Early Stage VC,,,,Venture Capital,Completed,,3.29,0.0192,-15.32,-7.1,70.34,1.45,50.87,-15.36,-15.7,96,35,57,10,29,29,"Diagnosis, Filters implantable into blood vessels, Pipes, Propulsion of electrically-propelled vehicles",6,,3,"Alpha Capital Anstalt, Clover Wolf Capital, Epoch Partners (Acquired/Merged)","The company filed for a second public offering on the Nasdaq stock exchange under the ticker symbol of ICCM on October 15, 2024. They intend to sell 22,222,222 shares at a price of $0.81 per share. The expected offering amount is $18 million. Previously the company (TAE: ICCM) received $15 million of development capital from Alpha Capital Anstalt, Clover Wolf and European Investment Fund on January 28, 2021 through a private placement. The company intends to use the proceeds to advance the development and commercialization of the ProSense cryoablation system. The company is being actively tracked by PitchBook.","Bridge Investment Fund, Docor International Management, European Investment Fund, Gemini Israel Ventures, Giza Venture Capital, TRD Instrum, VI Ventures, XT Group",
57408-94,Idomoo (TAE: IDMO),Idomoo Ltd.,"XMPie, Vintom, TwentyThree, Eyeview, Jivox, Affle 3i, Pixability, OneMob, Sezion, Strike Social, Smart Video, SourceKnowledge, Wistia, Ramp (Multimedia and Design Software), Quarry (Saint Jacobs), Iris.TV, AdGreetz, Vidyard, ClearSlide, Invodo, BlueRush, Zefr, SundaySky, VBrick, Dynamix.tv, Real Time Content",Idomoo Ltd is engaged in the development and sale of software for making custom videos.,Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Media and Information Services (B2B)","SaaS, TMT","customer engagement platform, customer relationship management, metadata api, personalized customer engagement, personalized video, real time content, video marketing software, video-as-a-service",Formerly VC-backed,58.02,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",98,TAE,IDMO,2007,2025-01-29,,Israel,"Raanana, Israel",105.33,2021-06-07,IPO,2021-06-07,22.96,Actual,105.33,Estimated,IPO,,Public Investment,2021-06-07,Completed,,,2012-08-05,3.05,Actual,Early Stage VC,10.62,Actual,,Venture Capital,Completed,,15.33,-0.0851,-6.26,5.81,12.49,12.77,14.92,-5.25,-5.81,44,21,28,15,1,1,"Electric digital data processing, Information storage based on relative movement between record carrier and transducer, Pictorial communication, Transmission of digital information",,,1,Target Global,"The company raised ILS 75 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of IDMO on June 7, 2021. After the offering, the company valued at ILS 344 million.","AccelerAsia, Chemi Peres, Disruptive Technologies Venture Capital, Eyal Gura, GlenRock Israel, Ion Pacific, Marker, Rami Kalish, Wekix",
12147-85,ImageSat International (TAE: ISI),ImageSat International N.V.,"Maxar Technologies, General Atomics, Spire, Astro Digital, Space-Eyes, Channel Logistics, BlackSky, Iceye, Northrop Grumman, SpaceKnow, Firefly Aerospace, DigitalGlobe, Axelspace","Imagesat International (I.S.I) Ltd is a provider of space-based intelligence & information solutions. The satellite services of the company include EROS C, EROS B, EROSAR, and global eye.",Business Products and Services (B2B),Commercial Services,Other Commercial Services,"Aerospace and Defense, Other Commercial Services*","Industrials, Space Technology, TMT","geospatial data, geospatial satellite, geospatial system, remote sensing device, satellite imagery data, satellite photographs",Private Equity-Backed,100.69,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed, Venture Capital",103,TAE,ISI,1997,2025-04-26,,Israel,"Or Yehuda, Israel",268.52,2022-02-14,IPO,2022-02-14,151.03,Actual,268.52,Estimated,IPO,,Public Investment,2022-02-14,Completed,,,,,,Early Stage VC,,,,Venture Capital,Completed,,58.0,0.3209,-8.31,44.35,167.13,6.38,271.2,14.75,-8.19,7,2,1,,6,6,"Measuring distances, levels or bearings",,,3,"Discount Capital, FIMI Opportunity Funds, Israel Aerospace Industries","The company raised NIS 480 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol ISI on February 14, 2022. A total of 25,263,158 shares were sold at a price of NIS 19 per share. After the offering, there was a total of 44,914,946 outstanding shares (excluding the over-allotment option) priced at NIS 19 per share, valuing the company at NIS 853.38 million. The total proceeds, before expenses, to the company was NIS 320 million and to the selling shareholders was NIS 160 million. In the offering, the company sold 16,842,105 shares and the selling shareholders sold 8,421,053 shares.","Elbit Systems, Pegasus Capital Advisors, The Challenge Fund - Etgar",
165200-05,Imco Industries (TAE: IMCO),Imco Industries Ltd,,"Imco Industries Ltd designs, develops and produces mechanical, electro-mechanical, electrical and electronic products, assemblies and sub-assemblies for airborne, land and naval applications. The company divides its products into following categories: Electrical and electronics, Electromechanical solutions, LED lighting solutions and Platforms. It supplies its products to the Israel Defense Forces, United States Army, Air Force and Navy and other .",Business Products and Services (B2B),Commercial Products,Aerospace and Defense,Aerospace and Defense*,Industrials,"electrical systems, electromechanical, military control system, naval, naval application, naval sonar",Corporation,,Generating Revenue,Publicly Held,Publicly Listed,278,TAE,IMCO,1974,2024-09-01,,Israel,"Tel-Hanan, Israel",,,,1992-04-09,,,,,IPO,,Public Investment,1992-04-09,Completed,,,1992-04-09,,,IPO,,,,Public Investment,Completed,,,,,,23.77,,,,,,,,,,,,,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of IMCO on April 9, 1992.",,
155938-60,impacX (TAE: WATR),Impacx.Io Ltd,,"Water Io Ltd Formerly Impacx.Io Ltd is engaged in the development and marketing of a platform for collecting information on the use of packaged consumer products. It brings an end-to-end connected experience for water, vitamins, pharma, and CPG companies through an IoT smart packaging platform.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,"Business/Productivity Software, Electronic Equipment and Instruments*, Electronics (B2C), Other Containers and Packaging","Advanced Manufacturing, Climate Tech, Internet of Things, Mobile, TMT","data analytics, digital packaging platform, food production, hydration monitoring, internet of packaging, iot, monitoring device, packaging, reusable bottles, smart packaging, sustainable packaging, vitamins and supplements",Formerly VC-backed,14.8,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",20,TAE,WATR,2015,2024-02-01,,Israel,"Rehovot, Israel",32.4,2021-09-13,IPO,2021-09-13,10.7,Estimated,32.4,Estimated,IPO,PIPE,Public Investment,2021-09-13,Completed,,,2015-12-01,0.55,Actual,Seed Round,9.91,Actual,Seed Round,Individual,Completed,,,,,,0.8,,,,,70,10,51,12,7,7,"Containers for storage or transport of articles or materials, Containers specially adapted for medical or pharmaceutical purposes, Household or table equipment, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Sanitary equipment not otherwise provided for",,,,,"The company raised ILS 34.5 million in its initial public offering on the Tel Aviv stock exchange under the ticker symbol of IMPC on September 13, 2021. After the offering, there was a total of 9,096,703 outstanding shares, valuing the company at ILS 104.5 million.","Bits x Bites, Club 100 plus, Coalition Capital, D√∂hler Ventures, Keiretsu Forum, Lior Shalev, Plug and Play Tech Center",
58764-25,InMode (NAS: INMD),InMode Ltd.,"OmniGuide, Cutera, Acutus Medical, Alma Lasers, Cynosure (Other Devices and Supplies), Ellipse, Atricure, Lumenis, Quanta Aesthetic Lasers USA, Wontech, Oscor, Candela Medical, Sisram Medical","InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.",Healthcare,Healthcare Devices and Supplies,Other Devices and Supplies,"Medical Supplies, Other Devices and Supplies*, Other Healthcare Technology Systems",Manufacturing,"body contouring, body treatment, face treatment, fractional resurfacing, laser hair removal, plastic surgery, skin treatment, skin treatment company",Formerly VC-backed,70.0,Profitable,Publicly Held,"Publicly Listed, Venture Capital",599,NAS,INMD,2008,2025-04-26,,Israel,"Yokneam, Israel",447.63,2019-08-08,IPO,2019-08-08,70.0,Actual,447.63,Estimated,IPO,,Public Investment,2019-08-08,Completed,,,2015-06-01,,,Early Stage VC,,,,Venture Capital,Completed,,394.82,-0.1976,181.28,-588.65,1100.83,317.07,593.79,113.26,112.53,71,34,44,11,16,16,"Diagnosis, Electric discharge tubes or discharge lamps, Electrotherapy, Filters implantable into blood vessels",27,,,,"The company raised $70 million in its initial public offering on the Nasdaq stock exchange under the ticker symbol of INMD on August 8, 2019. A total of 5,000,000 shares were sold at a price of $14 per share. After the offering, there was a total of 31,973,572 outstanding shares (excluding the over-allotment option) priced at $14 per share, valuing the company at $447.63 million. The underwriters were granted an option to purchase up to an additional 750,000 shares from the company to cover over-allotments, if any.","Israel Healthcare Ventures, SpaMedical International, Talent Resources Ventures",
232258-69,InnoCan Pharma (CNQ: INNO),Innocan Pharma Corporation Ltd.,"Foamix Pharmaceuticals, Formulex Pharma Innovations","InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,"Drug Delivery, Pharmaceuticals*",Cannabis,"cbd product, cbd-based product, drug delivery platform, pharmaceutical, pharmaceutical company, pharmaceutical product, pharmaceutical product company, pharmaceutical technology platform",Formerly VC-backed,19.73,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",11,CNQ,INNO,2018,2025-04-15,,Israel,"Herzliya, Israel",19.54,2019-09-29,IPO,2025-04-15,0.15,Actual,,,PIPE,,Corporate,2025-04-15,Completed,,,2018-05-31,,,Early Stage VC,,,,Venture Capital,Completed,,29.44,1.1555,-1.83,-5.0,34.67,26.19,38.72,0.96,0.93,18,7,2,16,,,"Making textile fabrics, Preparations for medical, dental or toiletry purposes, Specific therapeutic activity of chemical compounds or medicinal preparations",,,,,"The company (CNQ: INNO) received CAD 214,839 of development capital from undisclosed investors on April 15, 2025, through a private placement. Each unit includes one common share and one common share purchase warrant. The company intends to use the proceeds of the offering for working capital and general corporate purposes.",Invicta Ventures,
163750-96,Innoviz Technologies (NAS: INVZ),Innoviz Technologies Ltd.,"Aeva, Ouster, Luminar","Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,"Automotive, Business/Productivity Software, Electronic Equipment and Instruments*","Advanced Manufacturing, Autonomous cars, Construction Technology, Industrials, Internet of Things, Mobility Tech, Robotics and Drones, TMT","3d sensing, accurate mapping, autonomous driving, autonomous vehicles, lidar sensor, lidar technology, mobility tech, perception software, remote sensing sensor",Formerly VC-backed,638.98,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",415,NAS,INVZ,2016,2025-04-26,,Israel,"Rosh Haayin, Israel",1298.0,2021-04-06,Reverse Merger,2025-02-10,40.0,Estimated,,,PIPE,,Corporate,2025-02-10,Announced/In Progress,,,2016-03-31,8.99,Actual,Early Stage VC,16.75,Estimated,Series A,Venture Capital,Completed,,24.27,0.1625,-94.76,-38.35,158.27,-1.16,225.48,-94.13,-101.92,173,47,97,65,11,11,"Chemical or physical laboratory apparatus for general use, Electric digital data processing, Graphical data reading, Optical elements, systems or apparatus, Radio direction-finding",,,,,"The company (NAS: INVZ) is in talks to receive approximately $40 million of development capital from undisclosed investors through a private placement as of February 10, 2025. Each unit consists of one ordinary share and eight-tenths of a warrant to purchase one ordinary share. The net proceeds will be used for general business purposes. Previously, the company raised $40 million in its second public offering on the Nasdaq Stock Exchange under the ticker symbol of INVZ on February 10, 2025. A total of 28,776,978 units were sold at $1.39 per unit. Each unit consists of one ordinary share, and eight tenths of a warrant to purchase one ordinary share. The company is being actively tracked by PitchBook.","360 Capital, Amiti Ventures, Antara Capital, Aptiv, Bin Zhou, Cerca Partners, Champel Capital, China Merchants Capital, Collective Growth, Delek Group, Delphi Investments, Gaorong Capital, Gil Agmon, Glory Ventures, Harel Insurance Investments & Financial Services, Harman International, LM VENTURES, Magma Venture Partners, Magna International, Magna Technology Investments, Naver, New Alliance Capital, OurCrowd, Phoenix Financial (Multi-line Insurance), Plug and Play Tech Center, Primera Capital (Venture Capital), Samsung Catalyst Fund, SBVA, Sea Purity Investments, Shefa Capital, Shenzhen Capital Group, Startup Autobahn, Vertex Ventures Israel",
462351-52,Inspira Technologies (NAS: IINN),Inspira-Technologies OXY B.H.N. LTD.,,"Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.",Healthcare,Healthcare Devices and Supplies,Therapeutic Devices,Therapeutic Devices*,Manufacturing,"ards treatment, healthcare device, healthcare firm, medical device, medical device design, medical research, medical technology",Corporation,31.17,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed",37,NAS,IINN,2018,2025-04-26,,Israel,"Ra'anana, Israel",21.51,2023-04-04,Public Investment 2nd Offering,2022-08-10,1.02,Estimated,,,Public Investment 2nd Offering,,Public Investment,2022-08-10,Announced/In Progress,,,2021-07-14,16.03,Actual,IPO,42.95,Estimated,,Public Investment,Completed,,0.0,0.0,-11.05,-5.12,15.7,,20.11,-11.05,-11.22,,,,,,,,,,1,Armistice Capital,"The company filed for a second public offering on the Nasdaq stock exchange under the ticker symbol of IINN on August 10, 2022. The expected offering amount is $1.02 million. Previously, the company (NAS: IINN) is in talks to receive $3.23 million of development capital from undisclosed investors through a private placement as of December 27, 2024. Company consisting of 4,608,715 ordinary shares and warrants to purchase up to 4,608,715 ordinary shares at $0.70 per combined unit. The ordinary warrants have an eighteen-month term with a $1.10 exercise price. The company intends to use the net proceeds from the offering for working capital and general corporate purposes. Previously, The company (NAS: IINN) received $1.331393 million of development capital from undisclosed investors on November 15, 2024 through a private placement. The company is being actively tracked by PitchBook.",,
42498-82,InspireMD (NAS: NSPR),"InspireMD, Inc.","Cordis, Atricure, Boston Scientific, Oscor, Intact Vascular","InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.",Healthcare,Healthcare Devices and Supplies,Therapeutic Devices,"Other Devices and Supplies, Therapeutic Devices*",,"embolic protection, embolic protection device, embolization, medical device, medical devices, vascular procedures",Corporation,175.25,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, M&A, Publicly Listed, Venture Capital",86,NAS,NSPR,2005,2025-04-26,,Israel,"Tel Aviv, Israel",,,,2023-08-08,113.6,Estimated,,,PIPE,,Corporate,2023-08-08,Completed,,,2011-03-28,,,Reverse Merger,,,,Corporate,Completed,,7.01,0.1296,-32.01,-32.3,79.35,1.51,29.43,-33.22,-33.5,97,13,64,15,18,18,"Devices for introducing media into, or onto, the body, Filters implantable into blood vessels",8,,1,Saguaro Resources (Mineral Exploration Services),"The company (NAS:NSPR) received $113.6 million of development capital from undisclosed investors on August 8, 2023 through a private placement.","Genesis Capital Advisors, Israel Seed Partners, OrbiMed",
433942-57,IR Med (PINX: IRME),"IR Med, Ltd.","Cnoga, SHL Telemedicine","IR-Med Inc is a development stage medical device company developing its technology through its Subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with Artificial Intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time.",Healthcare,Healthcare Devices and Supplies,Monitoring Equipment,"Monitoring Equipment*, Other Healthcare Technology Systems",,"infrared light radiation, infrared spectroscopy, medical device, medical device developer, noninvasive detectors, spectrographic analysis",Formerly VC-backed,8.93,Generating Revenue,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",9,PINX,IRME,2012,2025-04-25,,Israel,"Rosh Pina, Israel",,,,2022-04-14,3.2,Actual,,,PIPE,,Corporate,2022-04-14,Completed,,,,,,Seed Round,,,Seed Round,Venture Capital,Completed,,0.0,0.0,-1.9,0.03,7.2,,32.96,-1.87,-1.9,17,7,8,4,5,5,"Computing arrangements based on specific computational models, Diagnosis",,,1,International Display Advertising,"The company (PINX:IRME) received $3.2 million of development capital from undisclosed investors on April 14, 2022 through a private placement. The Company intends to use the proceeds for general corporate purposes and to advance the development of its product candidates.",,
54703-63,JFrog (NAS: FROG),JFrog Ltd.,"Freshworks, GitLab, Sonatype, Gitlab China, Cloudsmith, Perforce Software, Plastic SCM, Pivotal Software, Electric Cloud, Nutanix, Wercker, Apollo GraphQL, Polyverse, Docker, ServiceNow, Superhub, Rancher Labs, Anchore, Atlassian, Asana, PagerDuty, SaltStack, Rhodecode, Chef Software, Parallels, XebiaLabs, Heroku, HashiCorp, CloudBees, Octopus Deploy, Aviatrix, Checkmarx, Clarive, CircleCI, CFEngine, VMware, Veracode, Microsoft Azure, Collab, Automic Software, Distelli, GitHub, Sumo Logic, Plutora, Nirmata, Itential, AppViewX, Micro Focus International, Microsoft, Snyk, International Business Machines, Amazon.com, Alphabet","JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.",Information Technology,Software,Software Development Applications,"Business/Productivity Software, Software Development Applications*","CloudTech & DevOps, Cybersecurity, Internet of Things, SaaS","application security, centralized database, continuous integration, continuous software testing, devops security platform, iot, saas, security, software, software distribution, software release management, software supply chain, supply chain platform",Formerly VC-backed,580.0,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",1600,NAS,FROG,2008,2025-04-26,,United States,"Sunnyvale, CA",3901.71,2020-09-16,IPO,2024-10-11,,,,,Buyout/LBO,,Private Equity,2024-10-11,Rumor/Speculation,,,2008-04-28,0.5,Actual,Angel (individual),,,Angel (individual),Individual,Completed,,428.49,0.2246999999999999,-69.24,-508.03,3889.36,330.19,2829.13,-69.64,-91.1,88,22,72,16,,,"Electric digital data processing, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Transmission of digital information",,,3,"Gemini Israel Ventures, Meritech Capital Partners, Pantheon International","The company (NAS:FROG) is rumored to be in talks with Permira and Hellman & Friedman regarding a potential LBO as of October 11, 2024 for an undisclosed amount. Previously, the company (NAS:FROG) received development capital from Meritech Capital Partners through a private placement. Pantheon International also participated in this round. The company is being actively tracked by PitchBook.","Battery Ventures, Dell Technologies Capital, Dharmesh Thakker, Geodesic Capital, Insight Partners, Notable Capital, Qumra Capital, Sapphire Ventures, Scale Venture Partners, Silicon Valley Investment Fund, Spark Capital, Spur Capital Partners, TeleSoft Partners, Vintage Investment Partners, VMware",
52853-05,Jungo Connectivity (TAE: JNGO),Jungo Connectivity Ltd.,Hum (Application Software),"Jungo Connectivity Ltd is engaged in the development of software that analyzes the condition of the driver and passengers using cameras inside the vehicle. Its products include WinDriver - PC driver development toolkit, MediaCore - automotive multimedia middleware, and DriverCore - PC USB communication drivers.",Information Technology,Communications and Networking,Connectivity Products,"Application Software, Connectivity Products*",TMT,"camera based drivers monitoring, drivers camera, drivers monitoring, drivers monitoring camera, drivers monitoring system",Formerly VC-backed,13.5,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",41,TAE,JNGO,1998,2025-04-21,Synamedia,Israel,"Netanya, Israel",90.5,2006-12-05,Merger/Acquisition,2021-07-28,,,,,IPO,,Public Investment,2021-07-28,Completed,,,1999-01-01,1.0,Actual,Seed Round,,,Seed Round,Venture Capital,Completed,,11.4,,,,9.36,,,,,14,9,6,4,4,4,"Graphical data reading, Image or video recognition or understanding, Signalling or calling systems, Vehicles, vehicle fittings, or vehicle parts, not otherwise provided for",,Synamedia,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of JNGO on July 28, 2021.","Artiman Ventures, Cipio Partners, Cisco Investments, D.Z. Israel Associates, Intel Capital, Lantiq Deutschland, Partech, TeleSoft Partners",
86184-10,Kadimastem (TAE: KDST),Kadimastem Ltd.,"Abeona Therapeutics, Lisata Therapeutics, Capricor Therapeutics, ProMIS Neurosciences, Dyne Therapeutics, Marinus Pharmaceuticals, Crinetics Pharmaceuticals, Lysosomal Therapeutics, Voyager Therapeutics, Alnylam Pharmaceuticals, Akari Therapeutics, SAGE Therapeutics, Yumanity Therapeutics, Ability Pharma, Quince Therapeutics, Dimension Therapeutics, Stealth BioTherapeutics, Bluebird Bio, Rhythm Pharmaceuticals, Medeia Therapeutics, Metabolic Solutions Development Company, Aragon Pharmaceuticals, Vertex Pharmaceuticals, Alzheon, Cassava Sciences, NexImmune, Praxis (Drug Discovery), Denali Therapeutics, ALSP, Cognition Therapeutics, Tiburio Therapeutics, Oligomerix, Bioasis Technologies, ICBI, Brainstorm Cell Therapeutics, Apellis Pharmaceuticals, Compass Therapeutics, AavantiBio, Cerecin, Alector, Prilenia, Triplet Therapeutics, Lucid Psycheceuticals, Akelos, Tetra Therapeutics, Ra Pharmaceuticals, XWPharma, Aro Biotherapeutics, Apeptico, NeuroNascent, Amunix Pharmaceuticals, Adverum Biotechnologies, Design Therapeutics, CervoMed, Mitobridge, Rodin Therapeutics, Cadent Therapeutics, Verge Genomics, QurAlis, Minerva Neurosciences",Kadimastem Ltd is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. It is developing revolutionary regenerative therapies based on stem cells.,Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Pharmaceuticals",Life Sciences,"advances biotechnology, allogeneic drugs, alstherapy, alstreatment, biotechnology and biopharmaceuticals, diabetes treatment, human embryonic stem cell, pharmaceutical, proprietary cell, stem cell therapeutic, stem cell therapy",Corporation,29.56,Clinical Trials - Phase 1,Publicly Held,"M&A, Publicly Listed",11,TAE,KDST,2009,2025-04-09,,Israel,"Ness Ziona, Israel",,,,2024-11-04,,,,,Merger/Acquisition,,Corporate,2024-11-04,Announced/In Progress,,,2013-06-09,5.56,Actual,IPO,,,,Public Investment,Completed,,0.0,0.0,-7.12,7.06,31.0,,16.13,-6.68,-7.09,44,6,33,3,8,8,"Investigating or analysing materials by determining their chemical or physical properties, Microorganisms or enzymes, Preparations for medical, dental or toiletry purposes",1,,4,"Alpha Capital Anstalt, Altshuler Shaham Investment House, Clover Wolf Capital, Ilex Medical","The company reached a definitive agreement to be acquired by NLS Pharmaceutics (NAS: NLSP) for an undisclosed amount on November 4, 2024. The acquisition will provide an opportunity for upside in the combined company with a promising cell therapy technological platform. The company is planning to close the deal approximately in June 2025. The company was in talks to acquire an undisclosed Company through a reverse merger for an undisclosed amount on May 28, 2024. Subsequently, the deal was canceled on May 28, 2024. The company is being actively tracked by PitchBook.",,NLS Pharmaceutics
51594-04,Kaltura (NAS: KLTR),"Kaltura, Inc.","Twilio, Pitcher, VBrick, Brightcove, TwentyThree, Brainshark, Ooyala, Sharestream, Qumu, Panopto","Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.",Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Communication Software, Media and Information Services (B2B)","EdTech, SaaS, TMT","advertisement serving, content syndication, open source model, video management, video publishing platform, video sharing",Formerly PE-Backed,366.1,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed, Venture Capital",563,NAS,KLTR,2006,2025-04-26,,United States,"New York, NY",383.0,2022-07-28,Buyout/LBO,2024-09-30,,,,,Secondary Transaction - Private,,Corporate,2024-09-30,Completed,,,2007-09-18,2.1,Estimated,Early Stage VC,,,Series A,Venture Capital,Completed,,178.72,0.0202,-31.31,-31.3,315.98,119.11,302.7,-19.27,-24.34,30,9,26,,4,4,"Broadcast communication, Electric digital data processing, Information storage based on relative movement between record carrier and transducer, Pictorial communication, Transmission of digital information",,,1,CF Private Equity,"The company was in talks to be acquired by Panopto, via its financial sponsor K1 Investment Management, through a $383 LBO on July 28, 2022. Subsequently, the deal was canceled.",".406 Ventures, Avalon Ventures, Daniel Leff, Eric Ma, Gera Venture Capital, Goldman Sachs Growth Equity, Intel Capital, Meaf Consultoria Em Educa√ß√£o, Mitsui Global Investment, Nexus Venture Partners, NGP Capital, Sapphire Ventures, Savano Capital Partners, SVB Financial Group, Waverley Capital",
11893-87,Kamada (TAE: KMDA),Kamada Ltd.,"CSL, Grifols, Octapharma","Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*, Therapeutic Devices",Life Sciences,"biopharmaceutical, biotechnology, biotechnology process, human plasma, pharmaceutical company, purification technology, therapeutic chromatographic purification, therapeutic program",Corporation,179.02,Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",374,TAE,KMDA,1990,2025-04-26,,Israel,"Rehovot, Israel",353.0,2023-08-30,PIPE,2023-08-30,60.0,Actual,353.0,Estimated,PIPE,,Corporate,2023-08-30,Completed,,,2005-08-31,,,IPO,,,,Public Investment,Completed,,160.95,0.1293,14.46,-67.37,380.73,69.97,287.15,26.29,11.88,81,14,37,10,34,34,"Peptides, Preparations for medical, dental or toiletry purposes, Specific therapeutic activity of chemical compounds or medicinal preparations",14,,1,FIMI Opportunity Funds,"FIMI Opportunity Funds acquired a 17% stake in the company (TAE:KMDA) on August 30, 2023 through a private placement. Proceeds from the private placement are expected to be used to support the Company's growth plans and execution of strategic business development opportunities.","Brosh Capital Partners, GlenRock Israel, Meitav, Proseed Capital, Shavit Capital, UDT Med Holdings",
181434-25,Kanabo Group (LON: KNB),Kanabo Group Plc,Argent BioPharma,"Kanabo Group PLC is a research and development company engaged in selling a range of THC-Free retail CBD products in the markets and it is in the process of developing medical cannabis products. Its reportable segments include Primary Care and Secondary Care. The Primary Care segment, which derives key revenue, includes Tele pharma services provided by GPS and The Secondary Care segment includes the development and distribution of cannabis-derived medical and wellness products. Geographically company has a presence in the United Kingdom and Israel.",Healthcare,Healthcare Devices and Supplies,Other Devices and Supplies,"Other Devices and Supplies*, Other Pharmaceuticals and Biotechnology",,"cannabis consumption, cannabis formulas, cannabis medical models, cannabis medicine, drug delivery system, research and development",Formerly VC-backed,5.73,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",17,LON,KNB,2017,2025-04-02,,United Kingdom,"London, United Kingdom",,,,2023-05-09,3.42,Actual,,,PIPE,,Corporate,2023-05-09,Completed,,,2017-03-01,,,Early Stage VC,,,Series A,Venture Capital,Failed/Cancelled,,1.44,0.4022,-10.3,-1.69,2.32,0.11,9.79,-8.71,-10.45,4,2,,,4,4,,,,3,"Caledonian Holding, Maven Capital Partners (Glasgow), Spinnaker Opportunities","The company (LON: KNB) received GBP 2.74 million of development capital from undisclosed investors on May 9, 2023 through a private placement.",Entourage Effect Capital,
54720-28,Kape Technologies,Kape Technologies plc,"BullGuard, F-Secure, WatchGuard Technologies, Barracuda Networks, Nexgate, Imperva, McAfee, Quick Heal Technologies, Cyren, Avira Operations, Doctor Web, Endgame (Network Management Software), Trusted Knight, Cylance, AVG Technologies, Digital Guardian, Adaptive Mobile Security, Forcepoint, Opswat, EScan, Zvelo, SentinelOne, Gemalto, Panda Security, N-able Technologies, Emsisoft, SonicWall, BitDefender, Avast, Netskope, Contrast Security, Quarri, PSafe Tecnologia, GuruCul, Agnitum, Promon (Network Management Software), Webroot, Cisco Systems, Zscaler, Avast Software, EnSilo, SentryBay, WithSecure, Palo Alto Networks, CrowdStrike Holdings, Sophos, Check Point Software Technologies, Gen Digital, Xcitium, IKARUS Security Software, Lookout, Cheetah Mobile","Kape Technologies PLC is a cybersecurity company engaged in the developing and distribution of a variety of digital products in the online security space. Its operating segments include Digital Privacy - comprising the group's Virtual Private Network products which comprise Cyberghost, Private Internet Access and Zenmate and Digital Security - comprising the group's end-point security and PC performance products. It offers products that provide online security, privacy, and an optimal online experience. The company's products include CyberGhost, ReImage, and Driver Agent.",Information Technology,Software,Network Management Software,Network Management Software*,TMT,"application provider, browser compatible, cybersecurity, internet security, javascript coding, security",Corporate Backed or Acquired,765.81,Generating Revenue,Acquired/Merged (Operating Subsidiary),"M&A, Publicly Listed, Venture Capital",301,,,2011,2025-04-03,Unikmind,United Kingdom,"London, United Kingdom",2000.75,2023-05-31,Secondary Transaction - Private,2023-05-31,450.62,Estimated,2000.75,Estimated,Secondary Transaction - Private,,Corporate,2023-05-31,Completed,,,,2.0,Actual,Angel (individual),,,Angel (individual),Individual,Completed,,623.48,1.703,70.92,135.8,1799.25,574.49,,254.79,100.09,,,,,,,,,Unikmind,,,"An undisclosed investor sold a 22.52% stake in the company to Unikmind for $450.62 million on May 31, 2023. After the acquisition, Unikmind owns a 98.54% stake in the company.","Gigi Levy-Weiss, Markat, NFX, Oren Zeev, Origin Capital (UK)",
168394-69,Kidoz (TSX: KIDZ),Kidoz Inc.,,"Kidoz Inc. is an AdTech software developer and the owner of the mobile Kidoz Safe Ad Network and the over-13 audience-focused Prado Network. The group helps create a free and safe mobile app environment for children by enabling content producers to monetize their apps and videos with safe, relevant, and engaging ads. Kidoz has developed advanced contextual targeting tools through the Kidoz SDK and Kidoz Privacy Shield, enabling the group to offer advertisers privacy-first solutions that comply with COPPA, GDPR-K, and other global privacy regulations. Through Kidoz and Prado, the company offers both managed and programmatic media solutions for advertisers and publishers, including SSP, DSP, SDK, and Ad Exchange capabilities.",Information Technology,Software,Entertainment Software,Entertainment Software*,TMT,"children games, gaming platform operator",Corporation,7.21,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed",43,TSX,KIDZ,1987,2025-04-26,,Canada,"Vancouver, Canada",,,,,2.0,Actual,,,PIPE,,Corporate,,Completed,,,2015-07-02,,,IPO,,,,Public Investment,Completed,,12.59,-0.1054,-1.18,-0.44,30.32,5.38,11.9,-0.86,-1.21,1,1,,,1,1,,,,,,The company (TSX: KIDZ) received $2 million of development capital on an undisclosed date through a private placement.,,
58748-05,Kornit Digital (NAS: KRNT),Kornit Digital Ltd,"Electronics For Imaging, AnaJet","Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.",Information Technology,Computer Hardware,Office Electronics,"Machinery (B2B), Office Electronics*","Industrials, Manufacturing, TMT","digital inkjet printer, digital printing, garments printing, garments printing solutions, textile printing",Formerly PE-Backed,256.35,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed",715,NAS,KRNT,2002,2025-04-26,,Israel,"Rosh Haayin, Israel",1091.95,2019-06-14,Public Investment 2nd Offering,2019-06-14,119.35,Actual,1091.95,Estimated,Public Investment 2nd Offering,,Public Investment,2019-06-14,Completed,,,,,,PE Growth/Expansion,,,,Private Equity,Completed,,203.83,-0.0726,-16.8,-445.5,838.11,91.76,989.36,-25.38,-38.43,250,71,146,56,48,48,"Coating compositions, Dyeing or printing textiles, Handling thin or filamentary material, Treating textile materials using liquids, gases or vapours, Typewriters",,,,,"The company raised $119.35 million in its second public offering on the Nasadq stock exchange under the ticker symbol of KRNT on June 14, 2019. A total of 4,340,000 shares were sold at $27.5 per share. The underwriters were granted an option to purchase up to an additional 651,000 shares from the company to cover over-allotments, if any.","Electronics For Imaging, Fortissimo Capital, Needham Capital Partners",
165201-85,Lachish Industries (TAE: LHIS),Lachish Industries Ltd,,Lachish Industries Ltd manufactures cattle feeding equipment. It provides self propelled and loading mixers; stationery mixers; and vertical trailers primarily to dairy farming and feedlot industries.,Business Products and Services (B2B),Commercial Products,Machinery (B2B),"Machinery (B2B)*, Other Agriculture","Industrials, Manufacturing","cattle, cattle feed, feed equipment, feed machinery, feed processing, feed processing service, loading mixers",Corporation,,Generating Revenue,Publicly Held,Publicly Listed,,TAE,LHIS,1956,2023-09-27,,Israel,"Sderot, Israel",,,,1992-10-08,,,,,IPO,,Public Investment,1992-10-08,Completed,,,1992-10-08,,,IPO,,,,Public Investment,Completed,,,,,,54.47,,,,,6,4,,,6,6,,,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of LHIS on October 8, 1992.",,
54534-70,Lifeward (NAS: LFWD),ReWalk Robotics Ltd.,"Myomo, Tyromotion, Touch Bionics, FREE Bionics, Ekso Bionics Holdings, Liberating Technologies, Hocoma, Bionik Laboratories, Cyberdyne (Therapeutic Devices), AlterG, Steeper, Reha Technology, Motorika Medical, Rex Bionics, Indigo (Monitoring Equipment), Aretech","Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.",Healthcare,Healthcare Devices and Supplies,Therapeutic Devices,Therapeutic Devices*,"Manufacturing, Robotics and Drones","bionics prosthesis, bionics prosthetics, medical device, medical exoskeleton, medical robotics startups, motorized legs, wearable exoskeleton, wearable robotic device, wearable robotic technology, wearable robotics",Formerly VC-backed,195.91,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",80,NAS,LFWD,2001,2025-04-26,,Israel,"Yokneam Illit, Israel",14.41,2018-11-16,Public Investment 2nd Offering,2025-01-08,5.0,Actual,,,PIPE,,Corporate,2025-01-08,Completed,,,,,,Early Stage VC,,,,Venture Capital,Completed,,25.66,0.8523999999999999,-28.94,-5.87,15.95,8.22,5.57,-25.7,-29.54,77,14,45,6,26,26,"Filters implantable into blood vessels, Manipulators, Physical therapy apparatus",4,,,,"The company (NAS: LFWD) received $5 million of development capital from undisclosed investors on January 8, 2025, through a private placement. The company intends to use the net proceeds from the offering for continuing commercial efforts, working capital and general corporate purposes.","Bearing Capital, Chaim Meir Tessler, Ionic Ventures, Israel Healthcare Ventures, Kreos Capital, LIP Ventures Boutique, OurCrowd, Pontifax Venture Capital, Previz Ventures, Ratio technologies (Israel), SCP Vitalife Partners, Shavit Capital, Technion Research and Development Foundation, Technion Seed, Timwell Corporation, Wolfpack Ventures, Yaskawa America",
11533-78,Magic Software Enterprises (TAE: MGIC),"Magic Software Enterprises, Ltd.","Appian, 74Software, Newgen Software Technologies, Altair Engineering (Business/Productivity Software), Progress Software, ServiceNow, Pivotal Software, Apperian, New Relic, Nutanix, ServiceMax, VMware, LANSA (Downers Grove), SAP, Kony, Betty Blocks, Cloud Elements, Salesforce, Simplifier, Astea International, Zinier, Jitterbit, Reflexis Systems, Liaison, Voyatek, Kickserv, Quickbase, Industrial and Financial Systems, TIBCO Software, K2 (Bellevue), Rogue Wave Software, Docker, Adeptia, Micro Focus International, Layer0, FieldEZ, Dispatch (Boston)","Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. It generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel; Europe; Japan, and Other countries.",Information Technology,Software,Software Development Applications,"Business/Productivity Software, Software Development Applications*","SaaS, TMT","application development, application platform, cloud-based, enterprise mobility, low coding / no coding, service management, software development, software solutions",Corporation,,Profitable,Publicly Held,"M&A, Publicly Listed",3628,TAE,MGIC,1983,2025-04-26,,Israel,"Or Yehuda, Israel",,,,2025-03-10,,,,,Merger/Acquisition,,Corporate,2025-03-10,Announced/In Progress,,,1991-08-16,,,IPO,,,,Public Investment,Completed,,552.52,0.0326,36.88,-26.68,681.17,157.18,615.27,82.06,61.24,,,,,,,,,,,,"The company (TAE: MGIC) reached a definitive agreement to be acquired by Matrix IT (TAE: MTRX) for an undisclosed amount on March 10, 2025. This deal once completed, will position the merged company as a significant player both in Israel and internationally. Previously, the company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of MGIC on August 16, 1991. The company is being actively tracked by PitchBook.",,Matrix IT
483423-85,Maris-Tech (NAS: MTEK),Maris-Tech Ltd,"General Dynamics Mission Systems, Northrop Grumman, General Dynamics","Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.",Business Products and Services (B2B),Commercial Products,Aerospace and Defense,Aerospace and Defense*,,"aerospace and defense company, aerospace and defense components, aerospace and defense firm, monitoring solution, video solution, video surveillance",Formerly Private Debt Financed,16.38,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Publicly Listed",13,NAS,MTEK,2008,2025-04-26,,Israel,"Rehovot, Israel",30.51,2022-02-02,IPO,2022-02-02,15.54,Actual,30.51,Estimated,IPO,,Public Investment,2022-02-02,Completed,,,2016-06-01,0.13,Actual,Debt - General,,,,Debt,Completed,Term Loan - 0.13M¬†$,6.08,0.508,-1.23,-1.25,16.93,3.52,37.09,-1.25,-1.35,2,1,2,,,,Coding,,,,,"The company raised $15.54 million in its initial public offering on the Nasdaq stock exchange under the ticker symbol of MTEK on February 2, 2022. A total of 3,700,477 units (which includes 3,690,477 Units and 10,000 Pre-Funded Units) were sold at a price of $4.2 per unit. Each unit consists of one ordinary share and one warrant to purchase one ordinary share and each Pre-Funded units consists of one Pre-Funded Warrant to purchase one ordinary share and one warrant to purchase one ordinary share. After the offering, there was a total of 7,265,289 outstanding shares (excluding the over-allotment option) priced at $4.2 per share, valuing the company at $30.51 million. The underwriters were granted an option to purchase up to an additional 555,071 units from the company to cover over-allotments, if any.",,
147636-64,Massivit 3D (TAE: MSVT),Massivit3D Printing Technologies Ltd.,,"Massivit 3D Printing Technologies Ltd is engaged in providing 3D printing solutions for the Engineering, Visual Communications, Entertainment, Academia, Interior Design, and Architectural markets.",Business Products and Services (B2B),Commercial Products,Machinery (B2B),"Machinery (B2B)*, Other Materials","3D Printing, Advanced Manufacturing, TMT","3d printer, 3d printing, 3d printing technology, digital printing, inkjet printer, large 3d printing",Formerly VC-backed,80.88,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",69,TAE,MSVT,2013,2025-04-21,,Israel,"Lod, Israel",201.37,2021-02-25,IPO,2021-02-25,51.56,Actual,201.37,Estimated,IPO,,Public Investment,2021-02-25,Completed,,,2016-02-17,19.69,Actual,Early Stage VC,50.61,Actual,,Venture Capital,Completed,,4.89,-0.6125,-16.16,-9.04,6.96,-2.02,-0.66,-15.1,-15.96,79,23,60,13,6,6,"Additive manufacturing, Casting of metals, Coating metallic material, Printing, duplicating, marking, or copying processes, Shaping or joining of plastics",,,,,"The company raised ILS 169 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of MSVT on February 25, 2021. After the offering, the company was valued at ILS 660 million.","Gadin Technologies, Stratasys (Computers, Parts and Peripherals), Yaskawa America",
436635-19,Matricelf (TAE: MTLF),Matricelf Ltd.,InVivo Therapeutics,Matricelf Ltd is engaged in research and development in the field of medicine and tissue engineering. It is a pioneering biotechnology company developing a platform for autologous matrix and cells implants for a wide range of medical conditions.,Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,Biotechnology*,"3D Printing, HealthTech, Life Sciences","3d bioprinting, biotechnology, regenerative medicine, spinal cord injury treatment, tissue engineering",Formerly VC-backed,9.63,Pre-Clinical Trials,Publicly Held,"Publicly Listed, Venture Capital",10,TAE,MTLF,2019,2024-06-26,,Israel,"Ness Ziona, Israel",21.53,2021-06-20,IPO,2021-06-20,7.38,Estimated,21.53,Estimated,IPO,,Public Investment,2021-06-20,Completed,,,2019-11-18,0.14,Actual,Grant,,,,Other,Completed,,,,,,13.68,,,,,,,,,,,,,,,,"The company raised ILS 24 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of MTLF on June 20, 2021. Previously, the company raised $1.25 million of convertible debt financing from undisclosed investors on February 4, 2021.",SEED AWARD,
98675-29,Maytronics (TAE: MTRN),Maytronics Ltd.,,"Maytronics Ltd is an Israel-based company which provides a complete solution for swimming pool care. It delivers automatic pool cleaners, environment-friendly water treatment systems, and pool safety products to residential and commercial swimming pool owners and operators across the world. The company's product brands are Dolphin line of robotic pool cleaners, the AQUAlife pool covers and Aqualarm and Espio pool alarms. Its operating segment includes Manufacturing of private pool cleaning robots as a key revenue driver; Manufacturing of public pool cleaning robots and Safety products and related pool products.",Information Technology,Computer Hardware,Other Hardware,Other Hardware*,"Manufacturing, Robotics and Drones","cleaning robot developer, robotic systems, swimming pool cleaning, swimming pool cleaning robot",Corporation,,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,753,TAE,MTRN,1983,2025-03-30,,Israel,"Kibbutz Yizre'el, Israel",,,,2004-08-15,,,,,IPO,,Public Investment,2004-08-15,Completed,,,2004-08-15,,,IPO,,,,Public Investment,Completed,,436.16,-0.1392,-9.16,258.12,116.45,157.19,531.73,38.19,12.85,495,102,329,86,80,80,"Buildings or like structures for particular purposes, Investigating or analysing materials by determining their chemical or physical properties, Measuring length, thickness or similar linear dimensions, Separation, Systems for controlling or regulating non-electric variables",,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of MTRN on August 15, 2004.",,
58701-16,MediWound (NAS: MDWD),MediWound Ltd.,"SolasCure, Tissue Regenix Group","MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,"Biotechnology, Pharmaceuticals*","Life Sciences, Manufacturing","biopharmaceutical firm, burns treatment, pharmaceutical, pharmaceutical drug product, pharmaceutical drug provider, pharmaceutical drugs, pharmaceuticals, wound management",Formerly PE-Backed,176.28,Generating Revenue/Not Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed, Venture Capital",111,NAS,MDWD,2001,2025-04-26,,Israel,"Yavne, Israel",106.48,2024-07-07,Merger/Acquisition,2024-07-15,6.69,Estimated,,,PIPE,,Corporate,2024-07-15,Completed,,,2004-01-01,,,PE Growth/Expansion,,,,Private Equity,Completed,,20.22,0.0822,-30.22,-2.64,195.4,2.63,152.96,-29.98,-31.46,74,11,46,11,17,17,"Diagnosis, Geophysics, Methods or apparatus for sterilising materials or objects in general, Preparations for medical, dental or toiletry purposes, Specific therapeutic activity of chemical compounds or medicinal preparations",14,,2,"Clal Biotechnology Industries, Deep Insight (Herzliya)","The company (NAS: MDWD) received ILS 25 million of development capital from M√∂lnlycke Health Care and other undisclosed investors on July 15, 2024 through a private placement. The company plans to use the net proceeds to advance EscharEx pre-commercial activities, expedite the development of large-scale manufacturing capabilities specifically for EscharEx, and support general corporate purposes.","Gandyr Investments, Harel Insurance Investments & Financial Services, Migdal Insurance and Financial Holdings, M√∂lnlycke Health Care, Teva Pharmaceutical Industries",
41514-13,Mer Telemanagement Solutions,"MTS IntegraTRAK, Inc.","A&B Groep, Intratem - Mobility Lifecycle Management, NetPlus Group, Source Loop, Network Control, Avotus, GlobalSign, Valicom, Market Data Services, MobiChord, One Source Communications, Veropath","Provider of communications and technology management services catering to enterprises and service providers. The company offers telecom expense management (TEM), enterprise mobility management, mobile virtual network operators and enablers and billing mobile money services and solutions.",Information Technology,Communications and Networking,Other Communications and Networking,"Consulting Services (B2B), Other Communications and Networking*, Telecommunications Service Providers","Internet of Things, Mobile, Mobile Commerce, TMT","data communication, mobile advertising, network services, technology managed services, technology management, technology management company",Corporate Backed or Acquired,2.2,Generating Revenue/Not Profitable,Acquired/Merged (Operating Subsidiary),"M&A, Publicly Listed",57,,,1984,2025-04-03,Entrypoint South,Israel,"Ra'anana, Israel",9.33,2016-05-19,PIPE,2023-01-01,,,,,Merger/Acquisition,Corporate Divestiture,Corporate,2023-01-01,Completed,,,1997-05-21,,,IPO,,,,Public Investment,Completed,,4.02,-0.2263,-1.81,-1.5,15.95,2.22,4.64,-2.09,-2.12,,,,,,,,,Entrypoint South,,,"The company, a subsidiary of SharpLink (NAS: SBET), was acquired by Entrypoint South for an undisclosed amount on January 1, 2023. With the acquisition, Entrypoint gains complementary solutions for present and new customers, creating a full ecosystem of telecommunications, core technology platforms and staff augmentation.",SharpLink Gaming,
62278-66,Micronet (TAE: MCRNT),Micronet Ltd.,,"Micronet Ltd is engaged in the development, manufacturing and marketing of mobile computing platforms for integration into fleet management and mobile workforce management solutions. It is an OEM vendor of mobile data terminals, supporting numerous fleet management, and mobile workforce management solutions and services in a variety of industries and vertical markets.",Information Technology,Software,Business/Productivity Software,Business/Productivity Software*,Mobile,"computing platform, mobile computing, mobile computing application, mobile computing platform, mobile computing product, mobile computing software, mobile workforce management",Corporate Backed or Acquired,2.08,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed",138,TAE,MCRNT,1982,2025-03-23,Tingo Group,Israel,"Rosh Haayin, Israel",14.69,2014-06-11,PIPE,,,,,,Merger/Acquisition,,Corporate,,Upcoming,,,2006-12-04,,,IPO,,,,Public Investment,Completed,,0.89,0.2239999999999999,-2.27,-4.47,6.66,-1.04,1.19,-2.31,-2.43,3,2,2,,1,1,"Electric digital data processing, Transmission of digital information",,,1,Tingo Group,"The company is in talks to be acquired by Jeen.ai for an undisclosed amount on September 17, 2024. Previously, the company raised NIS 4 million in its second public offering on the Tel Aviv stock exchange under the ticker symbol of MCRNT on June 22, 2020. The company is being actively tracked by PitchBook.",,
65677-33,Mobile Tornado Group (LON: MBT),Mobile Tornado Group PLC,"Avaya, Smith Micro Software, Vonage Holdings, Broadvoice, Sinch, IPCortex, Theatro, Bandwidth (US), Infobip, Mitto (Switzerland), tyntec, IVR Technology Group","Mobile Tornado Group PLC provides instant communication mobile applications serving the mobile data services market in the mobile communication industry. Its solutions include Push-To-Talk, Push-To-Locate, Push-To-Alert, and Push-To-Message. Geographically, it derives of its revenue from South America and has a presence in the UK, Europe, North America, Israel, Africa, and Asia/Pacific. The company generates revenue from License fees, Hardware and software, Professional Services, and Support and Maintenance.",Information Technology,Software,Communication Software,Communication Software*,"Mobile, TMT","communication software developer, instant communication, mobile communication software, mobile device software, workforce management",Corporation,11.11,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed",43,LON,MBT,1999,2025-04-10,,United Kingdom,"Harrogate, United Kingdom",15.13,2017-04-28,PIPE,2017-04-28,1.51,Estimated,15.13,Actual,PIPE,,Corporate,2017-04-28,Completed,,,2006-03-07,,,Reverse Merger,,,,Corporate,Completed,,2.61,-0.1484,-1.34,14.31,8.48,2.5,24.23,-1.23,-1.37,1,1,,,1,1,,,,3,"InTechnology, Investec, TMT Group","The company (LON: MBT) received GBP 1.2 million of financing from an undisclosed investor on April 28, 2017 through a private placement.",,
12402-73,Mobileye (NAS: MBLY),Mobileye Technologies Limited,"Ambarella, Arbe Robotics, Aeva, Velodyne Lidar, Torc Robotics, WeRide (Automotive), Drive.ai, Ottomatika, Optimus Ride, Zoox, Cipia, Roadstar.AI, Waymo, Princeton Lightwave, Movidius","Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.",Information Technology,Software,Business/Productivity Software,"Application Software, Application Specific Semiconductors, Automotive, Business/Productivity Software*","Artificial Intelligence & Machine Learning, Autonomous cars, Big Data, Industrials, Mobility Tech, TMT","accident reduction, autonomous car, autonomous driving, autonomous machine, autonomous vehicle, collision avoidance system, computer vision, drives assistance, machine learning, mobility tech",Formerly PE-Backed,961.0,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",3900,NAS,MBLY,1999,2025-04-26,Intel,Israel,"Shlomo Momo ha-Levi, Israel",16711.0,2022-10-26,IPO,2024-09-19,,,,,Secondary Transaction - Open Market,,,2024-09-19,Failed/Cancelled,,,,,,Early Stage VC,,,,Venture Capital,Completed,,1853.0,-0.0038,-2974.0,-1512.0,12293.63,894.0,10258.8,-2531.0,-3041.0,1642,277,1166,367,109,109,"Conjoint control of vehicle sub-units of different type or different function, Electric digital data processing, Image or video recognition or understanding, Measuring distances, levels or bearings, Systems for controlling or regulating non-electric variables",,,5,"Baillie Gifford, Intel, Norges Bank, Prudential Financial, Yissum","Intel (NAS: INTC) entered into an agreement to sell an undisclosed stake in the company (NAS: MBLY) on September 6, 2024. The company will not receive any proceeds from the offering. Subsequently, the offering was withdrawn on September 19, 2024. Previously Intel Overseas Funding Corporation sold a 4.78% stake in the company (NAS: MBLY) for $1.62 million on June 5, 2023. A total of 38,500,000 shares were sold for $42 per share. The company will not receive any proceeds from the offering.","ADIP, Alumni Ventures, Bank Leumi le-Israel, BlackRock Private Equity Partners, Blackstone, Catalyst Investments, Cinco Capital, Daniel Gutenberg, Enterprise Mobility Ventures, Enterprise Rent A Car Canada, Fidelity Investments, Gandyr Investments, General Atlantic, Gil Agmon, GlenRock Israel, Goldman Sachs Asset Management, Kilmahew Ventures, Motorola Solutions Venture Capital, Naftali Investments, Sailing Capital, Union Tech Ventures, Wellington Management",
108414-46,Mobilicom (NAS: MOB),Mobilicom Ltd.,,"Manufacturer of bound-free mobile wireless network solutions and products intended for the growing defense and commercial drones and robotics market. The company specializes in designing, developing and delivering smart solutions targeting global drone, robotics and autonomous system manufacturers, thereby helping detect, prevent and respond to multiple cyber threats and malicious attacks in real time without operator intervention.",Business Products and Services (B2B),Commercial Products,Electrical Equipment,"Electrical Equipment*, Other Commercial Products, Telecommunications Service Providers","Manufacturing, Robotics and Drones, TMT","4g technology, cloud security, drones, mission critical communication, network security, private network, security surveillance, wireless network",Corporation,9.64,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed",32,NAS,MOB,2017,2025-04-26,,Israel,"Shoham, Israel",32.76,2017-05-02,IPO,2023-10-10,10.0,Estimated,,,Public Investment 2nd Offering,,Public Investment,2023-10-10,Announced/In Progress,,,2017-01-17,14.33,Actual,Merger/Acquisition,14.33,Actual,,Corporate,Failed/Cancelled,,3.18,0.4498,-8.01,-8.36,12.84,1.83,,-7.84,-8.09,,,,,,,,,,,,"The company filed for a second public offering on the Nasdaq stock exchange under the ticker symbol of MOB on October 10, 2023. The expected offering amount is up to $10 million. Previously, the company (PINX: MILOF) received $2.95 million of development capital from undisclosed investors on January 26, 2024, through a private placement. The net proceeds will be used for working capital and general corporate purposes. The company is being actively tracked by PitchBook.",,First AU
54908-38,Monday.com (NAS: MNDY),monday.com Ltd.,"Asana, Smartsheet, Manifold (Business/Productivity Software)), Gitlab China, ServiceNow, Airtable, TeamSupport, Salesforce, Kissflow, Teamwork, Inflectra, ProjectManager, Changepoint, GitLab, ConnectWise, Freedcamp, Upland Software, 37signals, AdBrite (Certain Intellectual Property Assets), GanttPRO, Collab, Paymo(Oradea), Celoxis, Tasktop, Atlassian, Wrike, Tenrox, Symphony (New York), Planview, Conceptboard Cloud Service, Clarizen, Daptiv, LiquidPlanner, Forecast (Business/Productivity Software), Digital.ai, VivifyScrum, ProofHub, Planview PPM Pro, Kantask, Moxo, Mavenlink, Teambition, ChannelAdvisor, Base (Business/Productivity Software), Issuetrak, Workfront, Itdesign, Aha! (Business/Productivity Software), WorkBoardAI, Planisware, Midaxo, Acquire, Producteev, Quire (Business/Productivity Software), itdesign (IT Consulting and Outsourcing), The GenSight Group, Nutcache, Time Doctor, Clientjoy, ProjectWizards, PowerSteering, MeisterLabs Software, SS&C Intralinks, Clickup, Jive Software, ProModel, Trello, Taskworld, HubSpot, Notion Labs, Deven Software, Slack, Podio, HappyFox","Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.",Information Technology,Software,Software Development Applications,"Business/Productivity Software, Software Development Applications*","HR Tech, SaaS","business information management, business workflow management, email and authoring, enterprise collaboration software, kms, knowledge management system, project management system, work management platform, work management software",Formerly VC-backed,882.6,Profitable,Publicly Held,"Debt Financed, Publicly Listed, Venture Capital",2508,NAS,MNDY,2012,2025-04-26,,Israel,"Tel Aviv, Israel",6751.78,2021-06-10,IPO,2021-06-10,75.0,Actual,,,PIPE,,Venture Capital,2021-06-10,Completed,,,2012-08-01,1.5,Actual,Seed Round,,,Seed Round,Venture Capital,Completed,,972.0,0.3321,32.37,-1355.57,13911.89,868.3,10442.01,-14.47,-26.32,251,62,217,20,14,14,"Computing arrangements based on specific computational models, Electric digital data processing, Healthcare informatics, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Transmission of digital information",,,1,Zoom Communications,"The company (NAS: MNDY) received $75 million of development capital from Zoom Video Communications and Salesforce Ventures on June 10, 2021 through a private placement. The company issued 483871 ordinary shares at $155 price per share. Concurrently, the company raised $573.5 million in its initial public offering on the Nasdaq stock exchange under the ticker symbol of MNDY on June 10, 2021. A total of 3,700,000 shares were sold at a price of $155 per share. After the offering, there was a total of 43,559,876 outstanding shares (excluding the over-allotment option) priced at $155 per share, valuing the company at $6.75 billion. The underwriters were granted an option to purchase up to an additional 370,000 shares from the company to cover over-allotments, if any.","Entr√©e Capital, Founders Circle Capital, Genesis Partners, Hamilton Lane, HarbourVest Partners, Insight Partners, ION Asset Management, l1Capital Group, Launchbay Capital, Mubadala Investment Company, Salesforce Ventures, Sapphire Ventures, Stripes, Vintage Investment Partners",
123687-37,Motus GI Holdings (PINX: MOTS),"Motus GI Holdings, Inc.","KARL STORZ, Ambu, Medivators, C. R. Bard, Laborie Medical Technologies, Cogentix Medical, EndoChoice, Novadaq Technologies, Medical Measurement Systems, GI Supply, Cantel Medical, Conmed","Motus GI Holdings Inc is a medical technology company dedicated to improving endoscopy outcomes, lowering costs, and enhancing patient experiences. The company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the FDA) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (GI) endoscopy procedures. The Pure-Vu System is also CE marked in the European Economic Area (EEA) for use in colonoscopy.",Healthcare,Healthcare Devices and Supplies,Diagnostic Equipment,"Diagnostic Equipment*, Medical Supplies","Life Sciences, Oncology","clinical trials, endoscopy, endoscopy center, endoscopy device, endoscopy equipment, fecal fluid, medical technology company, prepped colon",Formerly VC-backed,74.58,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",15,PINX,MOTS,2008,2025-04-26,,United States,"Fort Lauderdale, FL",55.86,2018-12-20,Public Investment 2nd Offering,2023-05-19,3.5,Actual,,,PIPE,,Corporate,2023-05-19,Completed,,,,,,Accelerator/Incubator,,,,Other,Completed,,0.33,-0.4793,-10.59,-2.51,0.01,-0.08,-0.2,-9.26,-9.9,,,,,,,,13,,2,"Ascent Biomedical Ventures, Orchestra Medical Ventures","The company (NAS:MOTS) received $3.5 million of development capital from undisclosed investors through a private placement as of May 19, 2023. The company intends to use the net proceeds from the private placement for working capital and general corporate purposes.","GJG Life Sciences, Jacobs Investments, NGT HealthCare II, Perceptive Advisors, Pura Vida Investments, SternAegis Ventures",
60120-19,MTI Group (Israel) (LON: MWE),,"Antenna Products Corp., Narda-MITEQ, Mercury Systems, Miro Distribution, Cobham, Trivec Avant, Aethercomm, Gilat Satellite Networks, Mini-Circuits, Sierra Wireless, Comtech Telecommunications, Anaren","MTI Wireless Edge Ltd is an Israel-based company engaged in three segments; the antennas segment includes the development, design, manufacture, and marketing of antennas for the military and civilian sectors, Water solutions segment is a provider of remote control solutions for water and irrigation applications based on Motorola's IRRInet state of the art control, monitoring and communication technologies, and Distribution and Consultation segment provides consulting representation, and marketing services to foreign companies in the field of RF (radio frequency) and Microwave, including engineering services in the field of aerostat systems and system engineering services, and development, manufacture, and integration of communication systems and monitoring and control systems.",Information Technology,Communications and Networking,Wireless Communications Equipment,"Aerospace and Defense, Electrical Equipment, Wireless Communications Equipment*","Industrials, TMT","antenna system, commercial application, submarine platform",Formerly PE-Backed,12.2,Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",235,LON,MWE,1970,2025-04-16,MTI Computers & Software Services (1982),Israel,"Rosh Haayin, Israel",36.56,2006-03-16,IPO,2006-03-16,12.2,Actual,36.56,Actual,IPO,,Public Investment,2006-03-16,Completed,,,,,,PE Growth/Expansion,,,,Private Equity,Completed,,45.57,-0.0013,4.36,-5.06,49.39,14.2,42.85,6.38,4.9,37,12,23,3,11,11,"Antennas, Waveguides",,,1,Caledonian Holding,"The company raised GBP 7 million in its initial public offering on the AIM stock exchange under the ticker symbol of MWE on March 16, 2006. A total of 17,948,717 shares were sold at GBP 0.39 per share. After the offering, there was a total of 53,769,230 outstanding shares (excluding the over-allotment option) priced at GBP 0.39 per share, valuing the company at GBP 20 million.",Catalyst Investments,
115612-12,My Size (NAS: MYSZ),"My Size, Inc.","Metail, 3DLOOK, True Fit, Virtusize","My Size Inc is a USA-based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers and licensing cloud-enabled software subscriptions, associated software maintenance, and support.",Information Technology,Software,Business/Productivity Software,Business/Productivity Software*,"Mobile, TMT","apparel measurement, mobile app, mobile application, online clothes, smartphone application, smartphone application development firm",Corporation,18.5,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed",25,NAS,MYSZ,1999,2025-04-26,,Israel,"Airport City, Israel",,,,2023-01-30,7.23,Estimated,,,Secondary Transaction - Open Market,,,2023-01-30,Announced/In Progress,,,2005-09-01,,,IPO,,,,Public Investment,Completed,,8.26,0.1802,-3.99,-4.6,2.87,3.32,3.34,-3.72,-4.03,,,,,,,,,,,,"Selling stockholders entered into an agreement to sell its stake in the company (NAS:MYSZ) for $7.22 million on January 30, 2023. The company will not receive any proceeds from the offering. Previously, the company (NAS: MYSZ) received $8.5 million of development capital from undisclosed investors on October 27, 2021, through a private placement. The net proceeds from the offerings will be used for general corporate purposes, including working capital. The company is being actively tracked by PitchBook.",,
101948-14,Nano Dimension (NAS: NNDM),Nano Dimension Ltd.,"EnvisionTEC, Vader Systems, The ExOne Company, nScrypt, Nikon SLM Solutions, Shapeways Holdings, Kanfit, FATHOM (Oakland), Optomec, Xjet, Arcam, Desktop Metal, LulzBot","Manufacturer of intelligent machines intended for the fabrication of additively manufactured electronics. The company offers printed electronics, micro additive manufacturing, AI deep learning, SMT pick-and-place, and inkjet solutions.",Business Products and Services (B2B),Commercial Products,Machinery (B2B),Machinery (B2B)*,"3D Printing, Advanced Manufacturing, Manufacturing, Nanotechnology, TMT","3d printing, computer board, computer parts, electronics goods, inkjet deposition, intelligent machine",Corporate Backed or Acquired,1936.82,Generating Revenue/Not Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed, Venture Capital",509,NAS,NNDM,2012,2025-04-26,Lite-On Technology,Israel,"Ness Ziona, Israel",250.0,2022-01-01,Merger/Acquisition,2022-01-01,250.0,Actual,250.0,Estimated,Merger/Acquisition,,Corporate,2022-01-01,Completed,,,2012-01-01,,,Reverse Merger,,,,Corporate,Completed,,57.66,0.0684999999999999,-88.14,-748.83,22.38,27.17,,-56.53,-63.49,,,,,,,,,Lite-On Technology,,,"The company was acquired by Lite-On Technology (TAI: 2301) for $250 million in 2022. With this acquisition, Lite-On expands its range of 3D-printed antenna solutions.","Ayalim Trust Funds, Ilan Holdings, Israel Innovation Authority, Morris Kahn, Phoenix Finance & Investments, Shotfut Menayot Israel HaPhoenix Amitim, Wellborn Ventures, Z.B.I., Zeevi Bregman",
125087-32,Nano-x Imaging (NAS: NNOX),Nano-x Imaging Ltd.,,"Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.",Healthcare,Healthcare Devices and Supplies,Diagnostic Equipment,"Diagnostic Equipment*, Other Healthcare Technology Systems","Manufacturing, Nanotechnology","ct imaging, emission detection, imaging technology, medical imaging system, x-ray imaging, x-ray product",Formerly VC-backed,270.35,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",165,NAS,NNOX,2011,2025-04-26,,Israel,"Neve Ilan, Israel",805.59,2020-08-21,IPO,2023-07-26,30.0,Actual,,,PIPE,,Corporate,2023-07-26,Completed,,,2015-09-30,4.35,Actual,Seed Round,,,Seed Round,Venture Capital,Completed,,11.28,0.1391,-53.52,-65.76,334.75,-10.61,372.46,-45.01,-56.74,69,22,40,16,13,13,"Diagnosis, Electric discharge tubes or discharge lamps, Inorganic light-emitting semiconductor devices having potential barriers, Investigating or analysing materials by determining their chemical or physical properties, Semiconductor devices not covered by class h10",1,,2,"Gershon Capital, Happiness Capital","The company (NAS: NNOX) received $30 million of development capital from undisclosed investors on July 26, 2023, through a private placement. The company intends to use the net proceeds from the offering for general working capital purposes and further development of the Nanox.ARC, the Nanox.CLOUD and other products, and the manufacture and commercial deployment of the Nanox System. Previously, the company raised $165.22 million in its initial public offering on the NASDAQ stock exchange under the ticker symbol of NNOX on August 21, 2020. A total of 9,178,744 shares were sold at $18 per share. share. After the offering, there was a total of 44,754,976 outstanding shares (excluding the over-allotment option) priced at $18 per share, valuing the company at $805.58 million.","Asia Beam Limited, Foxconn Technology, FujiFilm (Diagnostic Equipment), Hon Hai Precision, Industrial Alliance Insurance and Financial Services, Israel Investment Fund Group, Oxen9, SK Telecom, Southern Israel Bridging Fund, Yozma Group Korea",
93590-83,NanoVibronix (NAS: NAOV),"NanoVibronix, Inc.","ConvaTec, KCI Holdings","NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.",Healthcare,Healthcare Devices and Supplies,Therapeutic Devices,Therapeutic Devices*,,"mechanical energy, medical device, pain treatment, therapeutic ultrasound, ultrasound therapy, wound healing",Corporation,20.2,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,15,NAS,NAOV,2003,2025-04-26,,United States,"New York, NY",,,,2023-09-01,5.0,Actual,,,PIPE,,Corporate,2023-09-01,Completed,,,2015-04-10,,,IPO,,,,Public Investment,Completed,,2.56,0.1205,-3.7,-0.64,3.91,1.51,1.03,-3.55,-3.55,32,10,19,1,12,12,"Devices for introducing media into, or onto, the body, Diagnosis, Methods or apparatus for sterilising materials or objects in general, Preparations for medical, dental or toiletry purposes",7,,3,"IDT, miriam winder, paul packer","The company (NAS: NAOV) received $5 million of development capital from undisclosed investors through a private placement on September 01, 2023. The company intends to use the net proceeds for general corporate purposes, including funding our development programs, commercial planning and sales and marketing expenses, potential strategic acquisitions, general and administrative expenses and working capital.",Collabrys,
97141-24,Nayax (TAE: NYAX),Nayax Ltd.,"VMC (UK), CPI (United States), PayRange, Parlevel Systems, 2Checkout, BlueSnap, ShinePay, PayAnywhere, Bindo Labs, Zettle, ShopKeep, Moneris Solutions, Cantaloupe Systems, Dream Payments, Payzer","Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It provides consumers with digital, cashless payments, and connected commerce experiences, enhancing consumer conversion and loyalty. Its platform addresses the entire unattended commerce value chain, including a payments infrastructure, a commerce software suite, a consumer engagement platform, and integrated POS devices. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.",Information Technology,Software,Financial Software,"Business/Productivity Software, Financial Software*, Other Hardware",FinTech,"automated machine, cashless payment, crm, customer relationship management, digital commerce, enterprise payment, fintech, monitoring services, payment platform, payment service, pos, telemetry platform",Formerly VC-backed,349.49,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, M&A, Private Equity, Publicly Listed, Venture Capital",1130,TAE,NYAX,2005,2025-04-26,,Israel,"Herzliya, Israel",1071.93,2021-05-13,IPO,2024-03-11,93.6,Actual,,,Public Investment 2nd Offering,,Public Investment,2024-03-11,Completed,,,2016-12-16,,,Corporate,,,Corporate,Corporate,Completed,,314.01,0.3334,-5.63,-37.55,1531.25,141.53,1027.67,20.59,-0.78,35,12,13,21,1,1,"Graphical data reading, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Time or attendance registers, Transmission, Wireless communication networks",,,,,"The company raised $93.6 million in its second public offering on the Nasdaq Stock Exchange under the ticker symbol of NYAX on March 11, 2024. A total of 3,600,000 shares were sold at $26 per share. The total proceeds, before expenses, to the company was $55.39 million, and to the selling shareholders was $26 million. In the offering, the company sold 2,130,435 shares and the selling shareholders sold 1,000,000 shares. The underwriters were granted an option to purchase up to an additional 469,565 shares from the selling shareholders to cover over-allotments, if any.","Elevator Lab, SafeCharge International Group",
91898-11,Neo Games,,"DB IT, Mirror Partner Utveckling, Myra (Systems and Information Management), Information Management Technologies, StadLine","NeoGames SA is a technology-driven firm primarily engaged in the lottery industry. It is a B2G and B2B technology and service provider to state lotteries and other lottery operators. It offers solutions for lottery games including instant and draw-based games via personal computers, smartphones, and handheld devices. The company provides services in four key areas namely, marketing operations, player operations, technology operations, and business operations.",Information Technology,IT Services,IT Consulting and Outsourcing,IT Consulting and Outsourcing*,TMT,"gaming content, gaming developer, gaming publisher, gaming studio, lottery games, lottery operator, lottery program, lottery support, lottery system, online scratch cards games",Corporate Backed or Acquired,69.66,Generating Revenue/Not Profitable,Acquired/Merged (Operating Subsidiary),"M&A, Publicly Listed",711,,,2005,2025-03-27,Aristocrat Leisure,Israel,"Tel Aviv, Israel",2200.0,2024-04-26,Merger/Acquisition,2024-04-26,2200.0,Actual,2200.0,Estimated,Merger/Acquisition,,Corporate,2024-04-26,Completed,,,2015-08-07,25.0,Actual,Corporate,85.03,Actual,Corporate,Corporate,Completed,,191.54,0.1559,-18.28,197.78,998.21,180.93,1151.85,63.89,7.95,,,,,,,,,Aristocrat Leisure,,,"The company was acquired by Aristocrat Leisure (ASX: ALL) for $2.2 billion on April 26, 2024. The acquisition allows Aristocrat to leverage its world-class gaming content, building customer relationships and expanding their capabilities across an even broader range of channels and geographies, adding further to the group's resilience and accelerating to the future.","Caesars Entertainment, William Hill",
465789-25,Neovasc Medical,Neovasc Medical Ltd.,,"Developer of pre-commercial vascular device in Or Yehuda, Israel. The company specializes in developing devices related to a novel catheter-based treatment for refractory angina, a debilitating condition resulting from inadequate blood flow to the heart muscle.",Healthcare,Healthcare Devices and Supplies,Therapeutic Devices,"Other Devices and Supplies, Therapeutic Devices*",,"healthcare device, heart device, medical device, medical therapy equipment, vascular devices",Corporate Backed or Acquired,,Generating Revenue,Acquired/Merged,M&A,,,,,2022-09-15,,Israel,Israel,,,,2008-07-01,,,,,Merger/Acquisition,,Corporate,2008-07-01,Completed,,,2008-07-01,,,Merger/Acquisition,,,,Corporate,Completed,,,,,,,,,,,3,3,,,3,3,,,Neovasc,,,The company was acquired by Neovasc (TSE: NVCN) for an undisclosed amount in July 2008. The company is no longer actively tracked by PitchBook.,,
289950-04,NeuroSense Therapeutics (NAS: NRSN),NeuroSense Therapeutics Ltd.,"Prilenia, AB Science, Amylyx, Biogen, Prothena, Alector, Apellis Pharmaceuticals","NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*",Life Sciences,"als drug development, als drugs, als treatment, chemistry, drugs and therapy, neurodegenerative diseases drugs, neurodegenerative diseases treatment, small molecule",Formerly VC-backed,27.79,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",15,NAS,NRSN,2017,2025-04-26,,United States,"Cambridge, MA",75.0,2024-04-15,PIPE,2024-12-31,5.0,Actual,,,PIPE,,Individual,2024-12-31,Completed,,,,0.28,Actual,Angel (individual),1.71,Actual,Angel (individual),Individual,Completed,,0.0,0.0,-10.21,-3.3,23.99,,27.55,-10.19,-10.21,18,3,13,5,,,"Preparations for medical, dental or toiletry purposes",6,,,,"The company (NAS: NRSN) received $5 million of development capital from Mr. Alon Ben-Noon on December 31, 2024 through a private placement. The placement consists of shares and warrants. The proceeds from the private placement are expected to be used for general corporate and working capital purposes.",,
468045-28,Next Vision Stabilized (TAE: NXSN),Next Vision Stabilized Systems Ltd,,"Next Vision Stabilized Systems Ltd is engaged in the field of micro stabilized gimballed cameras. It offers the widest range of stabilized cameras and accessories for commercial, industrial and security applications. The cameras can be mounted on ground, aerial and maritime platforms, and are the preferred choice where low SWaP2 (Size, Weight, Power and Price) without compromising performance is a key requirement. Its products include Colibri1, Colibri2, Colibri212, Nighthawk1, Nighthawk2, Nighthawk2-V, Nighthawk2-UZ, and Dragoneye2.",Business Products and Services (B2B),Commercial Products,Electrical Equipment,Electrical Equipment*,Manufacturing,"camera design, camera manufacturer, camera stabilizer manufacturer, camera system, photographic equipment, stabilized camera system",Corporation,,Profitable,Publicly Held,Publicly Listed,99,TAE,NXSN,2009,2025-04-26,,Israel,"Ra'anana, Israel",,,,2021-06-14,,,,,IPO,,Public Investment,2021-06-14,Completed,,,2021-06-14,,,IPO,,,,Public Investment,Completed,,114.93,1.2127,66.4,-122.11,2016.81,82.89,1222.84,73.76,72.61,6,1,4,,2,2,Pictorial communication,,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of NXSN on June 14, 2021.",,
279946-90,Nextage Cannabis Innovation (TAE: NXTG),Nextage Cannabis Innovation Ltd,"Corbus Pharmaceuticals, Cara Therapeutics, GW Pharmaceuticals, Abacus Health Products","Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,Pharmaceuticals*,"Cannabis, LOHAS & Wellness, Manufacturing","cannabinoid based pharmaceutical product, cannabis, cannabis developer, cannabis platform, cannabis researchers, contract development platform, gmp, gmp manufacturing, research lab",Corporation,,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,19,TAE,NXTG,,2025-04-18,,Israel,"Ness Ziona, Israel",,,,2020-08-30,,,,,Reverse Merger,,Corporate,2020-08-30,Completed,,,2020-08-30,,,Reverse Merger,,,,Corporate,Completed,,0.11,-0.5285,-0.88,0.06,9.71,0.02,6.94,-0.92,-0.92,,,,,,,,,,1,Micromedic Technologies,"The company acquired Micromedic Technologies (TAE: MCTC) through a reverse merger, resulting in the combined entity trading on the on the Tel Aviv Stock Exchange (TAE) under the ticker symbol NXTG on August 30, 2020.",,
179367-94,NextFerm (TAE: NXFR),NextFerm Technologies Ltd.,,"Nextferm Technologies Ltd is engaged in the research, development, production, and marketing of yeast-based technologies and products. Its products namely Astaferm and ProteVin mainly used by the food industry, including food additives, animal protein substitutes, and other products. Astaferm is an astaxanthin-rich extract derived from the Phaffia yeast.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Food Products, Other Commercial Products","Climate Tech, FoodTech, Life Sciences","alt-proteins, fermented protein, food technology platform, yeast culture, yeast engineering, yeast ingredients, yeast maker, yeast producer, yeast product",Formerly VC-backed,42.3,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",,TAE,NXFR,2013,2025-04-24,,Israel,"Yokneam, Israel",35.69,2021-01-26,IPO,2021-11-18,8.7,Actual,,,PIPE,,Corporate,2021-11-18,Completed,,,2016-01-01,5.0,Actual,Early Stage VC,8.65,Estimated,Series A,Venture Capital,Completed,,,,,,1.56,,,,,17,5,8,7,2,2,"Microorganisms or enzymes, Preparations for medical, dental or toiletry purposes, Treatment of flour or dough for baking",1,,,,The company (TAE: NXFR) received ILS 26.9 million of development capital from undisclosed investors in November 2021 through a private placement.,"Arancia, Cider Holdings, Food Lab Capital, Gadot Biochemical Industries, Horizon 2020, Merage venture capital, Orgad Agricultural Cooperative, Ortal, Yitong Capital",
58217-50,Nexxen (NAS: NEXN),Nexxen International Ltd.,"Outbrain, Getty Images, Millennial Media, Yeahmobi, Motive Interactive, Adsmovil, Sony Europe, The Kantar Group, Sizmek, Art of Click, Crisp Mobile, Blackfox, Fyber, Hipcricket (Mobile Advertising Business), Epsilon Data Management, XLMedia, ContactUs Reviews, Adxperience, Perform [cb], Mobvista, Performics, Illumin, Matomy Media Group, Perion Network, Digital Turbine, Voltari, Affle 3i, Emerge Digital Group, Dunnhumby (Media and Information Services), QuinStreet, Kargo (Media and Information Services), Kiip (Media and Information Services (B2B)), MaxPoint Interactive, Adello, Conversant., Spearad, Blue Track Media, Mirriad Advertising, PromoteIQ, Glispa, Viewbix, MyAppFree, Adobe, Adentro, Inmobi, Moasis, SessionM, YuMe (Media and Information Services (B2B)), Comscore, Marin Software, NativeX Holdings, AppNexus, NUVIAD, BidMind, Clickmob, HipCricket, Innovid, NextRoll, BuzzCity, Adyoulike, AppLovin, Percolate, Mapp Digital, Madison Logic, Tradelab, Yieldmo, MediaMath, MobileFuse, PropellerAds, KissMyAds, Welcome Software, Start.io, Cloud4Wi, Leanplum, Aarki, PubNative, Amobee, Swrve, Smaato, Crealytics, Teads, MobPartner","Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.",Business Products and Services (B2B),Commercial Services,Media and Information Services (B2B),"Media and Information Services (B2B)*, Other Commercial Services","Artificial Intelligence & Machine Learning, Big Data, TMT","artificial intelligence, data segmentation, marketing solutions, mobile marketing, mobile technology",Formerly Angel backed,0.6,Profitable,Publicly Held,"Pre-venture, Publicly Listed",854,NAS,NEXN,2007,2025-04-26,,United States,"New York, NY",,,,2014-07-31,,,,,Reverse Merger,,Corporate,2014-07-31,Completed,,,,0.6,Estimated,Angel (individual),,,Angel (individual),Individual,Completed,,365.48,0.1009,35.44,-149.87,608.17,304.46,527.62,99.5,40.82,5,4,1,,4,4,"Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes",,,1,Marimedia,"The company acquired Marimedia through a reverse merger, resulting in the combined entity trading on the London Stock Exchange under the ticker symbol MARI on July 31, 2014.",Itzhak Fisher,
41327-56,NICE (Business/Productivity Software) (TAE: NICE),NICE Limited,"LiveVox, Five9, Concentrix (IT Services & Consulting), Grow, Snap Pe, Genesys, Abrigo, Pegasystems, SAS Institute, Truth Technologies, ValidSoft, Onvisource, Satmetrix, Kampyle, Commence, Alteryx, InMoment, Boku Identity, Torch.AI, Ameyo, Actico, SAP, ActiveOps, Salesforce, Aravo, Quantifind, MapR, Mitek Systems, TIBCO Software, Fenergo, Reveal Group, 3CLogic, Service Management Group, SecureAuth, Talkdesk, Jumio, ResponseTek, Cyara, New Relic, Fraud.net, Smarsh, Ripjar, Opus Global, Velocify, Qubole, Calabrio, Global Speech Networks, Bright Pattern, Logi Analytics, Smartlogic, Sisense, JumpCloud, MicroStrategy (Business/Productivity Software), SurveyMonkey, Acqueon Technologies, Jacada, Sharpen Technologies, RDC (Business/Productivity Software), Dataiku, DialConnection, Sumo Logic, SNAP Innovation, Signifyd, Teradata, Platform28, Venminder, Sandsiv+, RingCentral, ThetaRay, Enlighten Operational Excellence, Elev∆í√¨o, C-Zentrix, Netcall, N. Harris Computer, Inbenta, Snapfi, Forsta (Business/Productivity Software), Looker, Aircall, Emailage, Novetta Solutions, Global Software (United States), Deep.BI, IDology (Network Management Software), Empirix, Oracle, Databricks, Global Relay Communications, Exotel, Medallia, DataRobot, Sensiple, Alpine Data, Dynatrace, Digital Reasoning, InsightSquared, Verafin, DIGIOP, GlobalVision Systems, Quantexa, CyberSource, Splunk, Verint Systems, Axonius, Klipfolio, Birst, NetScout Systems, CallMiner, Rapid7, Unito, Vocalcom, Nexthink, Tellius, ipSCAPE, Fuze (Communication Software), Synaptica (Business/Productivity Software), InsideSales, Fair Isaac, C1, Mimecast, Amperity, Alchemer, Clarabridge, RapidMiner, Wise.io, inContact, Urchin Software, Sutherland Global Services, Forter, Rifiniti, Sysdig, ThreatMetrix, Hortonworks, DataStax, Socure, Brandwatch, Feedzai, Directly, Firebase, ThoughtSpot, Domo, Trulioo, Proofpoint, Tonbeller, Securonix, TopQuadrant, Varonis Systems, Zix, EastNets, Questback, CipherCloud, Amazon Web Services, Bay Dynamics, SymphonyAI Sensa, Truework, Spoken (Business/Productivity Software), Concept Searching, Duo Security","Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. The company provides data analytics-based solutions through both a cloud platform and on-premises infrastructure. Within customer engagement, Nice's CXone platform delivers solutions focused on contact center software and workforce engagement management, or WEM. Contact center offerings include solutions for digital self-service, customer journey and experience optimization, and compliance. WEM products optimize call center efficiency, leveraging data and AI analytics for call volume forecasting and agent scheduling. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money laundering, and compliance solutions.",Information Technology,Software,Business/Productivity Software,"Automation/Workflow Software, Business/Productivity Software*, Financial Software","CloudTech & DevOps, FinTech, SaaS, TMT","cloudtech and devops, data security, public safety tool, robotics process automation, security software, security software task, security technology, technology and software",Corporation,,Profitable,Publicly Held,Publicly Listed,8726,TAE,NICE,1986,2025-04-26,,Israel,"Ra'anana, Israel",,,,1991-12-30,,,,,IPO,,Public Investment,1991-12-30,Completed,,,1991-12-30,,,IPO,,,,Public Investment,Completed,,2735.27,0.1505,442.59,-1058.1,9711.43,1825.75,9743.98,745.02,540.0,253,118,52,4,197,197,"Electric digital data processing, Information storage based on relative movement between record carrier and transducer, Signalling or calling systems, Telephonic communication, Transmission of digital information",,Nokia,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of NICE on December 30, 1991.",,
58888-36,Nova (Israel) (NAS: NVMI),Nova Ltd.,"KLA, Renishaw, Keysight Technologies, ams-OSRAM, KUKA (Electronic Equipment and Instruments), National Instruments","Nova Ltd is a semiconductor equipment manufacturer. The company provides metrology solutions for process control used in semiconductor manufacturing. The company offers in-line optical and x-ray stand-alone metrology systems, as well as integrated optical metrology systems. The product range consists of Nova 2040, Nova 3090Next, Nova i500 and i500 Plus, Nova T500, Nova T600, Nova V2600, HelioSense 100, Nova Hybrid Metrology solution, NovaMars. The company generates the majority of its revenue from China. Geographically the company has its business spread across the region of Taiwan, Korea, China, the United States, and Europe.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,"Business/Productivity Software, Electronic Equipment and Instruments*","Manufacturing, TMT","circuit, integrated circuit, integrated process control, manufacturing, optical tops, semiconductor platform",Formerly VC-backed,,Profitable,Publicly Held,"Publicly Listed, Venture Capital",1383,NAS,NVMI,1993,2025-04-26,,Israel,"Rehovot, Israel",,,,2000-04-11,,,,,IPO,,Public Investment,2000-04-11,Completed,,,,,,Early Stage VC,,,,Venture Capital,Completed,,672.4,0.2983,183.76,-350.47,5757.71,387.09,5360.91,199.12,181.74,742,207,439,57,246,246,"Electric discharge tubes or discharge lamps, Investigating or analysing materials by determining their chemical or physical properties, Measuring length, thickness or similar linear dimensions, Photomechanical production of textured or patterned surfaces, Semiconductor devices not covered by class h10",,,,,"The company completed its initial public offering on the Nasdaq stock exchange under the ticker symbol of NVMI on April 11, 2000.","Inventech Investment, Teuza",
54277-57,Novocure (NAS: NVCR),Novocure GmbH,"Perspective Therapeutics, Agios Pharmaceuticals, Exelixis","NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Drug Delivery, Drug Discovery","Life Sciences, Oncology","anti-mitotic treatment, tumor progression reverse, tumor treating field",Formerly VC-backed,882.0,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Publicly Listed, Venture Capital",1488,NAS,NVCR,2000,2025-04-26,,Switzerland,"Root, Switzerland",1818.89,2015-10-01,IPO,2024-05-02,400.0,,,,Debt Refinancing,Bonds,Debt,2024-05-02,Completed,400.0,Term Loan - 400.00M¬†$ (Senior; Floating),2004-01-01,,,Early Stage VC,,,,Venture Capital,Completed,,621.71,0.1827,-164.19,-232.4,2062.48,479.7,1682.17,-128.14,-139.89,1029,275,562,392,75,75,"Devices for introducing media into, or onto, the body, Diagnosis, Electrotherapy, Image data processing or generation, in general, Preparations for medical, dental or toiletry purposes",74,,,,"The company completed a $400 million debt refinancing round on May 2, 2024.","Annox Capital, Autonomy Ventures, EXOR Seeds, Index Ventures, Invus Opportunities, Johnson & Johnson Innovation - JJDC, Lars Albright, Pfizer Ventures, Stelac Capital Partners, Storford, Viceroy Ventures, Volati, WFD Ventures, Windham Capital Partners",
158969-89,NRGene (TAE: NRGN),NRGene Technologies Ltd,"Knome, Foundation Medicine, Genuity Science, Eagle Genomics, DNAnexus",NRGene Technologies Ltd is engaged in the development of artificial intelligence-based software for the analysis of genetic information in order to improve species of plants and animals.,Information Technology,Software,Business/Productivity Software,"Biotechnology, Business/Productivity Software*","AgTech, Climate Tech, FoodTech, Life Sciences, Supply Chain Tech, TMT","ag biotech, agriculture technology, alt-proteins, artificial intelligence, artificial intelligence software, breeding technology, genetic tools, genomics company, genomics platform, plant data & analysis, plant data and analysis, plant-based protein",Formerly VC-backed,31.03,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Publicly Listed, Venture Capital",29,TAE,NRGN,2009,2025-04-21,,Israel,"Ness Ziona, Israel",114.83,2021-01-26,IPO,2021-01-26,31.03,Estimated,114.83,Estimated,IPO,,Public Investment,2021-01-26,Completed,,,2012-02-21,,,Seed Round,,,Seed Round,Individual,Completed,,1.29,-0.3553,-3.36,-1.08,9.12,0.27,7.93,-2.8,-3.46,1,1,,1,,,"Measuring or testing processes involving enzymes, nucleic acids or microorganisms",,,,,"The company raised ILS 100 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of NRGN on January 26, 2021. After the offering, the company was valued at ILS 370 million.","Adama, Gadin Technologies, Waarde Capital",
168418-45,NRx Pharmaceuticals (NAS: NRXP),"NRx Pharmaceuticals, Inc.","SAGE Therapeutics, Intracellular Therapies, Relmada Therapeutics, Axsome Therapeutics, Pfizer Pakistan, Eli Lilly and Company","NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*, Pharmaceuticals",Life Sciences,"bipolar disorder, central nervous system disorder, central nervous system disorder treatment, chemistry, novel therapeutics, pharmaceutical, small molecule, suicidal crisis, suicide treatment",Formerly VC-backed,178.5,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed, Venture Capital",22,NAS,NRXP,2015,2025-04-26,,United States,"Wilmington, DE",486.0,2021-05-25,Reverse Merger,2024-08-13,16.0,,,,Debt - Acquisition,,Debt,2024-08-13,Completed,16.0,"Bonds - 16.00M¬†$ (Senior, Unsecured)",2016-11-21,6.7,Actual,Seed Round,91.0,Actual,Series B1,Venture Capital,Completed,,0.0,0.0,-25.13,5.13,35.02,,31.63,-24.93,-24.94,2,1,2,,,,"Preparations for medical, dental or toiletry purposes",10,,,,"The company raised $2.00 million in its second public offering on the Nasdaq stock exchange under the ticker symbol NRXP on April 15, 2024. A total of 607,000 shares were sold at $3.3 per share. The underwriters were granted an option to purchase up to an additional 1,000,000 shares from the company to cover over-allotments, if any.","Asland Capital Partners, Big Rock Partners Acquisition, Catalytic Impact Foundation, Global Emerging Markets, Impact Assets",
467142-94,Nur Ink Innovations (TAE: NURI),Nur Ink Innovations Ltd,,"Nur Ink Innovations Ltd is engaged in the research and development of water-based inks for digital printers. Some of the products of the company are Direct-to-Garment (DTG), Direct-to-Textile (DTT), Roll-to-roll printing of indoor & outdoor advertising, and wallpapers.",Business Products and Services (B2B),Commercial Services,Printing Services (B2B),Printing Services (B2B)*,,"digital printing, ink manufacturer, printing inks manufacturer",Corporation,,Generating Revenue,Publicly Held,Publicly Listed,,TAE,NURI,2018,2024-06-19,,Israel,"Magshimim, Israel",,,,2021-05-31,,,,,IPO,,Public Investment,2021-05-31,Completed,,,2021-05-31,,,IPO,,,,Public Investment,Completed,,,,,,12.02,,,,,4,3,,4,,,"Dyeing or printing textiles, Printing, duplicating, marking, or copying processes",,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of NURI on May 31, 2021.",,
472114-54,Nurexone Biologic (TSX: NRX),NurExone Biologic Inc.,,"NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*, Other Healthcare Technology Systems",Life Sciences,"biotech, biotech firm, biotechnology, drug discovery, spinal cord injury, spinal cord injury treatment",Corporation,9.16,Generating Revenue,Publicly Held,Publicly Listed,16,TSX,NRX,2011,2025-04-26,,Canada,"Toronto, Canada",9.83,2023-09-06,PIPE,2025-04-04,1.61,Actual,,,PIPE,,Corporate,2025-04-04,Completed,,,2022-05-31,,,Reverse Merger,,,,Corporate,Completed,,0.0,0.0,-5.04,-0.67,37.71,,28.13,-4.94,-5.03,5,3,,5,,,"Microorganisms or enzymes, Preparations for medical, dental or toiletry purposes",,,1,EnerSpar,"The company (TSX: NRX) received CAD 2.30 million of development capital from undisclosed investors on April 4, 2025 through a private placement. Each unit consisted of one common share in the capital of the company and one common share purchase warrant. The Company intends to use the proceeds of the Offering for working capital, ExoTop's establishment of a United States production facility and an uplisting to a major United States exchange, subject to requisite regulatory approval.",,
343156-78,Nutritional Growth Solutions (ASX: NGS),Nutritional Growth Solutions Ltd.,Else Nutrition Holdings,"Nutritional Growth Solutions Ltd is engaged in the business of developing produces and selling clinically tested protein supplements for children. It offers protein shakes and other products to improve the height and weight of children. It generates its revenues through the sale of its products directly to customers. Its brands include Horlicks, Healthy Heights, Pro Up, and Healthy Height China. Geographically it operates in the United States and the Rest of the World and the majority of its revenue comes from the united states.",Consumer Products and Services (B2C),Consumer Non-Durables,Food Products,"Beverages, Food Products*",,"healthy drinks branding, healthy drinks production, height increasing drinks, nutritional food, nutritional food producer, nutritional products",Corporation,7.42,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,,ASX,NGS,2010,2024-11-06,,Israel,"Tel Aviv, Israel",13.52,2020-10-30,IPO,2022-08-22,2.42,Actual,,,PIPE,,Corporate,2022-08-22,Completed,,,2020-10-30,4.99,Actual,IPO,13.52,Estimated,,Public Investment,Completed,,2.48,-0.1686,-2.9,0.13,2.6,0.81,3.92,-2.83,-2.83,21,2,21,,,,"Preparations for medical, dental or toiletry purposes",,,,,"The company (ASX: NGS) received AUD 3.48 million of development capital from undisclosed investors on August 22, 2022, through a private placement. Placement proceeds will be used to fund future purchase orders with Walmart and rollout marketing campaigns to Walmart customers and accelerate sales with other key retailers across North America and Southeast Asia.",,
158967-82,Nuvo,NUVO Inc.,"Prima-Temp, Monica Healthcare","Developer of a remote maternal-fetal monitoring platform designed to optimize pregnancy healthcare. The company offers remote access to medical-grade data to all key participants in the pregnancy care ecosystem, thereby enabling providers to conduct virtual well-being checks and remote non-stress-tests with expectant moms from anywhere, keeping patients and doctors connected at a time when it is needed most.",Healthcare,Healthcare Devices and Supplies,Monitoring Equipment,"Application Software, Electronic Equipment and Instruments, Monitoring Equipment*","Artificial Intelligence & Machine Learning, Big Data, FemTech, HealthTech, Wearables & Quantified Self","healthcare data analytics, maternal care, maternal care services, personalized care, pregnancy care, pregnancy management, pregnancy monitoring platform, proprietary software solutions, remote healthcare, remote monitoring, sensor-based technology, vertical application",Formerly VC-backed,73.0,Bankruptcy: Admin/Reorg,Privately Held (backing),"Publicly Listed, Venture Capital",82,,,2007,2025-03-20,,United States,"Aventura, FL",358.12,2022-01-28,IPO,2024-08-22,,,,,Bankruptcy: Admin/Reorg,,Bankruptcy,2024-08-22,Completed,,,2007-06-01,,,University Spin-Out,,,,Corporate,Completed,,0.0,,-37.76,-5.61,,,,-37.56,-37.76,,,,,,,,2,LAMF Global Ventures I,1,Ramot at Tel Aviv University,"The company filed for Chapter 11 bankruptcy on August 22, 2024. Previously, the company LAMF Global Ventures I through a reverse merger, resulting in the combined entity trading on the NASDAQ under the ticker symbol NUVO on May 2, 2024.","Gaingels, Gal Ventures, GEM Capital, Kli Capital, MedTech Innovator",
63374-86,Nyxoah (BRU: NYXH),Nyxoah S.A.,"Inspire Medical Systems, Respicardia, Cryosa, ResMed, DeVilbiss Healthcare, Somnics, Wellell, LivaNova, EPD Solutions, Vivos Therapeutics","Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.",Healthcare,Healthcare Devices and Supplies,Therapeutic Devices,Therapeutic Devices*,Life Sciences,"sleep disorder, sleep tech, sleep technology, therapeutic device, therapeutic device for sleep, treating obstructive sleep",Formerly VC-backed,279.35,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",184,BRU,NYXH,2009,2025-04-26,,Belgium,"Mont-Saint-Guibert, Belgium",444.31,2020-09-18,IPO,2024-10-07,27.0,Actual,,,PIPE,,Corporate,2024-10-07,Completed,,,,11.09,Estimated,Angel (individual),,,Angel (individual),Individual,Completed,,4.89,0.0398,-64.1,-65.45,228.96,3.21,268.47,-59.85,-62.81,338,33,285,26,27,27,"Circuit arrangements or systems for supplying or distributing electric power, Diagnosis, Electrotherapy",7,,2,"BlackRock, ResMed","The company (BRU: NYXH) received $27 million of development capital from BlackRock and undisclosed investors on October 7, 2024 through a private placement.","Andera Partners, Cochlear, Deerfield Partners, Gilde Healthcare, Horizon 2020, J√ºrgen Hambrecht, Noshaq, Otium Capital, Robelga SRL, Robert Taub, Soci√©t√© R√©gionale d'Investissement de Wallonie, SWIR, TCD Capital, TOGETHER Partnership, Uwe Wascher, Viralety Ventures",
181832-68,Oddity Tech (NAS: ODD),Oddity Tech Ltd.,"Aemi, Haus Labs by Lady Gaga, Beautycounter, Nars Cosmetics, Glossier, E.L.F. Beauty, Younique, Cult Beauty, ILIA Beauty, Too Faced Cosmetics, MAC Cosmetics, SAHI Cosmetics, Estee Lauder",ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.,Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Personal Products","Artificial Intelligence & Machine Learning, Augmented Reality, Life Sciences, Manufacturing","beauty product, beauty products, cosmetic ecommerce, crm, customer relationship management, ecommerce website, online retailer, personal care products",Formerly PE-Backed,111.4,Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",489,NAS,ODD,2013,2025-04-26,,United States,"New York, NY",1978.91,2023-07-19,IPO,2024-03-15,208.04,Actual,,,Secondary Transaction - Open Market,,,2024-03-15,Completed,,,2020-01-01,,,Later Stage VC,,,,Venture Capital,Completed,,647.04,0.272,101.49,-77.51,2470.4,468.32,2275.79,125.43,115.6,5,1,4,,1,1,Hairdressing or shaving equipment,,,2,"BDT & MSD Partners, L Catterton","L Catterton sold a 8.41% stake in the company (NAS:ODD) for $208.04 million on March 15, 2024. A total of A total of shares 4,782,609 were sold at a price of $43.50 per share. The company will not receive any proceeds from the offering.","Baillie Gifford, Fidelity Investments, First Light Capital Group, Franklin Templeton (San Mateo), iAngels, Thomas Tull",
61570-27,OdysightAI (NAS: ODYS),Odysight.AI Ltd,,"Odysight ai Inc is engaged in the development, production, and marketing of Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.",Healthcare,Healthcare Devices and Supplies,Diagnostic Equipment,Diagnostic Equipment*,"Manufacturing, TMT","endoscopy, manufacturing, medical imaging, medical imaging tool, micro imaging camera, visual solutions",Corporation,34.71,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",49,NAS,ODYS,2013,2025-04-26,,Israel,"Omer, Israel",,,,2025-02-12,21.5,Actual,,,Public Investment 2nd Offering,,Public Investment,2025-02-12,Completed,,,2019-12-30,,,Reverse Merger,,,,Corporate,Completed,,3.96,0.307,-11.77,-17.12,90.51,1.16,81.06,-12.38,-12.51,46,13,23,19,4,4,"Control or regulating systems in general, Diagnosis, Filters implantable into blood vessels, Pictorial communication, Printed circuits",,,3,"Intellisense Solutions, Phoenix Financial (Multi-line Insurance), Shotfut Menayot Israel HaPhoenix Amitim","The company raised $21.49 million in its second public offering on the Nasdaq Stock Exchange under the ticker symbol of ODYS on February 12, 2025. A total of 3,307,692 shares were sold at $6.5 per share. The underwriters were granted an option to purchase up to an additional 496,153 shares from the company to cover over-allotments, if any. Previously, the company (PINX: ODYS) received NIS 10.293 million of development capital from an undisclosed investor on July 15, 202, through a private placement. Funds will provide the capital necessary to accelerate Odysight.ai's sales, vertical expansion and strategic partnerships and enable it to become a leader in the video analytics cloud-based AI predictive maintenance market.","Arkin Capital, Xylo Technologies",
125878-51,One World Pharma (PINX: OWPC),One World Pharma Inc,"Medical Marijuana, Strainz","One World Products Inc along with its subsidiaries is engaged in the cultivation, production, and distribution of raw cannabis and hemp plant ingredients for both medical and industrial uses. It focuses on cultivating, processing, and supplying cannabis oil, distillate, and isolate to customer's specifications.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,Pharmaceuticals*,"Cannabis, LOHAS & Wellness","cannabis, cannabis cultivator, cannabis processor, cannabis production, raw cannabis",Corporation,0.08,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,10,PINX,OWPC,2014,2025-04-26,,United States,"Las Vegas, NV",0.53,2018-11-22,Merger/Acquisition,2018-11-22,0.35,Actual,0.53,Actual,Merger/Acquisition,,Corporate,2018-11-22,Completed,,,2015-09-25,0.08,Actual,IPO,,,,Public Investment,Completed,,0.01,-0.9468,-5.74,3.41,2.86,-0.17,10.91,-4.79,-4.8,,,,,,,,,OWP Ventures,,,"The company was acquired by OWP Ventures for $350,000 on November 22, 2018.",,
13347-82,Orad (TAE: ORAD),Orad Ltd.,ACORDE Technologies,"Orad Ltd provides integration services in the areas of security systems, fire protection equipment, communication equipment, as well as traffic and parking management systems. It provides solutions for security and perimeter protection, fire safety and detection, infrastructures, electromechanical systems, automation, and communications systems in Israel.",Business Products and Services (B2B),Commercial Services,Security Services (B2B),"Aerospace and Defense, Electronic Equipment and Instruments, Security Services (B2B)*","Industrials, Manufacturing, Robotics and Drones, TMT","communications & control, parking sensors, perimeter defense",Formerly PE-Backed,20.0,Generating Revenue,Publicly Held,"Debt Financed, Private Equity, Publicly Listed",201,TAE,ORAD,1971,2025-04-04,,Israel,"Holon, Israel",1.74,2011-10-23,Merger/Acquisition,2013-01-01,,,,,PIPE,,,2013-01-01,Completed,,,2006-02-05,10.0,Actual,PE Growth/Expansion,23.8,Actual,,Private Equity,Completed,,,,,,14.55,,,,,,,,,,,,,Adoram,1,Solag,The company (TAE: ORAD) received an undisclosed amount of financing from Solag in 2013.,Shamrock Israel Growth Fund,
41552-02,Oramed Pharmaceuticals (NAS: ORMP),Oramed Pharmaceuticals Inc.,"Phathom Pharmaceuticals, Rani Therapeutics, Emisphere Technologies, Lisata Therapeutics, VBI Vaccines (Drug Delivery), Pfizer Manufacturing Austria, ACADIA Pharmaceuticals, Ardelyx, Amicus Therapeutics, Apellis Pharmaceuticals, MOD3 Pharma, Pfizer Pakistan, Bluebird Bio, Auspex Pharmaceuticals, Sensulin, Zealand Pharma, Vaxart, Acer Therapeutics, Alzheon, Omeros, Antag Therapeutics, ViaCyte, Nymox Pharmaceutical, PepGen, ProMIS Neurosciences, Catalyst Pharmaceuticals, Intarcia, PhaseBio Pharmaceuticals, Novo Nordisk, OptiNose, Actinium Pharmaceuticals, Arcturus Therapeutics, Regenerative Medical Solutions, Ra Pharmaceuticals, Ability Pharma, Genentech, Diamyd Medical, Metabolic Solutions Development Company, Lineage Cell Therapeutics, GlaxoSmithKline Consumer Nigeria, Aegis Therapeutics, Aerami Therapeutics, Moderna, Critical Pharmaceuticals","Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.",Healthcare,Pharmaceuticals and Biotechnology,Drug Delivery,"Drug Delivery*, Pharmaceuticals",TMT,"drugs delivery, drugs delivery system, pharmaceutical, pharmaceutical developer, research service",Corporation,55.0,Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",13,NAS,ORMP,2002,2025-04-26,,United States,"New York, NY",,,,,,,,,Secondary Transaction - Open Market,,Private Equity,,Completed,,,2007-05-01,,,IPO,,,,Public Investment,Completed,,0.0,,-19.06,-141.56,95.18,,-45.23,-19.87,-20.07,,,,,,,,1,,2,"Guangxi Wuzhou Zhongheng Group Company, Hefei Tianhui Incubator of Technologies",Sinopharm Capital sold stake in the company (NAS: ORMP) for an undisclosed amount. The company will not receive any proceeds from the offering.,Sinopharm Capital,
101991-61,Orbit Communication Systems (TAE: ORBI),ORBIT Communication Systems Ltd.,O3B Networks,"Orbit Technologies Ltd is a provider of airborne communications, satellite-tracking, maritime, ground-station and new space solutions for commercial and government establishments. Its products include Audio Management System, Maritime SATCOM, Airborne Audio Management System, Maritime SATCOM, etc.",Information Technology,Communications and Networking,Telecommunications Service Providers,"Government, Other Communications and Networking, Telecommunications Service Providers*","Space Technology, TMT","communication management system, tracking & telemetry systems",Corporation,10.0,Profitable,Publicly Held,"Private Equity, Publicly Listed",210,TAE,ORBI,1950,2025-04-23,,Israel,"Netanya, Israel",,,,2017-11-30,10.0,Actual,,,PIPE,,Private Equity,2017-11-30,Completed,,,2000-02-03,,,IPO,,,,Public Investment,Completed,,70.05,0.1117,11.75,-23.94,245.15,26.89,172.17,16.37,12.86,23,13,15,1,7,7,"Antennas, Locks, Transmission, Transmission of digital information",,,1,FIMI Opportunity Funds,"FIMI Opportunity Funds acquired a 33.4% stake in the company (TAE: ORBI) on November 30, 2017 through a private placement. FIMI also received options to purchase additional Orbit shares for approximately $20 million. If fully realized, FIMI would possess 56% of the company's shares.",,
42240-25,Orgenesis (PINX: ORGS),"Orgenesis, Inc.","TiGenix, PeproTech, Regenerative Medical Solutions, Treefrog Therapeutics, Sernova, WindMIL Therapeutics, ViaCyte, Semma Therapeutics, Biological Industries, Histogen, Affinia Therapeutics, Miltenyi Biotec, Calimmune, Eurofins DiscoverX Products, ThermoGenesis Holdings, Osiris Therapeutics, Octane Medical Group, Axol Bioscience, Bluebird Bio, Lonza Group, WuXi AppTec, PierianDx","Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*",,"biotech firm, biotechnology, cell therapy, clinical development, clinical trials, gene therapy startups, inflammatory disease",Corporation,32.17,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed",146,PINX,ORGS,2008,2025-04-26,,United States,"Germantown, MD",0.23,2009-09-09,IPO,2024-04-11,8.34,Actual,,,Sale-Lease back facility,,Other,2024-04-11,Completed,,,2009-09-09,0.07,Actual,IPO,0.23,Estimated,,Public Investment,Completed,,0.9,-0.9357,-34.41,17.09,11.97,-12.27,33.93,-30.63,-32.45,84,26,38,23,23,23,"Apparatus for enzymology or microbiology, Microorganisms or enzymes, Preparations for medical, dental or toiletry purposes, Separation, Specific therapeutic activity of chemical compounds or medicinal preparations",,,3,"Phoenix Financial (Multi-line Insurance), Sphera Global Healthcare, Walloon Region","The Octomera Mobile Processing Units and Labs of the company was acquired by Germfree Laboratories through a $8.4 million sale-leaseback on April 11, 2024.",,
51552-82,Outbrain (NAS: OB),Outbrain Inc.,"Taboola, VideoAmigo, Stats Perform, Ooyala, Performics, Mintent, The Nielsen Company, Platform360, NativeX Holdings, Teads, ViralGains, Hipcricket (Mobile Advertising Business), OneSpot, SimpleReach, TripleLift, VideoElephant, Bidtellect, Thunder Industries, Apester, Tinuiti, Celtra, GroupM Worldwide, Tubular (Mountain View), Spoutable, Pixability, iProspect Germany, Kapost, Sharethrough, Nova (Toronto), nRelate, Zemanta, Brafton, PowerLinks, AdColony, vidIQ, VideoAmp, my6sense, KGL PubFactory, Nativo, Permutive, Storygize, Vidyard, Zefr, NextRoll, iProspect, GumGum, plista, DataXu, Flashstock, Vemba (Multimedia and Design Software), Uberflip, The Search Agency, MGID, 3Q/ Dept, RevContent","Outbrain Inc is a platform powering the open web that matches audiences with personalized content and ads, driving quality engagement. Its platform delivers ads to end-users that appear as links to articles, products, and videos on media partners' sites. It derives revenue from advertisers through user engagement with the ads that it places on media partners' web pages and mobile applications. The company has its geographic presence in Europe, the Middle East, and Africa followed by the USA and others.",Business Products and Services (B2B),Commercial Services,Media and Information Services (B2B),Media and Information Services (B2B)*,"AdTech, Mobile, TMT","advertisers platform, content discovery platform, content distribution, content promotion, content recommendation, crm, customer relationship management, web publishing",Formerly PE-Backed,554.52,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, M&A, Private Equity, Publicly Listed, Venture Capital",1800,NAS,OB,2006,2025-04-26,,United States,"New York, NY",1077.11,2021-07-23,IPO,2025-02-07,1587.5,,,,Debt - Acquisition,Acquisition Financing,Debt,2025-02-07,Completed,1587.5,"Bonds - 637.50M¬†$ (Senior, Secured; Equity Clawback; Fixed); Revolving Credit - 100.00M¬†$ (Syndicated; Floating)",2007-01-01,1.0,Actual,Seed Round,,,Seed Round,Venture Capital,Completed,,889.88,-0.0491,-0.71,-150.31,359.79,192.1,242.46,15.62,-3.86,69,43,60,,9,9,"Computing arrangements based on specific computational models, Electric digital data processing, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Transmission of digital information",,,2,"Gemini Israel Ventures, Viola Ventures","The company raised $160 million in its initial public offering on the NASDAQ stock exchange under the ticker symbol of OB on July 23, 2021. A total of 8,000,000 shares were sold at $20 per share. After the offering, there was a total of 53,855,531 outstanding shares (excluding the over-allotment option) priced at $20 per share, valuing the company at $1.08 billion. The underwriters were granted an option to purchase up to an additional 1,200,000 shares from the company to cover over-allotments, if any.","Bertelsmann, GlenRock Israel, HarbourVest Partners, Index Ventures, Jefferson Capital, J√©r√©mie Berrebi, Joyance Partners, LightSpeed Gemini Internet Lab, Lightspeed Venture Partners, Lightspeed Venture Partners Israel, Rhodium, SBNY, Spur Capital Partners, Susquehanna Growth Equity, The Baupost Group, Vintage Investment Partners, Vintage Partners Securities, Zohar Gilon",Taboola
158671-54,Pagaya (NAS: PGY),Pagaya Technologies Ltd.,"Axyon AI, Credibly, Aura (Financial Software), Tarya, LendKey, Behalf, Upstart Holdings, InCube Group, Creditplace, Prosper (Consumer Finance), Viteos Fund Services, Arcesium, Expensify, Blender","Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.",Information Technology,Software,Financial Software,"Financial Software*, Other Financial Services","Artificial Intelligence & Machine Learning, Big Data, FinTech, TMT","alternative asset management, alternative lending, asset management, credit score, enterprise resource planning, erp, financial management system, financial planning, financial software, financial technology, financial technology hub, investment advisor, investment house, online credit space, online lending, online lending market, online lending platform, underwriting",Formerly VC-backed,2380.8,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Publicly Listed, Venture Capital",553,NAS,PGY,2016,2025-04-26,,United States,"New York, NY",8500.0,2022-06-23,PIPE,2024-12-03,43.0,,,,Debt Refinancing,,Debt,2024-12-03,Completed,43.0,Revolving Credit - 15.00M¬†$; Term Loan - 28.00M¬†$,2016-05-08,1.25,Actual,Seed Round,,,Seed Round,Venture Capital,Completed,,1004.55,0.2999,-401.41,485.09,844.09,406.9,1367.71,-424.61,-453.41,,,,,,,,,,1,Healthcare of Ontario Pension Plan,"The company announced it will receive $140 million of debt refinancing on October 1, 2024. The remainder will support general corporate purposes. Previsouly, the company raised $652 million of debt financing on September 1, 2024.","32 Ventures, Aflac Ventures, Clal Insurance Enterprises Holdings, Digital Ventures (Bangkok), EJF Acquisition, G Squared, GF Capital Management & Advisors, GIC Private, Harvey Golub, Millennium New Horizons, Oak HC/FT, Poalim Equity, SCB 10X, Siam Commercial Bank, Tiger Global Management, Viola Ventures, Whale Rock Capital Management",
58785-13,PainReform (NAS: PRFX),PainReform Ltd,"Pacira BioSciences, Winston Pharmaceuticals, Durect","PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Drug Discovery*, Pharmaceuticals","HealthTech, Life Sciences","chemistry, narcotics control, non-opiate painkiller, pain medicine, pain therapeutic, pain treatment, painkiller, pharmaceutical, small molecule",Formerly VC-backed,49.2,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",6,NAS,PRFX,2007,2025-04-26,,Israel,"Tel Aviv, Israel",71.28,2020-09-01,IPO,2024-04-18,4.0,Actual,,,Public Investment 2nd Offering,,Public Investment,2024-04-18,Completed,,,,,,Early Stage VC,,,,Venture Capital,Completed,,0.0,0.0,-14.59,-4.22,4.43,,0.21,-14.66,-14.68,20,1,16,4,,,"Preparations for medical, dental or toiletry purposes",4,,,,"The company raised $4 million in its second public offering on the Nasdaq stock exchange under the ticker symbol of PRFX on April 18, 2024. A total of 5,000,000 shares were sold at $0.8 per share.","Medica Venture Partners, Poalim Equity, Viola Growth, XT Venture Capital",
147114-19,Palram Americas (TAE: PLRM),Palram Industries Ltd.,,"Palram Industries (1990) Ltd manufactures semi-finished extruded thermoplastic sheets, panel systems and finished products. Its products include four categories, namely, flat sheets, corrugated sheets, panel systems & specialty products. Its products used in construction and architectural projects, sign and display, agricultural, glazing, and fabrication. palram panel systems.",Business Products and Services (B2B),Commercial Products,Building Products,Building Products*,"Industrials, Manufacturing","building product, digital printing, environmental safety, flat sheet, foam unit, pvc sheets, pvc solutions",Corporation,0.01,Profitable,Publicly Held,"Publicly Listed, Venture Capital",1630,TAE,PLRM,1963,2024-12-28,,Israel,"Ramat Yohanan, Israel",,,,2014-07-09,0.01,Actual,,,PIPE,,Corporate,2014-07-09,Completed,,,2000-02-03,,,IPO,,,,Public Investment,Completed,,501.04,0.0877,62.13,-32.49,588.09,204.82,588.6,99.94,82.41,29,9,7,1,21,21,"Coating compositions, Horticulture, Layered products, Roof coverings, Structural elements",,,,,"The company (TAE:PLRM) received $12,500 of development capital from Ben Franklin Technology Partners of Northeastern Pennsylvania and Lehigh University Endowment on July 9, 2014 through a private placement.","Ben Franklin Technology Partners of Northeastern Pennsylvania, Lehigh University Endowment",
159385-60,ParaZero Technologies (NAS: PRZO),ParaZero Technologies Ltd,"Skycat, FIXAR, AVSS, UAV Navigation, Sky-Drones, Indemnis, Drone Rescue Systems","ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.",Information Technology,Computer Hardware,Other Hardware,Other Hardware*,"Industrials, Manufacturing, Robotics and Drones","aerospace company, aerospace company operator, commercial drones, drone technology, uas technology integration, unmanned aircraft",Formerly VC-backed,7.87,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",22,NAS,PRZO,2013,2025-04-26,Tonner Drones,Israel,"Kfar Saba, Israel",21.79,2023-07-27,IPO,2025-02-13,2.77,Actual,,,Public Investment 2nd Offering,,Public Investment,2025-02-13,Completed,,,2016-02-01,,,Angel (individual),,,Angel (individual),Individual,Failed/Cancelled,,0.93,0.5022,-11.05,-3.76,11.79,0.06,17.86,-11.23,-11.25,19,5,9,6,4,4,"Equipment for fitting in or to aircraft, Unmanned aerial vehicles [uav]",,,1,Xylo Technologies,"The company raised $2.77 million in its second public offering on the Nasdaq stock exchange under the ticker symbol of PRZO on February 13, 2025. A total of 2,518,182 shares were sold at $1.1 per share. Previously, the company (NAS:PRZO) received $5.1 million of development capital from undisclosed investors on October 30, 2023 through a private placement. Previously, the company raised $9.75 million in its initial public offering on the Nasdaq stock exchange under the ticker symbol of PRZO on July 27, 2023. A total of 1,950,000 shares were sold at $4 per share. After the offering, there was a total of 6,052,418 outstanding shares (excluding the over-allotment option) at $4 per share, valuing the company at $21.79 million. The underwriters were granted an option to purchase up to an additional 292,500 shares from the company to cover over-allotments, if any.","Club 100 plus, Keiretsu Forum, L.I.A. Pure Capital, Tonner Drones",
482598-28,Payment Financial Tech (TAE: PMNT),Payment Financial Technologies Ltd,,"Payment Financial Technologies Ltd owns the PaymenT brand which is a payment platform. It is a means of payment that allows businesses to offer financing to their customers easily, quickly, and conveniently and receive immediate payment for the products and services sold.",Information Technology,Software,Financial Software,Financial Software*,FinTech,"financial services infrastructure, payment platform",Corporation,,Generating Revenue,Publicly Held,Publicly Listed,,TAE,PMNT,,2024-01-17,,Israel,"Omar, Israel",,,,2021-10-13,,,,,IPO,,Public Investment,2021-10-13,Completed,,,2021-10-13,,,IPO,,,,Public Investment,Completed,,,,,,39.66,,,,,,,,,,,,,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of PMNT on October 13, 2021.",,
151896-25,Payton Planar Magnetics (BRU: PAY),Payton Planar Magnetics Ltd.,,"Payton Planar Magnetics Ltd Formerly Payton Planar Magnetics develops, manufactures and markets planar and conventional transformers and operates abroad through its subsidiaries and distributors. The business operates in one business segment that is Transformers. Geographically the company exports its services to Israel, Europe, America, and Asia. The Asian region generates maximum revenue for the company. The product line of the company consists of planar transformers, inductors, and off the shelf transformers. Export sales generate maximum revenue for the company.",Business Products and Services (B2B),Commercial Products,Electrical Equipment,"Electrical Equipment*, Electronic Components","Industrials, Manufacturing, TMT","power transformers, transformers, transformers coil, transformers parts, transformers product, transformers supply",Corporation,,Profitable,Publicly Held,Publicly Listed,170,BRU,PAY,1992,2024-11-28,,Israel,"Rishon LeZion, Israel",,,,1998-06-01,,,,,IPO,,Public Investment,1998-06-01,Completed,,,1998-06-01,,,IPO,,,,Public Investment,Completed,,50.83,-0.0735,13.31,-58.09,140.65,22.12,77.17,14.71,13.94,5,1,5,,,,Magnets,,,,,The company completed its initial public offering on the Euronext Brussels stock exchange under the ticker symbol of PAY in June 1998.,,
165078-55,PCB Technologies (TAE: PCBT),PCB Technologies Ltd.,,"P C B Technologies Ltd provides contract electronic manufacturing (CEM) services aimed at high end OEMs. It manufactures bare-board, rigid-flex Multi Layer boards, HDI boards, RF boards & provides complete board assemblies. It servs to markets such as Defense, Aerospace, Medical, RF/Microwave, Telecom and more. It also offers a complete line of bare board and assembled-board testing facilities, including in-circuit test (ICT), J-Tag, functional test and customized testing.",Business Products and Services (B2B),Commercial Services,BPO/Outsource Services,"BPO/Outsource Services*, Electrical Equipment",Manufacturing,"board assembly, contract electronic manufacturing, electronic manufacturing, electronic manufacturing services, manufacturing services provider, multiplayer board",Private Equity-Backed,,Profitable,Publicly Held,"Private Equity, Publicly Listed",774,TAE,PCBT,1981,2025-03-23,,Israel,"Migdal Haemek, Israel",69.57,2018-03-01,Buyout/LBO,2018-03-01,35.78,Actual,69.57,Estimated,Buyout/LBO,,Private Equity,2018-03-01,Completed,,,2004-12-09,,,IPO,,,,Public Investment,Completed,,152.88,0.1233,8.48,18.79,175.25,27.88,168.39,18.45,10.5,6,2,4,2,,,Printed circuits,,,2,"FIMI Opportunity Funds, Priortech Group","The company was acquired by FIMI Opportunity Funds through a NIS 125 million LBO on March 1, 2018. After a result of the transaction, the company will distribute a NIS 12 million dividend.",,
59060-80,Perion Network (TAE: PERI),"Perion Network, Ltd.","Inuvo, Glispa, Fyber, Aarki, AppLift, Tyroo Media, Magnite, Rocket Fuel, AppNexus, MediaMath, Chartboost, Inmobi, SessionM, VDX.tv, DataXu, DigitalGO, Criteo, Vserv, PubMatic, Braze, Madvertise Media, Amplitude, Celtra, Data.AI, Appodeal, Localytics, Adscend Media, NextRoll, BidMind, AppLovin, Dstillery, System1, Digital Turbine, Moloco, Manage.com Group, Synacor, Bitmovin, Data Axle, Vibes Media, Clutch (Pennsylvania), Smaato, InMarket Media, AdColony, Kissmetrics, Tappx, ironSource, Optimizely, Vantrix, Liftoff Mobile, SmarterHQ, Media.Net Advertising, Teads, Amobee, Punchh, Hipcricket (Mobile Advertising Business), Turn ( Media and Information Services), July Systems, PulsePoint, The Trade Desk, Millennial Media, Swrve, SITO Mobile, Apsalar, Flite (Media and Information Services (B2B)), Leanplum, Basis Technologies (Media and Information Services (B2B)), Placed, AppsFlyer, HipCricket, OpenX, Art of Click, Nexxen, Feedburner, Beachfront Media, Yeahmobi, Motive Interactive, Apptopia, Sizmek, Matomy Media Group, Odoo, Mixpanel, Certinia, Marin Software, wefi (Media and Information Services (B2B)), Brightcove, Airship, Adform, MoPub, Appnext, Inneractive, MobileAction, AdLib Mediation, PropellerAds, NativeX Holdings, Neura (Business/Productivity Software), MoEngage, Smartyads, Leadbolt, SweetLabs, Vungle, Crossinstall, Conversant., PlaceIQ, Sirius Media, Clicksor, Pendo, TUNE, RadiumOne, TubeMogul, Meta Platforms, Tapjoy, MobPartner","Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.",Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Media and Information Services (B2B)","AdTech, E-Commerce, Mobile, TMT","ad software, digital advertising, online advertisement, online publicity, seo, seo tools",Corporation,106.14,Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed",528,TAE,PERI,1999,2025-04-26,,Israel,"Holon, Israel",366.68,2021-01-21,Public Investment 2nd Offering,2021-01-21,57.39,Actual,366.68,Estimated,Public Investment 2nd Offering,,Other,2021-01-21,Completed,,,2006-01-30,18.75,Actual,IPO,70.3,Estimated,,Public Investment,Completed,,498.29,-0.3295,12.61,-351.03,399.28,165.68,42.88,11.67,-4.76,25,10,8,3,14,14,"Electric digital data processing, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes",,,,,"The company raised $57.38 million in its second public offering on the Nasdaq Stock Exchange under the ticker symbol of PERI on January 21, 2021. A total of 4,990,000 shares were sold at $11.50 per share. The underwriters were granted an option to purchase up to an additional 748,500 shares from the company to cover over-allotments, if any.","Austost Anstalt Schaan, Balmore S.A, JP Morgan Asset Management, JP Morgan Chase, Siparex Group, W Capital Partners",IAC
102263-14,Phinergy (TAE: PNRG),Phinergy Ltd,"Eos Energy Enterprises, Aquion Energy, UniEnergy Technologies, Ambri, Primus Power, Vionx Energy, Avalon Battery, E-Stone Batteries, Powermat, Green Charge Networks, ViZn Energy, SonicEnergy, WiTricity, Maxwell Technologies, C&D Technologies, Rongke Power, K2 Energy Solutions, Form Energy, EaglePicher Technologies, Jolt (Energy Storage), RedFlow, IDS Industries","Phinergy Ltd is a developer of clean and high energy-density systems based on metal-air technology. With its aluminium-air battery, the company has developed a way to generate electricity using aluminium as an energy source. The solutions offered by the company include Energy Back up, Energy Storage, and Electric Transportation.",Business Products and Services (B2B),Commercial Products,Electrical Equipment,Electrical Equipment*,"CleanTech, Climate Tech, Industrials, Mobility Tech, TMT","aluminum air battery, aluminum battery, battery storage, clean energy technology, energy generation system, energy storage system developer, grid infrastructure, metal air battery, storage system, zinc air battery",Formerly VC-backed,133.91,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",65,TAE,PNRG,2008,2024-11-08,,Israel,"Lod, Israel",299.84,2021-02-09,IPO,2021-02-09,60.92,Estimated,299.84,Estimated,IPO,,Public Investment,2021-02-09,Completed,,,2016-01-07,50.0,Actual,Later Stage VC,280.0,Actual,Series A,Venture Capital,Completed,,1.3,0.5249,-16.05,-8.52,36.2,-2.35,51.05,-13.85,-15.57,202,32,151,34,17,17,"Compounds of the metals beryllium, magnesium, aluminium, calcium, strontium, barium, radium, thorium, or of the rare-earth metals, Electrolytic or electrophoretic processes for the production of compounds or non-metals, Processes or means, Production and refining of metals, Semiconductor devices not covered by class h10",,,2,"Doral Group, Indian Oil Corporation","The company raised ILS 198.9 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of PNRG on February 9, 2021. A total of 153,000 units were sold. Each unit consisted of 100 shares and were sold at a price of ILS 13 per share. After the offering, the company was valued at ILS 978.9 million.","Arconic Ventures, Doral Energy Tech Ventures, Ilan Holdings",
160309-36,Photomyne (TAE: PHTM),Photomyne Ltd,"Photobucket, Shoebox, Momental",Photomyne Ltd is engaged in the development of artificial intelligence-based technology (AI) in the field of family photos. It builds apps for scanning photos.,Information Technology,Software,Multimedia and Design Software,"Application Software, Multimedia and Design Software*","Artificial Intelligence & Machine Learning, Mobile, TMT","ai technology platform, albums creation, computer vision, digital photo, email and authoring, kms, knowledge management system, photo editing mobile application, photo printing app, photo printing platform, photo scanning",Formerly VC-backed,22.6,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",24,TAE,PHTM,2014,2025-03-22,,Israel,"Bnei Brak, Israel",70.0,2021-03-11,IPO,2021-03-11,15.0,Actual,70.0,Actual,IPO,,Public Investment,2021-03-11,Completed,,,2016-03-31,2.6,Actual,Seed Round,,,Seed Round,Venture Capital,Completed,,,,,,22.38,,,,,8,1,8,,,,Image or video recognition or understanding,,,,,"The company raised $15 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of PHTM on March 11, 2021. After the offering, the company was valued at $70 million.","Eddy Shalev, GlenRock Israel, Maor Investments, Yariv Eisenberg, Yariv Gilat",
230770-99,PlantArcBio (TAE: PLNT),PlantArc Bio Ltd.,"Keygene, Rev Genomics, Moa Technology",Plantarc Bio Ltd is a biotech company in the field of gene discovery for improvement of productivity and performance in crops.,Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Other Agriculture","Climate Tech, FoodTech, Life Sciences","abiotic stresses, ag biotech, agriculture technology, alt-proteins, biotechnology platform, food security, herbicides tolerance, plant biotech, plant biotechnology, plant-based protein, seeds traits",Formerly Angel backed,3.0,Generating Revenue,Publicly Held,"Pre-venture, Publicly Listed",8,TAE,PLNT,2014,2024-12-18,,Israel,"Givat Chen, Israel",,,,2021-01-11,,,,,IPO,,Public Investment,2021-01-11,Completed,,,2018-07-11,3.0,Actual,Angel (individual),,,Angel (individual),Individual,Completed,,,,,,2.94,,,,,47,7,21,26,,,"Microorganisms or enzymes, New plants ornon-transgenic processes for obtaining them, Preservation of bodies of humans or animals or plants or parts thereof",,,,,"The company raised an undisclosed amount of funding in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of PLNT on January 11, 2021.",Israel Innovation Authority,
165194-65,Plasson Industries (TAE: PLSN),Plasson Industries Ltd,"Georg Fischer, Fusion Group, Radius Systems, DeZURIK, PLASSON, Doncasters Group, FlexSteel Holdings, Val-Matic","Plasson Industries Ltd provides solutions for connecting PE pipes. It offers ElectroFusion & Mechanical Fittings, Adjustable Elbow, Controllers, and PE Ball Valve, among others to municipal water distribution and gas conveyance systems, among others.",Business Products and Services (B2B),Commercial Products,Industrial Supplies and Parts,Industrial Supplies and Parts*,Manufacturing,"mechanical fittings, smart controllers",Corporation,,Profitable,Publicly Held,Publicly Listed,2576,TAE,PLSN,1964,2024-12-28,,Israel,"Menashe, Israel",,,,,,,,,IPO,,Public Investment,,Completed,,,,,,IPO,,,,Public Investment,Completed,,457.73,0.0377,38.56,88.6,525.26,183.73,577.93,87.06,61.1,76,19,36,4,36,36,"Animal husbandry, Devices for fastening or securing constructional elements or machine parts together, Pipes, Shaping or joining of plastics, Use of inorganic or non-macromolecular organic substances as compounding ingredients",,,,,The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of PLSN on an undisclosed date.,,
55599-04,Playtech (LON: PTEC),Playtech Plc,"Evolution (Casinos and Gaming), DoubleU Games, The Stars Group, Novomatic, Quickspin, Red7Mobile, Red Tiger Gaming, LNW Gaming, Big Time Gaming, Proactive Gaming Scandinavia, NetEnt, Product Madness, CasinoSecret, Zynga, Comtrade Gaming, Playtika Holding, Oryx Gaming, Miniclip, Play'n GO, Integrity Gaming, Head Digital Works, Mousebreaker, OpenBet Technologies, Goodgame","Playtech PLC specializes in gambling software for various online gambling networks that include online casinos, online bingo, mobile gaming, and online sports betting. The company's open platform software allows customers to build and market casino games that include blackjack, baccarat, slots, and roulette. The company's business segments are gaming B2B and gaming B2C. Gaming B2B is the division that operates casinos, services, sports, bingo, poker, and other B2B gambling. The segment gaming B2C controls Snaitech, Sun Bingo, and other B2C gambling. The company is based on the Isle of Man and generates the majority of its revenue from Italy and the United Kingdom.",Information Technology,Software,Entertainment Software,"Casinos and Gaming, Entertainment Software*","Mobile, SaaS, TMT","gaming, gaming site, gaming software, gaming studio, live gaming, online casino, online gaming application, poker, sports betting",Corporation,1111.37,Profitable,Publicly Held,"Debt Financed, Publicly Listed",8300,LON,PTEC,1999,2025-04-26,,United Kingdom,"Douglas, United Kingdom",1375.0,2018-11-22,Secondary Transaction - Private,2023-06-21,323.46,,,,Debt Refinancing,,Debt,2023-06-21,Completed,323.46,"Bonds - 323.46M¬†$ (Senior, Secured; Fixed)",2006-03-28,42.13,Actual,IPO,92.26,Estimated,,Public Investment,Completed,,917.62,0.0986,241.52,235.07,3045.76,,2908.15,321.17,126.39,129,42,90,14,25,25,"Card, board, or roulette games, Coin-freed or like apparatus, Educational or demonstration appliances, Electric digital data processing, Transmission of digital information",,,1,Morgan Stanley,"The company completed a EUR 300 million debt refinancing round on June 21, 2023.",Brickington Trading,
58928-77,Playtika Holding (NAS: PLTK),Playtika Holding Corp.,"Konami, Skillz, Zynga, Nexon, Innogames, Product Madness, NetEase, Halfbrick Studios, Netmarble, Miniclip, Nexon Mobile, Dear Villagers, Unity Software, Glu Mobile, Take-Two Interactive Software, Goodgame, Machine Zone, Rovio Entertainment, Naughty Dog, Coffee Stain Studios, Firefly Games, Omnidrone, Storm8, Gravity Company, NCSoft, Starbreeze, Scopely, Jam City, King.com, Kixeye, DoubleDown Interactive, This Game Studio, Activision Blizzard, PlayPhone, Gameloft, Codigames, BioWare, Certain Affinity, Wizards of the Coast, Pocket Gems, Digit Game Studios, Hatch (Entertainment Software), Steel Wool Games, Crytek, Tencent Holdings, Ubisoft Entertainment, Gameforge, Bungie, WildTangent, High 5 Games, Square Enix Holdings, Z2, Improbable Worlds, Epic Games, Atari, Kabam, Motiga, Kongregate, Plarium Global, ZeptoLab (United Kingdom), 99Games, Joyride Games, HashCube, Riot Games","Playtika Holding Corp is engaged in developing mobile games. Some of its games include Board Kings, House of Fun, Poker Heat, Slotomania, and Bingo Blitz. The company has built live game operations services and a proprietary technology platform to support its portfolio of games. It derives revenue from the sale of virtual items associated with online games. Geographically, the group has a business presence in the USA, EMEA, APAC, and Other regions of which key revenue is derived from the USA. It offers both Mobile and Web-based platforms.",Information Technology,Software,Entertainment Software,Entertainment Software*,"Gaming, Mobile, TMT","gaming business, gaming content, gaming developer, gaming publisher, gaming software, gaming studio, mobile games, proprietary media, social games, strategy games",Formerly PE-Backed,7567.84,Profitable,Publicly Held,"Debt Financed, M&A, Private Equity, Publicly Listed, Venture Capital",3500,NAS,PLTK,2010,2025-04-26,,Israel,"Herzliya, Israel",8659.73,2022-12-01,Secondary Transaction - Private,2023-04-26,624.97,Actual,,,Secondary Transaction - Private,,Corporate,2023-04-26,Completed,,,,1.0,Actual,Early Stage VC,,,,Venture Capital,Completed,,2549.3,-0.0069,162.2,1931.4,1971.04,1857.2,3885.13,545.3,379.6,21,13,14,6,1,1,"Card, board, or roulette games, Coin-freed or like apparatus, Computing arrangements based on specific computational models, Electric digital data processing, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes",,,4,"8th Wonder, Alibaba Group, Fortune Bliss Ventures, Hotlink Investment","Hotlink Investment and 8th Wonder Corporation sold their stake in the company to Fortune Bliss Ventures for $624.97 million on April 26, 2023.","Akilia Partners, Caesars Interactive Entertainment, CDH Investments, China Minsheng Trust, Giant Network, Gigi Levy-Weiss, Hony Capital, Kaedan Capital, NFX, Oceanwide Holdings, Yun Ma, Yunfeng Capital","Joffre Capital, Netmarble"
41501-71,Pluri (NAS: PLUR),Pluri Inc.,"Protagonist Therapeutics, Talisman Therapeutics, Numerate, Cyclenium Pharma, Verge Genomics, Axsome Therapeutics, AnGes, Quince Therapeutics, Dimension Therapeutics, ThermoGenesis Holdings, Alector, Denali Therapeutics, Sarepta Therapeutics, Alzheon, Compass Therapeutics, Prilenia, Mesoblast, Adverum Biotechnologies, Abeona Therapeutics, Crinetics Pharmaceuticals, Athersys, Rhythm Pharmaceuticals, Capricor Therapeutics, Amylyx, AavantiBio, Medeia Therapeutics, NRG Therapeutics, Cell Cure Neurosciences, Apellis Pharmaceuticals, NexImmune, Bluebird Bio, Oligomerix, Design Therapeutics","Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Drug Discovery","Advanced Manufacturing, AgTech, Beauty, FoodTech, Life Sciences, Manufacturing","alt-proteins, biotechnology, biotechnology agency, biotechnology company operator, cell research, cell therapy, cultivated protein, gene therapy startups, placenta cell, placental cell culture",Corporation,141.83,Profitable,Publicly Held,"M&A, Publicly Listed",118,NAS,PLUR,2001,2025-04-26,,Israel,"Haifa, Israel",176.47,2017-06-22,PIPE,2025-02-04,3.5,Estimated,,,PIPE,,Corporate,2025-02-04,Announced/In Progress,,,2003-06-10,,,Reverse Merger,,,,Corporate,Completed,,0.68,0.8992,-19.86,7.98,38.9,,34.2,-21.16,-21.42,2,2,,,2,2,,,,3,"A.I. Software, Indy MD Angels, Israeli Ministry of Economy","The company (NAS: PLUR) is in talks to receive approximately $3.5 million of development capital from the Merchant Adventure Fund through a private placement as of February 4, 2025. The proceeds from the placement will support the company's growth as a global leader in cell-based technology, reinforcing its ability to expand across multiple industries, including pharma, foodtech, and agtech, Also, the company (NAS: PLUR) is in talks to receive approximately $6.38 million of development capital from Mr. Alejandro Weinstein through a private placement as of January 23, 2025. The Company intends to use the net proceeds from the placement for working capital and general corporate purposes. Previously, the company (NAS: PLUR) received $8.2 million of development capital from undisclosed investors on December 15, 2022, through a private placement. The company is being actively tracked by PitchBook.",,"Innovation Medical Management Company, Merchant Adventure Fund"
98155-09,Plus500 (LON: PLUS),Plus500CY Ltd.,"OANDA, Markets.com, FxPro, GAIN Capital Forex.com UK, Currencies Direct, City Index, FairMarkets, Remitly, CurrencyFair, Liquidnet, XE.com, Tradeview Markets, GCI Financial, Exness, Wise (Financial Software), Trading 212, MoneyGram, AVAtrade, FXCM, Robinhood, Caxton, eToro, DEGIRO, ActivTrades, Pepperstone","Plus500 Ltd is an online provider of Contracts for Difference (CFDs). The company has developed and operates an online trading platform for retail customers to trade CFDs internationally, financial instruments comprising equities, indices, commodities, options, exchange-traded funds (ETFs), and foreign exchange. The trading platform is accessible from multiple operating systems including Windows, smartphones: iOS, Android, and Windows Phone, tablets: iOS, Android, and Surface, and web browsers. The group is engaged in three operating sectors: CFD trading; share dealing; and futures and options on futures. Geographically, European Economic Area, United Kingdom, Australia, and Rest of the World, of which it derives maximum revenue from European Economic Area.",Information Technology,Software,Financial Software,"Financial Software*, Other Financial Services","FinTech, SaaS","financial trading platform, online trading, online trading platform, trading facility, trading platform",Corporation,64.76,Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed",633,LON,PLUS,2008,2025-04-26,,Israel,"Haifa, Israel",2148.48,2018-09-25,Secondary Transaction - Open Market,2018-09-25,150.82,Actual,2148.48,Estimated,Secondary Transaction - Open Market,,Private Equity,2018-09-25,Completed,,,2013-07-24,64.76,Actual,IPO,172.27,Estimated,,Public Investment,Completed,,711.6,0.0553,273.1,-875.7,2941.05,,1485.93,285.6,279.4,,,,,,,,,,1,BlackRock,"BlackRock acquired 7.02% stake in the company for GBP 115.8 million on September 25, 2018.",Playtech,
55852-93,PolyPid (NAS: PYPD),PolyPid Ltd.,"Urogen Pharma, Pacira BioSciences, Heron Therapeutics, Flexion Therapeutics","PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.",Healthcare,Pharmaceuticals and Biotechnology,Drug Delivery,"Drug Delivery*, Drug Discovery, Pharmaceuticals","Life Sciences, Manufacturing","biopharma company, biopharmaceutical firm, chemistry, clinical stage biopharmaceutical, clinical stage biopharmaceutical company, drugs carrier, drugs delivery, drugs develpoment, infection medicine, lipid-based drugs, small molecule",Formerly VC-backed,203.78,Generating Revenue,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",61,NAS,PYPD,2008,2025-04-26,,Israel,"Petah Tikva, Israel",272.74,2020-06-26,IPO,2024-12-23,14.5,Actual,,,PIPE,,Corporate,2024-12-23,Completed,,,2010-10-20,1.4,Actual,Early Stage VC,3.5,Actual,Series A,Venture Capital,Completed,,0.0,0.0,-29.02,-6.02,26.5,,31.46,-26.41,-28.03,91,8,77,6,8,8,"Methods or apparatus for sterilising materials or objects in general, Preparations for medical, dental or toiletry purposes",7,,5,"Arc Ventures (United States), Aurum Ventures MKI, DAFNA Capital Management, Rosalind Advisors, Shavit Capital","The company (NAS:PYPD) received $14.5 million of development capital from undisclosed investors on December 23, 2024 through a private placement. The Company intends to use the net proceeds from the sale of the securities for its ongoing SHIELD II phase 3 clinical trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, working capital, and general corporate purposes.","Apple Core Holdings, Chaim Hurvitz, European Commission, Financi√®re Saint James, Guibor, Xenia Venture Capital",
98748-46,Polyrizon (NAS: PLRZ),Polyrizon Ltd.,,"Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Drug Discovery, Pharmaceuticals",Life Sciences,"anti-allergic drugs, anti-allergy medicine, biotechnology, biotechnology firm, biotechnology platform, biotechnology platform technology, nasal gel, nasal spray",Formerly Accelerator/Incubator backed,21.2,Generating Revenue/Not Profitable,Publicly Held,"M&A, Pre-venture, Publicly Listed",2,NAS,PLRZ,2005,2025-04-26,,Israel,"Raanana, Israel",,,,2025-04-01,17.0,Actual,,,PIPE,,Corporate,2025-04-01,Completed,,,2005-01-01,,,University Spin-Out,,,,Other,Completed,,0.0,0.0,-1.54,-2.55,13.54,,9.48,-1.43,-1.54,7,2,1,3,3,3,"Preparations for medical, dental or toiletry purposes",,Xylo Technologies,1,Ben-Gurion University of the Negev,"The company (NAS: PLRZ) received $17 million of development capital from undisclosed investors on April 1, 2025, through a private placement. Each unit consists of one ordinary share or pre-funded warrant, and one series A warrant to purchase one ordinary share per warrant. The company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.",Ofakim Hi-Tech Ventures,
222743-89,PomVom (TAE: PMVM),PomVom Ltd.,Rotor,Pomvom Ltd is a company engaged in providing digital platform that seamlessly connects guests to media of themselves captured by park or venue cameras.,Information Technology,Software,Entertainment Software,"Entertainment Software*, Movies, Music and Entertainment","Artificial Intelligence & Machine Learning, Mobile, TMT","computer vision analysis, machine learning and big data, manufacturing, mobile photo sharing, photo editing, photo editing application, photo exchange, photo sharing application, photo sharing platform",Formerly VC-backed,34.39,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",106,TAE,PMVM,2015,2025-04-01,,Israel,"Tel Aviv, Israel",41.12,2021-03-11,IPO,2025-01-06,5.32,Actual,,,PIPE,,Corporate,2025-01-06,Completed,,,2017-11-28,,,Accelerator/Incubator,,,,Other,Completed,,1.5,,,,20.79,,,,,4,1,4,,,,"Electric digital data processing, Information storage based on relative movement between record carrier and transducer",,,8,"Green Innovations, IBI Investment House, Israel-China Accelerator Program, MORE Investment House, Pontifax Venture Capital, Sigma Clarity, Tencent Cloud Native Accelerator, Unique Investments","The company (TAE:PMVM) received ILS 19.7 million of development capital from Creative Value Hedge Fund, IBI Investment House, Sigma Clarity, Pontifax Venture Capital, Unique Investments, MORE Investment House, Mr. Yitzhak Cohen, Mr. Marcus George, Ms. Sharon Zaworbach, Mr. Yoav Nahiron and others undisclosed investor January 6, 2025 through a private placement. The proceeds from the placement will be used to fund essential capital investments tied to existing and new agreements with leading industry groups.",,
504119-89,Propdo (TAE: PRPD),Propdo Ltd,,Propdo Ltd offers a digital real estate investment platform. It is engaged in the development of decision support software services in the real estate market. It provides real estate transaction solutions and price comparisons including the price of the apartment and predictions for the future.,Information Technology,Software,Business/Productivity Software,Business/Productivity Software*,Real Estate Technology,"ai-based technology, real estate software application, real estate software platform",Corporation,,Generating Revenue,Publicly Held,Publicly Listed,,TAE,PRPD,2020,2024-12-10,,Israel,"Gan, Israel",,,,,,,,,IPO,,Public Investment,,Completed,,,,,,IPO,,,,Public Investment,Completed,,,,,,32.22,,,,,,,,,,,,,,,,The company completed its its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of PRPD.,,
226524-79,Proprep,Proprep Education Inc,,"Developer of an e-learning platform designed to provide STEM students with clear and simple video tutorials and assessments. The company's platform makes use of video tutorials created by University professors that make learning contextual, visual, and practical, enabling students to receive a personalized educational experience.",Information Technology,Software,Educational Software,"Education and Training Services (B2B), Educational and Training Services (B2C), Educational Software*","EdTech, SaaS","edtech platform, education institution, educational application, educational learning, educational portal, e-learning platform, personalized learning, video tutorials",Venture Capital-Backed,1.7,Generating Revenue,Privately Held (backing),Venture Capital,18,,,2014,2025-03-24,,United States,"Anaheim, CA",,,,2019-06-06,,,,,Accelerator/Incubator,,Other,2019-06-06,Completed,,,2017-05-29,1.7,Actual,Seed Round,,,Seed Round,Venture Capital,Completed,,,,,,,,,,,,,,,,,,,,3,"LearnLaunch Fund + Accelerator, OneValley, S-Ventures (Israel)","The company joined OneValley on June 6, 2019.",,
41934-16,Protalix Biotherapeutics (ASE: PLX),"Protalix BioTherapeutics, Inc.","Apellis Pharmaceuticals, Astellas Pharma, Novartis, XBiotech, Eli Lilly and Company, Kymab, CaroGen, Biotest, Merck & Co., Sinovac, Karus Therapeutics, mAbxience, Paragon Bioservices, GSK, Brammer Bio, Oxford BioMedica, GeoVax Labs, Biosceptre, Medicago, Phyton Biotech, Pfizer Pakistan, CanSino Biologics, Apricus Biosciences, GlaxoSmithKline Consumer Nigeria, IBio, Tedor Pharma, MnPharm, Ortho-McNeil Pharmaceuticals, Altravax, FinVector, Crucell, Batavia Biosciences","Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Drug Discovery*, Pharmaceuticals",,"pharmaceutical, plant cell, protein expressions, recombinant protein",Formerly VC-backed,127.4,Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",213,ASE,PLX,1993,2025-04-26,,Israel,"Karmiel, Israel",166.67,2015-10-13,PIPE,2021-02-18,40.0,Actual,,,PIPE,,Corporate,2021-02-18,Completed,,,2001-01-01,,,Later Stage VC,,,,Venture Capital,Completed,,53.4,-0.184699999999999,2.93,-29.3,222.39,29.08,116.71,5.22,3.92,,,,,,,,16,,7,"Alrov Group, Highbridge Capital Management, Knight Therapeutics, MORE Investment House, Pfizer (Pharmaceuticals), Psagot Investment House, UBS O'Connor","The company (ASE: PLX) received $40 million of development capital from undisclosed investors on February 18, 2021, through a private placement. The company intends to use the net proceeds from the offering to fund clinical trials for its product candidates, to fund its research and development activities and for working capital and other general corporate purposes.","Atara Technology Ventures, Biocell Ltd, Docor International Management, Indy MD Angels, Israel Innovation Authority, Philip Frost, Pontifax Venture Capital, Tamares Group, Technorov Holdings, Ybox Real Estate, Ziff Brothers Investments",
459068-77,Pulsenmore (TAE: PULS),Pulsenmore Ltd.,"NovioScan, Philips, Sonavex, Butterfly Network","Pulsenmore Ltd is engaged in developing portable ultrasound devices for home use. Its ultrasound scanner dock's with patients' smartphones to deliver images that can be created anywhere, stored and forwarded for clinical review, or shared in an online consultation.",Healthcare,Healthcare Devices and Supplies,Monitoring Equipment,"Monitoring Equipment*, Therapeutic Devices","Digital Health, HealthTech, Mobile","imaging equipment, imaging tool, medical devices, teleconsultation service, telemedicine platform, telemedicine platform developer, transducers device, ultrasound device",Formerly VC-backed,97.0,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",63,TAE,PULS,2014,2025-03-12,,Israel,"Omer, Israel",230.0,2021-06-15,IPO,2022-05-16,50.0,Actual,,,PIPE,,Corporate,2022-05-16,Completed,,,2020-03-01,7.0,Actual,Later Stage VC,27.15,Estimated,Series A,Venture Capital,Completed,,2.59,0.5611999999999999,-9.85,-27.9,45.25,0.96,37.54,-10.39,-11.16,64,11,29,35,,,"Diagnosis, Electric digital data processing, Healthcare informatics, Measuring not specially adapted for a specific variable",5,,1,GE HealthCare Technologies,"The company (TAE: PULS) received $50 million of development capital from GE Healthcare on May 16, 2022, through a private placement. Previously, the company raised $40 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol PULS on June 15, 2021. After the offering, the company's valuation is at $230 million.","FujiFilm (Diagnostic Equipment), Israel Innovation Authority, Luzzatto & Luzzatto, Ragnar",
97491-25,Purple Biotech (TAE: PPBT),Purple Biotech Ltd.,"Zentalis Pharmaceuticals, Seagen","Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,"Drug Delivery, Pharmaceuticals*","Life Sciences, Oncology","cancer treatment, osteoarthritis drugs, pharmaceutical medicine, pharmaceutical medicine chemicals, pharmaceutical medicine development, pharmaceutical medicine supplier, pharmaceutical provider, tumor immune",Corporation,29.33,Generating Revenue,Publicly Held,"M&A, Publicly Listed",7,TAE,PPBT,1968,2025-04-26,,Israel,"Rehovot, Israel",14.24,2024-09-30,PIPE,2024-12-03,2.8,Estimated,,,PIPE,,Corporate,2024-12-03,Announced/In Progress,,,1978-09-03,,,IPO,,,,Public Investment,Completed,,0.0,0.0,-7.24,-8.34,7.3,,5.01,-7.31,-7.5,11,3,3,,8,8,"Preparations for medical, dental or toiletry purposes",3,Mainrom Line Logistics,1,Armistice Capital,"The company (TAE: PPBT) is in talks to receive $2.8 million of development capital from undisclosed investors through a private placement as of December 3, 2024. The company intends to use the net proceeds from the offering to fund the development of its oncology therapeutic candidates and for general working capital and corporate purposes. Previously, Armistice Capital acquired a 8.69% stake in the company (TAE: PPBT) on September 30, 2024 through a private placement. The investment is to capitalize on potential future gains from Purple Biotech's innovative pipeline. The company is being actively tracked by PitchBook.",,Xtl Biopharmaceuticals
58538-62,PV Nano Cell (PINX: PVNNF),PV Nano Cell Ltd.,,"PV Nano Cell Ltd is a conductive ink manufacturing company. It is engaged in developing, manufacturing, marketing & commercializing conductive inks for digital inkjet conductive printing applications. It develops the Sicrys family of single crystal nano-metric conductive inks for photovoltaic and printed electronics applications, as well as silver-based Sicrys inks for use in a range of inkjet printing electronics applications, including printing of circuit boards, mobile phone antennas, 3D printed electronic devices, radio-frequency identification chips, sensors, touchscreens, and other digitally printed electronics. Geographically, it generates revenue from Spain, Israel, United states, Japan, Germany, Other.",Business Products and Services (B2B),Commercial Products,Other Commercial Products,Other Commercial Products*,"CleanTech, Manufacturing, Nanotechnology","ink base, nano inkjet, nano metrics materials, silicon solar cell, solar cell technology, sustainable manufacturing process",Formerly VC-backed,11.66,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",13,PINX,PVNNF,2009,2025-03-24,,Israel,"Migdal Ha Emek, Israel",,,,2023-06-01,2.68,Estimated,,,PIPE,,Venture Capital,2023-06-01,Completed,,,,1.0,Estimated,Seed Round,,,Seed Round,Venture Capital,Completed,,0.48,-0.206799999999999,-2.07,1.19,0.23,0.15,2.17,-1.96,-2.0,30,5,22,3,5,5,"Cables, Chemical or physical processes, Coating compositions, Mixing, Working metallic powder",,,3,"GTRIMG Investments, Insight Capital (Business Products and Services), Ratio technologies (Israel)","The company (PINX:PVNNF) received $2.681 million of development capital from Insight Capital Ltd., Teuza and GTRIMG Investments on June 1, 2023, through a private placement. The Company expects to use the proceeds from the Private Placement to expand its operations and for general working capital.","GlenRock Israel, Infinity Group, Israel Electric, Israel G-Tek, PLD Capital, Slobel, Terra Venture Partners, Teuza",
167907-79,Qrons,"Qrons, Inc.","Glycostem Therapeutics, Voyager Therapeutics, Cytokinetics, CervoMed, Capricor Therapeutics, Neurona Therapeutics, Tetra Therapeutics, Intellia Therapeutics, CalciMedica, TiGenix, CuraSen, Agilis Biotherapeutics, T3D Therapeutics, Jaguar Gene Therapy, Senti Bio, Stemedica, Magenta Therapeutics, Orchard Therapeutics, Valo Therapeutics, Recombinetics, Solid Biosciences, NexImmune, Homology Medicines, NeuroNascent, Faron Pharmaceuticals, Fate Therapeutics, Anokion, Bioasis Technologies, Fauna Bio, Imbria Pharmaceuticals, Mozart Therapeutics, CSL Behring, Neurogene, GenSight Biologics, Taysha Gene Therapies, ALSP, AZTherapies, Medeia Therapeutics, Cerevance, Quince Therapeutics, ViaCyte, Dimension Therapeutics, Cerecin, Lycera, Kite Pharma, Gyroscope, Alzheon, Sharp Therapeutics, Adverum Biotechnologies, AB Science, ICBI, Eledon Pharmaceuticals, Travecta Therapeutics, Semma Therapeutics, Gain Therapeutics, Asceneuron, Biogen, DCPrime, CRISPR Therapeutics, Edgewise Therapeutics, TILT Biotherapeutics, Minerva Neurosciences, Cognition Therapeutics, Atox Bio, Sana Biotechnology, Lysosomal Therapeutics, Lucid Psycheceuticals, Ablynx, Lisata Therapeutics, Alector, ACADIA Pharmaceuticals, Kojin TX, Orgenesis, Annovis Bio, Axon Neuroscience, Xencor, Sangamo Therapeutics, MEI Pharma, Abeona Therapeutics, Tenaya Therapeutics, Amarantus BioScience Holdings, ElevateBio, Coya Therapeutics, Imara, Galapagos (Biotechnology), Evox Therapeutics, CytImmune Sciences, Immunocore Holdings, True North Therapeutics, Renova Therapeutics, Cadent Therapeutics, Phio Pharmaceuticals, ProMIS Neurosciences, Seneca Biopharma, Amicus Therapeutics, Juno Therapeutics, Verge Genomics, Spark Therapeutics, Genesis Therapeutics, Atomwise, Calimmune, Bristol-Myers Squibb, Editas Medicine, Gelesis Holdings, Amylyx, Bluebird Bio, TC Biopharm, Caribou Biosciences, Deep Genomics, Rappta Therapeutics, Denali Therapeutics, Lava Therapeutics, Avalo Therapeutics, Yumanity Therapeutics, Shire","Qrons Inc is a biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The company has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,Biotechnology*,Life Sciences,"brain injury, cell therapy, engineers mesenchymal stem, neuronal injury, scaffolding, traumatic brain injury",Corporate Backed or Acquired,1.18,Generating Revenue,Acquired/Merged,"M&A, Publicly Listed",4,,,2016,2025-02-05,,United States,"Long Island City, NY",,,,2025-02-04,,,,,Merger/Acquisition,,Corporate,2025-02-04,Completed,,,2017-01-01,0.3,Actual,Capitalization,,,,Individual,Completed,,0.0,0.0,-0.06,0.3,2.69,,3.01,0.01,0.01,1,1,,,1,1,,,First Person,,,"The company was acquired by First Person through a reverse merger on February 4, 2025. The acquisition helps First Person to accelerates growth, expands product distribution and builds a category-defining platform in science-backed cognitive supplements and alcohol-free social tonics. The company is no longer actively tracked by PitchBook.",,
58793-41,QuickLizard (TAE: QLRD),QuickLizard Ltd.,"Corent Technology, BigMachines, Logility (Acquired), SAS Institute, ToolsGroup, ChikPea, Vendavo, Gurobi Optimization, Vistaar Technologies, Syncron (Stockholm), Determine, Zylo, o9 Solutions, Sentient (Business/Productivity Software), Peak (Manchester), Unbxd, Amdocs, Aifora, Navetti, Eversight, Dealavo, Wiser Solutions, Predictix, Pricing Assistant, Revionics, Market6, Bringg, Profitero, Relex, Mi9 Retail, Retviews, FPX",Quicklizard Ltd is an artificial intelligence technology solution provider. The company provides solutions for dynamic pricing analysis and management.,Information Technology,Software,Business/Productivity Software,"Automation/Workflow Software, Business/Productivity Software*","Artificial Intelligence & Machine Learning, FoodTech, Restaurant Technology, SaaS","ai technology solutions, crm, customer relationship management, grocery store tech, grocery store technology, price optimization, pricing analysis, pricing analytics software, pricing management, pricing software, pricing solutions, pricing system, restaurant & retail tech, restaurant and retail technology",Formerly VC-backed,25.43,Generating Revenue,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",80,TAE,QLRD,,2025-03-21,,Israel,"Petach Tikva, Israel",50.73,2025-02-05,Buyout/LBO,2025-02-05,50.73,Actual,50.73,Estimated,Buyout/LBO,Public to Private,Private Equity,2025-02-05,Announced/In Progress,,,2010-09-14,0.4,Actual,Accelerator/Incubator,1.15,Estimated,,Other,Completed,,,,,,48.21,,,,,,,,,,,,,,2,"Publicis Sapient, Yelin Lapidot Investment House","The company has entered into a definitive agreement to be acquired by Riverwood Capital for NIS 186 million LBO on February 5, 2025 through a public-to-private transaction. The acquisition is aimed at boosting Quicklizard's research and development, hastening the evolution of its platform, and strengthening its position as the preferred pricing optimization platform for businesses around the world. Previously, the company (TAE:QLRD) received an undisclosed amount of development capital from Publicis Sapient on December 1, 2023 through a private placement. The company is being actively tracked by PitchBook.","Cockpit Innovation, Incentive Incubator, Peregrine Ventures",Riverwood Capital
41157-82,Radcom (NAS: RDCM),Radcom Ltd.,"Spirent Communications, EXFO, NEC (Japan), Kazakhtelecom, Solarflare, Telecom Argentina","Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.",Information Technology,Computer Hardware,"Computers, Parts and Peripherals","Computers, Parts and Peripherals*, Telecommunications Service Providers","SaaS, TMT","carrier grading service, communication network, customer experience management",Formerly VC-backed,2.5,Profitable,Publicly Held,"Debt Financed, M&A, Publicly Listed, Venture Capital",307,NAS,RDCM,1991,2025-04-26,,Israel,"Tel Aviv, Israel",,,,2017-10-01,32.4,Actual,,,Public Investment 2nd Offering,,Public Investment,2017-10-01,Completed,,,,,,Early Stage VC,,,,Venture Capital,Completed,,61.01,0.1823,6.97,-91.27,173.12,45.26,106.94,3.19,2.51,19,9,18,1,,,"Electric digital data processing, Transmission of digital information, Wireless communication networks",,,,,The company raised $32.399 million in a secondary public offering on the NASDAQ stock exchange under the ticker symbol of RDCM in October 2017.,"Concord Ventures (Israel), Evergreen Venture Partners, Genesis Partners, Pitango Venture Capital, Sofinnova Investments, Star Ventures, Walden Israel Venture Capital",
14619-34,RadView Software (PINX: RDVWF),RadView Software Inc.,"Flood IO, Neotys, SmartBear Software, TestCraft, Experitest, Odin (United Kingdom), Soasta, Sauce Labs, Perfecto, Ranorex, New Relic, Tricentis, Runscope, Testsigma, Mobile Labs, Code Climate, Browserling, Parasoft, Apiary, eureQa, Cypress.io, Shield34, Apica, BrowserStack, Functionize, Katalon, Appvance, BugBuster, Dynatrace, k6, Testim, TestObject, mabl, Scout APM, Uptrends, CrossBrowserTesting, Xamarin, Gatling, Firebase, Applitools, Postman, RobusTest, pCloud Design Labs, CloudQA, BlazeMeter, Site24x7, Applause, HeadSpin, Original Software, Equafy, BlueStripe Software, LambdaTest, Urchin Software, Zeenyx Software, LoadStorm, Monitis, Fiddler, SignalFx, Instart, Cohesity, Chef Software, Visio, Riverbed Technology","RadView Software Ltd provides application performance and load testing software. The company offers solutions like website load testing, java load performance testing, .NET load testing, oracle forms load testing, web services and APIs, continuous integration, CRM and ERP, and ellucian load testing.",Information Technology,Software,Software Development Applications,Software Development Applications*,"CloudTech & DevOps, TMT","internet application, loading performance, rapid testing, testing software, web services, website development, website loading testing",Formerly VC-backed,48.84,Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed, Venture Capital",51,PINX,RDVWF,1993,2025-04-26,,United States,"Bridgewater, NJ",163.67,2000-08-09,IPO,2006-01-30,2.84,Actual,,,PIPE,,Private Equity,2006-01-30,Completed,,,1995-12-18,,,Merger/Acquisition,,,,Corporate,Completed,,2.15,-0.1117,0.61,0.76,0.12,1.96,1.58,0.44,0.44,,,,,,,,,,2,"CA Technologies, Formula Ventures","The company (PINX: RDVWF) received $2.83 million of development capital from Fortissimo Capital and other undisclosed investors on January 30, 2006.","Fortissimo Capital, North Bridge Venture Partners, Platinum Technology International, RAD (Telecommunications Service Providers), Sadot Research & Development Fund",
41441-86,Radware (NAS: RDWR),Radware Ltd.,"A10 Networks, Check Point Software Technologies, Zscaler, NSFOCUS, NetScout Systems, Big Switch Networks, Corero Network Security, Oracle, Soha, Red Hat, Qualys, Nutanix, VMware, Impetus Technologies, Infosys, Tech Mahindra, Dell EMC, NetApp (Systems and Information Management), CommVault Systems, Akamai Technologies, Sophos, Biprogy, F5 (IT Consulting and Outsourcing), AppViewX, Hitachi Vantara, GoDaddy, Juniper Networks, Arista Networks, Infor Global Solutions, NoviFlow, Amazon Web Services, ValueLabs, CipherCloud, Rackspace Technology, Cloudflare, Firebase, Wipro, Spectrum - Business Services, Cisco Systems, International Business Machines, StackPath, Ixia, AT&T Cybersecurity, CDNetworks, Imperva, Barracuda Networks, WithSecure, F-Secure, Vonage Holdings, Citrix Systems, Hewlett Packard Enterprise, Gigamon, WatchGuard Technologies, Netscaler, CrowdStrike Holdings, Polaris FT, DOSarrest Internet Security, Anuta Networks, Mphasis Stelligent, Proofpoint, Silverline, Extreme Networks, Google Cloud Platform, Palo Alto Networks, 6Wind, Corsa, SonicWall, cPacket, Forcepoint, Gen Digital, Black Lotus Communications, Netskope, ScaleFT, NetNumber Global Data Services, McAfee, Incapsula, Prolexic Technologies, CDNify, Spirit Technology Services, Bear-Line","Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. It generates the majority of its revenue from the United States.",Information Technology,IT Services,Systems and Information Management,"Network Management Software, Operating Systems Software, Systems and Information Management*","Cybersecurity, SaaS, TMT","cloud protection, cloud protection platform, cyber security firm, integrated application delivery, internet protocol, internet traffic management, network security, secure networking",Formerly VC-backed,122.8,Profitable,Publicly Held,"Publicly Listed, Venture Capital",1208,NAS,RDWR,1996,2025-04-26,,Israel,"Tel Aviv, Israel",,,,2000-01-01,59.8,Actual,,,Public Investment 2nd Offering,,Public Investment,2000-01-01,Completed,,,,,,Early Stage VC,,,,Venture Capital,Completed,,274.88,0.052,6.04,-257.51,989.9,221.63,682.72,6.48,-5.36,285,108,239,19,27,27,"Computing arrangements based on specific computational models, Electric digital data processing, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Transmission of digital information",,,,,The company raised $59.8 million in its second public offering on the Nasdaq stock exchange under the ticker symbol of RDWR in January 2000.,"DFJ Tamir Fishman, Evergreen Venture Partners, Pitango Venture Capital, The Challenge Fund - Etgar",
222113-17,Rail Vision (NAS: RVSN),Rail Vision Ltd.,"Symeo, InTouchGPS","Rail Vision Ltd is a development-stage technology company that is engaged in the design, development, and assembly of railway detection systems designed to solve the challenges in railway operational safety, efficiency, and predictive maintenance. Its railway detection systems include different types of cameras, including optics, visible light spectrum cameras (video), and thermal cameras that transmit data to a ruggedized onboard computer which is designed to be suitable for the rough environment of a train's locomotive. It has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operator.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,"Electronic Equipment and Instruments*, Rail","Manufacturing, Mobility Tech","early warning system, obstacle detection, rail safety, railroad safety technology, safety devices manufacturer, train",Formerly VC-backed,56.5,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",49,NAS,RVSN,2016,2025-04-26,,Israel,"Raanana, Israel",65.65,2022-03-31,IPO,2024-01-01,3.5,Actual,,,PIPE,,Corporate,2024-01-01,Completed,,,2016-05-01,2.0,Actual,Seed Round,14.82,Estimated,Seed Round,Venture Capital,Completed,,1.3,8.1549,-30.71,-16.72,20.93,0.45,34.0,-29.04,-29.18,63,10,38,19,6,6,"Computing arrangements based on specific computational models, Guiding railway traffic, Image data processing or generation, in general, Pictorial communication, Vehicles, vehicle fittings, or vehicle parts, not otherwise provided for",,,2,"Foresight Autonomous Holdings, Knorr-Bremse","The company (NAS: RVSN) received $3.5 million of development capital from undisclosed investors in January 2024, through a private placement. Previously, the company (NAS: RVSN) received $6 million of development capital from Knorr-Bremse and other undisclosed investors on June 21, 2023, over 2 tranches through a private placement. The company closed tranche 1 by raising $ 2.69 million in May 2023. The company closed tranche 2 by raising $ 3.31 million on June 21, 2023.","Allied Systems Holdings, Keihanna Global Acceleration Program, Lubinski Group, Shrem-Zilberman",
58793-77,Rav-Bariach (08) Industries (TAE: BRIH),Rav-Bariach (08) Industries Ltd.,,"Rav Bariach (08) Industries Ltd operates in the door industry. The company is engaged in the production and marketing of products in the field of construction - doors, protection, protection, locking, and lockers.",Business Products and Services (B2B),Commercial Products,Building Products,"Building Products*, Other Commercial Products","Industrials, Manufacturing","building products, building products company, building products manufacturer, locking systems, locks mechanism, multi bolts locks, multi-bolt locking systems",Formerly PE-Backed,69.67,Generating Revenue/Not Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed",1295,TAE,BRIH,1973,2025-04-13,,Israel,"Ashkelon, Israel",192.92,2021-08-29,IPO,2021-08-29,38.58,Estimated,192.92,Estimated,IPO,,Private Equity,2021-08-29,Completed,,,2008-05-01,,,Bankruptcy: Admin/Reorg,,,,Bankruptcy,Completed,,180.72,-0.0559,-14.02,189.91,90.65,26.08,274.6,9.93,-6.38,26,15,11,1,14,14,"Aeroplanes, Devices for moving wings into open or closed position, Locks, Time or attendance registers",,,,,"The company raised NIS 125 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of BRIH on August 29, 2021. After the offering, the valuation of the company at NIS 625 million.","Bank Hapoalim, Clarity Capital (Tel Aviv), Poalim Equity",
13348-54,Raval ACS (TAE: RVL),Raval ACS Ltd.,,"Raval ACS Ltd is engaged in the development, production, and sale of internal and external fuel tank venting systems for the automobile industry. It provides solutions for gasoline, diesel and biofuel systems. The company exports its products to USA, Luxemburg, Germany, Russia, Israel, India, China, South Korea, and Japan.",Business Products and Services (B2B),Commercial Products,Industrial Supplies and Parts,"Industrial Supplies and Parts*, Road","Industrials, Manufacturing","fuel valves, rolls over valves, vents valves",Formerly PE-Backed,5.0,Profitable,Publicly Held,"Private Equity, Publicly Listed",1457,TAE,RVL,2000,2025-04-04,,Israel,"Beer Sheva, Israel",22.73,2004-03-15,PE Growth/Expansion,2015-12-01,,,,,Secondary Transaction - Private,,Other,2015-12-01,Completed,,,2004-03-15,5.0,Actual,PE Growth/Expansion,22.73,Estimated,,Private Equity,Completed,,239.76,-0.0495,4.37,54.77,50.9,47.75,120.25,30.85,7.31,1,1,,,1,1,,,,,,FIMI Opportunity Funds sold its stake in the company in December 2015 for an undisclosed sum.,"FIMI Opportunity Funds, Shamrock Holdings",
432701-74,Razor Labs (TAE: RZR),Razor Labs Ltd,,Razor Labs Ltd is engaged in the business of developing artificial intelligence based products and solutions for businesses.,Information Technology,Software,Business/Productivity Software,Business/Productivity Software*,Artificial Intelligence & Machine Learning,"analytics platform developer, analytics platform provider, analytics platform software, business process optimization, business process optimization platform, business process optimization services, enterprise asset management, enterprise resource planning",Corporation,35.57,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,41,TAE,RZR,2016,2025-03-12,,Israel,"Tel Aviv, Israel",180.9,2021-02-10,IPO,,,,,,Secondary Transaction - Open Market,,,,Completed,,,2021-02-10,35.57,Actual,IPO,180.9,Estimated,,Public Investment,Completed,,4.62,2.2562,-4.15,-10.13,53.81,1.92,52.9,-3.49,-4.39,1,1,,1,,,Control or regulating systems in general,,,1,Synerleap,"SynerLeap acquired a stake in the company (TAE:RZR). The company will not receive any proceeds from the offering. Previously, the company raised NIS 116.2 million in its initial public offering on the Tel Aviv stock exchange under the ticker symbol of RZR on February 10, 2021. The company valued at $591 million.",,
51247-27,RedHill Biopharma,RedHill Biopharma Ltd.,"Ironwood Pharmaceuticals, Phathom Pharmaceuticals, Anatara Lifesciences","Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*, Pharmaceuticals","Life Sciences, Oncology","drug developer, drug discovery, drug discovery firm, drug discovery system, drugs, healthcare, infectious disease, pharmaceuticals",Formerly VC-backed,157.64,Generating Revenue/Not Profitable,Privately Held (backing),"Private Equity, Publicly Listed, Venture Capital",35,,,2009,2025-04-26,,Israel,"Tel Aviv, Israel",,,,2024-04-03,1.25,Actual,,,PIPE,,Corporate,2024-04-03,Completed,,,2010-09-12,3.5,Actual,Early Stage VC,,,,Venture Capital,Completed,,8.04,0.2317,-8.27,-4.26,250.64,4.85,,-7.73,-8.35,203,23,148,20,35,35,"Preparations for medical, dental or toiletry purposes, Specific therapeutic activity of chemical compounds or medicinal preparations",20,,,,"The company (NAS: RDHL) received $1.25 million of development capital from undisclosed investors on April 3, 2024 through a private placement. The company intends to use the net proceeds from the offering for general corporate purposes and working capital.","Broadfin Capital, Excellence Investments Management and Securities, Kukbo Design, Migdal Insurance and Financial Holdings, OrbiMed, Rosalind Advisors, Sphera Funds Management, Volition Capital, Ybox Real Estate, Yelin Lapidot Investment House",
120583-00,Rekah Pharmaceutical Industries,REKAH Pharmaceutical Industries Ltd.,,"Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,"Distributors/Wholesale, Pharmaceuticals*",,"nutritional supplements, nutritional supplements product, otc drugs, pharmaceutical firm, pharmaceutical manufacturing, prescription drugs",Private Equity-Backed,,Profitable,Privately Held (backing),"Private Equity, Publicly Listed",447,,,1941,2025-04-13,,Israel,"Azur, Israel",27.07,2015-03-28,Buyout/LBO,2015-03-28,20.05,Actual,27.07,Estimated,Buyout/LBO,,Private Equity,2015-03-28,Completed,,,1994-01-01,,,IPO,,,,Public Investment,Completed,,86.27,0.0002,1.66,34.79,42.46,19.29,78.45,12.59,3.83,,,,,,,,,,1,FIMI Opportunity Funds,"The company was acquired by FIMI Opportunity Funds through a ILS 80 million LBO on March 28, 2015. The transaction values the company at ILS 108 million.",,
57861-55,Riskified (NYS: RSKD),Riskified Ltd.,"Teradata, Beabloo, Folloze, HubSpot, Movidesk, SalesLoft, Mindbody, Help Scout, Choozle, Conversocial, Helpshift, ClientSuccess, ContactEngine, CA Technologies, Act-On Software, Vint (Business/Productivity Software), 2Checkout, UserVoice, Comm100, Digital River, Signifyd, Totango, Vanilla., Pendo, Zendesk, Udesk, UserTesting, Return Path, ComAround","Riskified Ltd has built a next-generation eCommerce risk management platform that allows online merchants to create trusted relationships with their consumers. It generates revenue by granting merchants access to its eCommerce risk management platform and reviewing and approving eCommerce transactions for legitimacy. Its merchants include some of the ecommerce brands including Wayfair, Lastminute.com, SHEIN, and Macy's. Its merchants operate in a variety of verticals, including Payments, Money Transfer & Crypto, Tickets & Travel, Electronics, Home, Fashion & Luxury Goods, General Retail and Food. The company derived maximum revenue from Israel.",Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Media and Information Services (B2B)","Artificial Intelligence & Machine Learning, Big Data, Cybersecurity, SaaS, TMT","detection technology, ecommerce fraud protection solution, fraud prevention, fraud prevention service, fraud prevention system, fraud prevention tools, identity & access management, identity and access management, risk analysis, risk mitigation, risk mitigation software",Formerly VC-backed,594.77,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",693,NYS,RSKD,2012,2025-04-26,,United States,"New York, NY",3310.14,2021-07-29,IPO,2021-07-29,367.5,Actual,3310.14,Estimated,IPO,,Public Investment,2021-07-29,Completed,,,2013-07-09,1.65,Actual,Seed Round,4.96,Actual,Seed Round,Venture Capital,Completed,,327.52,0.1005,-34.92,-348.53,614.74,170.94,297.03,-43.79,-48.67,,,,,,,,,,4,"Fidelity Management & Research Company, General Atlantic, Plug and Play Tech Center, Winslow Capital Management","The company raised $367.5 million in its initial public offering on the New York Stock Exchange under the ticker symbol of RSKD on July 29, 2021. A total of 17,500,000 shares class A shares were sold at $21 per share. After the offering, there was a total of 157,625,498 outstanding shares class A shares (excluding the over-allotment option) at $21 per share, valuing the company at $3.31 billion. The total proceeds, before expenses, to the company was $363.3 million and to the selling shareholders was $4.2 million. In the offering, the company sold 17,300,000 shares and the selling shareholder sold 200,000 shares. The underwriters were granted an option to purchase up to an additional 2,625,000 additional Class A ordinary shares from the company to cover over-allotments, if any.","Agla√© Ventures, C4 Ventures, Capital One Ventures, Entr√©e Capital, Formation 8, Founder Collective, Genesis Partners, Groupe Arnault, Kreos Capital, NTT Docomo Ventures, Pascal Cagni, Phoenix Court, Phoenix Financial (Multi-line Insurance), Pitango Venture Capital, Qumra Capital, Robin Klein, T5 Capital, The Acceleration Group, The Goldman Sachs Group, Union Tech Ventures",
59511-34,Robo Group TEK,RoboGroup T.E.K. Ltd,,"RoboGroup TEK Ltd is a global, diversified enterprise with proprietary technologies on the forefront of robotics, motion control, and technology education. The company has taken its engineering and management expertise in the fields of automation, motion control, and algorithmic functions and developed several businesses related to these technologies. Intelitek, the company's educational division develops, manufactures and markets training products and e-learning systems. Intelitek is a world leader in engineering and manufacturing technology training systems.",Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, IT Consulting and Outsourcing","EdTech, TMT","proprietary technology, proprietary technology integration, proprietary technology platform, proprietary technology provider, proprietary technology solutions, proprietary technology tools, training product",Corporate Backed or Acquired,,Generating Revenue/Not Profitable,Acquired/Merged (Operating Subsidiary),"M&A, Publicly Listed",60,,,1982,2025-04-15,Yaskawa Electric,Israel,"Rosh Haayin, Israel",,,,2008-01-01,,,,,Merger/Acquisition,,Corporate,2008-01-01,Completed,,,1991-07-01,,,IPO,,,,Public Investment,Completed,,8.82,-0.3231,-6.32,5.03,19.07,3.29,24.2,-4.08,-5.9,6,4,2,,4,4,"Electric digital data processing, Static stores",,Yaskawa Electric,,,The company was acquired by Yaskawa Electric (TKS: 6506) for an undisclosed amount in 2008.,,
165529-27,RSL Electronics (TAE: RSEL),RSL Electronics Ltd,,"R SL Electronics Ltd develops and manufactures control, diagnostics and prognostics systems for aerospace, marine and land applications. Its solutions include airborne control systems and airborne health and usage management systems. The company's activity in the field is intended for upgrading engine control systems or controlling old server systems in military aircraft. It specialized in integrated smart solutions for Control & Utilities, Health Monitoring and Diagnostic & Prognostic for the defense, railroad and energy sectors.",Business Products and Services (B2B),Commercial Products,Aerospace and Defense,"Aerospace and Defense*, Electrical Equipment","Industrials, Manufacturing","aerospace, airborne system, aircraft, diagnostics, general electric, helicopter",Corporation,,Generating Revenue,Publicly Held,Publicly Listed,,TAE,RSEL,1986,2024-01-16,,Israel,"Migdal Ha'Emek, Israel",,,,2000-02-03,,,,,IPO,,Public Investment,2000-02-03,Completed,,,2000-02-03,,,IPO,,,,Public Investment,Completed,,,,,,15.16,,,,,7,1,1,,6,6,Control or regulating systems in general,,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of RSEL on February 3, 2000.",,
41276-89,Sapiens International Corporation (NAS: SPNS),Sapiens International Corporation N.V.,"Msg Life, Zywave, Ebix (Financial Software), SSP (United Kingdom ), RGI Group, OneShield, One (Folsom), TCube Solutions, Duck Creek Technologies, FirstBest","Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.",Information Technology,Software,Financial Software,"Financial Software*, IT Consulting and Outsourcing","FinTech, InsurTech, SaaS, TMT","banking software, decision making software, financial software, insurance software, insurance software developer, insurance software product, insurance software provider",Corporation,20.0,Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed",4850,NAS,SPNS,1982,2025-04-26,,Israel,"Holon, Israel",460.0,2015-10-20,Secondary Transaction - Private,2024-04-06,,,,,Merger/Acquisition,,Corporate,2024-04-06,Rumor/Speculation,,,1992-05-29,,,IPO,,,,Public Investment,Completed,,542.38,0.054,72.18,-152.44,1558.69,238.11,1378.69,104.43,84.36,,,,,,,,,,1,Formula Systems,"The company is rumored to be in talks regarding a potential acquisition for an undisclosed amount on April 6, 2024. Previously Francisco Partners was in talks to buy a 48% stake in the company from Formula Systems (1985) (NASDAQ: FORTY) for $220.8 million as of August 12, 2014. Subsequently, the deal was cancelled.",,Francisco Partners
61793-83,Sarine Technologies (SES: U77),Sarine Technologies Ltd,,"Sarine Technologies Ltd is a company engaged in the development and manufacturing of evaluation, planning, processing, and finishing systems for diamond and gemstone production. The company's products provide solutions for every stage of the rough diamond manufacturing process, from geometrical modeling and internal inclusion mapping of the rough stone, through determining the derivable polished gems, based on true dollar value. India is the principal market for these products. Sarine has operations in India, Africa, Europe, North America, Israel, the other countries, out of which the majority of the revenue is generated from India.",Business Products and Services (B2B),Commercial Products,Electrical Equipment,Electrical Equipment*,"Industrials, Manufacturing","diamond, dimond grading systems, manufacturing, precision machined",Corporation,,Profitable,Publicly Held,Publicly Listed,468,SES,U77,1988,2025-04-26,,Israel,"Kfar Saba, Israel",,,,2005-04-08,,,,,IPO,,Public Investment,2005-04-08,Completed,,,2005-04-08,,,IPO,,,,Public Investment,Completed,,39.2,-0.0872,1.07,-20.81,57.28,23.0,34.72,5.08,0.93,36,13,24,5,7,7,"Image data processing or generation, in general, Investigating or analysing materials by determining their chemical or physical properties, Measurement of intensity, velocity, spectral content, polarisation, phase or pulse characteristics of infrared, visible or ultraviolet light, Measuring length, thickness or similar linear dimensions, Working stone or stone-like materials",,,,,"The company completed its initial public offering on the Singapore Exchange under the ticker symbol of U77 on April 8, 2005. The shares were sold at a price of SGD 0.272 per share",,
233086-42,Sativus Tech (PINX: SATT),Sativus Tech Corp,,"Sativus Tech Corp is an agriculture technology company focusing on producing technology for the agriculture market for home, commercial, and medical use. The company produces automated plant growing devices managed and controlled by an artificial intelligence algorithm, allowing consumers to grow their own herbs and vegetables effortlessly from seed to plant. The company is in advanced stages of developing and testing a fully automated and remotely managed system for growing high-quality, high-yield saffron anywhere and anytime.",Business Products and Services (B2B),Commercial Products,Electrical Equipment,Electrical Equipment*,"AgTech, Cannabis, Climate Tech, LOHAS & Wellness, Manufacturing, Supply Chain Tech","automatic hydroponic growing machine, automatic hydroponic growing machine branding, automatic hydroponic growing machine company, cannabis automatic hydroponic growing machine, cannabis machine, indoor farming, indoor farming components",Corporation,4.0,Profitable,Publicly Held,"Debt Financed, M&A, Publicly Listed",36,PINX,SATT,2013,2025-04-10,,Israel,"Yokneam, Israel",2.77,2018-09-17,Secondary Transaction - Private,2019-08-06,,,,,Debt - General,,Debt,2019-08-06,Completed,,Revolving Credit - 30.00M¬†$,2018-09-17,0.55,Actual,Secondary Transaction - Private,2.77,Actual,,Corporate,Completed,,0.0,0.0,-0.68,2.92,0.38,,3.85,-0.91,-1.02,5,1,,,5,5,,,,1,Seedo Corp,"The company received $30 million of debt financing in the form of a line of credit from undisclosed lenders on August 6, 2019. Funds will be used to launch a home-grow unit leasing business model.",CNBX Pharmaceuticals,
434992-78,SavorEat (TAE: SVRT),SavorEat Ltd.,,"SavorEat Ltd is engaged in the business of developing meat-alternative products. The company operates in a single activity sector, which is the development of a technological platform for the production and roasting of meat substitutes through advanced digital production, including Three D printing. The company is developing a system for the production and printing of meat substitutes from plant-based products.",Consumer Products and Services (B2C),Consumer Non-Durables,Food Products,Food Products*,"Climate Tech, FoodTech, Restaurant Technology","alt-proteins, cooking robots, meat alternative, meat substitute, plant-based protein, smart kitchen, vegan food product",Formerly VC-backed,17.34,Product Development,Publicly Held,"Publicly Listed, Venture Capital",22,TAE,SVRT,2018,2025-03-21,,Israel,"Rehovot, Israel",25.0,2020-07-27,Seed Round,2020-11-25,12.59,Estimated,,,IPO,,Public Investment,2020-11-25,Completed,,,2020-07-05,1.75,Actual,Seed Round,7.0,Actual,Seed Round,Venture Capital,Completed,,,,,,2.19,,,,,5,2,,5,,,"Containers for storage or transport of articles or materials, Shaping or working of foodstuffs, not fully covered by a single other subclass",,,2,"Deloitte Launchpad, Yissum","The company raised an estimated ILS 42.6 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of SVRT on November 25, 2020. After the offering the company was valued at ILS 170 million.","Meitav Investment House, Mor-Langermann, Next Food",
100979-20,Scinai Immunotherapeutics (NAS: SCNI),Scinai Immunotherapeutics Ltd.,"aVaxziPen, Bluebird Bio, PaxVax, ViroPharma, Vical, Sinovac, NH TherAguix, Vaxart, Aceragen, AVEO Oncology, Zynerba Pharmaceuticals, VBI Vaccines","Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,"Other Healthcare Services, Pharmaceuticals*","LOHAS & Wellness, Manufacturing","biopharmaceutical, biopharmaceutical company, biopharmaceutical company development, biopharmaceuticals, clinical trials, flu vaccines, virus proteins",Corporate Backed or Acquired,43.38,Generating Revenue,Publicly Held,"M&A, Publicly Listed",31,NAS,SCNI,2003,2025-04-26,,Israel,"Jerusalem, Israel",38.21,2017-09-15,Public Investment 2nd Offering,2023-09-19,1.33,Actual,,,PIPE,,Corporate,2023-09-19,Completed,,,,,,Angel (individual),,,Angel (individual),Individual,Completed,,0.45,,4.7,0.2,2.35,,20.64,-3.88,-5.11,27,4,17,,10,10,"Peptides, Preparations for medical, dental or toiletry purposes",7,,2,"Angels High Tech Investments, Yorkville Advisors","The company (NAS: SCNI) received $1.33 million of development capital from undisclosed investors on September 19, 2023, through a private placement. The company issued 1,146,552 of the company's American Depositary Shares at a purchase price of $1.16 per ADS. The company intends to use the net proceeds from the offering for general working capital, research and development and general corporate purposes.","Coronis Partners, Israel Innovation Authority, Yeda Research and Development Company",
58956-40,SciSparc (NAS: SPRC),SciSparc Ltd.,"Acerus Pharmaceuticals, Akorn, IPI Legacy Liquidation, Lipocine, Auspex Pharmaceuticals, Medexus Pharmaceuticals, Antares Pharma, Hua Medicine, Catalyst Pharmaceuticals, ACADIA Pharmaceuticals, Flex Pharma, Orgenesis, Seneca Biopharma","SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Drug Discovery*, Pharmaceuticals",Life Sciences,"cannabinoid drugs, cannabinoid therapy, immunity drugs, immunotherapeutics, pharmaceutical, pharmaceutical company, pharmaceutical company advisory",Corporation,54.98,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",3,NAS,SPRC,2004,2025-04-26,,Israel,"Tel Aviv, Israel",48.0,2019-10-31,Merger/Acquisition,2023-10-13,5.02,Actual,,,PIPE,,,2023-10-13,Completed,,,2005-12-26,10.4,Actual,IPO,26.21,Actual,,Public Investment,Completed,,1.75,-0.4736,-5.68,-2.5,3.1,1.21,-0.42,-6.03,-6.52,73,10,37,21,15,15,"Heterocyclic compounds, Peptides, Preparations for medical, dental or toiletry purposes",9,,,,"The company (NAS: SPRC) received $5.02 million of development capital from undisclosed investors on October 13, 2023, through a private placement.",Gefen Biomed Investments,Quantum BioPharma
56039-14,Scodix (TAE: SCDX),Scodix LTD.,MBO Postpress Solutions,"Scodix Ltd is a provider of digital print enhancement presses in Graphic Arts, brings converters and PSPs (print service providers) in commercial print, web-to-print, publishing, folding carton, photo, tags, trade finishers and more, real and measurable added value to products. It operates in the field of research and development, production, marketing and sale worldwide of advanced digital systems for print enhancement. Its products include Scodix E106, Scodix Ultra 1000's Series, Scodix Studio, Scodix Polymers, among others.",Business Products and Services (B2B),Commercial Products,Machinery (B2B),Machinery (B2B)*,"Industrials, Manufacturing","printer supply, printing press design, printing press manufacturer, printing product, printing product design",Formerly VC-backed,53.88,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",126,TAE,SCDX,2007,2024-09-24,,Israel,"Rosh Haayin, Israel",,,,2021-07-22,18.88,Estimated,,,IPO,,Public Investment,2021-07-22,Completed,,,,16.0,Estimated,Early Stage VC,,,,Venture Capital,Completed,,,,,,23.72,,,,,63,18,39,6,18,18,"Apparatus for applying fluent materials to surfaces, in general, Coating metallic material, Graphical data reading, Layered products, Typewriters",,,1,Tene Capital,"The company raised an estimated ILS 62 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of SCDX on July 22, 2021.","Angeleno Group, Battery Ventures, Lightspeed Venture Partners, Lightspeed Venture Partners Israel, MoreVC, Sequoia Capital, Wekix",
41268-07,Senstar Technologies (NAS: SNT),Senstar Technologies Corporation,,"Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.",Information Technology,IT Services,IT Consulting and Outsourcing,"Business/Productivity Software, Electronic Equipment and Instruments, IT Consulting and Outsourcing*, Other Communications and Networking","Cybersecurity, Industrials, Manufacturing, TMT","computer-based security, military communications, security, security and safety, security service",Corporation,,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed",136,NAS,SNT,1984,2025-04-26,,Canada,"Ottawa, Canada",24.0,2016-09-07,Buyout/LBO,,,,,,Buyout/LBO,,Private Equity,,Upcoming,,,1993-03-23,,,IPO,,,,Public Investment,Completed,,35.75,0.0902999999999999,2.64,-20.03,80.82,22.92,61.32,5.09,4.36,55,17,17,1,37,37,"Guiding railway traffic, Signalling or calling systems",,,1,FIMI Opportunity Funds,"The company is in talks to be acquired by FIMI Opportunity Funds through an LBO as of May 22, 2020. FIMI, a controlling shareholder of Magal, currently owns 9,854,159 ordinary shares of Magal, representing approximately 42.6% of Magal's issued and outstanding shares. If FIMI purchases 8,669,029 Magal shares in the tender offer, FIMI will own approximately 80.0% of Magal's issued and outstanding shares.",,
58281-31,SentinelOne (NYS: S),"SentinelOne, Inc.","CrowdStrike Holdings, Rapid7, Trellix, AppRiver, Device Authority, McAfee, EScan, Illumio, Avira Operations, Sentryo, Acunetix, BitDefender, AVG Technologies, Seculert, GuruCul, SecPod, F-Secure, Cylance, Javelin (Artificial Intelligence Platform), Attivo Networks, BullGuard, PureSec, Tenable, Netskope, Saviynt, Contrast Security, Mandiant, Ayehu, Red Earth Software, Veracode, Quick Heal Technologies, GFI USA, SecuriThings, Absolute Security (Network Management Software), IKARUS Security Software, Fidelis Security, Cyphort, Carbon Black, Resolution1 Security, Smokescreen Technologies, Tesseract (Network Management Software), ForeScout Technologies, vArmour, Acalvio, Synack, Nyotron Information Security, Proofpoint, Securonix, NTT Application Security, Lookout, Malwarebytes, Check Point Software Technologies, ESET, Palo Alto Networks, Kaspersky Lab, Sasa Software, Bastille Networks, Ziften, Gen Digital, Infocyte, Huntress, K7 Computing, Avast Software, GoSecure (Network Management Software), Microsoft, Trend Micro",SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.,Information Technology,Software,Network Management Software,Network Management Software*,"Artificial Intelligence & Machine Learning, Cybersecurity, Internet of Things, SaaS","cloud security, endpoint detection & response, endpoint detection and response, endpoint protection platform, endpoint security, iot security, malware detection, threat prevention, threat remediation",Formerly VC-backed,1972.0,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",2800,NYS,S,2013,2025-04-26,,United States,"Mountain View, CA",8972.99,2021-06-30,IPO,2023-08-21,,,,,Buyout/LBO,,Private Equity,2023-08-21,Failed/Cancelled,,,2013-03-15,0.5,Actual,Seed Round,,,Seed Round,Venture Capital,Completed,,821.46,0.3225,-288.44,-721.9,6072.29,610.36,7055.96,-288.74,-331.54,90,23,76,11,3,3,"Electric digital data processing, Transmission of digital information",,,8,"Factorial Funds, H/L Ventures, Insight Partners, Platinum Capital vc, Redpoint Ventures, Sequoia Capital, Tiger Global Management, W Capital Partners","The company was in talks to be acquired by Catalyst Partners through an LBO as of August 21, 2023 for an undisclosed amount. Subsequently, the deal was cancelled.","345 Partners, Accel, Andreas Bechtolsheim, Ashton Kutcher, DCVC, ESO Fund, Granite Hill Capital Partners, Irving Investors, ITOCHU Technology Ventures, NextEquity Partners, Qualcomm Ventures, Samsung Venture Investment, Samuel Klatt, Shasta Ventures, SineWave Ventures, Sound Ventures, Suguru Yamaryo, The Westly Group, Third Point Ventures, UpWest, Vintage Investment Partners, Vista Equity Partners",
165106-54,Shalag Industries,Shalag Industries Ltd,,"Manufacturing and marketing of nonwovens intended for the hygienic and wipes markets in Israel. Its products include Baby Diapers and Adults, Feminine Hygiene, Dry Wipes, Wet Wipes, and Industrial Wipes.",Consumer Products and Services (B2C),Consumer Non-Durables,Personal Products,"Other Textiles, Personal Products*",Manufacturing,"fiber, hygienic paper, industrial wipes, manufacturing, nonwoven, wipes",Corporation,,Profitable,Privately Held (no backing),Publicly Listed,188,,,1983,2025-02-05,,Israel,"Kibbutz Shamir, Israel",,,,2004-06-08,,,,,IPO,,Public Investment,2004-06-08,Completed,,,2004-06-08,,,IPO,,,,Public Investment,Completed,,201.2,0.0177,9.44,14.15,112.88,37.09,113.58,21.21,8.9,,,,,,,,,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of SALG on June 8, 2004.",,
277225-48,Shamaym (TAE: SHMM),,,Shamaym Improve Ltd is engaged in the development of an artificial intelligence-based platform for producing lessons and briefing research processes. It operates in the field of collaborative technologies for work management. The company has developed a technological platform based on artificial intelligence and machine learning for extracting lessons and briefing-debriefing processes for continuous improvement.,Information Technology,Software,Educational Software,"Business/Productivity Software, Educational Software*, Human Capital Services",Artificial Intelligence & Machine Learning,"ai technology platform, enterprise resource planning, erp, learning and improvement, online learning, real time learning, teaching platform, training platform",Formerly VC-backed,2.05,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",30,TAE,SHMM,2015,2024-03-19,,Israel,"Tel Aviv, Israel",7.65,2021-06-07,IPO,2021-06-07,2.05,Estimated,7.65,Estimated,IPO,,Public Investment,2021-06-07,Completed,,,2015-01-01,,,Early Stage VC,,,,Venture Capital,Completed,,1.37,,,,2.7,,,,,,,,,,,,,,,,"The company raised ILS 6.7 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of SHMM on June 7, 2021. After the offering, the company was valued at ILS 25 million.","2B.VC, 2b-Community, Accomplice VC, Adi Pundak-Mintz, Ehud Mokady, Gigi Levy-Weiss, MassChallenge",
58814-02,Shekel Brainweigh,Shekel Scales (2008) Ltd.,,"Shekel Brainweigh Ltd is engaged in the development, planning, assembly and marketing of electronic weighing systems.. The company has three reportable segments which include Retail, Healthcare, and Industry. The majority of revenue derives from the Retail segment.",Healthcare,Healthcare Devices and Supplies,Monitoring Equipment,"Monitoring Equipment*, Other Devices and Supplies","HealthTech, Manufacturing, TMT","advances weighing system, force measurement application, manufacturing, retail weighing machine, weighing machine, weighing system",Formerly PE-Backed,8.46,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",135,,,1971,2025-04-04,,Israel,"Tel Aviv, Israel",7.55,2018-11-20,IPO,2018-11-20,7.3,Actual,7.55,Estimated,IPO,,Public Investment,2018-11-20,Completed,,,2010-10-28,1.16,Actual,PE Growth/Expansion,3.09,Estimated,,Private Equity,Completed,,27.17,0.0204999999999999,-5.05,20.63,3.1,9.5,25.17,-3.46,-3.46,55,18,29,12,14,14,"Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Measuring force, stress, torque, work, mechanical power, mechanical efficiency, or fluid pressure, Registering the receipt of cash, valuables, or tokens, Weighing",,,,,"The company raised AUD 10.5 million in its initial public offering on the Australian Securities Exchange Limited under the ticker symbol of SBW on November 20, 2018. A total of 30000000 shares were sold at AUD 0.35 per share.",TechnoPlus Ventures,
61298-92,SHL Telemedicine (SWX: SHLTN),SHL Telemedicine Ltd.,"CardioDiagnostics, AMD Global Telemedicine, CloudTag, Philips, CareClix, Rijuven, AliveCor, Zipnosis, SnapMD, GlobalMed, Teladoc Health, Doctor On Demand, Neurosynaptic Communications, Natali Healthcare, InTouch Health, TeleVital, Murj, Heal","SHL Telemedicine Ltd develops and markets personal telemedicine solutions. It consists of the transmission of medical data by an individual, from a remote location to a medical call center through telecommunication networks. The company offers solutions to subscribing patients, health insurance companies, hospitals, clinics, and physicians. It provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments Israel, Europe, and the rest of the world, out of which majority revenue comes from Israel.",Healthcare,Healthcare Devices and Supplies,Monitoring Equipment,"Monitoring Equipment*, Other Healthcare Technology Systems","Digital Health, HealthTech","chronic disease monitoring, digital medical care, medical assistance, personalized healthcare service, telemedicine, telemedicine device, telemedicine system",Formerly VC-backed,131.98,Generating Revenue/Not Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed, Venture Capital",583,SWX,SHLTN,1987,2025-04-26,,Israel,"Tel Aviv, Israel",118.0,2020-12-17,PIPE,2021-02-23,23.04,Actual,,,PIPE,,Corporate,2021-02-23,Completed,,,,,,Corporate,,,Corporate,Corporate,Completed,,56.78,-0.0052,-28.09,-1.4,38.76,25.79,47.7,-18.87,-26.41,,,,,,,,1,,1,Himalaya Capital,"The company (SWX:SHLTN) received CHF 20.6 million of development capital from undisclosed investors on February 23, 2021 through a private placement. The proceeds will be used to support growth of its current business operations in Germany and to build up its business in the US.","Alroy Group, Barak Capital, Philips",Shanghai Jiuchuan
62334-64,Silexion Therapeutics (NAS: SLXN),Silexion Therapeutics Corp.,,"Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*, Pharmaceuticals","Life Sciences, Oncology","biopharmaceutical firm, brain cancer, cancer treatment, chemotherapy care, oncology cure, rna interference, solid tumor cancers, tumor treatment",Formerly VC-backed,16.9,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed, Venture Capital",14,NAS,SLXN,2008,2025-04-26,,Israel,"Ramat-Gan, Israel",,,,2025-01-17,2.9,Actual,,,Public Investment 2nd Offering,,Public Investment,2025-01-17,Completed,,,2009-09-01,6.0,Actual,Grant,,,,Other,Completed,,0.0,0.0,-16.44,3.3,8.12,,5.56,-16.48,-16.5,,,,,,,,2,,,,"The company raised $2.9 in its second public offering on the Nasdaq stock exchange under the ticker symbol of SLXN on January 17, 2025. A total of 2,145,998 shares were sold at $1.35 per share.","Esperante Ventures, Israel Innovation Authority, Laursen Van Swieten, Moringa Acquisition, Yoram Bibring",
41513-05,Silicom (Kfar Saba) (NAS: SILC),Silicom Ltd.,"NEC (Japan), Super Micro Computer, Finisar, Advanced Micro Devices, EXFO, Cisco Systems, Dell Technologies, Maxim Integrated Products, Lenovo","Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.",Information Technology,Computer Hardware,"Computers, Parts and Peripherals","Computers, Parts and Peripherals*",TMT,"communication device, communication device producer, connectivity solutions, ethernet networking, networking, networking application",Corporation,,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,246,NAS,SILC,1987,2025-04-26,,Israel,"Kfar Saba, Israel",,,,1994-02-28,,,,,IPO,,Public Investment,1994-02-28,Completed,,,1994-02-28,,,IPO,,,,Public Investment,Completed,,58.11,-0.5318,-13.71,-65.68,78.13,16.6,36.83,-11.7,-13.91,8,5,4,,4,4,Electric digital data processing,,,,,"The company completed its initial public offering on the Nasdaq stock exchange under the ticker symbol of SILC on February 28, 1994.",,
13348-00,Silynx Communications (ASE: SYNX),Silynxcom Ltd,INVISIO,"Silynxcom Ltd is engaged in developing, manufacturing, marketing and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat-proven. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both in training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, market and sell push-to-talk devices, communication controllers, and communication device cables and connectors.",Business Products and Services (B2B),Commercial Products,Aerospace and Defense,"Aerospace and Defense*, Other Commercial Products","Industrials, Manufacturing","electronics manufacturer, headset product, headset systems, hearing amplifiers, hearing enhancement devices, hearing protection, hearing protection device, industrial communication, in-ear headphones, law enforcement equipment, law enforcement operations, military communications, noise control",Corporation,7.9,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,33,ASE,SYNX,2005,2025-04-26,,Israel,"Netanya, Israel",21.0,2024-01-12,IPO,2024-07-15,5.0,Estimated,,,Public Investment 2nd Offering,,Public Investment,2024-07-15,Announced/In Progress,,,2024-01-12,5.0,Actual,IPO,21.0,Estimated,,Public Investment,Completed,,9.89,0.1805,-1.19,-3.56,11.88,4.62,14.92,-0.96,-1.08,2,1,2,,,,"Circuit arrangements or systems for supplying or distributing electric power, Electrically-conductive connections",,,,,"The company filed for a second public offering on the New York Stock Exchange under the ticker symbol of SYNX on July 15, 2024 . They intend to sell 1,020,408 shares at a price of $4.9 per share. The expected offering is 5 million. They intend to sell 1,020,408 shares. Previously, the company raised $5 million in its initial public offering on the NYSE MKT LLC stock exchange under the ticker symbol of SYNX on January 12, 2024. A total of 1,250,000 shares were sold at $4 per share. After the offering, there was a total of 5,250,000 outstanding shares at $4 per share, valuing the company at $21 million. The underwriters were granted an option to purchase up to an additional 187,500 shares from the company to cover over-allotments, if any. The company is being actively tracked by PitchBook.",Shamrock Israel Growth Fund,
56026-99,SimilarWeb (NYS: SMWB),SimilarWeb Ltd.,"SEMrush, Comscore, ZoomInfo Technologies, Localytics, Data.AI, Optimizely, Gummicube, SimilarTech, WhatRunsWhere, Sensor Tower, BuiltWith, Pathmatics, InsideSales, 42matters, Jumpshot (Marketing Analytics), Kissmetrics, Adthena, Adbeat, Quantcast, AppsFlyer, Appsee, Verto Analytics, Insert (Application Software), Mixpanel, SalesLoft, gShift Labs, Apptopia, Tableau Software, Dun & Bradstreet, Longtail UX, Mattermark, MixRank, Majestic (Business/Productivity Software), iQuanti, Apsalar, Crayon (Business/Productivity Software), Monetate, KloudFuse, DueDil, InsightSquared, Clootrack, Prisync, Board International, BrightEdge (Business/Productivity Software), Swrve, Moz (Business/Productivity Software), Thunder Industries, Competitoor, Cuutio, Rival IQ, Ahrefs, AppTweak, L2, Contify, Social Status, Kompyte, SE Ranking, Airship, Phizzle, Exago, TUNE, BoxofAds, Everbooked, Clearbit, Searchmetrics, Facelift Data Studio, The Nielsen Company, TrackMaven, dv01, TIBCO Software, Feedburner, Trakomatic, Owler, Raven Tools, MobileAction, Dundas Data Visualization, LG Lugar de Gente, Unmetric, deltaDNA, CleverTap, Web CEO, GfK, MicroStrategy (Business/Productivity Software), SiteSpect, Spyfu, WordStream, CB Insights, GameAnalytics, Countly, Hitwise, Looker, Sisense, Appfigures, InsideView, LeadLedger, Distimo Holding, WebTrends, Domo, Alteryx, LinkResearchTools, Datanyze, CI Radar, Izenda","Similarweb Ltd provides a platform for digital intelligence, delivering a trusted, comprehensive, and detailed view of the digital world that empowers customers to accelerate their growth and become more competitive in the markets. Its proprietary technology analyzes billions of digital interactions and transactions every day from millions of websites and apps and turns these digital signals into actionable insights. The company generates revenues mainly from SaaS subscriptions, which comprise subscription fees from customers utilizing cloud-based digital intelligence solutions and other subscription-based solutions. Geographically, the majority of its revenue is derived from the United States and rest from Israel, United Kingdom, Europe, Asia Pacific and other regions.",Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Media and Information Services (B2B)","Artificial Intelligence & Machine Learning, Big Data, Marketing Tech, SaaS","competitive intelligence, crm, customer relationship management, digital strategy, market intelligence platform, online content, web traffic comparison",Formerly VC-backed,432.5,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Publicly Listed, Venture Capital",1085,NYS,SMWB,2007,2025-04-26,,United States,"New York, NY",1634.34,2021-05-13,IPO,2024-09-13,27.48,Actual,,,Secondary Transaction - Open Market,,,2024-09-13,Completed,,,2009-01-01,,,Accelerator/Incubator,,,,Other,Completed,,249.91,0.1463,-11.46,-24.14,641.1,195.1,1138.1,0.86,-9.66,1,1,,,1,1,,,,5,"Anglo-Peacock Nominees, Naspers, Prosus Ventures, Viola Growth, Yossi Vardi","Anglo-Peacock Nominees sold a 4.32% stake in the company (NYS: SMWB) for $27.475 million on September 13, 2024. A total of 3,500,000 shares were sold at a price of $7.85 per share. The company will not receive any proceeds from the offering.","CEIIF, David Alliance, Docor International Management, ION Asset Management, Kingfisher Investment Advisors, Kiri Capital, Lion Investment Partners, Moshe Lichtman, Naftali Investments, NFX, Saban Ventures, Seedcamp, Union Tech Ventures, Vintage Investment Partners, Viola Partners",
233679-79,SMX,"Security Matters, Ltd.",Claroty,"Provider of brand protection and supply chain integrity services intended to address the anti-counterfeit, brand protection, client liability and track and trace markets. The company commercializes the technology to permanently and irrevocably mark any object either solid, liquid, or gas, allowing identification, proof of authenticity, tracking supply chain movements and quality assurance and comprises a chemical-based hidden barcode system, alongside a unique reader to identify these codes and a blockchain record to store and protect ownership data.",Information Technology,IT Services,IT Consulting and Outsourcing,"IT Consulting and Outsourcing*, Network Management Software",,"anti-counterfeit measures, anti-counterfeit technology, authentication technology, branding protection, branding protection solution, software developer, supply chain integration, supply chain integration solution, supply chain integrity, supply chain intelligence, supply chain service provider, supply chain services",Corporation,21.21,Generating Revenue,Privately Held (no backing),"M&A, Publicly Listed",,,,2009,2025-04-01,,Australia,"Melbourne, Australia",,,,,,,,,Merger/Acquisition,,Corporate,,Upcoming,,,2018-10-15,4.3,Actual,IPO,,,,Public Investment,Completed,,,,,,,,,,,177,28,63,54,60,60,"Electric digital data processing, Graphical data reading, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Investigating or analysing materials by determining their chemical or physical properties, Postal sorting",,,,,"The company is in talks to be acquired by Ybyra Capital (BVMF: YBRA3) for an undisclosed amount on December 6, 2024. The acquisition is expected to create a powerful synergy, linking South America's vast natural resources with Asia's growing demand. Previously, The company (NAS: SMX) received AUD 5.35 million of development capital from undisclosed investors on September 12, 2024, through a private placement. The company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital. The company is being actively tracked by PitchBook.",,
277740-73,SofWave (TAE: SOFW),SofWave Medical Ltd.,,"Sofwave Medical Ltd is engaged in the development, marketing, and production of non-invasive technology for skin rejuvenation and firming treatment.",Healthcare,Healthcare Devices and Supplies,Other Devices and Supplies,Other Devices and Supplies*,"Beauty, HealthTech","anti-aging technology, anti-aging therapy, botox alternative therapy, derma tightening, dermatology, facial wrinkle remover, medical aesthetics, medical devices design",Formerly VC-backed,60.37,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",126,TAE,SOFW,2015,2024-11-20,,Israel,"Yokneam Illit, Israel",250.0,2021-05-18,IPO,2021-05-18,50.0,Actual,250.0,Estimated,IPO,,Public Investment,2021-05-18,Completed,,,2017-03-23,0.21,Actual,Accelerator/Incubator,0.42,Actual,,Other,Completed,,59.65,0.1856,-4.55,-20.22,156.99,45.34,120.87,-2.89,-4.68,35,7,10,22,3,3,"Diagnosis, Electrotherapy, Methods or apparatus for generating or transmitting mechanical vibrations of infrasonic, sonic, or ultrasonic frequency,e.g. for performing mechanical work in general, Printed circuits",11,,,,"The company raised $50 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of SOFW on May 18, 2021. After the offering, the company was valued at $250 million.","Alon MedTech Ventures, Gandyr Investments, Shimon Eckhouse, XT Venture Capital",
53935-48,Sol-Gel Technologies (NAS: SLGL),Sol-Gel Technologies Ltd.,"Dermata, Foamix Pharmaceuticals, Botanix Pharmaceuticals, Panaxia Pharmaceutical Industries, Brinton Pharmaceuticals, Attune Pharmaceuticals, Revance Therapeutics, Dermira, Clinuvel Pharmaceuticals, Formulex Pharma Innovations","Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Drug Discovery*, Pharmaceuticals",,"dermatology care, dermatology company, dermatology product, drugs delivery system, pharmaceutical, pharmaceutical company, skin treatment, topical dermatological drug",Formerly PE-Backed,112.8,Generating Revenue/Not Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed, Venture Capital",36,NAS,SLGL,1997,2025-04-26,,Israel,"Ness Ziona, Israel",161.55,2019-08-08,Public Investment 2nd Offering,2023-08-10,22.8,Actual,,,PIPE,,Corporate,2023-08-10,Completed,,,2001-12-09,,,Secondary Transaction - Private,,,,Corporate,Completed,,11.71,8.6993,-9.57,-26.74,21.79,,-10.14,,-11.32,310,71,150,44,116,116,"Chemical or physical processes, Preparations for medical, dental or toiletry purposes, Preservation of bodies of humans or animals or plants or parts thereof, Specific therapeutic activity of chemical compounds or medicinal preparations, Specific use of cosmetics or similar toiletry preparations",15,,1,Arkin Capital,"The company (NAS:SLGL) received $22.8 million of development capital from Armistice Capital and Mr. Arkin on August 10, 2023 through a private placement. The company intends to use the net proceeds from the Offerings to fund the acquisition of SGT-610, the topically-applied patidegib, a new chemical entity hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome, research and development activities for SGT-610 through its planned clinical trial and the remainder for working capital and other general corporate purposes.","Armistice Capital, dsm-firmenich Venturing, Evergreen Venture Partners, Jerusalem Venture Partners, Medica Venture Partners, Merck, Millennium Materials Technologies Fund, Poalim Equity, The Challenge Fund - Etgar",
51075-46,Solaredge Technologies (NAS: SEDG),"SolarEdge Technologies, Inc.","Enphase Energy, Canadian Solar, Goodwe, Tigo Energy, First Solar, SunPower (Alternative Energy Equipment), True Value Solar, Tata Power Solar Systems, Trina Solar, SMA Solar Technology, NanoFlex Power, Ascent Solar Technologies, SolarCity, Heliatek, Euro Therm, EnterSolar, SunEdison, Elemental Energy, HelioPower, PowerFilm, JinkoSolar Holding, Redback Technologies, REC Solar (San Luis Obispo), JA Solar Technology Company, Suniva, Sunworks, Growatt, Vivint Solar, Power-One, Sunrun, Sungevity, Sungrow Power Supply, SunPower Corporation Australia, Soligent Distribution, Stion, Luminace Holdings, Fronius, Trinity Solar, SolarWorld, LDK Solar, Diablo Solar Services, Advanced Energy Industries, Solar Alliance Energy, Cleanleaf Energy, Vertiv, Contemporary Amperex Technology","SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.",Energy,Energy Equipment,Alternative Energy Equipment,Alternative Energy Equipment*,"CleanTech, SaaS, TMT","photovoltaic array, power optimizers, power systems, solar, solar array, solar system",Formerly VC-backed,1350.73,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed, Venture Capital",3961,NAS,SEDG,2006,2025-04-26,,Israel,"Herzliya, Israel",685.17,2015-03-26,IPO,2024-06-28,337.0,Actual,,,Debt - General,,Debt,2024-06-28,Completed,,Bonds - (Unsecured; Convertible),2006-01-01,,,Early Stage VC,,,,Venture Capital,Completed,,901.46,-0.697099999999999,-1806.36,171.46,741.58,-877.2,867.79,-1674.68,-1734.55,1493,226,1075,343,75,75,"Apparatus for conversion between ac and ac, between ac and dc, or between dc and dc, and for use with mains or similar power supply systems, Circuit arrangements or systems for supplying or distributing electric power, Emergency protective circuit arrangements, Generation of electric power by conversion of infrared radiation, visible light or ultraviolet light, Inorganic semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation",,,,,"The company raised $337 million of debt financing on June 28, 2024. Previously The company raised $678.5 million in its second public offering on the Nasdaq stock exchange under the ticker symbol of SEDG on March 21, 2022. A total of 2,300,000 shares including over-allotment options were sold at a price of $295 per share. The underwriters were granted an option to purchase up to an additional 300,000 shares from the company to cover over-allotments if any. The over-allotment option was exercised in full","ADIP, ARB, CCM Energy, General Electric Ventures, Genesis Partners, Highland Ventures Group, Israel Secondary Fund, Jerusalem Global Ventures, JP Asia Capital, Kreos Capital, Lightspeed Venture Partners, Lightspeed Venture Partners Israel, NewWorld Capital Group, Norwest Venture Partners, Opus Capital, Orr Partners, Vertex Ventures Israel, Walden International",
339830-74,Solrom Holdings (TAE: SLRM),Solrom Holdings Ltd,,"Solrom Holdings Ltd formerly 3DM Digital Manufacturing Ltd is developing a laser-based printhead for the 3D printing of industrial products. It has developed a high-resolution semiconductor laser light source, an ideal SLS solution for virtually any thermoplastic material.",Business Products and Services (B2B),Commercial Products,Machinery (B2B),Machinery (B2B)*,"3D Printing, Advanced Manufacturing","3d printing technology, 3d printing technology development, additives manufacturing, digital manufacturing, industrial printing equipment, industrial printing technology",Formerly VC-backed,14.0,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",,TAE,SLRM,2016,2025-03-24,,Israel,"Rosh Haayin, Israel",2.0,2017-12-01,Seed Round,2021-06-21,13.0,Actual,,,IPO,,Public Investment,2021-06-21,Completed,,,2017-12-01,1.0,Actual,Seed Round,2.0,Estimated,Seed Round,Venture Capital,Completed,,,,,,2.63,,,,,2,1,,1,1,1,Shaping or joining of plastics,,,4,"Institutional Mortgage Capital, Meitav, Psagot Investment House, Sphera Funds Management","The company raised $13 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of SLRM on June 21, 2021. After the offering, there was a total of outstanding shares.","3D Ventures, Terra Venture Partners",
61238-44,Spacecom (TAE: SCC),Space-Communication Ltd.,"Bezeq Israel Telecommunications, Hispasat, Telesat Canada, Cellcom Israel, NSSLGlobal, VocalTec Communications","Space Communication Ltd is a satellite operator and satellite service provider. It provides broadcasting and communications services to Direct-to-home (DTH) operators, TV broadcasters and programmers, government and corporate organizations, and VSAT network operators.",Information Technology,Communications and Networking,Telecommunications Service Providers,Telecommunications Service Providers*,"Space Technology, TMT","broadband satellite, broadband service, satellite operator, satellite operator company, space communication system, telecommunication",Corporate Backed or Acquired,19.88,Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed, Venture Capital",63,TAE,SCC,1989,2025-04-06,Discount Investment,Israel,"Ramat Gan, Israel",127.45,2021-10-12,Merger/Acquisition,2023-02-16,,,,,PIPE,,Corporate,2023-02-16,Completed,,,2005-03-10,,,IPO,,,,Public Investment,Completed,,100.02,0.0086,16.21,288.64,5.4,34.75,291.77,90.73,39.6,,,,,,,,,Discount Investment,1,4iG,"4iG (BUD :4IG) acquired a 10.46% stake in the company (TAE:SCC) for an undisclosed amount on February 16, 2023, through a private placement. Previously, Investors sold a 9.538% stake in the company (TAE: SCC) on October 6, 2022. The company will not receive any proceeds from the offering.","Clal Insurance Enterprises Holdings, Eurocom Group, Halman Aldubi Investment House, Harel Insurance Investments & Financial Services, IBI Investment House, ION Asset Management, Israel Aerospace Industries, Menora Mivtachim Holdings, MER Group, Migdal Insurance and Financial Holdings, Sphera Funds Management",Beijing Xinwei Technology Group
101941-84,Splitit,Splitit Ltd.,"Adyen, Visa Europe, Total Merchant Services, Wirecard Solutions South Africa, Electronic Payments, Gopay Vietnam Payment Services, Boku (Other Financial Services), Moneris Solutions, Venmo, Klarna, Fidelity Payment, Payr, PayPal Braintree, iPay (Doha), Paysafe, Confido Legal, Integrity Payment Systems, ZooZ, Wirecard Turkey, BlueSnap, ConnexPay, NTT DATA Payment Services, iPAY, Visa, Pay and Shop, First Data, Block, Sezzle, Openpay (Financial Software), Payscout, Bambora (Worldline), Payvision, Stripe, Dwolla, Aduno, Aevi (Financial Software), Wirecard Austria, Iyzico, iPay (Financial Software), Visa France, BillingTree, Worldpay, Afterpay, QuadPay, PayU, Payletter, BluePay Mid-Atlantic, Concardis, Affirm","Splitit Payments Ltd is a cross-border payment solution enabling customers to pay for purchases with an existing debit or credit card by splitting the purchase into fee and interest-free monthly installments, without the need for registration, application, or approval. Splitit operates in three geographical regions: North America, the United Kingdom & Europe, and Australia.",Information Technology,Software,Financial Software,"Financial Software*, Other Financial Services","B2B Payments, FinTech, Mobile Commerce, SaaS","bnpl & credit, bnpl and credit, consumer credit, crm, customer relationship management, installments payment, interest-free installments, monthly installments, payment processing, payment security, payments process technology, vendor payment",Private Equity-Backed,150.53,Generating Revenue,Privately Held (backing),"Debt Financed, M&A, Private Equity, Publicly Listed, Venture Capital",83,,,2009,2025-02-17,,United States,"Atlanta, GA",50.0,2023-12-11,Buyout/LBO,2023-12-11,50.0,Actual,50.0,,Buyout/LBO,Public to Private,Private Equity,2023-12-11,Completed,,,2012-01-01,4.3,Actual,Seed Round,,,Seed Round,Individual,Completed,,,,,,0.06,,56.78,,,23,9,8,,15,15,"Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Shaping or joining of plastics",,,1,Motive Partners,"The company was acquired by Motive Partners through a $50 million public-to-private LBO on December 11, 2023. The investment is comprised of two US$25 million tranches. The first $25 million tranche will be invested immediately upon shareholder approval of the company voluntarily delisting and the second $25 million tranche will be invested upon the company achieving certain 2023 full-year financial performance milestones and the satisfaction of certain customary closing conditions.","AltaIR Capital, Finovate, Lafayette Plug And Play, Prytek, Simpel (Financial Software), Woodson Capital Management",
327243-25,Steakholder Foods (PINX: MTTCF),Steakholder Foods Ltd.,"Offbeast, CellX Biosolutions, Redefine Meat, CellX, Aleph Farms, Believer, Rebellyous Foods, Follow Your Heart, Mosa Meat, UPSIDE Foods, Novameat, DB Foods","Steakholder Foods Ltd is engaged in transforming the alternative protein industries through its technology. The group specializes in developing and selling 3D-printing production machines, supported by proprietary premix blends, formulated from the highest-quality raw ingredients. These tools help manufacturers of all sizes efficiently produce foods that meet consumer expectations for taste, texture, and appearance and offer a safe and sustainable alternative to industrialized meat and seafood production. The company's expertise in creating alternative protein products replicating traditional meats' complex textures such as beef steaks, white fish, shrimp, and eel. It also explores the integration of cultivated cells, preparing for future advancements in food technology.",Business Products and Services (B2B),Commercial Products,Machinery (B2B),"Machinery (B2B)*, Other Commercial Products","3D Printing, Climate Tech, FoodTech, Industrials, Manufacturing","3d print, 3d printing, additives manufacturing, alt-proteins, cellular agriculture, climate tech company, cultivated protein, cultured meat, meat manufacturer, meat manufacturing",Pending Transaction (M&A),61.64,Generating Revenue,Publicly Held,"M&A, Publicly Listed, Venture Capital",43,PINX,MTTCF,,2025-04-26,,Israel,"Rehovot, Israel",,,,2025-02-28,1.25,Actual,,,PIPE,,Venture Capital,2025-02-28,Announced/In Progress,,,,1.99,Actual,Seed Round,,,Seed Round,Venture Capital,Completed,,0.01,,-8.52,1.09,0.85,-0.01,-2.68,-8.01,-8.48,7,3,4,3,,,"Apparatus for enzymology or microbiology, Methods or apparatus for sterilising materials or objects in general, Microorganisms or enzymes, Shaping or joining of plastics, Wireless communication networks",,,,,"The company (PINX: MTTCF) is in talks to receive $1.25 million of development capital from Alumni Capital through a private placement as of February 28, 2025. The company intends to use the net proceeds as working capital for general corporate purposes. Concurrently, the company filed for a second public offering on the Over-The-Counter Pink Sheet stock exchange under the ticker symbol of MTTCF on April 4, 2022. The expected offering amount is up to $4 million. Previously, the company (PINX: MTTCF) received $6 million of development capital from undisclosed investors on July 27, 2023, through a private placement. The company is being actively tracked by PitchBook.","Adom Group, BioSphere Capital, Clal Finance Investment House, Meitav Investment House, MORE Investment House, Ophectra Real Estate & Investments, Paz Capital, Psagot Investment House, Rami Levi",Alumni Capital
484061-32,StickIT (CNQ: STKT),StickIt Technologies Inc,,StickIt Technologies Inc is a company which provides technology that provides an opportunity to develop and produce a wide variety of sticks with different aromas and percentages of CBD and THC. The main product of StickIt is its Extra-C sticks it includes a line of cannabinoid and non-cannabinoid sticks for smokables and a convenient way to enable people to smoke cannabis or consume terpenes or terpeniods by simply inserting the active material into any existing cigarettes.,Consumer Products and Services (B2C),Consumer Non-Durables,Other Consumer Non-Durables,"Internet Retail, Other Consumer Non-Durables*, Specialty Retail","Cannabis, E-Commerce, LOHAS & Wellness","cannabis cigarettes, cannabis cigars maker, cannabis product, cannabis stick, cbd stick, hemp cigarettes, hemp cigarettes product",Corporation,,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,,CNQ,STKT,2019,2024-08-07,,Canada,"Vancouver, Canada",,,,2023-10-27,,,,,IPO,,Public Investment,2023-10-27,Completed,,,2023-10-27,,,IPO,,,,Public Investment,Completed,,0.03,,-0.32,-0.31,0.41,-0.01,0.07,-0.31,-0.32,,,,,,,,,,,,"The company raised an undisclosed amount of funding in its initial public offering on the Canadian National Stock Exchange under the ticker symbol of STKT on October 27, 2023. After the offering, there was a total of 126,244,733 outstanding shares.",,
54544-15,Stratasys (Printing Services (B2B)) (NAS: SSYS),"Stratasys, Ltd.","Pl Euro Services, Cadimensions Inc., Quartus Engineering, Becoming 3D, Model Solution, Sculpteo, Ultimaker, Xometry, Markforged, The ExOne Company, RapidFit, 3D Systems","Stratasys Ltd is a polymer-based 3D printing solution, which provides a product life cycle, with multiple technologies and complete solutions for superior application fit, across industrial, healthcare, and consumer fields. It focuses, in particular, on polymer 3D printing solutions that address the fastest-growing manufacturing solutions viewed as the potential growth opportunity in the 3D printing industry. Its printers include FDM, PolyJet, Stereolithography, P3, and SAF. Its software is GrabCAD Software, Connectivity, Digital Anatomy Creator, and OpenAM Software. It generates revenue through 3D printing systems, related services, and consumables and by providing additive manufacturing solutions.",Business Products and Services (B2B),Commercial Services,BPO/Outsource Services,BPO/Outsource Services*,"3D Printing, Manufacturing","3d printing, 4d printing, industrial printing, manufacturing, polyjet printing, printing service, printing service firm, rapid prototyping",Corporation,601.28,Generating Revenue/Not Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed",1779,NAS,SSYS,1989,2025-04-26,,United States,"Eden Prairie, MN",857.14,2025-04-10,PIPE,2025-04-10,120.0,Actual,857.14,Estimated,PIPE,,Private Equity,2025-04-10,Completed,,,2000-06-28,,,Corporate,,,Corporate,Corporate,Completed,,572.46,-0.0878999999999999,-120.28,-118.61,793.45,256.82,522.79,-40.26,-85.66,2462,617,1880,232,350,350,"Additive manufacturing, Coating compositions, Electric digital data processing, Shaping or joining of plastics, Working metallic powder",,,2,"Fortissimo Capital, Nano Dimension","Fortissimo Capital acquired approximately 14% stake in the company (NAS:SSYS) for $120 million on April 10, 2025 through a private placement. Fortissimo's investment underscores confidence in the company's leadership and performance and improves its ability to deliver solutions that solve customer needs and its long-term growth potential.","Stratasys (Computers, Parts and Peripherals), Suny Cellular Communication",Desktop Metal
58612-15,SuperCom (NAS: SPCB),SuperCom Ltd.,"Tech Mahindra, Amazon Web Services, Idemia, MindTree, Wipro, Gemalto, Happiest Minds, Bundesdruckerei, CyberArk Software, YASH Technologies, Sophos, Secure Thingz","SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT and Connectivity, which is the key revenue driver; and Cyber Security. Besides, it also offers a wide range of solutions that include national ID registries, e-passports, biometric visas, automated fingerprint identification systems, digitized driver's licenses, and electronic voter registration and election management using the common platform. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and the Asia Pacific.",Information Technology,IT Services,Systems and Information Management,"IT Consulting and Outsourcing, Systems and Information Management*","Cybersecurity, Internet of Things, TMT","digital identity security, digital security, digital security market, digital security platform, digital security service, security solutions, security solutions services",Corporation,38.12,Generating Revenue/Not Profitable,Publicly Held,"M&A, Publicly Listed",121,NAS,SPCB,1988,2025-04-26,,Israel,"Tel Aviv, Israel",,,,2025-01-30,6.0,Estimated,,,PIPE,,Corporate,2025-01-30,Announced/In Progress,,,2005-02-17,,,IPO,,,,Public Investment,Completed,,26.84,0.0523,1.53,25.12,27.6,13.91,35.97,4.46,1.31,32,13,7,,25,25,"Graphical data reading, Layered products",,,,,"The company (NAS: SPCB) is in talks to receive approximately $6 million of development capital from undisclosed investors through a private placement as of January 30, 2025. The net proceeds will be used for working capital, research and development, potential acquisitions, and other general corporate purposes. Previously, the company (NAS: SPCB) received $4.37 million of development capital from undisclosed investors on January 23, 2025, through a private placement. The company is being actively tracked by PitchBook.",,
165195-91,Synel M L L Payway (TAE: SNEL),Synel M L L Payway Ltd,,"Synel M L L Payway Ltd is engaged in the development and production of data collection systems and solutions. It offers time and attendance terminals. It also provides access control products consisting of access keypad and stand alone controllers. It provides software and hardware solutions for the management of human resources in the organization which include payroll generation and attendance management, clearing pension funds, savings and investment, as well as intelligent management and analysis of physical security systems within the organization.",Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Electronic Equipment and Instruments, Human Capital Services",TMT,"attendance terminal, biometric attendance hardware, data collection system, time recording, workforce management app",Corporation,,Generating Revenue,Publicly Held,Publicly Listed,201,TAE,SNEL,1991,2023-09-14,,Israel,"Yokneam, Israel",,,,2000-07-18,,,,,IPO,,Public Investment,2000-07-18,Completed,,,2000-07-18,,,IPO,,,,Public Investment,Completed,,,,,,22.69,,,,,,,,,,,,,,,,"The company raised an undisclosed amount of funding in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of SNEL on July 18, 2000.",,
129127-06,T42 IoT Tracking Solutions (LON: TRAC),T42 IoT Tracking Solutions PLC,,"T42 IoT Tracking Solutions PLC group specializes in automated real-time systems for remote tracking and management of vehicles, containers, assets, and people. It offers real-time tracking systems for fleet management and security applications of the vehicle and driver, container monitoring, merchandise tracking, and management, and a personal locator for the protection of individuals. Its products include Watchlock, Software as a Service, Tetis, Kylos, and others. The firm has Hardware and SAS segments.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,"Electronic Equipment and Instruments*, Security Services (B2B), Wireless Communications Equipment","Industrials, Internet of Things, SaaS, TMT","gps tracking, real time tracking system, remote assets tracking, tracking system, vehicle tracking system",Corporation,8.24,Generating Revenue,Publicly Held,"Debt Financed, M&A, Publicly Listed",21,LON,TRAC,2004,2025-04-08,,United Kingdom,"St Helier, United Kingdom",2.03,2025-02-06,PIPE,2025-02-06,0.32,Actual,2.03,Estimated,PIPE,,Corporate,2025-02-06,Announced/In Progress,,,2013-02-27,4.22,Actual,IPO,22.07,Actual,,Public Investment,Completed,,4.34,0.2145,-1.04,4.64,1.79,2.23,7.9,0.57,0.09,1,1,,,1,1,,,,1,A-Labs,"The company (LON: TRAC) is in talks to sell a 16% stake to undisclosed investors for GBP 262,500, through a private placement as of February 6, 2025. The funds will also be used to to provide additional working capital to support existing and future orders accelerate manufacturing processes and expand the Company's marketing, focusing on the US and European sales markets. Previously, the company raised $1.3 million of debt financing in 2023. The company is being actively tracked by PitchBook.",,
41527-81,TAT Technologies (TAE: TATT),TAT Technologies Ltd.,"General Dynamics, Rolls-Royce Holdings, Safran Group, Rafael Advanced Defense Systems, L3 Harris Technologies, Northrop Grumman, BAE Systems, Genesys Aerosystems, Sumitomo Precision Products Company, Airbus Group, RTX, Woodward, SpaceX, GE Aerospace, Embraer, Danfoss, Aaon, Boeing, General Atomics, Pratt & Whitney, Bacharach, Gree Canada, Lockheed Martin, Carlisle Companies, Trane, Panasonic Compressor (Dalian), Novanta IMS","TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.",Business Products and Services (B2B),Commercial Products,Aerospace and Defense,Aerospace and Defense*,Manufacturing,"aerospace components, aerospace equipment, aircraft electronics, aircraft machinery, aviation, commercial product, defense equipment, heat exchange, landing gear, manufacturing, pumps and heater, valves actuators",Formerly PE-Backed,19.7,Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed",634,TAE,TATT,1969,2025-04-26,,Israel,"Kiryat Gat, Israel",161.29,2024-09-01,PIPE,2024-09-01,10.0,Actual,161.29,Estimated,PIPE,,Other,2024-09-01,Announced/In Progress,,,1987-03-01,,,IPO,,,,Public Investment,Completed,,152.12,0.3368,11.17,12.53,282.56,33.01,292.1,17.48,12.03,4,3,,1,3,3,Coating metallic material,,,1,FIMI Opportunity Funds,"The company (TAE:TATT) has entered into a definitive agreement to sell a 6.2% stake to undisclosed investors through a private placement as of September 1, 2024. Previously, FIMI Opportunity Funds sold a 24.96% stake in the company to an undisclosed buyer for ILS 129 million on September 2, 2024. The company is being actively tracked by PitchBook.","EN Shoham Business, Leap Tide Capital Management",
41126-95,Teva Pharmaceutical Industries (TAE: TEVA),Teva Pharmaceutical Industries Ltd.,"AbbVie, Pfizer (Pharmaceuticals), Dr. Reddy's Laboratories, Roche, SynCore Biotechnology Company, Sandoz Group, Evolus, AstraZeneca, Takeda Pharmaceutical, Hikma Pharmaceuticals, Merck & Co., Abbott India, Sun Pharmaceutical Industries, Novartis, Cipla, GSK, Phibro Animal Health, Novartis India, The Medicines Company, Sagent Pharmaceuticals, ANI Pharmaceuticals, Merck Biopharma, Par Pharmaceutical Companies, Virbac, Novo Nordisk, GlaxoSmithKline Pakistan, Cardinal Health, BioM‚àö¬©rieux (Diagnostic Equipment), Mylan, GlaxoSmithKline Consumer Nigeria, Merck","Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.",Healthcare,Pharmaceuticals and Biotechnology,Pharmaceuticals,"Biotechnology, Pharmaceuticals*","Life Sciences, Manufacturing","active pharmaceutical ingredients, biologics, generics medicine, migraine cure, pharmaceutical, pharmaceutical ingredients, specialty medicines platform",Corporation,21886.38,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, M&A, Private Equity, Publicly Listed, Venture Capital",35686,TAE,TEVA,1901,2025-04-26,,Israel,"Tel Aviv, Israel",19888.88,2017-12-01,Secondary Transaction - Open Market,2024-04-17,150.0,Actual,,,PIPE,,Venture Capital,2024-04-17,Completed,,,1990-03-26,,,IPO,,,,Public Investment,Completed,,16544.0,0.0441,-1639.0,14779.0,17075.99,8064.0,41403.02,777.0,-282.0,5959,1372,1673,387,3899,3899,"Acyclic or carbocyclic compounds, Devices for introducing media into, or onto, the body, Heterocyclic compounds, Peptides, Preparations for medical, dental or toiletry purposes",26,,6,"Abingworth, Allergan, Berkshire Hathaway, Fidelity Investments, Nordea Asset Management, The Capital Group Companies","The company (TAE:TEVA) received $150 million of development capital from Abingworth on April 17, 2024 through a private placement. The proceeds from the placement will be used to advance TEV-'248, a dual-action combination of an inhaled corticosteroid and a short-acting beta-agonist (ICS/SABA).",Soros Fund Management,Bausch Health Companies
64684-99,ThirdEye Systems (TAE: THES),ThirdEye Systems Ltd,,"Thirdeye Systems Ltd is involved in the manufacturing and marketing of electro-optical object recognition systems for skimmers and vehicles. The product portfolio of the company includes Chimera, Meduza, Tesseract, aEYE, and Goir among others.",Information Technology,Computer Hardware,Electronic Equipment and Instruments,"Business/Productivity Software, Electronic Equipment and Instruments*","Advanced Manufacturing, Artificial Intelligence & Machine Learning, Manufacturing, Robotics and Drones","artificial intelligence, autonomous machine, drones, intelligent robotics, monitoring, object recognition, object recognition system, sensors, threat alerts",Formerly Accelerator/Incubator backed,15.0,Generating Revenue/Not Profitable,Publicly Held,"M&A, Private Equity, Publicly Listed, Venture Capital",50,TAE,THES,2010,2025-01-28,,Israel,"Netanya, Israel",33.33,2025-01-28,PIPE,2025-01-28,10.0,Actual,33.33,Estimated,PIPE,,Corporate,2025-01-28,Announced/In Progress,,,,,,Accelerator/Incubator,,,,Other,Completed,,4.71,0.1845,-1.92,-0.93,38.55,1.52,23.95,-1.17,-1.35,2,1,,,2,2,,1,,1,New Horizon Group (Ramat Gan),"EDGE Group is in talks to acquire a 30% stake in the company (TAE:THES) through a private placement as of January 28, 2025. EDGE Group will invest $10 million as consideration for the stake. Previously, the company (TAE: THES) received $5 million of development capital from New Horizon Group on an undisclosed date through a private placement. The company is being actively tracked by PitchBook.",ICONYC Labs,EDGE Group (Abu Dhabi)
97758-82,TIGI (TAE: TIGI),TIGI Ltd.,,"Tigi Ltd is engaged in the development of technological solutions for the absorption and storage of solar energy. Its Honeycomb Collector product is efficient and cost-effective in high-temperature differential applications like space heating, industrial process heat, domestic hot water in cold climates as well as space cooling.",Energy,Energy Equipment,Alternative Energy Equipment,"Alternative Energy Equipment*, Energy Production","CleanTech, Industrials, Manufacturing","heat as a service solutions, heat collector, industrial heat pump, solar, solar thermal collector, solar thermal collectors",Corporation,4.01,Generating Revenue,Publicly Held,"Private Equity, Publicly Listed",45,TAE,TIGI,2007,2025-01-21,,Israel,"Hod HaSharon, Israel",,,,2024-07-12,3.74,Actual,,,PIPE,,Private Equity,2024-07-12,Completed,,,2021-03-14,,,IPO,,,,Public Investment,Completed,,,,,,14.0,,,,,32,8,27,1,4,4,"Domestic- or space-heating systems, Solar heat collectors",,,4,"EREN Groupe, JJRF, Niri Clear, Yairco","The company (TAE: TIGI) received ILS 14 million of development capital from JJRF Ltd and EREN Groupe on July 12, 2024 through a private placement.",,
43054-21,Tigo Energy (NAS: TYGO),"Tigo Energy, Inc.","SunPower (Alternative Energy Equipment), SMA Solar Technology, REC Solar (San Luis Obispo), Luminace Holdings, Trinity Solar, Solaredge Technologies, Enphase Energy, Redback Technologies, HelioPower, Sungevity, AlsoEnergy, Fronius, Omnidian, Heliatek, Vivint Solar, Sunrun, SolarCity, Yellow Door Energy, Inaccess","Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.",Energy,Energy Equipment,Alternative Energy Equipment,"Alternative Energy Equipment*, Application Software","CleanTech, Climate Tech","climate tech company, intermittent renewable energy, smart solar system, solar energy equipment, solar equipment, solar optimizer, solar photovoltaic, solar technology, string monitoring",Formerly VC-backed,167.64,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Publicly Listed, Venture Capital",140,NAS,TYGO,2007,2025-04-26,,United States,"Campbell, CA",275.0,2022-05-27,Later Stage VC,2024-11-26,14.22,Actual,,,Public Investment 2nd Offering,,Public Investment,2024-11-26,Completed,,,2008-06-01,7.66,Actual,Early Stage VC,14.75,Actual,Series A,Venture Capital,Completed,Bridge Loan - 0.22M¬†$,54.01,-0.6281,-62.75,22.22,52.63,-4.16,80.5,-50.87,-52.09,54,24,25,16,13,13,"Circuit arrangements or systems for supplying or distributing electric power, Generation of electric power by conversion of infrared radiation, visible light or ultraviolet light, Inorganic semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation, Systems for regulating electric or magnetic variables, Transmission",,,1,Roth CH Acquisition IV,"The company raised $14.22 million in its second public offering on the Nasdaq stock exchange under the ticker symbol of TYGO on November 26, 2024. A total of 14,814,020 shares were sold at $0.96 per share.","Alon Ventures, Bessemer Venture Partners, Clal Energy, Clal Industries, Energy Growth Momentum, Generation Investment Management, Inventech Investment, Kinnevik, Matrix, MoreVC, OVP Venture Partners, SMA Solar Technology, Sunshot Incubator Program",
165196-00,Tikun Olam Cannbit Pharmaceuticals (TAE: TKUN),Tikun Olam Cannbit Pharmaceuticals Ltd,,Tikun Olam Cannbit Pharmaceuticals Ltd is engaged in the business of growing and marketing medical cannabis.,Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,Drug Discovery*,Cannabis,"cannabis growing services, cannabis marketing, clinical research, growing cannabis, medical cannabis, medical cannabis company",Corporation,,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,51,TAE,TKUN,,2023-10-07,Tamir Fishman,Israel,"Tel Aviv, Israel",,,,2000-03-19,,,,,IPO,,Public Investment,2000-03-19,Completed,,,2000-03-19,,,IPO,,,,Public Investment,Completed,,9.37,-0.2097,-10.75,4.4,9.0,-0.33,9.56,-2.31,-10.25,,,,,,,,,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of TKUN on March 19, 2000.",Lifeist,
102714-22,Todos Medical (PINX: TOMDF),Todos Medical Ltd.,,"Todos Medical Ltd is an in vitro diagnostics company. Its operating segments are Breast Cancer Test, Alzheimer's, and COVID-19 testing. The company generates all of its revenue from the United States.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Laboratory Services (Healthcare)","FemTech, Life Sciences, Oncology","blood sample, cancer detection, infrared spectroscopy, signal processing, vitro diagnostics company, vitro diagnostics treatment",Formerly PE-Backed,1.07,Generating Revenue,Publicly Held,"Private Equity, Publicly Listed",7,PINX,TOMDF,2010,2025-04-08,,Israel,"Tel Aviv, Israel",,,,2021-09-23,0.71,Actual,,,PIPE,,Corporate,2021-09-23,Completed,,,2010-04-01,,,University Spin-Out,,,,Public Investment,Completed,,10.75,-0.0784,-38.77,35.82,0.02,4.48,56.63,-16.79,-17.58,34,4,26,3,5,5,"Investigating or analysing materials by determining their chemical or physical properties, Measurement of intensity, velocity, spectral content, polarisation, phase or pulse characteristics of infrared, visible or ultraviolet light",2,,1,Ben-Gurion University of the Negev,"The company (PINX:TOMDF) received ILS 2.29 million of development capital from undisclosed investors on September 23, 2021 through a private placement.","D.P.H. Investments, Horizon 2020",
226875-25,Together Pharma (TAE: TGTR),Together Pharma Ltd,,"Together Pharma Ltd is a Israel-based company. It is engaged in the growing, production, and distribution of medical cannabis products. It also exports medical cannabis from Israel. Geographically it operates in Israel, Europe, and Uganda. The majority of its revenue is generated from Israel.",Healthcare,Pharmaceuticals and Biotechnology,Other Pharmaceuticals and Biotechnology,"Cultivation, Other Pharmaceuticals and Biotechnology*","Cannabis, LOHAS & Wellness, Manufacturing","cannabis farming, cbd cream, cbd medicine, cbd oils, cbd pills, cbd product",Corporation,5.72,Generating Revenue,Publicly Held,Publicly Listed,,TAE,TGTR,1991,2024-12-26,,Israel,"Ashkelon, Israel",49.52,2019-09-02,PIPE,2021-01-10,0.03,Actual,,,PIPE,,Corporate,2021-01-10,Completed,,,1993-06-06,,,IPO,,,,Public Investment,Completed,,,,,,16.05,,,,,,,,,,,,,,1,Ralco Agencies Company,"The company (TAE:TGTR) received ILS 84,755 of development capital from undisclosed investors on January 10, 2021 through a private placement.",,
466816-06,Tondo (TAE: TNDO),Tondo Smart Ltd.,,Tondo Smart Ltd is engaged in the development and production of management and control technologies for a smart city.,Information Technology,Computer Hardware,Other Hardware,"Business/Productivity Software, Other Hardware*","Industrials, Internet of Things, TMT","enterprise asset management, enterprise resource planning, erp, iot platform, iot platform software, smart city, smart lighting, smart lighting system",Corporation,5.42,Generating Revenue,Publicly Held,Publicly Listed,10,TAE,TNDO,2016,2025-02-28,,Israel,"Tel Aviv, Israel",20.77,2021-10-21,IPO,2021-10-21,5.42,Actual,20.77,Estimated,IPO,,Public Investment,2021-10-21,Completed,,,2021-10-21,5.42,Actual,IPO,20.77,Estimated,,Public Investment,Completed,,,,,,13.02,,,,,3,2,3,,,,Electric heating,,,,,"The company raised ILS 17.5 million in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of TNDO on October 21, 2021. After the offering, the valuation of the company was at ILS 67 million.",,
452851-75,TopGum (TAE: TPGM),"TopGum Industries, Ltd.",,Top Gum Industries Ltd is engaged in the development and sale of nutritional supplements and confectionery products.,Consumer Products and Services (B2C),Consumer Non-Durables,Food Products,Food Products*,Manufacturing,"candy and sweets, confectionery candy, confectionery firm, confectionery food, nutrition supplements manufacturing, nutrition supplements product",Formerly PE-Backed,30.63,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed",202,TAE,TPGM,2004,2025-04-13,,Israel,"Sderot, Israel",,,,2021-08-12,30.63,Actual,,,IPO,,Public Investment,2021-08-12,Completed,,,2020-11-09,,,PE Growth/Expansion,,,,Private Equity,Completed,,59.27,0.2998,-6.49,21.06,244.62,20.51,216.87,-2.81,-5.26,6,1,2,4,,,"Cocoa, Foods, foodstuffs or non-alcoholic beverages, not otherwise provided for",,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of TPGM on August 12, 2021.",AP Partners,
155522-80,TruckNet (TAE: TRAN),Trucknet Enterprise LTD,,"Trucknet Enterprise Ltd provides fleet management companies with cloud-based transport optimization platform that delivers smart freight exchange to improve efficiency and profitability while reducing environmental impact. The system consists of the following components: the Trucknet platform that automatically matches empty vehicles to subcontractor requests from other companies, TMS is an internal schedule software for transportation companies, Driver Interface which is a mobile application for the driver, Tracker that is a mobile application for end-to-end delivery, currently in development, Trucknet Telematics which is a central interface for different telematics systems, in development.",Business Products and Services (B2B),Commercial Services,Logistics,"Business/Productivity Software, Logistics*","Industrials, SaaS, TMT","bulk transport, crosses company optimization, logistics systems, space sharing, transport optimization platform",Formerly VC-backed,,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",38,TAE,TRAN,2016,2025-03-26,,Israel,"Eilat, Israel",,,,2021-03-25,,,,,IPO,,Public Investment,2021-03-25,Completed,,,2017-09-01,,,Early Stage VC,,,,Venture Capital,Completed,,,,,,9.57,,,,,,,,,,,,,,,,"The company raised an undisclosed amount of funding in its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of TRAN on March 25, 2021.",Capital Nature,
151424-47,TSG IT Advanced Systems (TAE: TSG),TSG IT Advanced Systems Ltd,,"TSG IT Advanced Systems Ltd is a provider of C4ISTAR, Intelligence, HLS, and Cyber Security solutions that develop, integrate, and deliver mission-critical, turnkey solutions to various military forces, governmental agencies, and corporations. Its line of business are Command & Control, Intelligence, IT Systems & Telecom, Cyber Security, and Homeland Security.",Business Products and Services (B2B),Commercial Services,Security Services (B2B),"Application Software, Security Services (B2B)*","Industrials, TMT","cyber security, cyber security data, cyber security device, cyber security softwar, cyber security software, homeland security service",Corporation,16.78,Profitable,Publicly Held,"M&A, Publicly Listed",201,TAE,TSG,1969,2025-04-02,,Israel,"Tel Aviv, Israel",125.01,2024-07-31,IPO,2024-07-31,16.78,Estimated,125.01,Estimated,IPO,,Public Investment,2024-07-31,Completed,,,2016-05-10,51.53,Actual,Merger/Acquisition,51.53,Estimated,Corporate Divestiture,Corporate,Completed,,86.38,0.0902999999999999,2.66,21.72,135.3,19.68,,12.18,7.08,,,,,,,,,,,,"The company, a subsidiary of Ness Technologies (NASDAQ: NSTC) was acquired by Formula Systems (NASDAQ: FORTY) and Israel Aerospace Industries for $51.53 million on May 9, 2016. The acquisition allows both the companies to expand its defense and cyber security solutions.","Formula Systems, Israel Aerospace Industries",Ness Technologies (Teaneck)
435491-74,TurboGen CHP (TAE: TURB),Turbogen Ltd,,"Turbogen Ltd is engaged in developing multifuel CHP systems with a vision of providing on-site energy for buildings. Its CHP systems outperform current electric efficiency solutions, enabling fast ROI, lower building emissions, and peak saving for utilities. The company's multi-fuel technology enables hybrid Operations: Solar-Gas, Hydrogen-Gas, SOFC-Gas.",Energy,Energy Equipment,Other Equipment,Other Equipment*,Manufacturing,"aerospace engine, aerospace technology, chp engine, clean energy, energy generator",Corporation,,Generating Revenue,Publicly Held,Publicly Listed,,TAE,TURB,2014,2024-01-17,,Israel,"Petah Tikva, Israel",,,,2021-11-24,,,,,IPO,,Public Investment,2021-11-24,Completed,,,2021-11-24,,,IPO,,,,Public Investment,Completed,,,,,,55.25,,,,,22,6,13,8,1,1,"Gas-turbine plants, Generating combustion products of high pressure or high velocity, Non-positive displacement machines or engines, Spring, weight, inertia or like motors",,,,,"The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of TURB on November 24, 2021.",,
57088-09,Urogen Pharma (NAS: URGN),UroGen Pharma Ltd,"Cullgen, Bluebird Bio, Galapagos (Biotechnology), VelosBio, Xenetic Bioscience, Polaris Group (California), Sitka Biopharma, Juno Therapeutics, Dianomi Therapeutics, Talphera, Voyager Therapeutics, Rexahn Pharmaceuticals, Relmada Therapeutics, Regenxbio, Progenra, Heron Therapeutics, Accuronix Therapeutics, Acerus Pharmaceuticals, Actelion Pharmaceuticals, SAMYANG Biopharmaceuticals, Endocyte, Cornerstone Pharmaceuticals, Arrowhead Pharmaceuticals, Bonti","UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.",Healthcare,Pharmaceuticals and Biotechnology,Drug Delivery,"Drug Delivery*, Therapeutic Devices","Life Sciences, Oncology","drugs delivery technology, intra-cavitary disease, pharmaceutical, urinary tract treatment, urological disorder, urology treatment",Formerly VC-backed,477.65,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed, Venture Capital",235,NAS,URGN,2004,2025-04-26,,United States,"Princeton, NJ",155.64,2017-05-04,IPO,2024-09-25,25.0,Actual,,,General Corporate Purpose,,Debt,2024-09-25,Completed,25.0,Term Loan - 25.00M¬†$ (Recurring revenue based lending loans),2004-04-01,,,Accelerator/Incubator,,,,Other,Completed,,90.4,0.0929,-126.87,-113.3,454.95,81.52,321.77,-119.24,-120.42,101,23,63,6,32,32,"Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium, Devices for introducing media into, or onto, the body, Diagnosis, Preparations for medical, dental or toiletry purposes",20,,,,"The company raised $25 million of debt financing on September 25, 2024. The funds will be used to boost its general corporate and working capital requirements.","Acorn Bioventures, Altamont Pharmaceutical Holdings, Aravis, Arkin Capital, Bellco Capital, C.H. Health, Granot Ventures, Great Point Partners, Magna Capital Partners, Monograph Capital, OurCrowd, Pontifax Venture Capital, ProQuest Investments, RA Capital Management, RTW Investments, Tatham Investments, Telormedix, The Horton Fund, Two River Group",
54268-48,Varonis Systems (NAS: VRNS),"Varonis Systems, Inc.","Rapid7, Tenable, AvePoint, Profisee, Integrate.io, OneLogin, Xeratic, InMoment, Informatica, SAP, TIBCO Software, Matillion, SecureAuth, CommVault Systems, SolarWinds, Zaloni, Doxim, Collibra, Information Builders, Exonar, Syniti, Forcepoint, Identify3D, Talend, Infogix, Informatica Customer 360 Insights, Seclore, Rubrik",Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.,Information Technology,Software,Database Software,"Business/Productivity Software, Database Software*","Cybersecurity, SaaS, TMT","cloud transition, cloud transition strategy, cybersecurity firm, cybersecurity services, cybersecurity system, unstructured data, word processing",Formerly VC-backed,595.9,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",2406,NAS,VRNS,2004,2025-04-26,,United States,"New York, NY",524.38,2014-02-28,IPO,2021-02-11,450.0,Actual,,,Public Investment 2nd Offering,,Public Investment,2021-02-11,Completed,,,,3.53,Actual,Early Stage VC,6.29,Actual,Series A,Venture Capital,Completed,,550.95,0.1038,-95.76,185.99,4732.19,457.1,4863.16,-97.66,-108.79,262,67,200,17,45,45,"Computing arrangements based on specific computational models, Electric digital data processing, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Signalling or calling systems, Transmission of digital information",,,,,"The company raised $450 million in its second public offering on the Nasdaq stock exchange under the ticker symbol of VRNS on February 11, 2021. A total of 2,307,693 shares were sold at $195 per share. The underwriters were granted an option to purchase up to an additional 346,153 shares from the company to cover over-allotments, if any. The underwriters were granted an option to purchase up to an additional 346,153 shares from the company to cover over-allotments, if any.","Accel, EMC Ventures, Evergreen Venture Partners, Pitango Venture Capital, Qumra Capital, TriplePoint Capital",
51069-52,VBL Therapeutics,Vascular Biogenic Ltd.,"Dynavax Technologies, Jounce Therapeutics, Affimed, Inovio Pharmaceuticals, Ayala Pharmaceuticals, Genelux, Apexigen, Aduro Biotech, Amarantus BioScience Holdings, Immunocore Holdings, Agenus, Gilead Sciences, Amgen, Celyad Oncology, Immatics, Genomic Health, Regulus Therapeutics, Neurogene, VBI Vaccines, Vical, ProMIS Neurosciences, Aura Biosciences, BioNTech, Juno Therapeutics, Adaptimmune Therapeutics, Kite Pharma, Bluebird Bio, MediGene, Seneca Biopharma, Merrimack Pharmaceuticals, Dendreon, Catalyst Pharmaceuticals, NexImmune, Zynerba Pharmaceuticals, ViraTherapeutics, Brainstorm Cell Therapeutics, CuraSen","Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Drug Discovery, Therapeutic Devices","Life Sciences, Oncology","anti-inflammatory agent, atherosclerosis, drug development company, immune-inflammatory disease, pharmaceutical, psoriasis",Formerly VC-backed,231.7,Generating Revenue/Not Profitable,Acquired/Merged,"Private Equity, Publicly Listed, Venture Capital",7,,,2000,2025-03-26,,Israel,"Modiin, Israel",145.0,2023-10-16,Merger/Acquisition,2023-10-16,145.0,Actual,145.0,,Merger/Acquisition,,Corporate,2023-10-16,Completed,,,,76.0,Estimated,Early Stage VC,,,,Venture Capital,Completed,,0.0,,-7.85,-20.77,12.11,,-5.29,-7.95,-7.95,,,,,,,,,Notable Labs,3,"Aurum Ventures MKI, European Innovation Council Fund, Horizon 2020","The company was acquired by Notable Labs through a reverse merger, resulting in the combined entity trading on the Nasdaq Stock Exchange under the ticker symbol NTBL on October 16, 2023. The company is no longer actively tracked by PitchBook.","GlenRock Israel, JJD Holdings, Max Herzberg, Pitango Venture Capital, Teva Pharmaceutical Industries, The Keffi Group",
63370-54,Venus Concept (NAS: VERO),Venus Concept Inc.,"Cutera, Quanta System, Quanta Aesthetic Lasers USA, Lumenis, Sciton, Solta Medical, Cynosure (Other Devices and Supplies), Ulthera, IRIDEX, Atricure, Nova Medical Israel, Soliton, Avinger, Fotona, Candela Medical, Zeltiq Aesthetics","Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.",Healthcare,Healthcare Devices and Supplies,Other Devices and Supplies,"Other Devices and Supplies*, Other Healthcare Services",,"aesthetic medical devices, cellulite reduction, cosmetic procedures, healthcare device, medical aesthetic, noninvasive device",Formerly VC-backed,288.33,Generating Revenue/Not Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed, Venture Capital",292,NAS,VERO,2002,2025-04-26,,Canada,"Toronto, Canada",240.0,2019-11-07,Reverse Merger,2025-04-14,1.57,Estimated,,,PIPE,,Corporate,2025-04-14,Completed,,,2014-05-22,10.0,Actual,Later Stage VC,,,,Venture Capital,Completed,,64.83,-0.1509,-47.0,38.76,3.53,44.31,37.12,-36.04,-39.93,488,79,399,13,76,76,"Diagnosis, Electrotherapy, Filters implantable into blood vessels, Healthcare informatics, Image data processing or generation, in general",35,,5,"EW Healthcare Partners, HealthQuest Capital, Madryn Asset Management, Masters Capital Management, SEDCO Capital ( Asset Management)","The company (NAS: VERO) received $1.57 million of development capital from undisclosed investors on April 14, 2025 through a private placement. The company intends to use the net proceeds from the offering for general corporate purposes.","Aperture Venture Partners, Lincoln Park Capital, Longitude Capital, Restoration Robotics",
41512-42,Verint Systems (NAS: VRNT),Verint Systems Inc.,"Salesforce, Workday, ServiceNow, Pegasystems, SurveyMonkey, Satmetrix, Talkdesk, Genesys, Anaplan, Serraview, Global Speech Networks, ResponseTek, ActiveOps, Netcall, Sandsiv+, Teradata, Groove (Business/Productivity Software), Five9, Questback, SharingCloud, Aircall, Agilquest, SAP, Teleopti, Bright Pattern, Inbenta, Infor Global Solutions, Footmarks, Helpjuice, SAS Institute, 3CLogic, NICE (Business/Productivity Software), Medallia, Fuze (Communication Software), SugarCRM, Onvisource, Calabrio, N. Harris Computer, Qualtrics, Cisco Systems, Nextiva, Sage Group, InsideSales, Vocalcom, Zoho Corporation, Exotel, Mediatech cx, FireStream WorldWide, Global Software (United States), Fair Isaac, Condeco, Clarabridge, Gryphon.ai","Verint Systems Inc with its subsidiaries, helps brands provide Boundless customer experience (CX) automation. AI offers a solution, and that's where Verint comes in. It empowers brands with groundbreaking AI via a next-gen open platform. Its Verint Open Platform helps organizations increase CX automation to achieve their strategic objectives and realize ROI. Geographically, it derives a majority of its revenue from the United States.",Information Technology,Software,Business/Productivity Software,Business/Productivity Software*,"Big Data, TMT","actionable intelligence, actionable intelligence software, actionable intelligence software product, crm, customer relationship management, intelligence software",Corporation,3055.75,Profitable,Publicly Held,"Debt Financed, Private Equity, Publicly Listed",3800,NAS,VRNT,1994,2025-04-26,,United States,"Melville, NY",374.25,2002-05-16,IPO,2021-04-06,400.0,Actual,,,PIPE,,Private Equity,2021-04-06,Completed,,,2002-05-16,72.0,Actual,IPO,374.25,Estimated,Spin-Off,Public Investment,Completed,,909.19,-0.0013,82.27,231.38,1132.78,648.05,2278.13,149.01,101.88,375,132,266,1,108,108,"Electric digital data processing, Pictorial communication, Speech analysis techniques or speech synthesis, Telephonic communication, Transmission of digital information",,,2,"Altaroc Partners, Apax Partners","The company (NAS:VRNT) received $400 million of development capital from Apax Partners, Altamir, Altaroc Partners and PFR Ventures on April 6, 2021 through a private placement. The shares issued are preferred stock with a conversion price of $50.25. The placement was completed over two tranches.","Altamir, Mavenir Systems, PFR Ventures",
158981-32,Vidac Pharma Holding (STU: T9G),Vidac Pharma Holding PLC,"Gilead Sciences, Celgene, G1 Therapeutics, Loxo Oncology, Ability Pharma, Amgen, Savara, Merck & Co., Ona Therapeutics, Genentech, Vicore Pharma Holding, Biogen, Bristol-Myers Squibb, Biocon, Avalyn Pharma, AbbVie, Volastra, Eli Lilly and Company, Pfizer Pakistan, Lung Therapeutics","Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Biotechnology, Drug Discovery*, Pharmaceuticals","Life Sciences, Oncology","anticancer drug, chemistry, dermatology medicine, drug discovery, malignant diseases treatment, malignant drugs, oncology drug development, small molecule",Formerly VC-backed,29.65,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",6,STU,T9G,2012,2025-03-26,,United Kingdom,"London, United Kingdom",,,,2024-11-07,0.65,Actual,,,PIPE,,Corporate,2024-11-07,Completed,,,,,,Early Stage VC,,,,Venture Capital,Completed,,0.0,0.0,-1.59,0.26,29.65,,,-1.59,-1.59,34,6,22,5,7,7,"Heterocyclic compounds, Making articles of paper, cardboard or material worked in a manner analogous to paper, not provided for in subclasses b31b or b31c, Preparations for medical, dental or toiletry purposes, Specific therapeutic activity of chemical compounds or medicinal preparations",2,,,,"The company (STU:T9G) received EUR 600,000 of development capital from undisclosed investors on November 7, 2024 through a private placement. The proceeds will be used to drive a series of clinical trials, including a second Phase 2b clinical trial for VDA-1102 in advanced actinic keratosis (AK), an early form of skin cancer that can develop into cutaneous squamous cell carcinoma (CSCC).","Edward Saltzman, Gem Global Yield, Israel Biotech Fund, Mivtach Shamir Holdings, Robert Spiegel",
58569-67,VYNE Therapeutics (NAS: VYNE),VYNE Therapeutics Inc.,"Theravance Biopharma, Celgene, Talphera, Intercept Pharmaceuticals, Cipla, AzurRx BioPharma, InvaGen Pharmaceuticals, The Medicines Company, Tioga Pharmaceuticals, Salix Pharmaceuticals, Portola Pharmaceuticals, Evoke Pharma, Genentech, Aptalis Pharma, Amgen, Lannett Company, Impax Laboratories, Synergy Pharmaceuticals, Shire, Sucampo Pharmaceuticals, Rising Pharma Holdings, Biogen, Sagent Pharmaceuticals, Mallinckrodt Pharmaceuticals, Par Pharmaceutical Companies, Evolus, Representaciones e Investigaciones M‚àö¬©dicas, OrphoMed, Sandoz Group, Allergan, Ocera Therapeutics","VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Drug Discovery*, Pharmaceuticals",Life Sciences,"biopharmaceutical development, cough treatment, dermatological product, drug discovery, pharmaceutical, pruritus treatment",Formerly VC-backed,317.0,Generating Revenue/Not Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",13,NAS,VYNE,2003,2025-04-26,,United States,"Bridgewater, NJ",372.78,2018-01-25,IPO,,,,,,Secondary Transaction - Private,,Venture Capital,,Completed,,,2013-08-19,14.3,Actual,Early Stage VC,21.94,Actual,Series A,Venture Capital,Completed,,0.5,0.1816,-39.83,-61.42,21.75,,-20.64,-39.8,-39.8,164,42,98,10,56,56,"Devices for introducing media into, or onto, the body, Heterocyclic compounds, Preparations for medical, dental or toiletry purposes, Preservation of bodies of humans or animals or plants or parts thereof, Treatment of flour or dough for baking",37,,10,"Access Biotechnology, Acorn Bioventures, Cormorant Asset Management, Eventide Asset Management, LifeSci Venture Partners, Palo Alto Investors, Parkman Healthcare Partners, Remeditex Ventures, Soleus Capital, Surveyor Capital",Vivo Capital sold a stake in the company to an undisclosed buyer. The company is no longer actively tracked by PitchBook.,"Aisling Capital, Bay City Capital, Eight Roads, F-Prime Capital, Novo Holdings, Presidio Partners, Rock Springs Capital, Velocity Pharmaceutical Development, venBio, Vivo Capital",
54237-61,WalkMe (Business/Productivity Software),WalkMe Ltd.,"Amplitude, Whatfix, Heap, Appuri, Evergage, Mixpanel, Twilio Segment, EverString, Nosto, Natero, ChurnZero, AgilOne, Pendo, Monetate, Aptrinsic, Totango, CustomerSuccessBox, Userlane, Promoter.io, MadKudu, Epilogue Systems, Reltio, Appcues, 1World Online, Framed Data, ClientSuccess, RichRelevance, Jeeng, Toonimo, AppLearn, Assima, Movable Ink, Axonify, Medallia Strikedeck, Xyleme, CleverTap, Inline Manual, Nanorep, Catalyst.io, Baynote, Paymate Software, Inkling, uPerform, Chameleon (Business/Productivity Software), LearnUpon, Bolstra, UserGuiding, Elevio, Trakio, Akita (Business/Productivity Software), Gainsight, ProProfs, Peerius, Automatic Data Processing, Grovo, vTradEx, Helppier, Vigience, Acrobatiq, CLS Performance Solutions, Cerego, Iorad, AnswerDash, Iridize","Developer of a cloud-based digital adoption platform designed to simplify the user experience. The company platform includes interactive walkthroughs, on-screen guidance, task automation, user behavior analytics and customizable workflows, enabling organizations to enhance their onboarding and improve software efficiency.",Information Technology,Software,Business/Productivity Software,"Business/Productivity Software*, Media and Information Services (B2B)","Artificial Intelligence & Machine Learning, Big Data, Marketing Tech, SaaS","adoption platform, digital adoption software, digital platform, enterprise engagement platform, enterprise resource planning, online guidance",Formerly VC-backed,759.26,Generating Revenue/Not Profitable,Acquired/Merged (Operating Subsidiary),"Private Equity, Publicly Listed, Venture Capital",1091,,,2011,2025-04-03,SAP,Israel,"Tel Aviv, Israel",1500.0,2024-09-12,Merger/Acquisition,2024-09-12,1500.0,Estimated,1500.0,Estimated,Merger/Acquisition,,Corporate,2024-09-12,Completed,,,2012-04-12,1.0,Actual,Early Stage VC,3.67,Actual,Series A,Venture Capital,Completed,,272.99,0.0489,-45.19,-291.8,1309.94,232.71,1023.65,-45.86,-51.97,82,17,57,19,6,6,"Computing arrangements based on specific computational models, Electric digital data processing, Pictorial communication, Speech analysis techniques or speech synthesis, Transmission of digital information",,SAP,,,"The company was acquired by SAP (ETR: SAP) for $872.021 million on September 12, 2024. The acquisition enables SAP to double down on the support it provides to end users, helping them to quickly adopt new solutions and features to get the maximum value out of their IT investments.","EDBI, Flint Capital, Gemini Israel Ventures, Giza Venture Capital, Greenspring Associates, Insight Partners, KHK & Partners, Mangrove Capital Partners, Scale Venture Partners, Vitruvian Partners",
59784-31,Water Ways Technologies (TSX: WWT),Water Ways Technologies Inc.,,"Water Ways Technologies Inc is an agro-tech company that specializes in providing water irrigation solutions to agricultural producers. It designs, supplies and installs an irrigation system for application in various agricultural and aquacultural operations. The company has an operation in China, Mexico, Peru, Laos, Ethiopia, and Georgia.",Business Products and Services (B2B),Commercial Services,Other Commercial Services,"Cultivation, Other Commercial Services*",AgTech,"agricultural technology, agricultural technology systems, agro technology, irrigation solutions, irrigation technology, precision ag, precision agriculture, robotics & smart field equipment, robotics and smart field equipment, water irrigation",Corporation,4.43,Generating Revenue/Not Profitable,Publicly Held,Publicly Listed,2,TSX,WWT,2007,2025-04-26,,Canada,"Toronto, Canada",0.82,2007-04-20,IPO,2023-02-10,0.23,Actual,,,PIPE,,Corporate,2023-02-10,Completed,,,2007-04-20,0.64,Actual,IPO,0.82,Estimated,,Public Investment,Completed,,3.78,-0.4846,-4.87,2.09,0.54,-0.55,3.33,-4.8,-4.98,,,,,,,,,,,,"The company (TSX:WWT) received CAD 313,950 of development capital from undisclosed investors on February 10, 2023 through a private placement.",,
155253-88,Way2vat (ASX: W2V),Way2vat Ltd.,"Finly (Financial Software), FreshBooks, Proactis, Basware, BuyerQuest, SAP, Vroozi, Odoo, Expenzing, Airbase, Coupa, Databasics, Finnew Solutions, Tallie",Way 2 Vat Ltd is a technology company providing corporations with multiple financial instruments. It's patented and revolutionary AI technology drives products and serves the enterprise and SMB market. It is developing applications for automatic VAT reclaims and compliance for enterprises.,Information Technology,Software,Financial Software,"Accounting, Audit and Tax Services (B2B), Financial Software*","Artificial Intelligence & Machine Learning, FinTech, Mobile, SaaS, TMT","expense management, expense management app, expense management platform, expense management software, expense management solutions, expense manager, expenses management, financial management, travel management software, vat reclaim",Formerly VC-backed,23.77,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",47,ASX,W2V,2016,2025-04-17,,United Kingdom,"London, United Kingdom",22.43,2021-09-17,IPO,2024-02-27,2.77,Actual,,,PIPE,,Corporate,2024-02-27,Completed,,,2016-02-01,,,Capitalization,,,,Individual,Completed,,3.01,0.4675,-3.62,2.14,3.59,2.47,7.36,-3.4,-3.68,15,3,12,,3,3,"Electric digital data processing, Image or video recognition or understanding, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes",,Voxel (Financial Software),2,"Moneta Venture Capital, Poalim Equity","The company (ASX: W2V) received AUD 4.25 million of development capital from undisclosed investors on February 27, 2024, through a private placement.","daVinci Capital Group, Global Fintech Solutions, iAngels, Perennial Partners (Funds and Trusts), Possible Ventures, Prytek, Silverhorn Investment Advisors, Standard Bank, WorldQuant Ventures",
459571-69,Wilk Technologies (TAE: WILK),Wilk Technologies Ltd.,"Remilk, Imagindairy, Yofix","Wilk Technologies Ltd formerly Biomilk Ltd develops progressive technologies for producing cultured animal milk, cultured human breast milk, and high-grade HMO.",Consumer Products and Services (B2C),Consumer Non-Durables,Food Products,Food Products*,FoodTech,"breast milk, cultivated protein, food technology, health benefits, milk ingredients, milk production",Formerly VC-backed,12.37,Product Development,Publicly Held,"Publicly Listed, Venture Capital",13,TAE,WILK,2018,2025-02-15,,Israel,"Rehovot, Israel",,,,2023-05-16,3.42,Actual,,,PIPE,,Corporate,2023-05-16,Completed,,,2020-09-01,3.53,Actual,Early Stage VC,,,,Venture Capital,Completed,,,,,,4.32,,,,,13,2,11,1,1,1,"Apparatus for enzymology or microbiology, Microorganisms or enzymes",,,6,"Danone, Fantasy Networks, Paz Capital, Steakholder Foods, The Central Bottling Company, Yissum","The company (TAE:WILK) received ILS 12.5 million of development capital from Steakholder Foods and Danone and other investors on May 16, 2023 through a private placement. Previously, the company (TAE: WILK) received ILS 12.38 million of development capital from Danone, Steakholder Foods, The Central Bottling Company and other undisclosed investors on April 2, 2023 through a private placement.",,
51726-07,Wix.com (NAS: WIX),"Wix.com, Inc","Squarespace, Jimdo, Feedburner, WebAct, Webydo, PrestaShop, AppDirect, Shift4Shop, BigCommerce, 1ShoppingCart.com (Internet Software), Insightly, Volusion, Shopify, Webflow, Mindbody, HubSpot, Agendize, Magento Commerce, Pipedrive, Mono Solutions, Mag+, WP Engine, Salesboom, Newfold Digital, By Afro, Tidy (Software Development Applications), OpenText, Development Studio, Picnic Media (New Orleans), Siderblue, Yell (Media and Information Services (B2B)), Keap, Zenfolio, MacroHype, Umbu Games, Camilyo, Blue Fountain Media, WooCommerce, KloudFuse, AKQA Leap, VML, 1xINTERNET, Openwave Computing, Agile CRM, Yola, Strikingly, Cloudflare, Freshworks, Nextsulting, Workarea, PhotoShelter, Fuse (Software Development Applications), Drupal, Weebly, Bluehost, iBuildApp, Code and Theory, Shoutem, Pagecloud, Urchin Software, Automattic, AppsBuilder, Datacom, Mongolia, Visio, Orckestra Technologies, Zebra Imaging","Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves, or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years has invested heavily and introduced its Wix Studio offering for partners, who are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.",Information Technology,Software,Internet Software,"Internet Software*, Media and Information Services (B2B)","SaaS, TMT","application software maker, customized website, marketing products, personalized website, web development platform, web publishing platform, website building, website design, website developer",Formerly VC-backed,152.94,Profitable,Publicly Held,"Private Equity, Publicly Listed, Venture Capital",5283,NAS,WIX,2006,2025-04-26,,Israel,"Tel Aviv, Israel",603.92,2013-11-06,IPO,,,,,,Secondary Transaction - Open Market,,,,Completed,,,,,,Accelerator/Incubator,,,,Other,Completed,,1760.65,0.1274,138.32,-136.43,9265.13,1196.02,11772.57,144.25,113.14,519,72,372,112,35,35,"Electric digital data processing, Image data processing or generation, in general, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes, Transmission of digital information, Wireless communication networks",,,,,Mangrove Capital Partners and Cambridge Investment Research sold their stake in the company (NAS:WIX) on an undisclosed date. The company will not receive any proceeds from the offering.,"Alex Ferrara, Benchmark Capital Holdings, Bessemer Venture Partners, Cambridge Investment Research, DAG Ventures, DS Capital, Eilon Tirosh, Insight Partners, Itzik Ben-Bassat, Mangrove Capital Partners, Michael Jackson, Venture Initiation Program",
41541-49,Xtl Biopharmaceuticals (TAE: XTLB),XTL Biopharmaceuticals Ltd,"Celgene, Vicore Pharma Holding, Gilead Sciences, Genentech, Pfizer Pakistan, G1 Therapeutics, Avalyn Pharma, Loxo Oncology, Savara, Biogen, Eli Lilly and Company, Volastra, Bristol-Myers Squibb, GlaxoSmithKline Consumer Nigeria, Novartis, Cipla, Bright Data, Oxylabs","XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.",Healthcare,Pharmaceuticals and Biotechnology,Drug Discovery,"Drug Discovery*, Other Information Technology, Pharmaceuticals","Artificial Intelligence & Machine Learning, Big Data, Life Sciences","biopharmaceutical, biotech work, pharmaceutical company, pharmaceutical purpose",Formerly VC-backed,39.84,Generating Revenue,Publicly Held,"Publicly Listed, Venture Capital",4,TAE,XTLB,1993,2025-04-26,,Israel,"Ramat Gan, Israel",21.97,2003-07-16,Secondary Transaction - Private,2024-08-14,1.5,Actual,,,PIPE,,Corporate,2024-08-14,Completed,,,2004-11-19,1.34,Actual,Later Stage VC,,,,Venture Capital,Completed,,0.16,,-1.06,-1.55,11.67,,10.89,,-1.06,46,18,8,,38,38,"Heterocyclic compounds, Preparations for medical, dental or toiletry purposes",4,,2,"Israel Healthcare Ventures, Shore Capital Group","The company (TAE: XTLB) received $1.5 million of development capital from undisclosed investors on August 14, 2024, through a private placement.","Biomedical Investments, Concord Ventures (Israel), Inventech Investment, Medica Venture Partners, The Challenge Fund - Etgar, XT Venture Capital",
165067-39,YB Urban Renewal Residential Development (TAE: YBRD),YB Urban Renewal Residential Development Ltd,,"YB Urban Renewal Residential Development Ltd formerly Cannassure Therapeutics Ltd is an Israel based company that operates in the medical cannabis field. The company is engaged in producing and supplying GMP approved, premium cannabis extracts, derivatives, cannabinoids, terpenes & flavonoids, based on GAP in-door cultivation, and GMP operations.",Healthcare,Pharmaceuticals and Biotechnology,Biotechnology,"Biotechnology*, Other Pharmaceuticals and Biotechnology",Cannabis,"cannabinoid medicine, cannabis, cannabis flowers, cannabis product, medical cannabis product, pharmaceutical",Corporation,,Generating Revenue,Publicly Held,Publicly Listed,,TAE,YBRD,1970,2025-01-23,,Israel,"Ashdod, Israel",,,,2018-12-01,,,,,IPO,,Public Investment,2018-12-01,Completed,,,2018-12-01,,,IPO,,,,Public Investment,Completed,,,,,,1.33,,,,,,,,,,,,,,,,The company completed its initial public offering on the Tel Aviv Stock Exchange under the ticker symbol of CSURE-M in December 2018.,,
109063-09,Zoomd (TSX: ZOMD),Zoomd Ltd,"Ingenious Technologies, Affle 3i, Illumin, Adcore, Birst, Full Circle Insights, Beckon, C3 Metrics, Origami Logic, Hive9, VigLink, ClickBank, Everflow (US), Sourcepoint, Insticator, Partnerize, Allocadia, TUNE, MoEngage, Zinfi, Datorama, CJ Affiliate, CAKE Software, Resonance AI, Convertro, MarketShare, Brierley, M.T. Performance Marketing, AdThrive, Swiftype, InboxDollars, Ividence, MSIGHTS, CleverTap, Visual IQ, Snipp Interactive, Skimlinks, Domo, Unity Software, Digital Turbine (Advertisers & Publishers Business)","Zoomd Technologies Ltd has developed a proprietary patented technology that targets the needs of many segments of the digital marketing industry. It focuses on efficient user acquisition for companies and products aimed at mobile users. The Company leverages onsite search, providing increased monetization and engagement for publishers as well as more efficient management of digital advertising budgets for media agencies and advertisers, targeting usually mobile app user acquisition.",Business Products and Services (B2B),Commercial Services,Media and Information Services (B2B),"Business/Productivity Software, Media and Information Services (B2B)*","AdTech, Mobile, Real Estate Technology, SaaS","enterprise software, mobile advertising, search recommendation platform, search technology service, site-search recommendation",Formerly VC-backed,6.99,Profitable,Publicly Held,"Publicly Listed, Venture Capital",71,TSX,ZOMD,2012,2025-04-26,,Canada,"Toronto, Canada",,,,2018-09-26,,,,,Reverse Merger,,Corporate,2018-09-26,Completed,,,2014-05-01,4.0,Actual,Angel (individual),,,Angel (individual),Individual,Completed,,54.5,0.6970000000000001,8.91,-5.68,37.21,21.5,53.73,11.53,9.53,4,1,4,,,,"Electric digital data processing, Information and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes",,Dataminers Capital,,,"The company acquired DataMiners Capital (TSX-V: DMC.H) through a reverse merger, resulting in the combined entity trading on the TSX Venture Exchange under the ticker symbol DMC.H on September 26, 2018.","Gave Lowe, Gigi Levy-Weiss, Google Israel, IBM Alpha Zone Accelerator, Moonbow Ventures, Moshe Lichtman, Rafi Gidron, Rafi Wren, SmartInvest Ventures",
101135-44,ZOOZ Power (TAE: ZOOZ),ZOOZ Power Ltd,"Amber Kinetics, ADS-TEC Energy, Levistor, Revterra, Expion360, Alfen, FreeWire","Zooz Power Ltd is a provider of Flywheel-based Power Boosting solutions enabling widespread deployment of ultra-fast charging infrastructure for electric vehicles (EV) while overcoming existing grid limitations. ZOOZ pioneers its flywheel-based power boosting technology, enabling efficient utilization and power management of a power-limited grid at an EV charging site. Its Flywheel technology allows high-performance, reliable, and cost-effective ultra-fast charging infrastructure. ZOOZ Power's sustainable, power-boosting solutions are built with longevity and the environment in mind, helping its customers and partners accelerate the deployment of fast-charging infrastructure, thus facilitating improved utilization rates, efficiency and greater flexibility.",Business Products and Services (B2B),Commercial Products,Electrical Equipment,Electrical Equipment*,"CleanTech, Climate Tech, Manufacturing, Mobility Tech, TMT","charging solutions, charging station network, electric vehicle, energy storage system, ev charging technology, kinetic energy storage, renewable energy storage, smart storage services",Formerly VC-backed,49.44,Generating Revenue/Not Profitable,Publicly Held,"Publicly Listed, Venture Capital",38,TAE,ZOOZ,2013,2025-04-26,,Israel,"Lod, Israel",58.2,2021-04-21,IPO,2022-03-17,29.35,Actual,,,PIPE,,Corporate,2022-03-17,Completed,,,2013-01-01,,,Accelerator/Incubator,,,,Other,Completed,,1.04,0.3626,-10.99,-3.58,19.84,-0.49,20.61,-10.65,-11.02,,,,,,,,,,7,"Afcon Holdings, Bloom Ventures, Darwin Capital, MORE Investment House, Phoenix Financial (Multi-line Insurance), The Blue Minds Group, Yelin Lapidot Investment House","The company (TAE: ZOOZ) received ILS 96 million of development capital from Afcon Holdings, MORE Investment House (TAE: MRIN), Yelin Lapidot Investment House, Meitav Investment House and Phoenix Insurance Company (TAE: PHOE) on March 17, 2022, through a private placement. The raised capital will be used by the company to accelerate marketing and sales in the European and U.S. markets, to build operations for the growing demand for its products, and to accelerate technology and product development in order to become a leading supplier in the global market of electric vehicle charging infrastructure. Bloom Ventures also participated in this round. Previously, the company (TAE: ZOOZ) received ILS 13.8 million of development capital from Argento Technological Properties and other institutional investors on March 14, 2022, through a private placement.","BIRD Foundation, Capital Nature, Free Electrons, Goldbell Investments, iArgento Group, Israel G-Tek, L Marks, Ratio technologies (Israel), Zhengzhou Runner Electric",
